Document:

EX-10.88

Exhibit
10.88 

EXECUTION COPY

AMENDMENT NO. 1 TO CREDIT AGREEMENT

     AMENDMENT dated as of December 5, 2008 to the Credit Agreement dated as of April 19, 2007
among KING PHARMACEUTICALS, INC., as Borrower, the Lenders party thereto (the “Lenders”),
CREDIT SUISSE, CAYMAN ISLANDS BRANCH, as Administrative Agent, Collateral Agent and Swingline
Lender, and the other agents party thereto (as amended prior to the date hereof, the “Existing
Credit Agreement”).

PRELIMINARY STATEMENTS

     Pursuant to the Merger Agreement (such term and other terms used but not otherwise defined in
these Preliminary Statements having the meanings set forth in Article I of the Existing Credit
Agreement as amended hereby (the “Amended Credit Agreement”)) the Borrower intends to
acquire (the “Acquisition”) all of the Shares pursuant to a two-step transaction in which
(a) Merger Sub will acquire pursuant to the Tender Offer, for a purchase price of $37 per share in
cash, those Shares that have been validly tendered and not withdrawn and accepted for payment
pursuant to the Tender Offer and (b) on the Merger Date and in accordance with the Merger
Agreement, Merger Sub will be merged with and into the Target with the Target being the surviving
corporation (the “Merger”), and each Share not acquired in the Tender Offer will be
converted into the right to receive $37 in cash pursuant to, and subject to the provisions of, the
Merger Agreement. The Borrower also intends to enter into the Term Loan Credit Agreement (the term
loan facility set forth therein, the “Term Loan Facility”), the proceeds of which are to be
used to enable Merger Sub to pay a portion of the Acquisition Consideration together with fees and
expenses incurred in connection with the Transactions.

     In connection with the foregoing, Borrower has requested that the Lenders amend the Existing
Credit Agreement to, among other things, permit the Acquisition and the Term Loan Facility. The
Lenders have agreed to make such amendments on the terms, and subject to the conditions, set forth
herein.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and
for other good and valuable consideration, the sufficiency and receipt of which are hereby
acknowledged, the parties hereto hereby agree as follows:

     Section 1.  Defined Terms; References. Unless otherwise specifically
defined herein, each term used herein that is defined in the Amended Credit Agreement has the
meaning assigned to such term in the Amended Credit Agreement. Each reference to “this Agreement”,
“hereof”, “hereunder”, “herein” and “hereby” and each other similar reference in the Existing
Credit Agreement, and each reference in any other Loan Document to “the Credit Agreement”,
“thereof”, “thereunder”, “therein” or “thereby” or other similar reference to the Existing Credit
Agreement, shall, after the Amendment No. 1 Effective Date (as defined in Section 3 of this
Amendment), refer to the Existing Credit Agreement as amended hereby.

     Section 2.
Amendments to Existing Credit Agreement. With effect from the Amendment No. 1
Effective Date, the Existing Credit Agreement (but not the Exhibits

 

 

and Schedules attached thereto, which shall be replaced on or prior to the Amendment No. 1
Effective Date as set forth in Section 3(t) below) shall be amended to read in its entirety as set
forth in Exhibit A hereto.

     Section 3. Conditions to Effectiveness of Amendments to Existing Credit Agreement. The
amendments set forth in Section 2 shall become effective on the date (the “Amendment No. 1
Effective Date”) on which, and only when, each of the following conditions shall have been
satisfied:

     (a) The Administrative Agent shall have received, on behalf of itself, the Lenders and the
Issuing Banks, a favorable written opinion of (a) Dewey & LeBoeuf LLP, counsel for the Borrower, in
form and substance reasonably satisfactory to the Administrative Agent, and (b) each other counsel
that delivers an opinion in respect of the Term Loan Facility, in form and substance reasonably
satisfactory to the Administrative Agent, in each case (A) dated the Amendment No. 1 Effective
Date, (B) addressed to the Administrative Agent, the Issuing Banks and the Lenders, and (C)
covering such other matters relating to the Loan Documents and the Transactions as the
Administrative Agent shall reasonably request. The Borrower hereby requests such counsel to deliver
such opinions.

     (b) The Administrative Agent shall have received (i) a copy of the certificate or articles of
incorporation, including all amendments thereto, of each Loan Party, certified as of a recent date
by the Secretary of State of the state of its organization, and a certificate as to the good
standing of each Loan Party as of a recent date, from such Secretary of State; (ii) a certificate
of the Secretary or Assistant Secretary of each Loan Party dated the Amendment No. 1 Effective Date
and certifying (A) that attached thereto is a true and complete copy of the by-laws of such Loan
Party as in effect on the Amendment No. 1 Effective Date and at all times since a date prior to the
date of the resolutions described in clause (B) below, (B) that attached thereto is a true and
complete copy of resolutions duly adopted by the Board of Directors of such Loan Party authorizing
the execution, delivery and performance of the Loan Documents to which such person is a party and,
in the case of the Borrower, the Borrowings under the Amended Credit Agreement, and that such
resolutions have not been modified, rescinded or amended and are in full force and effect, (C) that
the certificate or articles of incorporation of such Loan Party have not been amended since the
date of the last amendment thereto shown on the certificate of good standing furnished pursuant to
clause (i) above, and (D) as to the incumbency and specimen signature of each officer executing any
Loan Document or any other document delivered in connection herewith on behalf of such Loan Party;
(iii) a certificate of another officer as to the incumbency and specimen signature of the Secretary
or Assistant Secretary executing the certificate pursuant to clause (ii) above; and (iv) such other
documents as the Lenders, the Issuing Banks or the Administrative Agent, may reasonably request.

     (c) The Administrative Agent shall have received a certificate, dated the Amendment No. 1
Effective Date and signed by a Financial Officer of the Borrower, confirming compliance as of the
Amendment No. 1 Effective Date with the conditions precedent set forth in paragraphs (b), (c) and
(d) of Section 4.01 of the Amended Credit Agreement and paragraphs (h)(iii), (h)(iv), (h)(v), (i),
(j), (m)(ii), (o), (p) and (q) of this Section 3.

 

 

     (d) After giving effect to the Transactions occurring on the Amendment No. 1 Effective Date,
the Borrower and the Subsidiaries shall have outstanding no Indebtedness for borrowed money or
preferred stock other than (i) Indebtedness under the Loan Documents, (ii) the Convertible Notes,
(iii) Term Indebtedness and (iv) other Indebtedness permitted under Section 6.01 of the Amended
Credit Agreement (other than clause (m) thereof).

     (e) The Collateral Agent shall have received a fully executed copy of the Security Documents
which (i) shall be in form and substance substantially identical to the Security Documents
delivered on or prior to the Amendment No. 1 Effective Date in connection with the Term
Indebtedness, (ii) shall provide that the Obligations are guaranteed by substantially all Domestic
Subsidiaries (and other Subsidiaries guaranteeing the Term Indebtedness) as of the Amendment No. 1
Effective Date subject only to exceptions and limitations substantially identical to those
applicable to guarantees in favor of the Term Indebtedness and (iii) shall provide that the
Obligations and the guarantees thereof shall be secured by a perfected first priority lien on
substantially all assets of the Borrower and its Domestic Subsidiaries, which lien shall rank pari
passu with the lien securing the Term Indebtedness and which liens shall be subject only to
exceptions and limitations substantially identical to those applicable to the liens securing the
Term Indebtedness. The Security Documents shall have been duly executed by each Loan Party that is
to be a party thereto and shall be in full force and effect on the Amendment No. 1 Effective Date.
The Collateral Agent on behalf of the Secured Parties shall have a security interest in the
Collateral of the type and priority described in each Security Document.

     (f) The Collateral Agent shall have received a Perfection Certificate with respect to the Loan
Parties dated the Amendment No. 1 Effective Date and duly executed by a Responsible Officer of the
Borrower, and shall have received the results of a search of the Uniform Commercial Code filings
(or equivalent filings) made with respect to the Loan Parties in the states (or other
jurisdictions) of formation of such persons, in which the chief executive office of each such
person is located and in the other jurisdictions in which such persons maintain property, in each
case as indicated on such Perfection Certificate, together with copies of the financing statements
(or similar documents) disclosed by such search, and accompanied by evidence satisfactory to the
Collateral Agent that the Liens indicated in any such financing statement (or similar document)
would be permitted under Section 6.02 or have been or will be contemporaneously released or
terminated.

     (g) The Administrative Agent shall have received a copy of, or a certificate as to coverage
under, and an insurance broker’s letter with respect to, the insurance policies required by Section
5.02 of the Amended Credit Agreement and the applicable provisions of the Security Documents, each
of which shall be endorsed or otherwise amended to include a customary lender’s loss payable
endorsement and to name the Collateral Agent as additional insured, in form and substance
satisfactory to the Administrative Agent.

     (h) (i) The definitive documents filed with the SEC with respect to the commencement of the
Tender Offer shall have been provided to the Administrative Agent prior to the Amendment No. 1
Effective Date (or, in the case of any amendments, supplements or other modifications that were
subsequently filed, prior to the filing thereof), and the terms and conditions thereof and
documentation relating thereto (the “Tender Offer Documentation”) shall be in form and
substance reasonably satisfactory to

 

 

the Agents (it being understood that the Tender Offer Documentation dated September 12, 2008,
as extended on October 13, 2008 and as further extended on November 24, 2008 and as amended to
reflect the changes thereto set forth in the Merger Agreement as in effect on the date hereof is in
form and substance satisfactory to the Agents) and shall be in full force and effect, (ii) the
Tender Offer Documentation shall not have been altered, amended or otherwise changed or
supplemented, in each case in any respect that could reasonably be expected to be materially
adverse to the rights or interests of the Administrative Agent or the Lenders, and no condition
thereto shall have been waived, altered, amended or otherwise changed or supplemented, in each case
without the prior written consent of the Administrative Agent (such consent not to be unreasonably
withheld or delayed), (iii) all material aspects of the Tender Offer shall have been consummated in
accordance with applicable laws and the description thereof in the Tender Offer Documentation, (iv)
the offer price in the Tender Offer shall not exceed an amount mutually agreed upon by the
Administrative Agent and the Borrower, and (v) Merger Sub shall have accepted for payment, pursuant
to the Tender Offer, a number of Shares (x) equal to at least a majority of the total number of
Shares outstanding and (y) representing at least a majority of the combined voting power of all
equity securities of the Target, in each case on a fully diluted basis (the “Minimum Acceptance
Condition”).

     (i) The Borrower shall have paid Acquisition Consideration from cash and cash equivalents on
hand (and not from the proceeds of the Loans, loans under the Term Loan Credit Agreement or any
other Indebtedness) in an amount not less than the greater of (i) $1,000,000,000 and (ii) the
amount necessary to purchase Shares in an amount sufficient to satisfy the Minimum Acceptance
Condition.

     (j) All shareholder rights plans, “poison pill” or any similar plans or charter or by-law
provisions and all anti-takeover or similar statutes, including Section 203 of the Delaware General
Corporations Law, are or will be invalid or inapplicable to the acquisition of Shares pursuant to
the Transactions and to the Borrower, the Target, Merger Sub and their Affiliates.

     (k) The Administrative Agent shall have received copies of the Merger Agreement and all
certificates, opinions and other documents delivered thereunder, certified by a Financial Officer
as being complete and correct.

     (l) The Administrative Agent shall have received a fully executed copy of the Term Loan Credit
Agreement, which agreement (i) shall have terms (other than pricing and yield), taken as a whole,
not less favorable in any material respect to the Loan Parties or the Lenders than the terms set
forth on Exhibit B hereto or than the Amended Credit Agreement (as such Amended Credit Agreement
may be further amended prior to the Amendment No. 1 Effective Date pursuant to Section 5 below),
(ii) shall have a maturity not earlier than the maturity of the Credit Facilities and (iii) shall
be in an aggregate committed amount of not greater than $300,000,000 (it being understood that to
the extent not satisfying the requirements set forth in clause (i) through (iii) above, such Term
Loan Credit Agreement must be in form and substance reasonably satisfactory to the Required
Lenders). The Term Loan Credit Agreement shall be in full force and effect on the Amendment No. 1
Effective Date and, simultaneously with the effectiveness of this Amendment, the first drawing
under the Term Loan Credit Agreement shall have occurred.

 

 

     (m) (i) The Lenders shall have received the financial statements and opinions referred to in
Section 3.05 of the Amended Credit Agreement, none of which shall demonstrate a material adverse
change in the financial condition of the Borrower or the Target, as applicable, from (and shall not
otherwise be materially inconsistent with) the financial statements or forecasts previously
provided to the Lenders (it being agreed that the financial statements provided to the Joint
Arrangers prior to November 23, 2008 are satisfactory) and (ii) there shall have been no material
change to the capital stock of the Borrower or the Target since November 23, 2008.

     (n) The Administrative Agent shall have received a certificate from the chief financial
officer of the Borrower certifying that the Borrower and its Subsidiaries, on a consolidated basis
after giving effect to the Transactions to occur on the Amendment No. 1 Effective Date, are
solvent.

     (o) The Administrative Agent shall be satisfied, in its reasonable judgment, that the
Borrower’s Consolidated EBITDA for the four-fiscal quarter period ended at least 30 days prior to
the Amendment No. 1 Effective Date (excluding Consolidated EBITDA of the Target and its
subsidiaries) shall not be less than $500,000,000.

     (p) All requisite Governmental Authorities and third parties shall have approved or consented
to the Transactions and the other transactions contemplated hereby to the extent required (except
to the extent such approvals or consents are not material to the Transactions or the other
transactions contemplated hereby), all applicable appeal periods shall have expired and there shall
not be any pending or threatened litigation, governmental, administrative or judicial action that
could reasonably be expected to restrain, prevent or impose materially burdensome conditions on the
Transactions or the other transactions contemplated hereby. Without limiting the foregoing, the
waiting periods under the Hart-Scott-Rodino Antitrust Improvement Act 1976 (as amended, the
“HSR Act”) shall have expired or have been terminated.

     (q) The Administrative Agent shall have received evidence reasonably satisfactory to it that
the Borrower shall have received a public corporate credit rating of B+ or higher by S&P and a
public corporate family rating of B1 or higher by Moody’s, in each case as of the Amendment No. 1
Effective Date and after giving effect to the Transactions.

     (r) The Lenders shall have received, to the extent requested, all documentation and other
information required by regulatory authorities under applicable “know your customer” and anti-money
laundering rules and regulations, including the Patriot Act.

     (s) The Borrower shall have paid to the Administrative Agent, for the account of each Lender
delivering an executed counterpart of this Amendment to the Administrative Agent at or prior to
5:00 p.m. New York City time on December 5, 2008, an amendment fee (the “Amendment Fee”)
equal to 1.00% of such Lender’s Revolving Credit Commitment (whether used or unused) on such date;
provided that no such fee shall be required to be paid to any Lender that agrees, in its sole
discretion and in writing, to waive such fee. The Administrative Agent shall also have received
all other fees and other amounts due and payable on or prior to the Amendment No. 1 Effective Date,
including, to the extent invoiced, reimbursement or payment of all fees and out-of-pocket expenses
(including fees, charges and disbursements of outside counsel) required to be

 

 

reimbursed or paid by any Loan Party under the Amended Credit Agreement or under any other
Loan Document.

     (t) The Borrower shall have delivered to the Administrative Agent (i) Schedules to the Amended
Credit Agreement in form and substance reasonably satisfactory to the Required Lenders; provided
that the parties hereto agree that (x) Schedule 1.01(b), 1.01(c), 3.08, 3.19(a), 3.19(c), 3.20(a)
and 3.20(b) shall be deemed to be satisfactory to the Required Lenders to the extent that they are
substantially identical to the corresponding Schedules delivered under the Term Loan Credit
Agreement and (y) Schedule 1.01(a), 2.01 and 2.04 shall be deemed to be satisfactory to the
Required Lenders to the extent that they are substantially identical to the Schedules attached to
the Existing Credit Agreement updated solely with respect to contact information and to reflect an
increase, if any, in the Revolving Credit Commitments as described in Section 5(c) below and (ii)
Exhibits to the Amended Credit Agreement in form and substance reasonably satisfactory to the
Required Lenders; provided that the parties hereto agree that (x) Exhibit D, E and F will be deemed
to be satisfactory to the Required Lenders if they satisfy the requirements relating to Security
Documents set forth in Section 3(e) above, (y) Exhibits G-1, G-2 and G-3 will not be modified or
replaced on the Amendment No. 1 Effective Date and (z) all other Exhibits will be deemed to be
satisfactory to the Required Lenders if they are substantially identical in form and substance to
the corresponding Exhibits to the Existing Credit Agreement with only such modifications as are
necessary to reflect the changes made to the Existing Credit Agreement by this Amendment.

The Administrative Agent shall notify the Borrower and the Lenders of the Amendment No. 1 Effective
Date, and such notice shall be conclusive and binding.

     Section 4. Certain Consequences Of Effectiveness. On and after the Amendment No. 1
Effective Date, the rights and obligations of the parties to the Existing Credit Agreement and each
other Loan Document (as defined in the Existing Credit Agreement, the “Existing Loan
Documents”) shall be governed by the Amended Credit Agreement and each Existing Loan Document
as amended pursuant to the terms hereof; provided that the rights and obligations of the parties to
the Existing Credit Agreement and the other Existing Loan Documents with respect to the period
prior to the Amendment No. 1 Effective Date shall continue to be governed by the provisions of the
Existing Credit Agreement and the other Existing Loan Documents prior to giving effect to this
Amendment and the amendments contemplated hereby. On and after the Amendment No. 1 Effective Date,
the Exhibits and Schedules attached to the Existing Credit Agreement shall be deemed to be replaced
in their entirety with the Exhibits and Schedules delivered in accordance with Section 3(t).

     Section 5. Certain Consents.

     (a) Each Lender party hereto hereby authorizes the Administrative Agent and/or the Collateral
Agent (as appropriate) on behalf of all Lenders to enter into such Security Documents (including
any amendments, modifications or restatements of any existing Security Documents as defined in the
Existing Credit Agreement (the “Existing Security Documents”)) and hereby consents to any
amendments, modifications or restatements of Existing Security Documents as the Administrative
Agent shall deem necessary or advisable to satisfy the condition set forth in Section 3(e) (it
being understood and agreed that the same Security Documents and the same granting clause

 

 

may secure the Obligations as well as the obligations of the Loan Parties in respect of the
Term Loan Facility).

     (b) Each Lender party hereto hereby further authorizes the Administrative Agent to modify
Exhibit A hereto (and in so doing to modify the Amended Credit Agreement) at any time prior to the
Amendment No. 1 Effective Date to the extent such modifications are necessary or in the reasonable
judgment of the Administrative Agent desirable to ensure that the Term Loan Credit Agreement, taken
as a whole, is not less favorable to the Loan Parties or the Lenders in any material respect than
the Amended Credit Agreement (taking into account customary differences in the facilities
documented thereunder).

     (c) Each Lender party hereto hereby authorizes the Administrative Agent to modify Exhibit A
hereto (and in so doing to modify the Amended Credit Agreement) at any time prior to the Amendment
No. 1 Effective Date to reflect an increase in the Revolving Credit Commitments of not more than
$50,000,000 (it being understood that any Lender approached to provide all or any portion of such
additional Revolving Credit Commitments may elect, in its sole discretion, to decline or to provide
such additional Revolving Credit Commitments). Such modifications shall include changes necessary
or in the reasonable judgment of the Administrative Agent desirable to achieve pro rata treatment
of such additional Revolving Credit Commitments with the existing Revolving Credit Commitments,
including as to participation in Letters of Credit and allocation of outstanding Loans.

     Any such amendment, modification or restatement referred to in this Section 5 shall become
effective upon the written agreement of the Administrative Agent, the applicable Loan Parties and
any lender providing any portion of the increase in the Revolving Credit Commitments set forth in
clause (c) above without any further action or consent from any other Lender being required.

     Section 6.
 Binding Effect. This Amendment shall become effective and legally binding when
it shall have been executed by the Borrower, the Administrative Agent, the Collateral Agent, each
Issuing Bank and the Swingline Lender and the Administrative Agent (or its counsel) shall have
received from the Required Lenders (as defined in the Existing Credit Agreement) either (i) a
counterpart of this Amendment signed on behalf of such party or (ii) written evidence satisfactory
to the Administrative Agent (which may include facsimile transmission of a signed signature page of
this Amendment) that such party has signed a counterpart of this Amendment. This Amendment shall
bind each party’s successors and assigns, including any Person to whom any Lender party hereto
assigns any of its interests, rights and obligations under the Existing Credit Agreement.

     Section 7.
Governing Law. This Amendment shall be governed by, and construed in
accordance with, the laws of the State of New York.

     Section 8.  Counterparts. This Amendment may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument. Delivery by telecopier of an executed counterpart of a
signature page to this Amendment shall be effective as delivery of an original executed counterpart
of this Amendment.

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
respective authorized officers as of the day and year first above written.

	 	 	 	 	 
	 	KING PHARMACEUTICALS, INC., as 

     Borrower,

 	 
	 	By:  	/s/
Brian A. Markison	 
	 	 	Name:  	Brian A. Markison	 
	 	 	Title:  	Chairman, President and

Chief Executive Officer	 

8

 

	 	 	 	 	 

	 	 	 	 	 
	 	CREDIT SUISSE, CAYMAN ISLANDS

     BRANCH, as Lender, Administrative 

     Agent, Collateral Agent, Swingline

      Lender and Issuing Bank,

 	 
	 	By:  	/s/
John D. Toronto	 
	 	 	Name:  	
John D. Toronto	 
	 	 	Title:  	Director	 
	 

	 	 	 	 	 
	 	 	 
	 	By:  	/s/
Shaheen Malik	 
	 	 	Name:  	Shaheen Malik	 
	 	 	Title:  	Associate	 

 

 

	 	 	 	 	 

	 	 	 	 	 
	 	WACHOVIA BANK, NATIONAL 

     ASSOCIATION, as Lender,

 	 
	 	By:  	/s/
David Gillespie	 
	 	 	Name:  	David Gillespie	 
	 	 	Title:  	Managing Director	 

 

 

	 	 	 	 	 

	 	 	 	 	 
	 	BANK HAPOALIM B.M.

 	 
	 	By:  	/s/
James P. Surless	 
	 	 	Name:  	James P. Surless	 
	 	 	Title:  	Vice President	 
	 	

 	 
	 	By:  	/s/
Charles McLaughlin	 
	 	 	Name:  	Charles McLaughlin	 
	 	 	Title:  	Senior Vice President	 

 

 

	 	 	 	 	 

	 	 	 	 	 
	 	BANK OF AMERICA, N.A.

 	 
	 	By:  	/s/
Robert La Porte	 
	 	 	Name:  	Robert La Porte	 
	 	 	Title:  	Vice President	 

 

 

	 	 	 	 	 

	 	 	 	 	 
	 	CHANG HWA COMMERCIAL BANK, LTD.

NEW YORK BRANCH	 
	 
	 	By:  	/s/
Jim C.Y. Chen	 
	 	 	Name:  	Jim C.Y. Chen	 
	 	 	Title:  	VP & General Manager	 

 

 

	 	 	 	 	 

	 	 	 	 	 
	 	CITIBANK, N.A.

 	 
	 	By:  	/s/
Allen Fisher	 
	 	 	Name:  	Allen Fisher	 
	 	 	Title:  	Vice President	 

 

 

	 	 	 	 	 
	 	DnB NOR BANK ASA

 	 
	 	By:  	/s/
Thomas Tangen	 
	 	 	Name:  	Thomas Tangen	 
	 	 	Title:  	First Vice President	 
	 	

 	 
	 	By:  	/s/
Kristin Riise	 
	 	 	Name:  	Kristin Riise	 
	 	 	Title:  	VP	 

 

 

	 	 	 	 	 
	 	FIRST COMMERCIAL BANK, LOS ANGELES BRANCH	 
	 
	 	By:  	/s/
Rong-Ko Chen	 
	 	 	Name:  	Rong-Ko Chen	 
	 	 	Title:  	VP & General Manager	 

 

 

	 	 	 	 	 
	 	FIRST TENNESSEE BANK, NATIONAL
ASSOCIATION, as Lender

 	 
	 	By:  	/s/
Freddie H. Malone	 
	 	 	Name:  	Freddie H. Malone	 
	 	 	Title:  	Vice President	 

 

 

	 	 	 	 	 
	 	FORTIS BANK

 	 
	 	By:  	/s/
Denis McHugh	 
	 	 	Name:  	Denis McHugh	 
	 	 	Title:  	Senior Managing Director	 

 

 

	 	 	 	 	 
	 	JPMORGAN CHASE BANK, NA.

 	 
	 	By:  	/s/
Barbara R. Marks	 
	 	 	Name:  	Barbara R. Marks	 
	 	 	Title:  	Executive Director	 

 

 

	 	 	 	 	 
	 	THE ROYAL BANK OF SCOTLAND PLC

 	 
	 	By:  	/s/
Scott MacVicar	 
	 	 	Name:  	Scott MacVicar	 
	 	 	Title:  	Vice President	 

 

 

	 	 	 	 	 
	 	UBS LOAN FINANCE LLC, as Lender

 	 
	 	By:  	/s/
Richard L. Tavrow	 
	 	 	Name:  	Richard L. Tavrow	 
	 	 	Title:  	Director	 
	 	

 	 
	 	By:  	/s/
/s/ Mary E. Evans	 
	 	 	Name:  	Mary E. Evans	 
	 	 	Title:  	Associate Director	 

 

 

	 	 	 	 	 
	 	U.S BANK, NA.

 	 
	 	By:  	/s/
Thomas A. Heckman	 
	 	 	Name:  	Thomas A. Heckman	 
	 	 	Title:  	Vice President	 

 

 

Exhibit A

 

CREDIT AGREEMENT

Dated as of April 19, 2007,

as amended by Amendment No. 1 dated December 5, 2008

among

KING PHARMACEUTICALS, INC.,

THE LENDERS NAMED HEREIN,

CREDIT SUISSE, CAYMAN ISLANDS BRANCH

as Administrative Agent,

as Collateral Agent and

as Swingline Lender,

BANK OF AMERICA, N.A.,

and

UBS SECURITIES LLC,

as Co-Syndication Agents

CITIGROUP GLOBAL MARKETS INC.,

WACHOVIA BANK, NATIONAL ASSOCIATION,

and

THE ROYAL BANK OF SCOTLAND PLC,

as Co-Documentation Agents

U.S. BANK NATIONAL ASSOCIATION,

as Managing Agent

 

CREDIT SUISSE SECURITIES (USA) LLC, and

WACHOVIA CAPITAL MARKETS, LLC

as Joint Lead Arrangers and Joint Bookrunners

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	ARTICLE I

	 
	 	 	 	 
	Definitions

	 
	 	 	 	 
	SECTION 1.01. Defined Terms
	 	 	1	 
	SECTION 1.02. Terms Generally
	 	 	32	 
	SECTION 1.03. Pro Forma Calculations
	 	 	33	 
	 
	 	 	 	 
	ARTICLE II

	 
	 	 	 	 
	The Credits

	 
	 	 	 	 
	SECTION 2.01. Commitments
	 	 	33	 
	SECTION 2.02. Loans
	 	 	33	 
	SECTION 2.03. Swingline Loans
	 	 	36	 
	SECTION 2.04. Letters of Credit
	 	 	38	 
	SECTION 2.05. Borrowing Procedure
	 	 	44	 
	SECTION 2.06. Evidence of Debt; Repayment of Loans
	 	 	45	 
	SECTION 2.07. Fees
	 	 	45	 
	SECTION 2.08. Interest on Loans
	 	 	47	 
	SECTION 2.09. Default Interest
	 	 	47	 
	SECTION 2.10. Alternate Rate of Interest
	 	 	47	 
	SECTION 2.11. Termination and Reduction of Commitments
	 	 	48	 
	SECTION 2.12. Conversion and Continuation of Borrowings
	 	 	48	 
	SECTION 2.13. Voluntary Prepayment; Mandatory Prepayments and Commitment Reductions
	 	 	50	 
	SECTION 2.14. Reserve Requirements; Change in Circumstances
	 	 	53	 
	SECTION 2.15. Change in Legality
	 	 	55	 
	SECTION 2.16. Indemnity
	 	 	56	 
	SECTION 2.17. Pro Rata Treatment
	 	 	56	 
	SECTION 2.18. Sharing of Setoffs
	 	 	57	 
	SECTION 2.19. Payments
	 	 	57	 
	SECTION 2.20. Taxes
	 	 	58	 
	SECTION 2.21. Assignment of Commitments Under Certain Circumstances; Duty to Mitigate
	 	 	60	 
	 
	 	 	 	 
	ARTICLE III

	 
	 	 	 	 
	Representations and Warranties

	SECTION 3.01. Organization; Powers
	 	 	61	 

i

 

	 	 	 	 	 
	 	 	Page	 
	SECTION 3.02. Authorization
	 	 	62	 
	SECTION 3.03. Enforceability
	 	 	62	 
	SECTION 3.04. Governmental Approvals
	 	 	62	 
	SECTION 3.05. Financial Statements
	 	 	62	 
	SECTION 3.06. No Material Adverse Change
	 	 	64	 
	SECTION 3.07. Title to Properties; Possession Under Leases
	 	 	64	 
	SECTION 3.08. Subsidiaries
	 	 	65	 
	SECTION 3.09. Litigation; Compliance with Laws
	 	 	65	 
	SECTION 3.10. Agreements
	 	 	66	 
	SECTION 3.11. Federal Reserve Regulations
	 	 	66	 
	SECTION 3.12. Investment Company Act
	 	 	66	 
	SECTION 3.13. Use of Proceeds
	 	 	66	 
	SECTION 3.14. Tax Returns
	 	 	66	 
	SECTION 3.15. No Material Misstatements
	 	 	67	 
	SECTION 3.16. Employee Benefit Plans
	 	 	67	 
	SECTION 3.17. Environmental Matters
	 	 	67	 
	SECTION 3.18. Insurance
	 	 	69	 
	SECTION 3.19. Security Documents
	 	 	69	 
	SECTION 3.20. Location of Real Property and Leased Premises
	 	 	70	 
	SECTION 3.21. Labor Matters
	 	 	70	 
	SECTION 3.22. Solvency
	 	 	70	 
	SECTION 3.23. Transaction Documents
	 	 	71	 
	SECTION 3.24. Sanctioned Persons
	 	 	71	 
	 
	 	 	 	 
	ARTICLE IV

	 
	 	 	 	 
	Conditions of Lending

	 
	 	 	 	 
	SECTION 4.01. All Credit Events
	 	 	72	 
	SECTION 4.02. Effective Date
	 	 	73	 
	 
	 	 	 	 
	ARTICLE V

	 
	 	 	 	 
	Affirmative Covenants

	 
	 	 	 	 
	SECTION 5.01. Existence; Compliance with Laws; Businesses and Properties
	 	 	75	 
	SECTION 5.02. Insurance
	 	 	75	 
	SECTION 5.03. Obligations and Taxes
	 	 	77	 
	SECTION 5.04. Financial Statements, Reports, etc
	 	 	77	 
	SECTION 5.05. Litigation and Other Notices
	 	 	80	 
	SECTION 5.06. Information Regarding Collateral
	 	 	80	 
	SECTION 5.07. Maintaining Records; Access to Properties and Inspections; Maintenance of Ratings
	 	 	81	 
	SECTION 5.08. Use of Proceeds
	 	 	81	 
	SECTION 5.09. Employee Benefits
	 	 	81	 

ii

 

	 	 	 	 	 
	 	 	Page	 
	SECTION 5.10. Compliance with Environmental Laws
	 	 	82	 
	SECTION 5.11. Preparation of Environmental Reports
	 	 	82	 
	SECTION 5.12. Compliance with Laws
	 	 	82	 
	SECTION 5.13. Further Assurances
	 	 	82	 
	SECTION 5.14. Interest Rate Protection
	 	 	83	 
	SECTION 5.15. Consummation of the Merger
	 	 	83	 
	 
	 	 	 	 
	ARTICLE VI

	 
	 	 	 	 
	Negative Covenants

	 
	 	 	 	 
	SECTION 6.01. Indebtedness
	 	 	84	 
	SECTION 6.02. Liens
	 	 	87	 
	SECTION 6.03. Sale and Leaseback Transactions
	 	 	89	 
	SECTION 6.04. Investments, Loans and Advances
	 	 	89	 
	SECTION 6.05. Mergers, Consolidations, Sales of Assets and Acquisitions
	 	 	92	 
	SECTION 6.06. Restricted Payments; Restrictive Agreements
	 	 	93	 
	SECTION 6.07. Transactions with Affiliates
	 	 	94	 
	SECTION 6.08. Business of Borrower and Subsidiaries
	 	 	94	 
	SECTION 6.09. Other Indebtedness and Agreements
	 	 	94	 
	SECTION 6.10. Capital Expenditures
	 	 	95	 
	SECTION 6.11. Consolidated Interest Expense Coverage Ratio
	 	 	96	 
	SECTION 6.12. Maximum Leverage Ratio
	 	 	97	 
	SECTION 6.13. Fiscal Year
	 	 	99	 
	SECTION 6.14. Certain Equity Securities
	 	 	99	 
	 
	 	 	 	 
	ARTICLE VII

	 
	 	 	 	 
	Events of Default

	 
	 	 	 	 
	ARTICLE VIII

	 
	 	 	 	 
	The Administrative Agent and the Collateral Agent

	 
	 	 	 	 
	ARTICLE IX

	 
	 	 	 	 
	Miscellaneous

	 
	 	 	 	 
	SECTION 9.01. Notices
	 	 	106	 
	SECTION 9.02. Survival of Agreement
	 	 	109	 
	SECTION 9.03. Binding Effect
	 	 	109	 
	SECTION 9.04. Successors and Assigns
	 	 	109	 

iii

 

	 	 	 	 	 
	 	 	Page	 
	SECTION 9.05. Expenses; Indemnity
	 	 	115	 
	SECTION 9.06. Right of Setoff
	 	 	116	 
	SECTION 9.07. APPLICABLE LAW
	 	 	117	 
	SECTION 9.08. Waivers; Amendments
	 	 	117	 
	SECTION 9.09. Interest Rate Limitation
	 	 	118	 
	SECTION 9.10. Entire Agreement
	 	 	119	 
	SECTION 9.11. WAIVER OF JURY TRIAL
	 	 	119	 
	SECTION 9.12. Severability
	 	 	119	 
	SECTION 9.13. Counterparts
	 	 	119	 
	SECTION 9.14. Headings
	 	 	120	 
	SECTION 9.15. Jurisdiction; Consent to Service of Process
	 	 	120	 
	SECTION 9.16. Confidentiality
	 	 	121	 
	SECTION 9.17. Lender Action
	 	 	121	 
	SECTION 9.18. Patriot Act
	 	 	122	 
	SECTION 9.19. No Fiduciary Duty
	 	 	122	 

iv

 

	 	 	 
	SCHEDULES:
	 	 
	 
	 	 
	Schedule 1.01(a)

	 	Existing Letters of Credit
	Schedule 1.01(b)

	 	Subsidiary Guarantors
	Schedule 1.01(c)

	 	Mortgaged Property
	Schedule 2.01

	 	Lenders and Commitments
	Schedule 3.08

	 	Subsidiaries
	Schedule 3.09

	 	Litigation
	Schedule 3.17

	 	Environmental Matters
	Schedule 3.18

	 	Insurance
	Schedule 3.19(a)

	 	UCC Filing Offices
	Schedule 3.19(c)

	 	Mortgage Filing Offices
	Schedule 3.20(a)

	 	Owned Real Property
	Schedule 3.20(b)

	 	Leased Real Property
	Schedule 6.01

	 	Existing Indebtedness
	Schedule 6.02

	 	Existing Liens
	Schedule 6.04(a)

	 	Existing Investments
	 
	 	 
	EXHIBITS:
	 	 
	 
	 	 
	Exhibit A

	 	Form of Administrative Questionnaire
	Exhibit B

	 	Form of Assignment and Acceptance
	Exhibit C

	 	Form of Borrowing Request
	Exhibit D

	 	Form of Guarantee and Collateral Agreement
	Exhibit E

	 	Form of Mortgage
	Exhibit F

	 	Form of Affiliate Subordination Agreement
	Exhibit G-1

	 	Form of Opinion of James Elrod, Esq., General Counsel of the Borrower
	 
	Exhibit G-2

	 	Form of Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., special counsel to the Borrower
	 
	Exhibit G-3

	 	Form of Opinion of Bass, Berry & Sims PLC, Tennessee counsel to the Borrower
	 
	Exhibit H

	 	Form of Compliance Certificate

v

 

     CREDIT AGREEMENT dated as of April 19, 2007 as amended by Amendment No. 1 dated December 5,
2008 (as further amended, supplemented or otherwise modified from time to time, this
“Agreement”), among KING PHARMACEUTICALS, INC., a Tennessee corporation (the
“Borrower”); the Lenders (as defined in Article I); CREDIT SUISSE, a bank organized under
the laws of Switzerland, acting through its Cayman Islands Branch, as administrative agent and
collateral agent for the Lenders (in such capacity, the “Administrative Agent” and the
“Collateral Agent”), and as swingline lender (in such capacity, the “Swingline
Lender”), Bank of America, N.A. and UBS Securities LLC, as co-syndication agents (in such
capacity, “Co-Syndication Agents”); Citigroup Global Markets Inc., Wachovia Bank, National
Association and The Royal Bank of Scotland plc, as co-documentation agents (in such capacity, the
“Co-Documentation Agents”); U.S. Bank National Association, as managing agent (in such
capacity, the “Managing Agent”); and the Issuing Banks (as defined in Article I).

               The Borrower has requested the Lenders to extend credit in the form of Revolving Loans at any
time and from time to time on or after the Effective Date and prior to the Maturity Date, in an
aggregate principal amount at any time outstanding not in excess of $475,000,000. The Borrower has
requested the Swingline Lender to extend credit, at any time and from time to time prior to the
Maturity Date, in the form of Swingline Loans in an aggregate principal amount at any time
outstanding not in excess of $20,000,000. The Borrower has requested that the Issuing Banks issue
letters of credit, in an aggregate face amount at any time outstanding not in excess of $40,000,000
to support payment obligations incurred in the ordinary course of business by the Borrower and the
Subsidiaries. The proceeds of the Revolving Loans and of the Swingline Loans are to be used by the
Borrower and the Subsidiaries to provide working capital and for other general corporate purposes,
including permitted acquisitions and the refinancing of amounts outstanding under the Existing
Credit Agreement, and the Letters of Credit are to be used by the Borrower and the Subsidiaries for
general corporate purposes. The Lenders, the Swingline Lender and the Issuing Banks have agreed to
extend such credit on the terms and subject to the conditions set forth herein.

               Accordingly, the parties hereto hereby agree as follows:

ARTICLE I

Definitions

               SECTION 1.01. Defined Terms. As used in this Agreement, the following terms shall have the
meanings specified below:

1

 

               “ABR Borrowing” shall mean a Borrowing comprised of ABR Loans.

               “ABR Loan” shall mean any ABR Revolving Loan or Swingline Loan.

               “ABR Revolving Loan” shall mean any Revolving Loan bearing interest at a rate
determined by reference to the Alternate Base Rate in accordance with the provisions of Article II.

               “Acquired Entity” shall have the meaning assigned to such term in Section 6.04(l).

               “Acquisition” shall mean the acquisition by Borrower of all the Shares pursuant to a
two-step transaction in which (a) Merger Sub will acquire pursuant to the Tender Offer, for a
purchase price of $37 per share in cash, those Shares that have been validly tendered and not
withdrawn and accepted for payment pursuant to the Tender Offer and (b) on the Merger Date and in
accordance with the Merger Agreement, Merger Sub will be merged with and into the Target with the
Target being the surviving corporation, and each Share not acquired in the Tender Offer will be
converted into the right to receive $37 in cash pursuant to, and subject to the provision of, the
Merger Agreement.

               “Acquisition Consideration” shall mean the consideration paid in respect of those
Shares that have been validly tendered and not withdrawn in the Tender Offer and that have been
accepted for payment on the Amendment No. 1 Effective Date, the consideration paid in respect of
those additional Shares that are validly tendered and not withdrawn in a subsequent offering period
pursuant to the Tender Offer, and the consideration paid on or immediately after the effective date
of the Merger and to pay the appraised value of any Shares held by holders who have properly
perfected rights to appraisal in accordance with Section 262 of the Delaware General Corporation
Law.

               “Acquisition Transactions” shall have the meaning set forth in Section 3.02.

               “Adjusted LIBO Rate” shall mean, with respect to any Eurodollar Borrowing for any
Interest Period, an interest rate per annum equal to the product of (a) the LIBO Rate in effect for
such Interest Period and (b) Statutory Reserves.

               “Administrative Agent” shall have the meaning assigned to such term in the preamble to
this Agreement.

               “Administrative Agent Fees” shall have the meaning assigned to such term in Section
2.07(b).

2

 

               “Administrative Questionnaire” shall mean an Administrative Questionnaire in the form
of Exhibit A, or such other form as may be supplied from time to time by the Administrative
Agent.

               “Affiliate” shall mean, when used with respect to a specified person, another person
that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is
under common Control with the person specified.

               “Affiliate Subordination Agreement” shall mean an Affiliate Subordination Agreement in
the form of Exhibit F pursuant to which intercompany obligations and advances owed by any Loan
Party to a person that is not a Loan Party are subordinated to the Obligations.

               “Agents” shall have the meaning assigned to such term in Article VIII.

               “Agreement” shall have the meaning assigned to such term in the preamble hereto.

               “Aggregate Revolving Credit Exposure” shall mean the aggregate amount of the Lenders’
Revolving Credit Exposures.

               “Agreement Value” shall mean, for each Hedging Agreement, on any date of
determination, the maximum aggregate amount (giving effect to any netting agreements) that the
Borrower or any Subsidiary would be required to pay if such Hedging Agreement were terminated on
such date.

               “Alternate Base Rate” shall mean, for any day, a rate per annum equal to the greater
of (a) the Prime Rate in effect on such day and (b) the Federal Funds Effective Rate in effect on
such day plus 1/2 of 1%. If for any reason the Administrative Agent shall have determined (which
determination shall be conclusive absent manifest error) that it is unable to ascertain the Federal
Funds Effective Rate, including the inability of the Administrative Agent to obtain sufficient
quotations in accordance with the terms of the definition thereof, the Alternate Base Rate shall be
determined without regard to clause (b) of the preceding sentence until the circumstances giving
rise to such inability no longer exist. Any change in the Alternate Base Rate due to a change in
the Prime Rate or the Federal Funds Effective Rate shall be effective on the effective date of such
change in the Prime Rate or the Federal Funds Effective Rate, as the case may be.

               “Alpharma Convertible Note Indenture” shall mean the Indenture dated as of March 20,
2007, as supplemented by the First Supplemental Indenture dated March 20, 2007, each between
Alpharma Inc. and U.S. Bank National Association, as trustee, as in effect on the Amendment No. 1
Effective Date.

3

 

               “Alpharma Convertible Notes” shall mean the 2.125% convertible senior notes due 2027
issued by Alpharma Inc. pursuant to the Alpharma Convertible Note Indenture and outstanding on the
Amendment No. 1 Effective Date.

               “Alpharma Escrow Account” shall have the meaning assigned to such term in Section
5.16.

               “Amendment No. 1” shall mean Amendment No. 1 to this Agreement, dated as of December
5, 2008, among the Borrower, the Swingline Lender, the Issuing Bank, the Administrative Agent and
the Collateral Agent and the lenders party thereto.

               “Amendment No. 1 Effective Date” shall have the meaning assigned to such term in
Amendment No. 1.

               “Applicable Commitment Reduction Date” shall mean (a) with respect to the Net Cash
Proceeds of any Asset Sale, Equity Issuance, incurrence or issuance of Indebtedness, ARS
Liquidation Event or Extraordinary Receipt, the earliest of (i) the third Business Day following
the date of receipt by the Borrower or any Subsidiary of such Net Cash Proceeds, (ii) the date
designated as the Applicable Commitment Reduction Date by notice in writing from the Borrower to
the Administrative Agent and (iii) solely in the case of Net Cash Proceeds from any Asset Sales or
ARS Liquidation Event, the date on which any loans outstanding under the Term Loan Credit Agreement
are prepaid from the proceeds of such Asset Sale or ARS Liquidation and (b) with respect to any
prepayments required to be made pursuant to Section 2.13(g) from Excess Cash Flow, the earliest of
(i) the 90th day following the end of each fiscal year of the Borrower, commencing with
the first fiscal year ending after the Term Loan Facility Termination, (ii) the date on which the
financial statements with respect to such period are delivered pursuant to Section 5.04(a) and
(iii) the date designated as the Applicable Commitment Reduction Date by notice in writing from the
Borrower to the Administrative Agent.

               “Applicable Percentage” shall mean, for any day (a) with respect to any Eurodollar
Revolving Loan, 5.00% per annum, (b) with respect to any ABR Loan, 4.00% per annum, and (c) with
respect to the Commitment Fees, 0.50% per annum.

               “ARS Liquidation Event” shall mean any event which enables the Borrower or any
Subsidiary to convert its auction rate securities into cash or other immediately available funds
(whether through incurring Permitted ARS Indebtedness, the redemption of such auction rate
securities by the issuer thereof, the repurchase of such auction rate securities by the seller
thereof, the sale of such auction rate securities by the Borrower or such Subsidiary, or
otherwise).

4

 

               “Asset Sale” shall mean the sale, transfer or other disposition (by way of merger,
casualty, condemnation or otherwise) by the Borrower or any of the Subsidiaries to any person other
than the Borrower or any Subsidiary Guarantor of (a) any Equity Interests of any of the
Subsidiaries (other than directors’ qualifying shares) or (b) any other assets of the Borrower or
any of the Subsidiaries (other than (i) inventory (including raw material), damaged, obsolete,
surplus or worn out assets, scrap and Permitted Investments, in each case disposed of in the
ordinary course of business, (ii) dispositions between or among Foreign Subsidiaries, (iii)
dispositions of Margin Stock for cash and for fair market value as determined in good faith by the
board of directors of the Borrower; provided that the cash proceeds received in connection with any
such disposition are held in cash or Permitted Investments, (iv) solely for the purpose of Section
2.13(e), any ARS Liquidation Event and (v) any sale, transfer or other disposition or series of
related sales, transfers or other dispositions having a value not in excess of $500,000).

               “Assignment and Acceptance” shall mean an assignment and acceptance entered into by a
Lender and an assignee, and accepted by the Administrative Agent, in the form of Exhibit B
or such other form as shall be approved by the Administrative Agent.

               “Board” shall mean the Board of Governors of the Federal Reserve System of the United
States of America.

               “Borrower” shall have the meaning assigned to such term in the preamble to this
Agreement.

               “Borrower Materials” shall have the meaning assigned to such term in Section 9.01.

               “Borrowing” shall mean a group of Loans of a single Class and Type made by the Lenders
on a single date and as to which a single Interest Period is in effect.

               “Borrowing Request” shall mean a request by the Borrower in accordance with the terms
of Section 2.05 and substantially in the form of Exhibit C, or such other form as shall be
approved by the Administrative Agent.

               “Breakage Event” shall have the meaning assigned to such term in Section 2.16.

               “Business Day” shall mean any day other than a Saturday, Sunday or day on which banks
in New York City are authorized or required by law to close; provided, however, that when used in
connection with a Eurodollar Revolving Loan, the term “Business Day” shall also exclude any day on
which banks are not open for dealings in dollar deposits in the London interbank market.

5

 

               “Capital Expenditures” shall mean, for any period, (a) the additions to property,
plant and equipment and other capital expenditures of the Borrower and its consolidated
Subsidiaries that are (or should be) set forth in a consolidated statement of cash flows of the
Borrower for such period prepared in accordance with GAAP and (b) Capital Lease Obligations or
Synthetic Lease Obligations incurred by the Borrower and its consolidated Subsidiaries during such
period, but excluding in each case any such expenditure made to restore, replace or rebuild
property to the condition of such property immediately prior to any damage, loss, destruction or
condemnation of such property, to the extent such expenditure is made with insurance proceeds,
condemnation awards or damage recovery proceeds relating to any such damage, loss, destruction or
condemnation.

               “Capital Lease Obligations” of any person shall mean the obligations of such person to
pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real
or personal property, or a combination thereof, which obligations are required to be classified and
accounted for as capital leases on a balance sheet of such person under GAAP, and the amount of
such obligations shall be the capitalized amount thereof determined in accordance with GAAP.

               A “Change in Control” shall be deemed to have occurred if (a) any “person” or “group”
(within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934, as amended, as in effect
on the date hereof) shall own, directly or indirectly, beneficially or of record, shares
representing more than 20% of the aggregate ordinary voting power represented by the issued and
outstanding capital stock of the Borrower, (b) a majority of the seats (other than vacant seats) on
the board of directors of the Borrower shall at any time be occupied by persons who were neither
(i) nominated by the board of directors of the Borrower nor (ii) appointed by directors so
nominated, or (c) any change in control (or similar event, however denominated) with respect to the
Borrower or any of the Subsidiaries shall occur under and as defined in any indenture or agreement
in respect of Material Indebtedness to which the Borrower or any Subsidiary is a party.

               “Charges” shall have the meaning assigned to such term in Section 9.09.

               “Class”, when used in respect of any Loan or Borrowing, shall refer to whether such
Loan or Borrowing shall be a Revolving Loan or Borrowing or a Swingline Loan, and, in the case of a
Revolving Loan or Borrowing and, when used in reference to any Commitment, refers to whether such
Commitment is a Revolving Credit Commitment or Swingline Commitment.

               “Code” shall mean the Internal Revenue Code of 1986, as amended from time to time.

6

 

               “Collateral” shall mean all the “Collateral” as defined in any Security Document and
shall also include the Mortgaged Properties.

               “Collateral Agent” shall have the meaning assigned to such term in the preamble to
this Agreement.

               “Commitment” shall mean a Revolving Credit Commitment or Swingline Commitment.

               “Commitment Fee” shall have the meaning assigned to such term in Section 2.07(a).

               “Communications” shall have the meaning assigned to such term in Section 9.01.

               “Confidential Information” shall have the meaning assigned to such term in
Section 9.16.

               “Confidential Information Memorandum” shall mean the Confidential Information
Memorandum of the Borrower dated November 2008.

               “Controlled Deposit Account” shall have the meaning assigned to such term in the
Guarantee and Collateral Agreement.

               “Consolidated EBITDA” shall mean, for any period, Consolidated Net Income for such
period plus (a) without duplication and to the extent deducted in determining such Consolidated Net
Income, the sum of (i) consolidated interest expense for such period, (ii) the aggregate amount of
letter of credit fees paid during such period, (iii) consolidated income tax expense for such
period, (iv) all amounts attributable to depreciation and amortization expense for such period, (v)
all extraordinary charges for such period, (vi) all other non-cash charges (other than the
write-down of current assets) for such period, (vii) all Milestone expenses paid during such
period, (viii) Transaction Fees paid in cash during such period, (ix) all other non-recurring cash
charges incurred for such period in connection with the Merger (including payments to officers,
employees and directors as change of control payments, severance payments, special or retained
bonuses and charges for repurchases or rollover of, or modifications to, stock options); provided
that no more than $75,000,000 in the aggregate may be added back pursuant to this clause during the
term of this Agreement and (x) all other non-recurring cash charges incurred during such period;
provided that no more than $125,000,000 in the aggregate may be added back pursuant to this clause
during the term of this Agreement and minus (b) without duplication (i) all cash payments made
during such period on account of reserves, restructuring charges and other non-cash charges added
to Consolidated Net Income pursuant to clause (a)(vi) above in a previous period and (ii) to the
extent included in determining such Consolidated Net Income, any extraordinary gains and all non-cash

7

 

items of income for such period, all as determined on a consolidated basis with respect
to the Borrower and the Subsidiaries in accordance with GAAP; provided that solely for purposes of
calculating the Leverage Ratio in connection with determining compliance with Section 6.12 for any
period and the Consolidated Interest Expense Coverage Ratio with respect to the first three full
fiscal quarters ended after the Amendment No. 1 Effective Date (A) the Consolidated EBITDA of any
Acquired Entity acquired by the Borrower or any Subsidiary pursuant to a Permitted Acquisition
during such period shall be included on a pro forma basis for such period (assuming the
consummation of such acquisition and the incurrence or assumption of any Indebtedness in connection
therewith occurred as of the first day of such period) and (B) the Consolidated EBITDA of any
person or line of business sold or otherwise disposed of by the Borrower or any Subsidiary during
such period shall be excluded for such period (assuming the consummation of such sale or other
disposition and the repayment of any Indebtedness in connection therewith occurred as of the first
day of such period). For purposes of determining the Consolidated Interest Expense Coverage Ratio
and the Leverage Ratio as of or for the periods ended on March 31, 2009 and June 30, 2009,
Consolidated EBITDA will be deemed to be equal to (i) for the fiscal quarter ended June 30, 2008,
$175,000,000 and (ii) for the fiscal quarter ended September 30, 2008, $189,000,000.

               “Consolidated Interest Expense” shall mean, for any period, the interest expense, both
expensed and capitalized (including the interest component in respect of Capital Lease Obligations
and Synthetic Lease Obligations), accrued or paid by the Borrower and the Subsidiaries during such
period, determined on a consolidated basis in accordance with GAAP. For purposes of the foregoing,
interest expense shall be determined after giving effect to any net payments made or received by
the Borrower and the Subsidiaries with respect to interest rate Hedging Agreements.

               “Consolidated Interest Expense Coverage Ratio” shall mean, for any period, the ratio
of (a) Consolidated EBITDA for such period to (b) Consolidated Interest Expense for such period;
provided that (i) for the purpose of determining the Consolidated Interest Expense Coverage Ratio,
no effect shall be given to FASB Staff Position No. APB 14-1 dated May 9, 2008 and (ii) for the
first three consecutive full fiscal quarters ending on or after the Amendment No. 1 Effective Date,
Consolidated Interest Expense shall be deemed to be equal to (a) the Consolidated Interest Expense
for the first such fiscal quarter, multiplied by 4, (b) the sum of Consolidated Interest Expense
for the first and second such fiscal quarters, multiplied by 2 and (c) the sum of Consolidated
Interest Expense for the first, second and third fiscal quarters ended, multiplied by 4/3,
respectively.

               “Consolidated Net Income” shall mean, for any period, the net income or loss of the
Borrower and the Subsidiaries for such period, as determined on a consolidated basis in accordance with GAAP; provided that there

8

 

shall be
excluded (a) the income of any person (other than the Borrower) in which any other person (other
than the Borrower or a Wholly Owned Subsidiary or any director holding qualifying shares in
accordance with applicable law) has a joint equity interest, except to the extent of the amount of
dividends or other distributions actually paid to the Borrower or a Wholly Owned Subsidiary by such
person during such period, (b) the income of any Subsidiary to the extent that the declaration or
payment of dividends or similar distributions by the Subsidiary of that income is not at the time
permitted by operation of the terms of its charter or any agreement, instrument, judgment, decree,
statute, rule or governmental regulation applicable to such Subsidiary, (c) the income or loss of
any person accrued prior to the date it becomes a Subsidiary or is merged into or consolidated with
the Borrower or any Subsidiary or the date that such person’s assets are acquired by the Borrower
or any Subsidiary, and (d) any gains attributable to sales of assets out of the ordinary course of
business.

               “Control” shall mean the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of a person, whether through the ownership of
voting securities, by contract or otherwise, and the terms “Controlling” and “Controlled” shall
have meanings correlative thereto.

               “Convertible Note Indenture” shall mean the Indenture dated as of March 29, 2006,
between King Pharmaceuticals, Inc., the subsidiary guarantors party thereto and The Bank of New
York Trust Company, N.A., as trustee.

               “Convertible Notes” shall mean 11/4% convertible senior notes
due April 1, 2026, issued pursuant to the Convertible Note Indenture.

               “Co-Documentation Agent” shall have the meaning assigned to such term in the preamble
to this Agreement.

               “Co-Syndication Agent” shall have the meaning assigned to such term in the preamble to
this Agreement.

               “Credit Event” shall have the meaning assigned to such term in Section 4.01.

               “Credit Facilities” shall mean the revolving credit, swingline and letter of credit
facilities provided for by this Agreement.

               “Current Assets” shall mean, at any time, the consolidated current assets (other than
cash and Permitted Investments) of the Borrower and the Subsidiaries.

               “Current Liabilities” shall mean, at any time, the consolidated current liabilities of
the Borrower and the Subsidiaries at such time, but

9

 

excluding, without duplication, (a) the current portion of any long-term Indebtedness and (b)
outstanding Revolving Loans and Swingline Loans.

               “Default” shall mean any event or condition which upon notice, lapse of time or both
would constitute an Event of Default.

               “Defaulting Lender” shall mean (a) any Lender that has (i) defaulted in its obligation
to make a Loan or to fund its participation in a Letter of Credit or Swingline Loan required to be
made or funded by it hereunder, or (ii) notified the Administrative Agent or a Loan Party in
writing that it does not intend to satisfy any such obligation, or (b) any Lender that has become
insolvent, is the subject of any bankruptcy, insolvency, receivership or similar proceedings or the
assets or management of which has been taken over by (or at the direction of) any Governmental
Authority; provided that, for the purpose of Sections 2.03(a) and 2.21(a), “Defaulting Lender”
shall include any Lender that, in the good faith judgment of the Swingline Lender, is reasonably
likely to become a Defaulting Lender; and provided further that, for the purpose of Sections
2.04(a) and 2.21(a), “Defaulting Lender” shall include any Lender that, in the good faith judgment
of the Issuing Bank, is reasonably likely to become a Defaulting Lender.

               “Deposit Account Control Agreement” shall have the meaning assigned to such term in
the Guarantee and Collateral Agreement.

               “Disqualified Stock” shall mean any Equity Interest that, by its terms (or by the
terms of any security into which it is convertible or for which it is exchangeable), or upon the
happening of any event, (a) matures (excluding any maturity as the result of an optional redemption
by the issuer thereof) or is mandatorily redeemable, pursuant to a sinking fund obligation or
otherwise, or is redeemable at the option of the holder thereof, in whole or in part, or requires
the payment of any cash dividend or any other scheduled payment constituting a return of capital,
in each case at any time on or prior to the first anniversary of the Maturity Date, or (b) is
convertible into or exchangeable (unless at the sole option of the issuer thereof) for (i) debt
securities or (ii) any Equity Interest referred to in clause (a) above, in each case at any time
prior to the first anniversary of the Maturity Date; provided that for the purpose of this
definition, the Maturity Date shall be determined without regard to the proviso to the definition
thereof.

               “dollars” or “$” shall mean lawful money of the United States of America.

               “Domestic Subsidiary” shall mean a Subsidiary incorporated or organized under the laws
of the United States of America, any State thereof or the District of Columbia.

10

 

               “Effective Date” shall mean the date on which the conditions set forth in Section 4.02
are satisfied (or waived in accordance with Section 9.08).

               “environment” shall mean ambient air, surface water and groundwater (including potable
water, navigable water and wetlands), the land surface or subsurface strata or as otherwise defined
in any Environmental Law.

               “Environmental Claim” shall mean any written allegation, notice of violation, claim,
demand, order, directive, cost recovery action or other cause of action by, or on behalf of, any
Governmental Authority or any person for damages, injunctive or equitable relief, personal injury
(including sickness, disease or death), Remedial Action costs, tangible or intangible property
damage, natural resource damages, nuisance, pollution, any adverse effect on the environment caused
by any Hazardous Material, or for fines, penalties or restrictions, resulting from or based upon
(a) the existence, or the continuation of the existence, of a Release (including sudden or
non-sudden, accidental or non-accidental Releases), (b) exposure to any Hazardous Material, (c) the
presence, use, handling, generation, transportation, storage, treatment or disposal of any
Hazardous Material or (d) the violation or alleged violation of any Environmental Law or
Environmental Permit.

               “Environmental Law” shall mean any and all applicable present and future treaties,
laws (including common law), rules, regulations, codes, ordinances, orders, decrees, judgments,
injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental
Authority, relating in any way to the environment, preservation or reclamation of natural
resources, the management, Release or threatened Release of or exposure to any Hazardous Material
or to health and safety matters, including, but not limited to, the Comprehensive Environmental
Response, Compensation, and Liability Act of 1980, as amended, 42 U.S.C. § 9601 et seq.
(collectively “CERCLA”), the Solid Waste Disposal Act, as amended by the Resource
Conservation and Recovery Act of 1976 and the Hazardous and Solid Waste Amendments of 1984, 42
U.S.C. § 6901 et seq., the Federal Water Pollution Control Act, as amended, 33 U.S.C. § 1251 et
seq., the Clean Air Act of 1970, as amended, 42 U.S.C. § 7401 et seq., the Toxic Substances Control
Act of 1976, 15 U.S.C. § 2601 et seq., the Occupational Safety and Health Act of 1970, as amended,
29 U.S.C. § 651 et seq., the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.
§ 11001 et seq., the Safe Drinking Water Act of 1974, as amended, 42 U.S.C. § 300(f) et seq., the
Hazardous Materials Transportation Act, 49 U.S.C. § 5101 et seq., the Federal Insecticide,
Fungicide and Rodenticide Act, 7 U.S.C. § 136 et seq., and any similar or implementing foreign,
state or local law, and all amendments or regulations promulgated under any of the foregoing.

               “Environmental Permit” shall mean any permit, approval, authorization, certificate,
license, variance, filing or permission required by or from any Governmental Authority pursuant to
any Environmental Law.

11

 

               “Equity Interests” shall mean shares of capital stock, partnership interests,
membership interests in a limited liability company, beneficial interests in a trust or other
equity ownership interests in any person, and any option, warrant or other right entitling the
holder thereof to purchase or otherwise acquire any such equity interest.

               “Equity Issuance” shall mean any issuance or sale by the Borrower or any Subsidiary of
any Equity Interests of the Borrower or such Subsidiary, as applicable, except in each case for (a)
any issuance or sale to the Borrower or any Subsidiary, (b) any issuance of directors’ qualifying
shares, and (c) sales or issuances of common stock of the Borrower to management or employees of
the Borrower or any Subsidiary under any employee stock incentive, stock option or stock purchase
plan (or other equity-based compensation plan or arrangement) or employee benefit plan in existence
from time to time.

               “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as the same
may be amended from time to time.

               “ERISA Affiliate” shall mean any trade or business (whether or not incorporated) that,
together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the
Code, or solely for purposes of Section 302 of ERISA and Section 412 of the Code, is treated as a
single employer under Section 414 of the Code.

               “ERISA Event” shall mean (a) any “reportable event,” as defined in Section 4043 of
ERISA or the regulations issued thereunder, with respect to a Plan; (b) the adoption of any
amendment to a Plan that would require the provision of security pursuant to Section 401(a)(29) of
the Code or Section 307 of ERISA; (c) the existence with respect to any Plan of an “accumulated
funding deficiency” (as defined in Section 412 of the Code or Section 302 of ERISA), whether or not
waived; (d) the filing pursuant to Section 412(d) of the Code or Section 303(d) of ERISA of an
application for a waiver of the minimum funding standard with respect to any Plan; (e) the
incurrence of any liability under Title IV of ERISA with respect to the termination of any Plan or
the withdrawal or partial withdrawal of the Borrower or any of its ERISA Affiliates from any Plan
or Multiemployer Plan; (f) the receipt by the Borrower or any ERISA Affiliate from the PBGC or a
plan administrator of any notice relating to the intention to terminate any Plan or Plans or to
appoint a trustee to administer any Plan; (g) the receipt by the Borrower or any ERISA Affiliate of any notice concerning the imposition
of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be,
insolvent or in reorganization, within the meaning of Title IV of ERISA; and (h) the occurrence of
a “prohibited transaction” with respect to which the Borrower or any of the Subsidiaries is a
“disqualified person” (within the meaning of Section 4975 of the Code) with respect to which the
Borrower or any such Subsidiary could otherwise have or incur material liabilities.

12

 

               “Eurodollar Borrowing” shall mean a Borrowing comprised of Eurodollar Revolving Loans.

               “Eurodollar Revolving Loan” shall mean any Revolving Loan bearing interest at a rate
determined by reference to the Adjusted LIBO Rate in accordance with the provisions of Article II.

               “Event of Default” shall have the meaning assigned to such term in Article VII.

               “Excess Cash Flow” shall mean, for any fiscal year of the Borrower, the excess of (a)
the sum, without duplication, of (i) Consolidated EBITDA for such fiscal year and (ii) reductions
to non-cash working capital of the Borrower and the Subsidiaries for such fiscal year (i.e., the
decrease, if any, in Current Assets minus Current Liabilities from the beginning to the end of such
fiscal year) over (b) the sum, without duplication, of (i) the amount of any Taxes payable in cash
by the Borrower and the Subsidiaries with respect to such fiscal year, (ii) Consolidated Interest
Expense for such fiscal year paid in cash, (iii) Capital Expenditures made in cash in accordance
with Section 6.10 during such fiscal year, except to the extent financed with the proceeds of
Indebtedness, equity issuances, casualty proceeds, condemnation proceeds or other proceeds that
would not be included in Consolidated EBITDA, (iv) permanent repayments of Indebtedness (other than
mandatory prepayments of Loans under Section 2.13) made in cash by the Borrower and the
Subsidiaries during such fiscal year, but only to the extent that the Indebtedness so prepaid by
its terms cannot be reborrowed or redrawn and such prepayments do not occur in connection with a
refinancing of all or any portion of such Indebtedness, (v) the aggregate amount of letter of
credit fees paid in cash by the Borrower and the Subsidiaries during such fiscal year, (vi) the
aggregate amount of Milestone payments made in cash by the Borrower and the Subsidiaries during
such fiscal year, (vii) to the extent added to Consolidated Net Income in the calculation of
Consolidated EBITDA for such fiscal year, (x) all Transaction Fees paid in cash during such fiscal
year, (y) the aggregate amount of other non-recurring cash charges incurred during such fiscal year
in connection with the Merger (including payments to officers, employees and directors as change of
control payments, severance payments, special or retained bonuses and charges for repurchases or
rollover of, or modifications to, stock options); provided that no more than $75,000,000 in the
aggregate may be deducted pursuant to this clause (y) during the term of this Agreement and (z) the
aggregate amount of other non-recurring cash charges incurred by the Borrower and the Subsidiaries
during such fiscal year; provided that no more than $125,000,000 in the aggregate may be deducted
pursuant to this clause (z) during the term of this Agreement and (viii) additions to non-cash
working capital for such fiscal year (i.e., the increase, if any, in Current Assets minus Current
Liabilities from the beginning to the end of such fiscal year).

13

 

               “Excluded Taxes” shall mean, with respect to the Administrative Agent, any Lender or
Issuing Bank or any other recipient of any payment to be made by or on account of any obligation of
the Borrower hereunder, (a) income or franchise taxes imposed on (or measured by) its net income by
the United States of America, or by the jurisdiction under the laws of which such recipient is
organized or in which its principal office is located or, in the case of any Lender, in which its
applicable lending office is located (provided, however, that none of any Lender or Issuing Bank or
any other recipient shall be deemed to be located in any jurisdiction solely as a result of
receiving any payments under, or taking any other action related to, any loan under this or any
other agreement), (b) any branch profits taxes imposed by the United States of America or any
similar tax imposed by any other jurisdiction described in clause (a) above and (c) in the case of
a Foreign Lender (other than an assignee pursuant to a request by the Borrower under Section 
2.21(a)), any withholding tax that (i) is in effect and would apply to amounts payable to such
Foreign Lender at the time such Foreign Lender becomes a party to this Agreement (or designates a
new lending office), except to the extent that such Foreign Lender (or its assignor, if any) was
entitled, at the time of designation of a new lending office (or assignment), to receive additional
amounts from the Borrower with respect to any withholding tax pursuant to Section 2.20(a) or
(ii) is attributable to such Foreign Lender’s failure to comply with Section 2.20(e).

               “Existing Credit Agreement” shall mean the Credit Agreement dated as of April 23,
2002, as amended by the First Amendment dated as of March 22, 2006, among the Borrower, the lenders
named therein, and Credit Suisse, as administrative agent and collateral agent.

               “Existing Letters of Credit” means the existing letters of credit issued under the
Existing Credit Agreement and listed on Schedule 1.01(a). The Borrower shall be deemed to have
requested the issuance of each Existing Letter of Credit for the purpose hereof.

               “Extraordinary Receipt” shall mean any cash received by or paid to or for the account
of the Borrower or any Subsidiary in respect of any purchase price adjustments or indemnity
payments payable in connection with the Acquisition.

               “Federal Funds Effective Rate” shall mean, for any day, the weighted average (rounded
upwards, if necessary, to the next 1/100 of 1%) of the rates on overnight Federal funds
transactions with members of the Federal Reserve System arranged by Federal funds brokers, as
published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such
rate is not so published for any day that is a Business Day, the average (rounded upwards, if
necessary, to the next 1/100 of 1%) of the quotations for the day for such transactions received by
the Administrative Agent from three Federal funds brokers of recognized standing selected by it.

14

 

               “Fee Letter” shall mean the Fee Letter dated March 5, 2007, among the Borrower, the
Administrative Agent and Credit Suisse.

               “Fees” shall mean the Commitment Fees, the Administrative Agent Fees, the L/C
Participation Fees and the Issuing Bank Fees.

               “Financial Officer” of any person shall mean the chief financial officer, principal
accounting officer, treasurer or controller of such person.

               “Foreign Lender” shall mean any Lender that is organized under the laws of a
jurisdiction other than that in which the Borrower is located. For purposes of this definition,
the United States of America, each State thereof and the District of Columbia shall be deemed to
constitute a single jurisdiction.

               “Foreign Subsidiary” shall mean any Subsidiary that is not a Domestic Subsidiary.

               “Fronting Fee” shall have the meaning assigned to such term in Section 2.07(c).

               “GAAP” shall mean United States generally accepted accounting principles applied on a
consistent basis.

               “Governmental Authority” shall mean any Federal, state, local, foreign or
transnational court or governmental agency, authority, instrumentality or regulatory body.

               “Granting Lender” shall have the meaning assigned to such term in Section 9.04(i).

               “Guarantee” of or by any person shall mean any obligation, contingent or otherwise, of
such person guaranteeing or having the economic effect of guaranteeing any Indebtedness of any
other person (the “primary obligor”) in any manner, whether directly or indirectly, and
including any obligation of such person, direct or indirect, (a) to purchase or pay (or advance or
supply funds for the purchase or payment of) such Indebtedness or to purchase (or to advance or
supply funds for the purchase of) any security for the payment of such Indebtedness, (b) to
purchase or lease property, securities or services for the purpose of assuring the owner of such
Indebtedness of the payment of such Indebtedness or (c) to maintain working capital, equity capital
or any other financial statement condition or liquidity of the primary obligor so as to enable the
primary obligor to pay such Indebtedness; provided, however, that the term “Guarantee” shall not
include endorsements for collection or deposit in the ordinary course of business.

15

 

               “Guarantee and Collateral Agreement” shall mean the Guarantee and Collateral
Agreement, substantially in the form of Exhibit D, among the Borrower, the Subsidiaries party
thereto and the Collateral Agent.

               “Guarantors” shall mean the Subsidiary Guarantors.

               “Hazardous Materials” shall mean all explosive or radioactive substances or wastes,
hazardous or toxic substances or wastes, pollutants, solid, liquid or gaseous wastes, including
petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated
biphenyls (“PCBs”) or PCB containing materials or equipment, radon gas, infectious or
medical wastes and all other substances or wastes of any nature regulated pursuant to any
environmental law.

               “Health Care Laws” shall mean any and all applicable current and future treaties,
laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices or
binding agreements issued, promulgated or entered into by the Food and Drug Administration, the
Center for Medicare and Medicaid Services, the Department of Health and Human Services
(“HHS”), the Office of Inspector General of HHS, the Drug Enforcement Administration or any
other Governmental Authority (including any professional licensing laws, certificate of need laws
and state reimbursement laws), relating in any way to the manufacture, distribution, marketing,
sale, supply or other disposition of any product or service of the Borrower or any Subsidiary, the
conduct of the business of the Borrower or any Subsidiary, the provision of health care services
generally, or to any relationship among the Borrower and the Subsidiaries, on the one hand, and
their suppliers and customers and patients and other end-users of their products and services, on
the other hand.

               “Hedging Agreement” shall mean any interest rate protection agreement, foreign
currency exchange agreement, commodity price protection agreement or other interest or currency
exchange rate or commodity price hedging arrangement.

               “HSR Act” shall mean the Hart-Scott-Rodino Antitrust Improvement Act of 1970.

               “Indebtedness” of any person shall mean, without duplication, (a) all obligations of
such person for borrowed money, (b) all obligations of such person evidenced by bonds, debentures,
notes or similar instruments, (c) all obligations of such person upon which interest charges are
customarily paid, (d) all obligations of such person under conditional sale or other title
retention agreements relating to property or assets purchased by such person, (e) all obligations
of such person issued or assumed as the deferred purchase price of property or services (excluding
trade accounts payable and accrued obligations incurred in the ordinary course of business), (f)
all Indebtedness of others secured

16

 

by (or for which the holder of such Indebtedness has an existing right, contingent or
otherwise, to be secured by) any Lien on property owned or acquired by such person, whether or not
the obligations secured thereby have been assumed, (g) all Guarantees by such person of
Indebtedness of others, (h) all Capital Lease Obligations of such person, (i) all Synthetic Lease
Obligations of such person, (j) net obligations of such person under any Hedging Agreements, valued
at the Agreement Value thereof, (k) all obligations of such person to purchase, redeem, retire,
defease or otherwise make any payment in respect of any Equity Interests of such person or any
other person or any warrants, rights or options to acquire such equity interests, valued, in the
case of redeemable preferred interests, at the greater of its voluntary or involuntary liquidation
preference plus accrued and unpaid dividends, (l) all obligations of such person as an account
party in respect of letters of credit and (m) all obligations of such person in respect of bankers’
acceptances. The Indebtedness of any person shall include the Indebtedness of any partnership in
which such person is a general partner.

               “Indemnified Taxes” shall mean Taxes other than Excluded Taxes.

               “Indemnitee” shall have the meaning assigned to such term in Section 9.05(b).

               “Interest Payment Date” shall mean (a) with respect to any ABR Loan (including any
Swingline Loan), the last Business Day of each March, June, September and December, and (b) with
respect to any Eurodollar Loan, the last day of the Interest Period applicable to the Borrowing of
which such Loan is a part and, in the case of a Eurodollar Borrowing with an Interest Period of
more than three months’ duration, each day that would have been an Interest Payment Date had
successive Interest Periods of three months’ duration been applicable to such Borrowing.

               “Interest Period” shall mean, with respect to any Eurodollar Borrowing, the period
commencing on the date of such Borrowing and ending on the numerically corresponding day in the
calendar month that is 1, 2, 3 or 6 (or, if agreed to by each Lender, 9) months thereafter, as the
Borrower may elect; provided, however, that, (a) if any Interest Period would end on a day other
than a Business Day, such Interest Period shall be extended to the next succeeding Business Day,
unless such next succeeding Business Day would fall in the next calendar month, in which case such
Interest Period shall end on the next preceding Business Day, (b) any Interest Period that begins
on the last Business Day of a calendar month (or on a day for which there is no numerically
corresponding day in the calendar month at the end of such Interest Period) shall end on the last
Business Day of the calendar month at the end of such Interest Period and (c) no Interest Period
for any Loan shall extend beyond the maturity date of such Loan. Interest shall accrue from and
including the first day of an Interest Period to but excluding the last day of such Interest
Period. For purposes hereof, the date of a Borrowing initially shall be the date on which such

17

 

Borrowing is made and thereafter shall be the effective date of the most recent conversion or
continuation of such Borrowing.

               “Issuing Bank” shall mean, at any time, Credit Suisse and each other person that is
listed on Schedule 2.04 or that shall have become an Issuing Bank hereunder as provided in Section
2.04(j) (other than any person that shall have ceased to be an Issuing Bank as provided in Section
2.04(i)), each in its capacity as an issuer of Letters of Credit hereunder.

               “Issuing Bank Agreement” shall have the meaning assigned to such term in Section
2.04(j).

               “Issuing Bank Fees” shall have the meaning assigned to such term in Section 2.07(c).

               “Joint Arrangers” shall mean Credit Suisse Securities (USA) LLC and Wachovia Capital
Markets, LLC.

               “L/C Commitment” shall mean, as to each Issuing Bank, the commitment of such Issuing
Bank to issue Letters of Credit pursuant to Section 2.04. The initial amount of each Issuing
Bank’s L/C Commitment is specified on Schedule 2.04 or in the Issuing Bank Agreement pursuant to
which it shall have become an Issuing Bank.

               “L/C Disbursement” shall mean a payment or disbursement made by an Issuing Bank
pursuant to a Letter of Credit.

               “L/C Exposure” shall mean at any time the sum of (a) the aggregate undrawn amount of
all outstanding Letters of Credit at such time plus (b) the aggregate principal amount of all L/C
Disbursements that have not yet been reimbursed at such time. The L/C Exposure of any Lender at
any time shall mean its Pro Rata Percentage of the aggregate L/C Exposure at such time.

               “L/C Participation Fee” shall have the meaning assigned to such term in
Section 2.07(c).

               “Lenders” shall mean the financial institutions listed on Schedule 2.01 and
any other financial institution that has become a party hereto pursuant to an Assignment and
Acceptance, other than any such financial institution that has ceased to be a party hereto pursuant
to an Assignment and Acceptance. Unless the context clearly indicates otherwise, the term
“Lenders” shall include the Swingline Lender.

               “Letter of Credit” shall mean (i) any letter of credit issued pursuant to Section 2.04
and (ii) the Existing Letters of Credit.

18

 

               “Leverage Ratio” shall mean, on any date, the ratio of (a) Total Funded Debt on such
date to (b) Consolidated EBITDA for the most recently ended period of four fiscal quarters, all as
determined on a consolidated basis in accordance with GAAP.

               “LIBO Rate” shall mean, with respect to any Eurodollar Borrowing for any Interest
Period, the rate per annum determined by the Administrative Agent at approximately 11:00 a.m.,
London time, on the date which is two Business Days prior to the beginning of such Interest Period
by reference to the British Bankers’ Association Interest Settlement Rates for deposits in dollars
(as set forth by any service selected by the Administrative Agent which has been nominated by the
British Bankers’ Association as an authorized information vendor for the purpose of displaying
rates) for a period equal to such Interest Period, provided that, to the extent that an interest
rate is not ascertainable pursuant to the foregoing provisions of this definition, the “LIBO
Rate” shall be the interest rate per annum determined by the Administrative Agent equal to the
average of the rates per annum (rounded upwards, if necessary, to the next 1/16 of 1%) at which
deposits in dollars are offered for such Interest Period by two major banks selected by the
Administrative Agent in the London interbank market at approximately 11:00 a.m., London time, on
the date two Business Days prior to the beginning of such Interest Period. In the event that such
rate is not available at such time for any reason, then the “LIBO Rate” with respect to such
Eurodollar Borrowing for such Interest Period shall be the rate (rounded upwards, if necessary, to
the next 1/16 of 1%) at which dollar deposits of an amount equal to the applicable Loans and for a
maturity comparable to such Interest Period are offered by the principal London office of the
Administrative Agent in immediately available funds in the London interbank market at approximately
11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period.

               “Lien” shall mean, with respect to any asset, (a) any mortgage, deed of trust, lien,
pledge, encumbrance, charge or security interest in or on such asset, (b) the interest of a vendor
or a lessor under any conditional sale agreement, capital lease or title retention agreement (or
any financing lease having substantially the same economic effect as any of the foregoing) relating
to such asset and (c) in the case of securities, any purchase option, call or similar right of a
third party with respect to such securities.

               “Loan Documents” shall mean this Agreement, the Letters of Credit, the Security
Documents, any promissory notes issued pursuant to Section 2.06 and any other document executed in
connection with the foregoing.

               “Loan Parties” shall mean the Borrower and the Subsidiary Guarantors.

               “Loans” shall mean the Revolving Loans and the Swingline Loans.

19

 

               “Managing Agent” shall have the meaning assigned to such term in the preamble to this
Agreement.

               “Margin Stock” shall have the meaning assigned to such term in Regulation U.

               “Material Adverse Effect” shall mean one or more events, changes or effects which,
individually or in the aggregate, have had or could reasonably be expected to have a material
adverse effect on (a) the business, assets, results of operations, condition (financial or
otherwise) or prospects of the Borrower and the Subsidiaries, taken as a whole, (b) the ability of
the Borrower or any other Loan Party to perform any of its obligations under any Loan Document to
which it is or will be a party or (c) the validity or enforceability of any of the Loan Documents
or any other documents entered into in connection with the Transactions or other transactions
contemplated thereby or the rights, remedies and benefits available to the parties thereunder;
provided that solely for the purposes of determining whether the condition in Section 4.01(b) has
been satisfied on the Amendment No. 1 Effective Date, a “Material Adverse Effect” shall be
deemed to have occurred for purposes of Section 3.06(a) if (x) there shall have occurred any event,
change or condition since December 31, 2007 that, individually or in the aggregate, has had, or
could reasonably be expected to have, a material adverse effect on the business, assets,
liabilities, operations, condition (financial or otherwise), operating results, projections or
prospects of the Target and its subsidiaries, taken as a whole, or (y) there shall have occurred
any event, change or condition since December 31, 2007 that, individually or in the aggregate, has
had, or could reasonably be expected to have, a material adverse effect on the business, assets,
liabilities, operations, condition (financial or otherwise), operating results, projections or
prospects of the Borrower and its subsidiaries, taken as a whole. For the avoidance of doubt,
neither a Skelaxin Expiration Event nor a Skelaxin Trigger Event shall constitute a Material
Adverse Effect.

               “Material Foreign Subsidiary” shall mean any Foreign Subsidiary (a) the consolidated
revenues of which for the most recent period of four fiscal quarters of the Borrower for which
audited financial statements have been delivered pursuant to Section 5.04 were greater than 2.5% of
the Borrower’s total consolidated revenues for such period or (b) the consolidated assets of which
as of the end of such period were greater than 2.5% of the Borrower’s total consolidated assets as
of such date.

               “Material Indebtedness” shall mean Indebtedness (other than the Loans and Letters of
Credit), or obligations in respect of one or more Hedging Agreements, of any one or more of the
Borrower or any Subsidiary in an aggregate principal amount exceeding $35,000,000. For purposes of
determining Material Indebtedness, the “principal amount” of the obligations of the Borrower or any
Subsidiary in respect of any Hedging Agreement at any time shall be the Agreement Value of such
Hedging Agreement at such time.

20

 

               “Material Leased Property” shall have the meaning assigned to such term in Section
3.20(b).

               “Maturity Date” shall mean April 19, 2012; provided that, notwithstanding the
foregoing, the Maturity Date shall be October 1, 2011 (or, if such date is not a Business Day, the
immediately preceding Business Day) unless (a) the Convertible Notes shall have been refinanced in
full on terms reasonably satisfactory to the Administrative Agent on or prior to October 1, 2011
and (b) the Administrative Agent shall have notified the Borrower in writing on or prior to October
1, 2011 of the satisfaction of clause (a).

               “Maximum Rate” shall have the meaning assigned to such term in Section 9.09.

               “Merger” shall mean the merger on the Merger Date of Merger Sub with and into Target,
with Target being the surviving entity, in accordance with the Merger Agreement.

               “Merger Agreement” shall mean the Agreement and Plan of Merger dated as of November
23, 2008 among the Borrower, Merger Sub and the Target, as amended from time to time in compliance
with Section 6.09(b).

               “Merger Date” shall mean the date on which the Merger is consummated.

               “Merger Sub” shall mean Albert Acquisition Corp., a wholly owned Delaware subsidiary
of the Borrower.

               “Milestone” shall mean all in-process research and development costs and payments due
upon achievement of certain clinical, regulatory and sales conditions.

               “Moody’s” shall mean Moody’s Investors Service, Inc., or any successor thereto.

               “Mortgaged Properties” shall mean, initially, the owned real properties and leasehold
and subleasehold interests of the Loan Parties specified on Schedule 1.01(c), and shall include
each other parcel of real property and improvements thereto with respect to which a Mortgage is
granted pursuant to Section 5.13.

               “Mortgages” shall mean the mortgages, deeds of trust, leasehold mortgages, assignments
of leases and rents, modifications and other security documents delivered pursuant to Section 3(e)
of Amendment No. 1 or pursuant to Section 5.13, each substantially in the form of Exhibit E.

21

 

               “Multiemployer Plan” shall mean a multiemployer plan as defined in Section 4001(a)(3)
of ERISA.

               “Non-Consenting Lender” means any Lender that withholds its consent to any proposed
amendment, modification or waiver that cannot become effective without the consent of such Lender
under Section 9.08, and that has been consented to by the Required Lenders.

               “Net Cash Proceeds” shall mean (a) with respect to any Asset Sale, the cash proceeds
thereof (including cash proceeds subsequently received (as and when received) in respect of
non-cash consideration initially received), net of (i) selling expenses (including actual broker’s
fees or commissions, legal fees, transfer and similar taxes and the Borrower’s good faith estimate
of income taxes paid or payable in connection with such sale), (ii) amounts provided as a reserve,
in accordance with GAAP, against any liabilities under any indemnification obligations or purchase
price adjustment associated with such Asset Sale (provided that, to the extent and at the time any
such amounts are released from such reserve, such amounts shall constitute Net Cash Proceeds) and
(iii) the principal amount, premium or penalty, if any, interest and other amounts on any
Indebtedness for borrowed money (other than Term Indebtedness) which is secured by the asset sold
in such Asset Sale and which is required to be repaid with such proceeds (other than any such
Indebtedness assumed by the purchaser of such asset); provided, however, that, if (x) the Borrower
shall deliver a certificate of a Financial Officer to the Administrative Agent at the time of
receipt thereof setting forth the Borrower’s intent to reinvest such proceeds in productive assets
of a kind then used or usable in the business of the Borrower and its Subsidiaries within 180 days
of receipt of such proceeds, (y) no Default or Event of Default shall have occurred and shall be
continuing at the time of such certificate or at the proposed time of the application of such
proceeds, and (z) such proceeds are not proceeds of any Required Divestiture, such proceeds shall
not constitute Net Cash Proceeds except to the extent that either (A) such proceeds are not so
used, and no legally binding commitment to so use such proceeds has been entered into with an
entity that is not an Affiliate of the Borrower or its Subsidiaries, on or prior to the end of such
180-day period or (B) a legally binding commitment to so use such proceeds has been entered into on
or prior to the end of such 180-day period with an entity that is not an Affiliate of the Borrower
or its Subsidiaries, but such proceeds are not so used on or prior to the 90th day following the
end of such 180-day period, in either case, at which time such proceeds shall be deemed to be Net
Cash Proceeds; provided further that no cash proceeds of an Asset Sale shall constitute Net Cash
Proceeds until the aggregate amount of all Net Cash Proceeds from Asset Sales (without giving
effect to this proviso) exceeds $5,000,000; (b) with respect to any issuance or incurrence of
Indebtedness or any Equity Issuance or with respect to any ARS Liquidation Event, the cash proceeds
thereof, net of all taxes and customary fees, commissions, costs and other expenses incurred in
connection therewith (and, in

22

 

the case of any ARS Liquidation Event, net of the principal amount, premium or penalty, if
any, interest or other amount on any Permitted ARS Indebtedness which is required to be paid with
such proceeds); and (c) with respect to any Extraordinary Receipt, the cash proceeds thereof;
provided further that for purposes of this definition, an ARS Liquidation Event shall be governed
by clause (b).

               “Obligations” shall mean all obligations defined as “Revolving Secured Obligations” in
the Guarantee and Collateral Agreement and the guarantees thereof set forth in the Guarantee and
Collateral Agreement.

               “OFAC” shall have the meaning assigned to such term in Section 3.24.

               “Other Taxes” shall mean any and all present or future stamp or documentary taxes or
any other excise or property taxes, charges or similar levies arising from any payment made under
any Loan Document from the execution, delivery or enforcement of, or otherwise with respect to, any
Loan Document.

               “Patriot Act” shall have the meaning assigned to such term in Section 9.18.

               “PBGC” shall mean the Pension Benefit Guaranty Corporation referred to and defined in
ERISA.

               “Perfection Certificate” shall have the meaning assigned to such term in the Guarantee
and Collateral Agreement.

               “Permitted Acquisition” shall have the meaning assigned to such term in Section
6.04(l).

               “Permitted ARS Indebtedness” shall mean any Indebtedness of the Borrower or any other
Loan Party that is secured solely by Liens permitted under Section 6.02(o) and that is otherwise on
terms and conditions reasonably satisfactory to the Administrative Agent.

               “Permitted Investments” shall mean:

     (a) direct obligations of, or obligations the principal of and interest on which are
unconditionally guaranteed by, the United States of America (or by any agency thereof to
the extent such obligations are backed by the full faith and credit of the United States
of America), in each case maturing within one year from the date of issuance thereof;

     (b) investments in commercial paper maturing within 270 days from the date of
issuance thereof and having, at the date of acquisition, a

23

 

rating of at least “Prime 1” (or the then equivalent grade) by Moody’s or “A-1” (or
the then equivalent grade) by S&P;

     (c) investments in certificates of deposit, banker’s acceptances and time deposits
maturing within one year from the date of acquisition thereof issued or guaranteed by or
placed with, and money market deposit accounts issued or offered by, the Administrative
Agent, the Collateral Agent or any domestic office of any commercial bank organized under
the laws of the United States of America or any State thereof that has a combined capital
and surplus and undivided profits of not less than $500,000,000 and that issues (or the
parent of which issues) commercial paper rated at least “Prime 1” (or the then equivalent
grade) by Moody’s or “A-1” (or the then equivalent grade) by S&P;

     (d) fully collateralized repurchase agreements with a term of not more than 30 days
for securities described in clause (a) above and entered into with a financial institution
satisfying the criteria of clause (c) above;

     (e) investments in “money market funds” within the meaning of Rule 2a-7 of the
Investment Company Act of 1940, as amended, substantially all of whose assets are invested
in investments of the type described in clauses (a) through (d) above;

     (f) other short-term investments utilized by Foreign Subsidiaries in accordance with
normal investment practices for cash management in investments of a type analogous to the
foregoing; and

     (g) other investment instruments approved in writing by the Required Lenders.

          For the avoidance of doubt, auction rate securities shall not constitute Permitted
Investments.

               “person” shall mean any natural person, corporation, business trust, joint venture,
association, company, limited liability company, partnership, Governmental Authority or other
entity.

               “Plan” shall mean any employee pension benefit plan (other than a Multiemployer Plan)
subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 307 of ERISA,
and in respect of which the Borrower or any ERISA Affiliate is (or, if such plan were terminated,
would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of
ERISA.

24

 

               “Platform” shall have the meaning assigned to such term in Section 9.01.

               “Prime Rate” shall mean the rate of interest per annum announced from time to time by
the Administrative Agent as its prime rate in effect at its principal office in New York City, New
York; each change in the Prime Rate shall be effective on the date such change is announced as
being effective.

               “Properties” shall have the meaning assigned to such term in Section 3.17(a).

               “Pro Rata Percentage” of any Lender at any time shall mean the percentage of the Total
Revolving Credit Commitment represented by such Lender’s Revolving Credit Commitment. In the event
the Revolving Credit Commitments shall have been terminated, the Pro Rata Percentages of the
Lenders shall be determined by reference to the Revolving Credit Commitments most recently in
effect (giving effect to any assignments pursuant to Section 9.04).

               “Public Lender” shall have the meaning assigned to such term in Section 9.01.

               “Qualified Capital Stock” of any person shall mean any Equity Interest of such person
that is not Disqualified Stock.

               “Register” shall have the meaning assigned to such term in Section 9.04(d).

               “Regulation T” shall mean Regulation T of the Board as from time to time in effect and
all official rulings and interpretations thereunder or thereof.

               “Regulation U” shall mean Regulation U of the Board as from time to time in effect and
all official rulings and interpretations thereunder or thereof.

               “Regulation X” shall mean Regulation X of the Board as from time to time in effect and
all official rulings and interpretations thereunder or thereof.

               “Related Fund” shall mean, with respect to any Lender that is a fund that invests in
loans, any other fund that invests in loans and is managed by the same investment advisor as such
Lender or by an Affiliate of such investment advisor.

               “Related Parties” shall mean, with respect to any specified person, such person’s
Affiliates and the respective directors, officers, employees, trustees, agents and advisors of such
person and such person’s Affiliates.

25

 

               “Release” shall mean any spilling, leaking, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, emanating
or migrating of any Hazardous Material in, into, onto or through the environment.

               “Remedial Action” shall mean (a) “remedial action” as such term is defined in CERCLA,
42 U.S.C. Section 9601(24), and (b) all other actions required by any Governmental Authority or
voluntarily undertaken to: (i) clean up, remove, treat, abate or in any other way address any
Hazardous Material in the environment; (ii) prevent the Release or threat of Release, or minimize
the further Release of any Hazardous Material so it does not migrate or endanger or threaten to
endanger public health, welfare or the environment; or (iii) perform studies and investigations in
connection with, or as a precondition to, clause (i) or (ii) above.

               “Required Divestiture” means any Asset Sale required by the applicable Governmental
Authority as a condition to obtaining any approval to, or as a condition to not objecting to,
restraining or preventing, the Acquisition under the HSR Act.

               “Required Lenders” shall mean, at any time, Lenders having Revolving Loans, L/C
Exposures, Swingline Exposures and unused Revolving Credit Commitments representing a majority of
the sum of all outstanding Revolving Loans, L/C Exposures, Swingline Exposures and unused Revolving
Credit Commitments.

               “Responsible Officer” of any person shall mean the chief executive officer, the
president or any Financial Officer of such person and any other officer or similar official thereof
responsible for the administration of the obligations of such person in respect of this Agreement.

               “Restricted Indebtedness” shall mean Indebtedness of the Borrower or any Subsidiary,
the payment, prepayment, repurchase or defeasance of which is restricted under Section 6.09.

               “Restricted Payment” shall mean any dividend or other distribution (whether in cash,
securities or other property) with respect to any Equity Interests in the Borrower or any
Subsidiary, or any payment (whether in cash, securities or other property), including any sinking
fund or similar deposit, on account of the purchase, redemption, retirement, acquisition,
cancellation or termination of any Equity Interests in the Borrower or any Subsidiary.

               “Revolving Borrowing” shall mean a Borrowing comprised of Revolving Loans.

26

 

               “Revolving Credit Commitment” shall mean, with respect to each Lender, the commitment
of such Lender to make Revolving Loans hereunder as set forth on Schedule 2.01, or in the
Assignment and Acceptance pursuant to which such Lender assumed its Revolving Credit Commitment, as
applicable, as the same may be (a) reduced from time to time pursuant to Section 2.11 or 2.13 and
(b) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to
Section 9.04.

               “Revolving Credit Exposure” shall mean, with respect to any Lender at any time, the
aggregate principal amount at such time of all outstanding Revolving Loans of such Lender, plus the
aggregate amount at such time of such Lender’s L/C Exposure, plus the aggregate amount at such time
of such Lender’s Swingline Exposure.

               “Revolving Loans” shall mean the revolving loans made by the Lenders to the Borrower
pursuant to Section 2.01. Each Revolving Loan shall be a Eurodollar Revolving Loan or an ABR
Revolving Loan.

               “S&P” shall mean Standard & Poor’s Ratings Services, or any successor thereto.

               “SEC” shall mean the U.S. Securities and Exchange Commission, or any Governmental
Authority succeeding to any of its principal functions.

               “Secured Parties” shall mean the “Revolving Secured Parties” as defined in the
Guarantee and Collateral Agreement.

               “Security Documents” shall mean the Mortgages, the Guarantee and Collateral Agreement
and each of the security agreements, mortgages and other instruments and documents executed and
delivered pursuant to any of the foregoing or pursuant to Section 5.13.

               “Shares” shall mean all of the issued and outstanding shares of Class A Common Stock,
par value $0.20 per share, together with the associated preferred stock purchase rights, of the
Target.

               “Skelaxin Expiration Event” shall mean that any one or more of the following shall
have occurred: (i) U.S. Patent Nos. 6,407,128, 6,683,102 or any other United States Patent listed
in the Food and Drug Administration’s Orange Book with reference to Skelaxin (the “Skelaxin
Patents”) shall have expired, (ii) any final non-appealable judgment of any court of competent
jurisdiction shall have been entered holding that any Skelaxin Patent is non-infringed, invalid or
unenforceable or (iii) any authorized sale in the United States of a Food and Drug Administration
approved generic product of the same dosage, form and strength as Skelaxin (metaxalone) shall have
occurred.

27

 

               “Skelaxin Trigger Event” shall mean that, as a result of a Skelaxin Expiration Event,
the revenue of the Borrower and the Subsidiaries for any fiscal quarter shall be more than 20% less
than the revenue of the Borrower and the Subsidiaries for the corresponding fiscal quarter of the
prior fiscal year, in each case as determined on a consolidated basis in accordance with GAAP.

               “SPC” shall have the meaning assigned to such term in Section 9.04(i).

               “Specified Share” shall mean (i) at any time following the Term Loan Facility
Termination, 100% and (ii) at any time prior to the Term Loan Facility Termination, a fraction
expressed as a percentage, the numerator of which is the outstanding Revolving Credit Commitment at
such time and the denominator of which is the sum of (x) the outstanding Revolving Credit
Commitment at such time whether used or unused plus (y) the aggregate outstanding amounts of loans
and unused commitment under the Term Loan Credit Agreement at such time.

               “Statutory Reserves” shall mean a fraction (expressed as a decimal), the numerator of
which is the number one and the denominator of which is the number one minus the aggregate of the
maximum reserve percentages (including any marginal, special, emergency or supplemental reserves)
expressed as a decimal established by the Board for Eurocurrency Liabilities (as defined in
Regulation D of the Board). Such reserve percentages shall include those imposed pursuant to such
Regulation D. Eurodollar Revolving Loans shall be deemed to constitute Eurocurrency Liabilities
and to be subject to such reserve requirements without benefit of or credit for proration,
exemptions or offsets that may be available from time to time to any Lender under such
Regulation D. Statutory Reserves shall be adjusted automatically on and as of the effective date
of any change in any reserve percentage.

               “subsidiary” shall mean, with respect to any person (herein referred to as the
“parent”), any corporation, partnership, limited liability company, association or other business
entity (a) of which securities or other ownership interests representing more than 50% of the
equity or more than 50% of the ordinary voting power or more than 50% of the general partnership
interests are, at the time any determination is being made, owned, Controlled or held, or (b) that
is, at the time any determination is made, otherwise Controlled, by the parent or one or more
subsidiaries of the parent or by the parent and one or more subsidiaries of the parent.

               “Subsidiary” shall mean any and all subsidiaries of the Borrower.

               “Subsidiary Guarantor” shall mean each Subsidiary listed on Schedule 1.01(b), and each
other Subsidiary that is or becomes a party to the Guarantee and Collateral Agreement.

28

 

               “Swingline Commitment” shall mean the commitment of the Swingline Lender to make loans
pursuant to Section 2.03, as the same may be reduced from time to time pursuant to Sections 2.11 or
2.13.

               “Swingline Exposure” shall mean at any time the aggregate principal amount at such
time of all outstanding Swingline Loans. The Swingline Exposure of any Lender at any time shall
equal its Pro Rata Percentage of the aggregate Swingline Exposure at such time.

               “Swingline Lender” shall have the meaning assigned to such term in the preamble to
this Agreement.

               “Swingline Loan” shall mean any loan made by the Swingline Lender pursuant to
Section 2.03.

               “Swingline Maturity Date” shall mean, as to any Swingline Loan, the earlier of the
Maturity Date and the date that is 30 days after the date on which such Loan was made.

               “Synthetic Lease” shall mean, as to any person, any lease (including leases that may
be terminated by the lessee at any time) of any property (whether real, personal or mixed) (a) that
is accounted for as an operating lease under GAAP and (b) in respect of which the lessee retains or
obtains ownership of the property so leased for U.S. federal income tax purposes, other than any
such lease under which such person is the lessor.

               “Synthetic Lease Obligations” shall mean, as to any person, an amount equal to the
capitalized amount of the remaining lease payments under any Synthetic Lease that would appear on a
balance sheet of such person in accordance with GAAP if such obligations were accounted for as
Capital Lease Obligations.

               “Synthetic Purchase Agreement” shall mean any swap, derivative or other agreement or
combination of agreements pursuant to which the Borrower or any Subsidiary is or may become
obligated to make (a) any payment in connection with a purchase by any third party from a person
other than the Borrower or any Subsidiary of any Equity Interest or Restricted Indebtedness or (b)
any payment (other than on account of a permitted purchase by it of any Equity Interest or
Restricted Indebtedness) the amount of which is determined by reference to the price or value at
any time of any Equity Interest or Restricted Indebtedness; provided that no phantom stock or
similar plan providing for payments only to current or former directors, officers or employees of
the Borrower or the Subsidiaries (or to their heirs or estates) shall be deemed to be a Synthetic
Purchase Agreement.

               “Target” shall mean Alpharma Inc., a Delaware corporation.

29

 

               “Taxes” shall mean any and all present or future taxes, levies, imposts, duties,
deductions, charges or withholdings imposed by any Governmental Authority.

               “Tender Offer” shall mean the offer to purchase for cash all of the Shares by Merger
Sub pursuant to the Tender Offer Documentation and in accordance with the Merger Agreement.

               “Tender Offer Documentation” shall mean the definitive documents filed with the SEC
with respect to the Tender Offer, including (x) the Offer to Purchase for Cash all outstanding
Shares dated as of September 12, 2008 as extended on October 13, 2008 and further extended on
November 24, 2008 and as modified to reflect the changes thereto set forth in the Merger Agreement
and (y) the related Letter of Transmittal, each as amended from time to time in compliance with
Section 6.09(b).

               “Term Indebtedness” shall mean Indebtedness of the Borrower under the Term Loan Credit
Agreement and all guarantees thereof by any Subsidiary Guarantor and all refinancings, renewals and
extensions thereof that are permitted by Section 6.01(l).

               “Term Liens” shall have the meaning assigned to such term in Section 6.02(r).

               “Term Loan Credit Agreement” shall mean the Term Loan Credit Agreement dated as of the
Amendment No. 1 Effective Date among the Borrower, Credit Suisse as Administrative Agent, and the
other agents and lenders party thereto from time to time, as amended from time to time in
accordance with Section 6.09 and any term loan credit agreement governing any refinancing, renewal
or extension of Indebtedness thereunder as permitted by Section 6.01(l).

               “Term Loan Documents” shall mean the “Loan Documents” under, and as defined in, the
Term Loan Credit Agreement, and any documents governing refinancings, renewals and extensions of
the Indebtedness under the Term Loan Credit Agreement that are permitted by Section 6.01(l).

               “Term Loan Facility Termination” shall occur when all commitments under the Term Loan
Credit Agreement shall have terminated or expired, and the principal of all loans outstanding under
the Term Loan Credit Agreement, and all interest on such loans and all other amounts outstanding
under the Term Loan Credit Agreement (other than contingent indemnification and expense
reimbursement obligations as to which no claim shall have been asserted) shall have been paid in
full.

               “Term Refinanced Indebtedness” shall have the meaning assigned to such term in Section
6.01(l).

30

 

               “Term Refinancing Indebtedness” shall have the meaning assigned to such term in
Section 6.01(l).

               “Total Funded Debt” shall mean, as of any date of determination, without duplication,
the aggregate principal amount of Indebtedness of the Borrower and the Subsidiaries outstanding as
of such date (other than Indebtedness of the type referred to in clauses (i), (j), (k) and (l) of
the definition of such term, except, (x) in the case of such clause (j), to the extent of the
Agreement Value of any Hedging Agreement that has been terminated and (y) in the case of such
clause (l), to the extent of any unreimbursed drawings thereunder).

               “Total Revolving Credit Commitment” shall mean, at any time, the aggregate amount of
the Revolving Credit Commitments, as in effect at such time.

               “Transaction Fees” means fees or expenses in an aggregate amount not exceeding
$70,000,000 for the term of this Agreement incurred or paid by Borrower or any Subsidiary in
connection with the Transactions.

               “Transactions” shall mean, collectively, (a) the execution, delivery and performance
by the Borrower and Merger Sub of the Merger Agreement and the consummation of the Merger and the
other transactions contemplated thereby, (b) the consummation of the Tender Offer, (c) the
execution, delivery and performance by the Loan Parties of the Loan Documents and the Term Loan
Documents to which they are a party and the making of the borrowings hereunder or thereunder and
(d) the payment of related fees and expenses.

               “Type”, when used in respect of any Loan or Borrowing, shall refer to the Rate by
reference to which interest on such Loan or on the Loans comprising such Borrowing is determined.
For purposes hereof, the term “Rate” shall include the Adjusted LIBO Rate and the Alternate
Base Rate.

               “Uniform Commercial Code” shall mean the Uniform Commercial Code in effect from time
to time in the State of New York; provided, however, that if by reason of mandatory provisions of
law, the perfection or the effect of perfection or non-perfection of the security interest in any
item or portion of the Collateral is governed by the Uniform Commercial Code as in effect in a
jurisdiction other than the State of New York, “Uniform Commercial Code” shall mean the
Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions
hereof relating to such perfection or effect of perfection or non-perfection.

               “Uniform Customs” shall have the meaning assigned to such term in Section 9.07.

31

 

          “Wholly Owned Subsidiary” of any person shall mean a subsidiary of such person of
which securities (except for directors’ qualifying shares) or other ownership interests
representing 100% of the Equity Interests are, at the time any determination is being made, owned,
Controlled or held by such person or one or more wholly owned Subsidiaries of such person or by
such person and one or more wholly owned Subsidiaries of such person.

          “Withdrawal Liability” shall mean liability to a Multiemployer Plan as a result of a
complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of
Subtitle E of Title IV of ERISA.

          “Withdrawal Certificate” shall have the meaning assigned to such term in Section 5.16.

          SECTION 1.02. Terms Generally. The definitions in Section 1.01 shall apply equally to both
the singular and plural forms of the terms defined. Whenever the context may require, any pronoun
shall include the corresponding masculine, feminine and neuter forms. The words “include”,
“includes” and “including” shall be deemed to be followed by the phrase “without limitation”. The
word “will” shall be construed to have the same meaning and effect as the word “shall”. All
references herein to Articles, Sections, Exhibits and Schedules shall be deemed references to
Articles and Sections of, and Exhibits and Schedules to, this Agreement unless the context shall
otherwise require. Except as otherwise expressly provided herein, (a) any reference in this
Agreement to any Loan Document shall mean such document as amended, restated, supplemented or
otherwise modified from time to time, in each case in accordance with the express terms of this
Agreement, (b) any reference to any statute, regulation or other law shall be construed (i) as
referring to such statute, regulation or other law as from time to time amended, supplemented or
otherwise modified (including by succession of comparable successor statutes, regulations or other
laws) and (ii) to include all official rulings and interpretations thereunder, (c) any reference
herein to any person shall be construed to include such person’s successors and assigns, (d) the
words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer
to this Agreement in its entirety and not to any particular provision hereof, (e) the words
“assets” or “property” shall be construed to have the same meaning and effect and to refer to any
and all tangible and intangible assets and properties, including cash, securities, accounts and
contract rights and (f) all terms of an accounting or financial nature shall be construed in
accordance with GAAP, as in effect from time to time; provided, however, that, if the Borrower
notifies the Administrative Agent that the Borrower requests an amendment to any provision hereof
to eliminate the effect of any change occurring after the Amendment No. 1 Effective Date in GAAP or
in the application thereof on the operation of such provision (or if the Administrative Agent
notifies the Borrower that the Required Lenders request an amendment to any provision hereof for
such purpose), regardless of whether any such notice is given before or after such change in GAAP
or in the

32

 

application thereof, then such provision shall be interpreted on the basis of GAAP as in effect and
applied immediately before such change shall have become effective until such notice shall have
been withdrawn or such provision amended in accordance herewith.

          SECTION 1.03. Pro Forma Calculations. All computations required to be made hereunder to
demonstrate pro forma compliance with any covenant after giving effect to any acquisition,
investment, sale, disposition or similar event shall reflect on a pro forma basis such event and,
to the extent applicable, the historical earnings and cash flows associated with the assets
acquired or disposed of and any related incurrence or reduction of Indebtedness, but shall not take
into account any projected synergies or similar benefits expected to be realized as a result of
such event; provided that projected synergies or similar benefits may be included to the extent
permitted to be recognized in pro forma statements prepared in accordance with Regulation S-X under
the Securities Act.

ARTICLE II

The Credits

          SECTION 2.01. Commitments. Subject to the terms and conditions and relying upon the
representations and warranties herein set forth, each Lender agrees, severally and not jointly, to
make Revolving Loans to the Borrower, at any time and from time to time on or after the Effective
Date and until the earlier of the Maturity Date and the termination of the Revolving Credit
Commitment of such Lender in accordance with the terms hereof, in an aggregate principal amount at
any time outstanding that will not result in such Lender’s Revolving Credit Exposure exceeding such
Lender’s Revolving Credit Commitment. Within the limits set forth in the preceding sentence and
subject to the terms, conditions and limitations set forth herein, the Borrower may borrow, pay or
prepay and reborrow Revolving Loans.

          SECTION 2.02. Loans. (a) Each Loan (other than Swingline Loans) shall be made as part of a
Borrowing consisting of Loans made by the Lenders ratably in accordance with their applicable
Commitments; provided, however, that the failure of any Lender to make any Loan shall not in itself
relieve any other Lender of its obligation to lend hereunder (it being understood, however, that no
Lender shall be responsible for the failure of any other Lender to make any Loan required to be
made by such other Lender). Except for Loans deemed made pursuant to paragraph (f) below, the
Loans comprising any Borrowing shall be in an aggregate principal amount that is (i) an integral
multiple of $1,000,000 and not less than $1,000,000 or (ii) equal to the remaining available
balance of the Revolving Credit Commitments.

33

 

          (b) Subject to Sections 2.10 and 2.15, each Borrowing (other than Swingline Loans) shall
be comprised entirely of ABR Loans or Eurodollar Revolving Loans as the Borrower may request
pursuant to Section 2.05. Each Swingline Loan shall be an ABR Loan. Each Lender may at its
option make any Eurodollar Revolving Loan by causing any domestic or foreign branch or
Affiliate of such Lender to make such Loan; provided that any exercise of such option shall
not affect the obligation of the Borrower to repay such Loan in accordance with the terms of
this Agreement. Borrowings of more than one Type may be outstanding at the same time;
provided, however, that the Borrower shall not be entitled to request any Borrowing that, if
made, would result in more than ten Eurodollar Borrowings being outstanding hereunder at any
time. For purposes of the foregoing, Borrowings having different Interest Periods,
regardless of whether they commence on the same date, shall be considered separate
Borrowings.

          (c) Except with respect to Loans made pursuant to paragraph (f) below, each Lender shall
make each Loan to be made by it hereunder on the proposed date thereof by wire transfer of
immediately available funds to such account in New York City as the Administrative Agent may
designate not later than 12:00 (noon), New York City time, and the Administrative Agent shall
promptly credit the amounts so received to an account in the name of the Borrower designated
by the Borrower in the applicable Borrowing Request (or, in the case of Loans made on the
Effective Date, first apply such amounts to pay amounts outstanding under the Existing Credit
Agreement) or, if a Borrowing shall not occur on such date because any condition precedent
herein specified shall not have been met, return the amounts so received to the respective
Lenders.

          (d) Unless the Administrative Agent shall have received notice from a Lender prior to
the date of any Borrowing that such Lender will not make available to the Administrative
Agent such Lender’s portion of such Borrowing, the Administrative Agent may assume that such
Lender has made such portion available to the Administrative Agent on the date of such
Borrowing in accordance with paragraph (c) above and the Administrative Agent may, in
reliance upon such assumption, make available to the Borrower on such date a corresponding
amount. If the Administrative Agent shall have so made funds available then, to the extent
that such Lender shall not have made such portion available to the Administrative Agent, such
Lender and the Borrower severally agree to repay to the Administrative Agent forthwith on
demand such corresponding amount together with interest thereon for each day from the date
such amount is made available to the Borrower until the date such amount is repaid to the
Administrative Agent at (i) in the case of the Borrower, the interest rate applicable at the
time to the Loans comprising such Borrowing (which payment shall not

34

 

constitute a waiver of, or otherwise adversely affect, the Borrower’s rights against
such Lender, if any) and (ii) in the case of such Lender, a rate determined by the
Administrative Agent to represent its cost of overnight or short-term funds (which
determination shall be conclusive absent manifest error). If such Lender shall repay to the
Administrative Agent such corresponding amount, such amount shall constitute such Lender’s
Loan as part of such Borrowing for purposes of this Agreement.

          (e) Notwithstanding any other provision of this Agreement, the Borrower shall not be
entitled to request any Borrowing or the conversion or continuation of any Borrowing if the
Interest Period requested with respect thereto would end after the Maturity Date.

          (f) If the applicable Issuing Bank shall not have received from the Borrower the payment
required to be made by Section 2.04(e) in respect of any L/C Disbursement within the time
specified in such Section, such Issuing Bank will promptly notify the Administrative Agent of
the amount of such L/C Disbursement and the Administrative Agent will promptly notify each
Lender of such amount and its Pro Rata Percentage thereof. Each Lender shall pay by wire
transfer of immediately available funds to the Administrative Agent not later than 2:00 p.m.,
New York City time, on such date (or, if such Lender shall have received such notice later
than 12:00 (noon), New York City time, on any day, not later than 11:00 a.m., New York City
time, on the immediately following Business Day), an amount equal to such Lender’s Pro Rata
Percentage of such L/C Disbursement (it being understood that (i) if the conditions precedent
to borrowing set forth in Sections 4.01(b) and 4.01(c) have been satisfied, such amount shall
be deemed to constitute an ABR Revolving Loan of such Lender and, to the extent of such
payment, the obligations of the Borrower in respect of such L/C Disbursement shall be
discharged and replaced with the resulting ABR Borrowing, and (ii) if such conditions
precedent to borrowing have not been satisfied, then any such amount paid by any Lender shall
not constitute a Loan and shall not relieve the Borrower from its obligation to reimburse
such L/C Disbursement), and the Administrative Agent will promptly pay to such Issuing Bank
amounts so received by it from the Lenders. The Administrative Agent will promptly pay to
such Issuing Bank any amounts received by it from the Borrower pursuant to Section 2.04(e)
prior to the time that any Lender makes any payment pursuant to this paragraph (f); any such
amounts received by the Administrative Agent thereafter will be promptly remitted by the
Administrative Agent to the Lenders that shall have made such payments and to such Issuing
Bank, as their interests may appear. If any Lender shall not have made its Pro Rata
Percentage of such L/C Disbursement available to the Administrative Agent as provided above,
such Lender and the Borrower severally agree to pay interest on such amount, for each day
from and including the date such

35

 

amount is required to be paid in accordance with this paragraph to but excluding the
date such amount is paid, to the Administrative Agent for the account of such Issuing Bank at
(i) in the case of the Borrower, a rate per annum equal to the interest rate applicable to
ABR Revolving Loans pursuant to Section 2.08(a) (which payment shall not constitute a waiver
of, or otherwise adversely affect, the Borrower’s rights against such Lender, if any) and
(ii) in the case of such Lender, for the first such day, the Federal Funds Effective Rate,
and for each day thereafter, the Alternate Base Rate.

          SECTION 2.03. Swingline Loans. (a) Swingline Commitment. Subject to the terms and
conditions and relying upon the representations and warranties herein set forth, the Swingline
Lender agrees to make loans to the Borrower at any time and from time to time on and after the
Effective Date and until the earlier of the Maturity Date and the termination of the Revolving
Credit Commitments in accordance with the terms hereof, in an aggregate principal amount at any
time outstanding that will not result in (i) the aggregate principal amount of all Swingline Loans
exceeding $20,000,000 or (ii) the Aggregate Revolving Credit Exposure, after giving effect to any
Swingline Loan, exceeding the Total Revolving Credit Commitment; provided that the Swingline Lender
shall not make a Swingline Loan to refinance an outstanding Swingline Loan. Each Swingline Loan
shall be in a principal amount that is an integral multiple of $500,000. Within the foregoing
limits, the Borrower may borrow, pay or prepay and reborrow Swingline Loans hereunder, subject to
the terms, conditions and limitations set forth herein. Notwithstanding anything to the contrary
contained in this Section 2.03 or elsewhere in this Agreement, (i) the Swingline Lender shall not
be obligated to make any Swingline Loan at a time when a Lender is a Defaulting Lender unless the
Swingline Lender has entered into arrangements satisfactory to it and the Borrower to eliminate the
Swingline Lender’s risk with respect to the Defaulting Lender’s or Defaulting Lenders’
participation in such Swingline Loans, including by cash collateralizing such Defaulting Lender’s
or Defaulting Lenders’ Pro Rata Percentage of the outstanding Swingline Loans, and (ii) the
Swingline Lender shall not make any Swingline Loan after it has received written notice from the
Borrower, any other Loan Party or the Required Lenders stating that a Default or an Event of
Default exists and is continuing until such time as the Swingline Lender shall have received
written notice (A) of rescission of all such notices from the party or parties originally
delivering such notice or notices or (B) of the waiver of such Default or Event of Default in
accordance with Section 9.08(b).

          (b) Swingline Loans. The Borrower shall notify the Swingline Lender (with a
copy to the Administrative Agent) by facsimile, or by telephone (promptly confirmed by
facsimile), not later than 10:00 a.m., New York City time, on the day of a proposed Swingline
Loan. Such notice shall be delivered on a Business Day, shall be irrevocable, shall refer to
this Agreement and shall specify the requested date (which shall be a Business

36

 

Day) and amount of such Swingline Loan. The Swingline Lender shall make each Swingline
Loan available to the Borrower by means of a credit to the general deposit account of the
Borrower with the Swingline Lender by 2:00 p.m., New York City time, on the day such
Swingline Loan is so requested.

          (c) Prepayment. The Borrower shall have the right at any time and from time to
time to prepay any Swingline Loan, in whole or in part, upon giving irrevocable written or
facsimile notice (or telephone notice promptly confirmed by written, or facsimile notice) to
the Swingline Lender (with a copy to the Administrative Agent) before 12:00 (noon), New York
City time, on the date of prepayment at the Swingline Lender’s address for notices specified
on Schedule 2.01.

          (d) Interest. Each Swingline Loan shall be an ABR Loan and, subject to the
provisions of Section 2.09, shall bear interest as provided in Section 2.08(a).

          (e) Participations. The Swingline Lender may, by written notice given to the
Administrative Agent not later than 10:00 a.m., New York City time, on any Business Day, in
its sole discretion, require the Lenders to acquire participations on such Business Day in
all or a portion of the Swingline Loans outstanding; provided that such notice shall be
deemed to have been automatically given upon the occurrence of a Default or an Event of
Default under Article VII(g) or Article VII(h)) or upon the exercise of any of the remedies
provided in the last paragraph of Article VII. Such notice shall specify the aggregate
amount of Swingline Loans in which Lenders will participate. The Administrative Agent will,
promptly upon receipt of such notice, give notice to each Lender, specifying in such notice
such Lender’s Pro Rata Percentage of such Swingline Loan or Loans. In furtherance of the
foregoing, each Lender hereby irrevocably, absolutely and unconditionally agrees, upon
receipt of notice as provided above, to pay to the Administrative Agent, for the account of
the Swingline Lender, such Lender’s Pro Rata Percentage of such Swingline Loan or Loans.
Each Lender acknowledges and agrees that its obligation to acquire participations in
Swingline Loans pursuant to this paragraph is irrevocable, absolute and unconditional and
shall not be affected by any circumstance whatsoever, including the occurrence and
continuance of a Default or an Event of Default or the termination of the Revolving Credit
Commitments, and that each such payment shall be made without any offset, abatement,
withholding or reduction whatsoever. Each Lender shall comply with its obligation under this
paragraph by wire transfer of immediately available funds, in the same manner as provided in
Section 2.02(c) with respect to Loans made by such Lender (and Section 2.02(c) shall apply,
with the necessary changes, to the payment obligations of the Lenders) and the Administrative
Agent shall promptly pay to the Swingline Lender the amounts so received by it from the

37

 

Lenders. The Administrative Agent shall notify the Borrower of any participations in
any Swingline Loan acquired pursuant to this paragraph and thereafter payments in respect of
such Swingline Loan shall be made to the Administrative Agent and not to the Swingline
Lender. Any amounts received by the Swingline Lender from the Borrower in respect of a
Swingline Loan after receipt by the Swingline Lender of the proceeds of a sale of
participations therein shall be promptly remitted to the Administrative Agent; any such
amounts received by the Administrative Agent shall be promptly remitted by the Administrative
Agent to the Lenders that shall have made their payments pursuant to this paragraph and to
the Swingline Lender, as their interests may appear. The purchase of participations in a
Swingline Loan pursuant to this paragraph shall not relieve the Borrower of any default in
the payment thereof.

          SECTION 2.04. Letters of Credit. (a) General. (i) The Borrower may request the
issuance of a Letter of Credit (A) for its own account or (B) for the account of any Subsidiary, in
a form reasonably acceptable to the Administrative Agent and the applicable Issuing Bank, at any
time and from time to time on and after the Effective Date while the Revolving Credit Commitments
remain in effect. This Section shall not be construed to impose an obligation upon any Issuing
Bank to issue any Letter of Credit that is inconsistent with the terms and conditions of this
Agreement. Notwithstanding anything to the contrary contained in this Section 2.04 or elsewhere in
this Agreement, in the event that a Lender is a Defaulting Lender, no Issuing Bank shall be
required to issue any Letter of Credit unless such Issuing Bank has entered into arrangements
satisfactory to it and the Borrower to eliminate such Issuing Bank’s risk with respect to the
participation in Letters of Credit by all such Defaulting Lenders, including by cash
collateralizing each such Defaulting Lender’s Pro Rata Percentage of each L/C Disbursement. The
Borrower unconditionally and irrevocably agrees that, in connection with any Letter of Credit
referred to in clause (B) of the first sentence of this paragraph, it will be fully responsible for
the reimbursement of L/C Disbursements, the payment of interest thereon and the payment of L/C
Participation Fees and other fees due under Section 2.07 to the same extent as if it were the sole
account party in respect of such Letter of Credit (the Borrower hereby irrevocably waiving any
defenses that might otherwise be available to it as a guarantor of the obligations of any
Subsidiary that shall be an account party in respect of any such Letter of Credit).

          (ii) On the Effective Date, each Issuing Bank that has issued an Existing Letter of
Credit shall be deemed, without further action by any party hereto, to have granted to each
Lender and each Lender shall be deemed to have purchased from such Issuing Bank a
participation in such Existing Letter of Credit in accordance with paragraph (d) below. On
and after the Effective Date, each Existing Letter of Credit shall constitute a Letter of
Credit for all purposes hereof. Any Lender that issued an Existing Letter of

38

 

Credit but shall not have entered into an Issuing Bank Agreement shall have the rights of an
Issuing Bank as to such Letter of Credit for purposes of this Section 2.04.

          (b) Notice of Issuance; Amendment, Renewal, Extention; Certain Conditions. In
order to request the issuance of a Letter of Credit (or to amend, renew or extend an existing
Letter of Credit), the Borrower shall hand deliver or facsimile to the applicable Issuing
Bank and the Administrative Agent (reasonably in advance of the requested date of issuance,
amendment, renewal or extension) a notice requesting the issuance of a Letter of Credit, or
identifying the Letter of Credit to be amended, renewed or extended, the date of issuance,
amendment, renewal or extension, the date on which such Letter of Credit is to expire (which
shall comply with paragraph (c) below), the amount of such Letter of Credit, the name and
address of the beneficiary thereof and such other information as shall be necessary to
prepare such Letter of Credit. A Letter of Credit shall be issued, amended, renewed or
extended only if, and upon issuance, amendment, renewal or extension of each Letter of Credit
the Borrower shall be deemed to represent and warrant that, after giving effect to such
issuance, amendment, renewal or extension (A) the L/C Exposure shall not exceed $40,000,000,
(B) the Aggregate Revolving Credit Exposure shall not exceed the Total Revolving Credit
Commitment and (C) the portion of the L/C Exposure attributable to Letters of Credit of the
Issuing Bank requested to issue or amend, renew or extend such Letter of Credit shall not
exceed the L/C Commitment of such Issuing Bank.

          (c) Expiration Date. Each Letter of Credit shall expire at the close of
business on the earlier of (i) the date one year after the date of the issuance of such
Letter of Credit and (ii) the date that is five Business Days prior to the Maturity Date,
unless such Letter of Credit expires by its terms on an earlier date; provided that any
Letter of Credit may provide for renewal thereof under customary “evergreen” provisions
reasonably satisfactory to the applicable Issuing Bank for additional one-year periods (which
shall in no event extend beyond the date referred to in clause (ii) above).

          (d) Participations. By the issuance of a Letter of Credit and without any
further action on the part of the applicable Issuing Bank or the Lenders, the applicable
Issuing Bank hereby grants to each Lender, and each such Lender hereby acquires from the
applicable Issuing Bank, a participation in such Letter of Credit equal to such Lender’s Pro
Rata Percentage of the aggregate amount available to be drawn under such Letter of Credit,
effective upon the issuance of such Letter of Credit. In consideration and in furtherance of
the foregoing, each Lender hereby irrevocably, absolutely and unconditionally agrees to pay
to the Administrative Agent, for the account of the applicable Issuing Bank, such

39

 

Lender’s Pro Rata Percentage of each L/C Disbursement made by each Issuing Bank and not
reimbursed by the Borrower forthwith on the date due as provided in Section 2.02(f). Each
Lender acknowledges and agrees that its obligation to acquire participations pursuant to this
paragraph in respect of Letters of Credit is irrevocable, absolute and unconditional and
shall not be affected by any circumstance whatsoever, including the occurrence and
continuance of a Default or an Event of Default or the termination of the Revolving Credit
Commitments, and that each such payment shall be made without any offset, abatement,
withholding or reduction whatsoever.

          (e) Reimbursement. If an Issuing Bank shall make any L/C Disbursement in
respect of a Letter of Credit, the Borrower shall pay or cause the Subsidiary for whose
account such Letter of Credit shall have been issued to pay to the Administrative Agent an
amount equal to such L/C Disbursement not later than two hours after the Borrower shall have
received notice from the Issuing Bank that payment of such draft will be made, or, if the
Borrower shall have received such notice later than 10:00 a.m., New York City time, on any
Business Day, not later than 10:00 a.m., New York City time, on the immediately following
Business Day.

          (f) Obligations Absolute. The Borrower’s obligations to reimburse L/C
Disbursements as provided in paragraph (e) above shall be absolute, unconditional and
irrevocable, and shall be performed strictly in accordance with the terms of this Agreement,
under any and all circumstances whatsoever, and irrespective of:

     (i) any lack of validity or enforceability of any Letter of Credit or any
Loan Document, or any term or provision therein;

     (ii) any amendment or waiver of or any consent to departure from all or any
of the provisions of any Letter of Credit or any Loan Document;

     (iii) the existence of any claim, setoff, defense or other right that the
Borrower, any other party guaranteeing, or otherwise obligated with, the
Borrower, any Subsidiary or other Affiliate thereof or any other person may at
any time have against the beneficiary under any Letter of Credit, any Issuing
Bank, the Administrative Agent or any Lender or any other person, whether in
connection with this Agreement, any other Loan Document or any other related or
unrelated agreement or transaction;

     (iv) any draft or other document presented under a Letter of Credit proving
to be forged, fraudulent, invalid or insufficient in any respect or any statement
therein being untrue or inaccurate in any respect;

40

 

     (v) payment by any Issuing Bank under a Letter of Credit against
presentation of a draft or other document that does not comply with the terms of
such Letter of Credit; and

     (vi) any other act, or omission to act, or delay of any kind of any Issuing
Bank, the Lenders, the Administrative Agent or any other person or any other
event or circumstance whatsoever, whether or not similar to any of the foregoing,
that might, but for the provisions of this Section, constitute a legal or
equitable discharge of the Borrower’s obligations hereunder.

          Without limiting the generality of the foregoing, it is expressly understood and agreed that
the absolute and unconditional obligation of the Borrower hereunder to reimburse L/C Disbursements
will not be excused by the gross negligence or willful misconduct of the Issuing Banks. However,
the foregoing shall not be construed to excuse any Issuing Bank from liability to the Borrower to
the extent of any direct damages (as opposed to consequential damages, claims in respect of which
are hereby waived by the Borrower to the extent permitted by applicable law) suffered by the
Borrower that are caused by such Issuing Bank’s gross negligence or willful misconduct in
determining whether drafts and other documents presented under a Letter of Credit comply with the
terms thereof; it is understood that any Issuing Bank may accept documents that appear on their
face to be in substantial compliance with the terms of a Letter of Credit, without responsibility
for further investigation, and make payment under such Letter of Credit, unless, in the Issuing
Bank’s judgment, it has received information that proves any such documents to be forged or
fraudulent; provided that the Issuing Bank shall not be liable in any respect for any error made as
a result of, or damages resulting from, the exercise of its judgment with regard to any such
documents if such judgment is made in good faith. The parties hereto expressly agree that (i) such
Issuing Bank’s exclusive reliance on the documents presented to it under such Letter of Credit as
to any and all matters set forth therein, including reliance on the amount of any draft presented
under a Letter of Credit, whether or not the amount due to the beneficiary thereunder equals the
amount of such draft and whether or not any document presented pursuant to the Letter of Credit
proves to be insufficient in any respect, if such document on its face appears to be in substantial
compliance with the terms of the Letter of Credit, and whether or not any other statement or any
other document presented pursuant to the Letter of Credit proves to be forged, fraudulent or
invalid or any statement therein proves to be inaccurate or untrue in any respect whatsoever and
(ii) any noncompliance in any immaterial respect of the documents presented under the Letter of
Credit with the terms thereof shall, in each case, be deemed not to constitute willful misconduct
or gross negligence of the applicable Issuing Bank.

          (g) Disbursement Procedures. The applicable Issuing Bank shall, promptly
following its receipt thereof, examine all documents

41

 

purporting to represent a demand for payment under a Letter of Credit. The Issuing Bank
shall as promptly as possible give telephonic notification, confirmed by facsimile, to the
Administrative Agent and the Borrower of such demand for payment and whether the Issuing Bank
has made or will make an L/C Disbursement thereunder; provided that any failure to give or
delay in giving such notice shall not relieve the Borrower of its obligation to reimburse the
Issuing Bank and the Lenders with respect to any such L/C Disbursement. The Administrative
Agent shall promptly give each Lender notice thereof.

          (h) Interim Interest. If an Issuing Bank shall make any L/C Disbursement in
respect of a Letter of Credit, then, unless the Borrower shall reimburse such L/C
Disbursement in full on such date, the unpaid amount thereof shall bear interest for the
account of the Issuing Bank, for each day from and including the date of such L/C
Disbursement, to but excluding the earlier of the date of payment by the Borrower or the date
on which interest shall commence to accrue thereon as provided in Section 2.02(f), at the
rate per annum that would apply to such amount if such amount were an ABR Loan.

          (i) Resignation or Removal of an Issuing Bank. An Issuing Bank may resign at
any time by giving 90 days’ prior written notice to the Administrative Agent, the Lenders and
the Borrower, and may be removed at any time by the Borrower by notice to such Issuing Bank,
the Administrative Agent and the Lenders. Upon the acceptance of any appointment as an
Issuing Bank hereunder by a Lender that shall agree to serve as a successor Issuing Bank,
such successor shall succeed to and become vested with all the interests, rights and
obligations of such retiring Issuing Bank. Upon the resignation or removal of an Issuing
Bank hereunder, such Issuing Bank shall be discharged from its obligations to issue
additional Letters of Credit hereunder. At the time such resignation or removal shall become
effective, the Borrower shall pay all fees accrued for the account of the Issuing Bank under
Section 2.07(c)(ii) and not yet paid. After the resignation or removal of an Issuing Bank
hereunder, such Issuing Bank shall remain a party hereto and shall continue to have all the
rights and obligations of an Issuing Bank under this Agreement and the other Loan Documents
with respect to Letters of Credit issued by it prior to such resignation or removal, but
shall not be required to issue additional Letters of Credit.

          (j) Designation of Additional Issuing Banks. From time to time, the Borrower
may by notice to the Administrative Agent and the Lenders designate one or more Lenders (with
the consent of each such Lender) reasonably acceptable to the Administrative Agent as
additional Issuing Banks. The acceptance by a Lender of any appointment as an Issuing Bank
hereunder shall be evidenced by an agreement (an “Issuing 

42

 

Bank Agreement”), which shall be in a form satisfactory to the Borrower and the
Administrative Agent, shall set forth the L/C Commitment and Issuing Bank Fees of such Lender
and shall be executed by such Lender, the Borrower and the Administrative Agent and, from and
after the effective date of such agreement, (i) such Lender shall have all the rights and
obligations of an Issuing Bank under this Agreement and the other Loan Documents and (ii)
references herein and in the other Loan Documents to the term “Issuing Bank” shall be deemed
to include such Lender in its capacity as an Issuing Bank. Any Lender designated as an
issuing bank pursuant to this paragraph (j) shall be deemed to be an “Issuing Bank” (in
addition to being a Lender) in respect of Letters of Credit issued or to be issued by such
Lender, and, with respect to such Letters of Credit, such term shall thereafter apply to the
other Issuing Bank and such Lender.

          (k) Cash Collateralization. If any Event of Default shall occur and be
continuing, the Borrower shall, on the Business Day it receives notice from the
Administrative Agent or the Required Lenders (or, if the maturity of the Loans has been
accelerated, Lenders holding participations in outstanding Letters of Credit representing
greater than 50% of the aggregate undrawn amount of all outstanding Letters of Credit)
thereof, deposit in an account with the Collateral Agent, for the benefit of the Lenders, an
amount in cash equal to the L/C Exposure as of such date; provided that the obligation to
deposit such cash collateral shall become effective immediately, and such deposit shall
become immediately due and payable in immediately available funds, without demand or other
notice of any kind, upon the occurrence of any Event of Default with respect to the Borrower
described in clause (g) or (h) of Article VII. Such deposit shall be held by the Collateral
Agent as collateral for the payment and performance of the Obligations. The Collateral Agent
shall have exclusive dominion and control, including the exclusive right of withdrawal, over
such account. Other than any interest earned on the investment of such deposits in Permitted
Investments, which investments shall be made at the option and sole discretion of the
Collateral Agent, such deposits shall not bear interest. Interest or profits, if any, on
such investments shall accumulate in such account. Moneys in such account shall
(i) automatically be applied by the Administrative Agent to reimburse the Issuing Banks for
L/C Disbursements for which they have not been reimbursed, (ii) be held for the satisfaction
of the reimbursement obligations of the Borrower for the L/C Exposure at such time and
(iii) if the maturity of the Loans has been accelerated (but subject to the consent of
Lenders holding participations in outstanding Letters of Credit representing greater than 50%
of the aggregate undrawn amount of all outstanding Letters of Credit), be applied to satisfy
the Obligations. If the Borrower is required to provide an amount of cash collateral
hereunder as a result of the occurrence of an Event of Default, such amount (to the extent

43

 

not applied as aforesaid) shall be returned to the Borrower within three Business Days
after all Events of Default have been cured or waived.

          (l) Issuing Bank Reports. Unless otherwise agreed by the Administrative Agent,
each Issuing Bank shall report in writing to the Administrative Agent (i) on or prior to each
Business Day on which such Issuing Bank issues, amends, renews or extends any Letter of
Credit, the date of such issuance, amendment, renewal or extension, and the face amounts of
the Letters of Credit issued, amended, renewed or extended by it and outstanding after giving
effect to such issuance, amendment, renewal or extension (and whether the amounts thereof
shall have changed), it being understood that such Issuing Bank shall not effect any
issuance, renewal, extension or amendment resulting in an increase in the aggregate amount of
the Letters of Credit issued by it without first obtaining written confirmation from the
Administrative Agent that such increase is then permitted under this Agreement, (ii) on each
Business Day on which such Issuing Bank makes any L/C Disbursement, the date, currency and
amount of such L/C Disbursement, (iii) on any Business Day on which the applicable Borrower
fails to reimburse an L/C Disbursement required to be reimbursed to such Issuing Bank on such
day, the date of such failure and the currency and amount of such L/C Disbursement and
(iv) on any other Business Day, such other information as the Administrative Agent shall
reasonably request as to the Letters of Credit issued by such Issuing Bank.

          SECTION 2.05. Borrowing Procedure. In order to request a Borrowing (other than a Swingline
Loan, or a deemed Borrowing pursuant to Section 2.02(f), as to which this Section 2.05 shall not
apply), the Borrower shall notify the Administrative Agent of such request by telephone (a) in the
case of a Eurodollar Borrowing, not later than 12:00 (noon), New York City time, three Business
Days before a proposed Borrowing, and (b) in the case of an ABR Borrowing, not later than 12:00
(noon), New York City time, one Business Day before a proposed Borrowing. Each such telephonic
Borrowing Request shall be irrevocable, and shall be confirmed promptly by hand delivery or
facsimile to the Administrative Agent of a written Borrowing Request and shall specify the
following information: (i) whether such Borrowing is to be a Eurodollar Borrowing or an ABR
Borrowing; (ii) the date of such Borrowing (which shall be a Business Day), (iii) the number and
location of the account to which funds are to be disbursed; (iv) the amount of such Borrowing; and
(v) if such Borrowing is to be a Eurodollar Borrowing, the Interest Period with respect thereto;
provided, however, that, notwithstanding any contrary specification in any Borrowing Request, each
requested Borrowing shall comply with the requirements set forth in Section 2.02. If no election
as to the Type of Borrowing is specified in any such notice, then the requested Borrowing shall be
an ABR Borrowing. If no Interest Period with respect to any Eurodollar Borrowing is specified in
any such notice, then the Borrower shall be deemed to have selected an Interest Period of

44

 

one month’s duration. The Administrative Agent shall promptly advise the applicable Lenders of any
notice given pursuant to this Section 2.05 (and the contents thereof), and of each Lender’s portion
of the requested Borrowing.

          SECTION 2.06. Evidence of Debt; Repayment of Loans. (a) The Borrower hereby
unconditionally promises to pay to the Administrative Agent for the account of each Lender (i) the
then unpaid principal amount of each Revolving Loan on the Maturity Date and (ii) the then unpaid
principal amount of each Swingline Loan on the applicable Swingline Maturity Date.

          (b) Each Lender shall maintain in accordance with its usual practice an account or
accounts evidencing the indebtedness of the Borrower to such Lender resulting from each Loan
made by such Lender from time to time, including the amounts of principal and interest
payable and paid to such Lender from time to time under this Agreement.

          (c) The Administrative Agent shall maintain accounts in which it will record (i) the
amount of each Loan made hereunder, the Class and Type thereof and, if a Eurodollar Revolving
Loan, the Interest Period applicable thereto, (ii) the amount of any principal or interest
due and payable or to become due and payable from the Borrower to each Lender hereunder and
(iii) the amount of any sum received by the Administrative Agent hereunder from the Borrower
or any Guarantor and each Lender’s share thereof.

          (d) The entries made in the accounts maintained pursuant to paragraphs (b) and (c) above
shall be prima facie evidence of the existence and amounts of the obligations therein
recorded; provided, however, that the failure of any Lender or the Administrative Agent to
maintain such accounts or any error therein shall not in any manner affect the obligation of
the Borrower to repay the Loans in accordance with their terms.

          (e) Any Lender may request that Loans made by it be evidenced by a promissory note. In
such event, the Borrower shall prepare, execute and deliver to such Lender a promissory note
payable to such Lender and its registered assigns and in a form and substance reasonably
acceptable to the Administrative Agent and the Borrower. Notwithstanding any other provision
of this Agreement, in the event any Lender shall request and receive such a promissory note,
the interests represented by such note shall at all times (including after assignment
pursuant to Section 9.04) be represented by one or more promissory notes payable to the payee
named therein or its registered assigns.

          SECTION 2.07. Fees. (a) The Borrower agrees to pay to each Lender, through the
Administrative Agent, on the last Business Day of March, June, September and December in each year
and on the date on which the last of

45

 

the Commitments of such Lender shall expire or be terminated as provided herein, a commitment fee
(a “Commitment Fee”) equal to the Applicable Percentage per annum on the daily unused
amount of the Revolving Credit Commitment of such Lender during the preceding quarter (or other
period commencing with the date hereof or ending with the date on which the last of the Commitments
of such Lender shall expire or be terminated). All Commitment Fees shall be computed on the basis
of the actual number of days elapsed in a year of 360 days. The Commitment Fee due to each Lender
shall commence to accrue on the date hereof and shall cease to accrue on the date on which the last
of the Commitments of such Lender shall expire or be terminated as provided herein. For purposes
of calculating Commitment Fees only, no portion of the Revolving Credit Commitments shall be deemed
utilized by virtue of any Swingline Loan being outstanding.

          (b) The Borrower agrees to pay to the Administrative Agent, for its own account, the
administrative fees set forth in the Fee Letter at the times and in the amounts specified
therein (the “Administrative Agent Fees”).

          (c) The Borrower agrees to pay (i) to each Lender, through the Administrative Agent, on
the last Business Day of March, June, September and December of each year and on the date on
which the Revolving Credit Commitment of such Lender shall be terminated as provided herein,
a fee (an “L/C Participation Fee”) calculated on such Lender’s Pro Rata Percentage of
the daily aggregate L/C Exposure (excluding the portion thereof attributable to unreimbursed
L/C Disbursements) during the preceding quarter (or shorter period commencing with the date
hereof or ending with the Maturity Date or the date on which all Letters of Credit have been
canceled or have expired and the Revolving Credit Commitments of all Lenders shall have been
terminated) at a rate equal to the Applicable Percentage from time to time used to determine
the interest rate on Borrowings comprised of Eurodollar Revolving Loans pursuant to
Section 2.08 and (ii) to each Issuing Bank with respect to each Letter of Credit issued
thereby (A) on the last Business Day of March, June, September and December of each year and
on the date on which all Letters of Credit issued by such Issuing Bank have been canceled or
have expired, a fronting fee equal to a percentage per annum (as shall be agreed upon by the
Borrower and such Issuing Bank) of the average daily aggregate face amount, during the
preceding quarter (or shorter period, as provided above), of all outstanding Letters of
Credit issued by such Issuing Bank (the “Fronting Fee”) and (B) the standard,
issuance, drawing and amendment fees specified from time to time by such Issuing Bank
(together with the Fronting Fee, the “Issuing Bank Fees”). All L/C Participation
Fees and Fronting Fees shall be computed on the basis of the actual number of days elapsed in
a year of 360 days.

46

 

          (d) All Fees shall be paid on the dates due, in immediately available funds, to the
Administrative Agent for distribution, if and as appropriate, among the Lenders, except that
the Issuing Bank Fees shall be paid directly to the applicable Issuing Banks. Once paid,
none of the Fees shall be refundable under any circumstances; provided, however, that the
foregoing shall in no event constitute a waiver of or otherwise affect any claims the
Borrower may have against any other party to this Agreement.

          SECTION 2.08. Interest on Loans. (a) Subject to the provisions of Section 2.09, the Loans
comprising each ABR Borrowing, including each Swingline Loan, shall bear interest (computed on the
basis of the actual number of days elapsed over a year of 365 or 366 days, as the case may be, when
the Alternate Base Rate is determined by reference to the Prime Rate and over a year of 360 days at
all other times) at a rate per annum equal to the Alternate Base Rate plus the Applicable
Percentage.

          (b) Subject to the provisions of Section 2.09, the Loans comprising each Eurodollar
Borrowing shall bear interest (computed on the basis of the actual number of days elapsed
over a year of 360 days) at a rate per annum equal to the Adjusted LIBO Rate for the Interest
Period in effect for such Borrowing plus the Applicable Percentage.

          (c) Interest on each Loan shall be payable on the Interest Payment Dates applicable to
such Loan except as otherwise provided in this Agreement. The applicable Alternate Base Rate
for any day or Adjusted LIBO Rate for each Interest Period or day within an Interest Period,
as the case may be, shall be determined by the Administrative Agent, and such determination
shall be conclusive absent manifest error.

          SECTION 2.09. Default Interest. If the Borrower shall default in the payment of the
principal of or interest on any Loan or any other amount becoming due hereunder, by acceleration or
otherwise, or under any other Loan Document, the Borrower shall on demand from time to time pay
interest, to the extent permitted by law, on such defaulted amount to but excluding the date of
actual payment (after as well as before judgment) (a) in the case of overdue principal, at the rate
otherwise applicable to such Loan pursuant to Section 2.08 plus 2% per annum and (b) in all other
cases, at the rate per annum applicable at such time to ABR Loans plus 2% per annum.

          SECTION 2.10. Alternate Rate of Interest. In the event and on each occasion that on the
day two Business Days prior to the commencement of any Interest Period for a Eurodollar Borrowing
the Administrative Agent shall have determined that dollar deposits in the principal amounts of the
Loans comprising such Borrowing are not generally available in the London interbank market, or that
the rates at which such dollar deposits are being offered will not exceed the cost to any Lender of
making or maintaining its Eurodollar Revolving

47

 

Loan during such Interest Period, or that reasonable means do not exist for ascertaining the
Adjusted LIBO Rate, the Administrative Agent shall, as soon as practicable thereafter, give written
or facsimile notice (which, in the case of a facsimile notice, shall be followed by a written
notice) of such determination to the Borrower and the Lenders. In the event of any such
determination, until the Administrative Agent shall have advised the Borrower and the Lenders that
the circumstances giving rise to such notice no longer exist, any request by the Borrower for a
Eurodollar Borrowing pursuant to Section 2.05 or 2.12 shall be deemed to be a request for an
ABR Borrowing. Each determination by the Administrative Agent hereunder shall be conclusive absent
manifest error.

          SECTION 2.11. Termination and Reduction of Commitments. (a)The Revolving Credit
Commitments, the Swingline Commitment and the L/C Commitments shall automatically terminate at
5:00 p.m., New York City time, on the Maturity Date.

          (b) Upon at least three Business Days’ prior irrevocable written or facsimile notice to
the Administrative Agent, the Borrower may at any time in whole permanently terminate, or
from time to time in part permanently reduce the Revolving Credit Commitments; provided,
however, that (i) each partial reduction of the Revolving Credit Commitments shall be in an
integral multiple of $1,000,000 and in a minimum amount of $5,000,000 and (ii) the Total
Revolving Credit Commitment shall not be reduced to an amount that is less than the Aggregate
Revolving Credit Exposure at the time.

          SECTION 2.12. Conversion and Continuation of Borrowings. The Borrower shall have the right
at any time upon prior irrevocable notice to the Administrative Agent (a) not later than
12:00 (noon), New York City time, one Business Day prior to conversion, to convert any Eurodollar
Borrowing into an ABR Borrowing, (b) not later than 12:00 (noon), New York City time, three
Business Days prior to conversion or continuation, to convert any ABR Borrowing (other than a
Swingline Loan) into a Eurodollar Borrowing or to continue any Eurodollar Borrowing as a Eurodollar
Borrowing for an additional Interest Period, and (c) not later than 12:00 (noon), New York City
time, three Business Days prior to conversion, to convert the Interest Period with respect to any
Eurodollar Borrowing to another permissible Interest Period, subject in each case to the following:

     (i) each conversion or continuation shall be made pro rata among the Lenders
in accordance with the respective principal amounts of the Loans comprising the
converted or continued Borrowing;

     (ii) if less than all the outstanding principal amount of any Borrowing
shall be converted or continued, then each resulting

48

 

Borrowing shall satisfy the limitations specified in Sections 2.02(a)
and (b) regarding the principal amount and maximum number of Borrowings of the
relevant Type;

     (iii) each conversion shall be effected by each Lender and the
Administrative Agent by recording for the account of such Lender the new Loan of
such Lender resulting from such conversion and reducing the Loan (or portion
thereof) of such Lender being converted by an equivalent principal amount;
accrued interest on any Eurodollar Revolving Loan (or portion thereof) being
converted shall be paid by the Borrower at the time of conversion;

     (iv) if any Eurodollar Borrowing is converted at a time other than the end
of the Interest Period applicable thereto, the Borrower shall pay, upon demand,
any amounts due to the Lenders pursuant to Section 2.16;

     (v) any portion of a Borrowing maturing or required to be repaid in less
than one month may not be converted into or continued as a Eurodollar Borrowing;

     (vi) any portion of a Eurodollar Borrowing that cannot be converted into or
continued as a Eurodollar Borrowing by reason of the immediately preceding clause
shall be automatically converted at the end of the Interest Period in effect for
such Borrowing into an ABR Borrowing;

     (vii) upon notice to the Borrower from the Administrative Agent, which may
be given at the request of any Lender, after the occurrence and during the
continuance of a Default or Event of Default, no outstanding Loan may be
converted into, or continued at the end of the applicable Interest Period as, a
Eurodollar Revolving Loan.

          Each notice pursuant to this Section shall be irrevocable and shall refer to this Agreement
and specify (i) the identity and amount of the Borrowing that the Borrower requests be converted or
continued, (ii) whether such Borrowing is to be converted to or continued as a Eurodollar Borrowing
or an ABR Borrowing, (iii) if such notice requests a conversion, the date of such conversion (which
shall be a Business Day) and (iv) if such Borrowing is to be converted to or continued as a
Eurodollar Borrowing, the Interest Period with respect thereto. If no Interest Period is specified
in any such notice with respect to any conversion to or continuation as a Eurodollar Borrowing, the
Borrower shall be deemed to have selected an Interest Period of one month’s duration. The
Administrative Agent shall advise the Lenders of any notice given pursuant to this Section and of
each Lender’s portion of any converted or continued Borrowing.

49

 

If the Borrower shall not have given notice in accordance with this Section to continue any
Borrowing into a subsequent Interest Period (and shall not otherwise have given notice in
accordance with this Section to convert such Borrowing), such Borrowing shall, at the end of the
Interest Period applicable thereto (unless repaid pursuant to the terms hereof), automatically be
continued into a new Interest Period as an ABR Borrowing.

          SECTION 2.13. Voluntary Prepayment; Mandatory Prepayments and Commitment Reductions.
(a)The Borrower shall have the right at any time and from time to time to prepay any Borrowing, in
whole or in part, upon at least three Business Days’ prior written or facsimile notice (or
telephone notice promptly confirmed by written or fax notice) in the case of Eurodollar Loans, or
written or fax notice (or telephone notice promptly confirmed by written or fax notice) at least
one Business Day prior to the date of prepayment in the case of ABR Loans, to the Administrative
Agent before 12:00 (noon), New York City time; provided, however, that each partial prepayment
shall be in an amount that is an integral multiple of $1,000,000 and not less than $1,000,000.

          (b) Each notice of voluntary prepayment shall specify the prepayment date and the
principal amount of each Borrowing (or portion thereof) to be prepaid, shall be irrevocable
and shall commit the Borrower to prepay such Borrowing by the amount stated therein on the
date stated therein. All prepayments (whether voluntary or mandatory) under this Section
shall be subject to Section 2.16 but otherwise without premium or penalty. All prepayments
(whether voluntary or mandatory) under this Section 2.13 shall be accompanied by accrued and
unpaid interest on the principal amount being prepaid to but excluding the date of payment.

          (c) In the event of any termination of all the Revolving Credit Commitments, the
Borrower shall, on the date of such termination, repay or prepay all its outstanding
Revolving Loans and all outstanding Swingline Loans and replace or cause to be canceled (or
make other arrangements satisfactory to the Administrative Agent and each Issuing Bank with
respect to) all outstanding Letters of Credit issued by such Issuing Bank. If, after giving
effect to any partial reduction of the Revolving Credit Commitments (including for the
avoidance of doubt, any mandatory or scheduled commitment reduction pursuant to this
Section 2.13) or at any other time, the Aggregate Revolving Credit Exposure would exceed the
Total Revolving Credit Commitment, then the Borrower shall, on the date of such reduction or
at such other time, repay or prepay Revolving Borrowings or Swingline Loans (or a combination
thereof) and, after the Revolving Borrowings and Swingline Loans shall have been repaid or
prepaid in full, replace or cause to be canceled (or make other arrangements satisfactory to
the Administrative Agent and each Issuing Bank with respect to) Letters of Credit issued by
such Issuing Bank in an amount sufficient to eliminate such excess.

50

 

          (d) Subject to clause (l) below, on each date set forth below or, if such date is not a
Business Day, on the next preceding Business Day, the Revolving Credit Commitments shall be
automatically and permanently reduced to the amount set forth below for such date (in each
case unless permanently reduced to or below such amount prior to such date).

	 	 	 	 	 
	Step-Down Date	 	Amount
	March 31, 2009
	 	$	457,187,500	 
	June 30, 2009
	 	$	439,375,000	 
	September 30, 2009
	 	$	421,562,500	 
	December 31, 2009
	 	$	403,750,000	 
	March 31, 2010
	 	$	380,000,000	 
	June 30, 2010
	 	$	356,250,000	 
	September 30, 2010
	 	$	332,500,000	 
	December 31, 2010
	 	$	308,750,000	 
	March 31, 2011
	 	$	285,000,000	 
	June 30, 2011
	 	$	261,250,000	 
	September 30, 2011
	 	$	237,500,000	 
	December 31, 2011
	 	$	213,750,000	 
	March 31, 2012
	 	$	190,000,000	 

          (e) Subject to clause (l) below, in the event and on each occasion that Borrower or any
Subsidiary receives Net Cash Proceeds from any Asset Sale, the Revolving Credit Commitments
shall be automatically and permanently reduced on the Applicable Commitment Reduction Date by
an amount equal to (i) the Specified Share multiplied by (ii) the amount of such Net Cash
Proceeds.

          (f) Subject to clause (l) below, in the event and on each occasion that, following the
Term Loan Facility Termination, the Borrower or any Subsidiary receives Net Cash Proceeds
from any Equity Issuance, the Revolving Credit Commitments shall be automatically and
permanently reduced on the Applicable Commitment Reduction Date by an amount equal to 50% of
the amount of such Net Cash Proceeds.

          (g) Subject to clause (l) below, on each Applicable Commitment Reduction Date with
respect to Excess Cash Flow prepayments, the Revolving Credit Commitments shall be
automatically and permanently reduced by an amount equal to 50% of Excess Cash Flow for

51

 

the fiscal year then ended; provided that the percentage referred to above shall be
reduced to 25% if (1) the Leverage Ratio at the end of such fiscal year is less than 1.75 to
1.0 and (2) no Default or Event of Default shall have occurred and be continuing on such
Applicable Commitment Reduction Date.

          (h) Subject to clause (l) below, in the event and on every occasion that, following the
Term Loan Facility Termination, the Borrower or any Subsidiary receives Net Cash Proceeds
from the issuance or incurrence of Indebtedness for money borrowed (other than any cash
proceeds from the issuance of Indebtedness for money borrowed permitted pursuant to
Section 6.01), the Revolving Credit Commitments shall be automatically and permanently
reduced on the Applicable Commitment Reduction Date by an amount equal to the amount of such
Net Cash Proceeds.

          (i) Subject to clause (l) below, in the event and on every occasion that the Borrower or
any Subsidiary shall receive Net Cash Proceeds from any ARS Liquidation Event, the Revolving
Credit Commitments shall be automatically and permanently reduced on the Applicable
Commitment Reduction Date by an amount equal to (i) the Specified Share multiplied by (ii)
100% of such Net Cash Proceeds.

          (j) Subject to clause (l) below, in the event and on every occasion that, following the
Term Loan Facility Termination, the Borrower or any Subsidiary shall receive Net Cash
Proceeds from any Extraordinary Receipt, the Revolving Credit Commitments shall be
automatically and permanently reduced on the Applicable Commitment Reduction Date by an
amount equal to the amount of such Net Cash Proceeds.

          (k) The Borrower shall deliver to the Administrative Agent, at the time of each
Commitment reduction required under clauses (e) through (j) of this Section 2.13, a
certificate signed by a Financial Officer of the Borrower setting forth in reasonable detail
the calculation of the amount of such reduction and any prepayment of Loans or arrangements
with respect to Letters of Credit required pursuant to clause (c) hereof in connection with
such reduction. The Borrower shall provide at least three days’ prior written notice of such
reduction and prepayment specifying the Applicable Commitment Reduction Date and, if
applicable, the Type of each Loan being prepaid and the principal amount of each Loan (or
portion thereof) to be prepaid or arrangements required to be made with respect to Letters of
Credit.

          (l) No reduction in Revolving Credit Commitments shall be required pursuant to clauses
(d) through (j) of this Section 2.13 to the extent that immediately after giving effect to
such reduction the aggregate

52

 

amount of the Revolving Credit Commitments would be less than $150,000,000.

          SECTION 2.14. Reserve Requirements; Change in Circumstances. (a) Notwithstanding any
other provision of this Agreement, if after the date of this Agreement any change in applicable law
or regulation or in the interpretation or administration thereof by any Governmental Authority
charged with the interpretation or administration thereof (whether or not having the force of law)
shall change the basis of taxation of payments to any Lender or Issuing Bank of the principal of or
interest on any Eurodollar Revolving Loan made by such Lender or any Fees or other amounts payable
hereunder (other than changes in respect of taxes imposed on the overall net income of such Lender
or Issuing Bank by the jurisdiction in which such Lender or Issuing Bank has either its principal
office or applicable lending office or by any political subdivision or taxing authority therein),
or shall impose, modify or deem applicable any reserve, special deposit or similar requirement
against assets of, deposits with or for the account of or credit extended by any Lender or Issuing
Bank (except any such reserve requirement which is reflected in the Adjusted LIBO Rate) or shall
impose on such Lender or Issuing Bank or the London interbank market any other condition affecting
this Agreement or Eurodollar Revolving Loans made by such Lender or any Letter of Credit or
participation therein, and the result of any of the foregoing shall be to increase the cost to such
Lender or Issuing Bank of making or maintaining any Eurodollar Revolving Loan or increase the cost
to any Lender of issuing or maintaining any Letter of Credit or purchasing or maintaining a
participation therein or to reduce the amount of any sum received or receivable by such Lender or
Issuing Bank hereunder (whether of principal, interest or otherwise) by an amount determined in
good faith by such Lender or Issuing Bank to be material, then the Borrower will pay to such Lender
or Issuing Bank, as the case may be, upon demand such additional amount or amounts as will
compensate such Lender or Issuing Bank, as the case may be, for such additional costs incurred or
reduction suffered.

          (b) If any Lender or Issuing Bank shall have determined that the adoption after the date
hereof of any law, rule, regulation, agreement or guideline regarding capital adequacy, or
any change after the date hereof in any such law, rule, regulation, agreement or guideline
(whether such law, rule, regulation, agreement or guideline has been adopted) or in the
interpretation or administration thereof by any Governmental Authority charged with the
interpretation or administration thereof, or compliance by any Lender (or any lending office
of such Lender) or Issuing Bank or any Lender’s or Issuing Bank’s holding company with any
request or directive regarding capital adequacy (whether or not having the force of law) of
any Governmental Authority has or would have the effect of reducing the rate of return on
such Lender’s or the Issuing Bank’s capital or on the capital of such Lender’s or Issuing
Bank’s holding company, if any, as a consequence

53

 

of this Agreement or the Loans made or participations in Letters of Credit purchased by
such Lender pursuant hereto or the Letters of Credit issued by such Issuing Bank pursuant
hereto to a level below that which such Lender or Issuing Bank or such Lender’s or Issuing
Bank’s holding company could have achieved but for such applicability, adoption, change or
compliance (taking into consideration such Lender’s or Issuing Bank’s policies and the
policies of such Lender’s or Issuing Bank’s holding company with respect to capital adequacy)
by an amount deemed by such Lender or Issuing Bank to be material, then from time to time the
Borrower shall pay to such Lender or Issuing Bank, as the case may be, such additional amount
or amounts as will compensate such Lender or Issuing Bank or such Lender’s or Issuing Bank’s
holding company for any such reduction suffered.

          (c) A certificate of a Lender or Issuing Bank setting forth the amount or amounts
necessary to compensate such Lender or Issuing Bank or its holding company, as applicable, as
specified in paragraph (a) or (b) above, together with an explanation in reasonable detail,
shall be delivered to the Borrower. In determining any additional amounts owing under this
SectionSECTION 2.14, each Lender or Issuing Bank will act reasonably and in good faith and
will use averaging and attribution methods which are reasonable; provided that such Lender’s
or Issuing Bank’s determination of compensation owing under this SectionSECTION 2.14 shall,
absent manifest error, unreasonableness or bad faith, be final and conclusive and binding on
all parties hereto. The Borrower shall pay such Lender or Issuing Bank the amount shown as
due on any such certificate delivered by it within 15 days after its receipt of the same;
provided that if the Borrower shall reasonably dispute such amount, the amount due shall be
paid within three Business Days after such dispute is resolved.

          (d) Failure or delay on the part of any Lender or Issuing Bank to demand compensation
for any increased costs or reductions in amounts received or receivable or reduction in
return on capital shall not constitute a waiver of such Lender’s or Issuing Bank’s right to
demand such compensation; provided that the Borrower shall not be required to compensate a
Lender or Issuing Bank pursuant to this Section for any increased costs or reductions
incurred more than 90 days prior to the date that such Lender or Issuing Bank, as the case
may be, notifies the Borrower of the change in law or other circumstance giving rise to such
increased costs or reductions and of such Lender’s or Issuing Bank’s intention to claim
compensation therefor; provided further that, if the change in law or other circumstance
giving rise to such increased costs or reductions is retroactive, then the 90 day period
referred to above shall be extended to include the period of retroactive effect thereof. The
protection of this Section shall be available to each Lender and Issuing Bank regardless of
any possible contention of the invalidity or inapplicability of the law, rule, regulation,

54

 

agreement, guideline or other change or condition that shall have occurred or been
imposed.

          SECTION 2.15. Change in Legality. (a) Notwithstanding any other provision of this
Agreement, if, after the date hereof, any change in any law or regulation or in the interpretation
thereof by any Governmental Authority charged with the administration or interpretation thereof
shall make it unlawful for any Lender to make or maintain any Eurodollar Revolving Loan or to give
effect to its obligations as contemplated hereby with respect to any Eurodollar Revolving Loan,
then, by written notice to the Borrower and to the Administrative Agent:

     (i) such Lender may declare that Eurodollar Revolving Loans will not
thereafter (for the duration of such unlawfulness) be made by such Lender
hereunder (or be continued for additional Interest Periods) and ABR Loans will
not thereafter (for such duration) be converted into Eurodollar Revolving Loans,
whereupon any request for a Eurodollar Borrowing (or to convert an ABR Borrowing
to a Eurodollar Borrowing or to continue a Eurodollar Borrowing for an additional
Interest Period) shall, as to such Lender only, be deemed a request for an ABR
Loan (or a request to continue an ABR Loan as such for an additional Interest
Period or to convert a Eurodollar Revolving Loan into an ABR Loan, as the case
may be), unless such declaration shall be subsequently withdrawn; and

     (ii) such Lender may require that all outstanding Eurodollar Revolving Loans
made by it be converted to ABR Loans, in which event all such Eurodollar
Revolving Loans shall be automatically converted to ABR Loans as of the effective
date of such notice as provided in paragraph (b) below.

In the event any Lender shall exercise its rights under clause (i) or (ii) above, all payments and
prepayments of principal that would otherwise have been applied to repay the Eurodollar Revolving
Loans that would have been made by such Lender or the converted Eurodollar Revolving Loans of such
Lender shall instead be applied to repay the ABR Loans made by such Lender in lieu of, or resulting
from the conversion of, such Eurodollar Revolving Loans.

          (b) For purposes of this Section 2.15, a notice to the Borrower by any Lender shall be
effective as to each Eurodollar Revolving Loan made by such Lender, if lawful, on the last
day of the Interest Period currently applicable to such Eurodollar Revolving Loan; in all
other cases such notice shall be effective on the date of receipt by the Borrower.

55

 

          SECTION 2.16. Indemnity. The Borrower shall indemnify each Lender against any actual loss
or expense that such Lender may sustain or incur as a consequence of (a) any event, other than a
default by such Lender in the performance of its obligations hereunder, which results in (i) such
Lender receiving or being deemed to receive any amount on account of the principal of any
Eurodollar Revolving Loan prior to the end of the Interest Period in effect therefor, (ii) the
conversion of any Eurodollar Revolving Loan to an ABR Loan, or the conversion of the Interest
Period with respect to any Eurodollar Revolving Loan, in each case other than on the last day of
the Interest Period in effect therefor, or (iii) any Eurodollar Revolving Loan to be made by such
Lender (including any Eurodollar Revolving Loan to be made pursuant to a conversion or continuation
under Section 2.12) not being made after notice of such Loan shall have been given by the Borrower
hereunder (any of the events referred to in this clause (a) being called a “Breakage
Event”) or (b) any default in the making of any payment or prepayment of any Eurodollar
Revolving Loan required to be made hereunder. In the case of any Breakage Event, such actual loss
shall include an amount equal to the excess, as reasonably determined by such Lender, of (i) its
actual cost (which may be determined by such Lender by any reasonable method) of obtaining funds
for the Eurodollar Revolving Loan that is the subject of such Breakage Event for the period from
the date of such Breakage Event to the last day of the Interest Period in effect (or that would
have been in effect) for such Loan over (ii) the amount of interest likely to be realized by such
Lender in redeploying the funds released or not utilized by reason of such Breakage Event for such
period. A certificate of any Lender setting forth any amount or amounts which such Lender is
entitled to receive pursuant to this Section 2.16, together with an explanation in reasonable
detail, shall be delivered to the Borrower. In determining any additional amounts owing under this
Section 2.16, each Lender or Issuing Bank will act reasonably and in good faith; provided that such
Lender’s or Issuing Bank’s determination of compensation owing under this Section 2.16 shall,
absent manifest error, unreasonableness or bad faith, be final and conclusive and binding on all
parties hereto.

          SECTION 2.17. Pro Rata Treatment. Except as provided below in this Section 2.17 with
respect to Swingline Loans and as required under Section 2.15, each Borrowing, each payment or
prepayment of principal of any Borrowing, each payment of interest on the Loans of any Class, each
payment of commitment fees with respect to Commitments of any Class, each reduction of the
Commitments of any Class and each conversion of any Borrowing to or continuation of any Borrowing
as a Borrowing of any Type shall be allocated pro rata among the Lenders in accordance with their
respective applicable Commitments (or, if such Commitments shall have expired or been terminated,
in accordance with the respective principal amounts of their outstanding Loans of the applicable
Class). For purposes of determining the available Revolving Credit Commitments of the Lenders at
any time, each outstanding Swingline Loan shall be deemed to have utilized the Revolving Credit
Commitments of the Lenders

56

 

(including those Lenders which shall not have made Swingline Loans) pro rata in accordance with
such respective Revolving Credit Commitments. Each Lender agrees that in computing such Lender’s
portion of any Borrowing to be made hereunder, the Administrative Agent may, in its discretion,
round each Lender’s percentage of such Borrowing to the next higher or lower whole dollar amount.

          SECTION 2.18. Sharing of Setoffs. Each Lender agrees that if it shall, through the
exercise of a right of banker’s lien, setoff or counterclaim against the Borrower or any other Loan
Party, or pursuant to a secured claim under Section 506 of Title 11 of the United States Code or
other security or interest arising from, or in lieu of, such secured claim, received by such Lender
under any applicable bankruptcy, insolvency or other similar law or otherwise, or by any other
means, obtain payment (voluntary or involuntary) in respect of any Loan or Loans or L/C
Disbursement as a result of which the unpaid principal portion of its Loans and participations in
Swingline Loans and L/C Disbursements shall be proportionately less than the unpaid principal
portion of the Loans and participations in Swingline Loans and L/C Disbursements of any other
Lender, it shall be deemed simultaneously to have purchased from such other Lender at face value,
and shall promptly pay to such other Lender the purchase price for, a participation in the Loans,
participations in Swingline Loans and L/C Exposure, as the case may be, of such other Lender, so
that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the
aggregate unpaid principal amount of the Loans and L/C Exposure and participations in Loans and L/C
Exposure held by all the Lenders; provided, however, that (i) if any such participations are
purchased pursuant to this Section 2.18 and the payment giving rise thereto shall thereafter be
recovered, such participations shall be rescinded to the extent of such recovery and the purchase
price restored without interest, and (ii) the provisions of this paragraph shall not be construed
to apply to any payment made by the Borrower pursuant to and in accordance with the express terms
of this Agreement or any payment obtained by a Lender as consideration for the assignment of or
sale of a participation in any of its Loans or participations in Swingline Loans or L/C
Disbursements to any assignee or participant, other than to the Borrower or any of the Subsidiaries
or any Affiliate thereof (as to which the provisions of this paragraph shall apply). The Borrower
expressly consents to the foregoing arrangements and agrees that any Lender holding a participation
deemed to have been so purchased may exercise any and all rights of banker’s lien, setoff or
counterclaim with respect to any and all moneys owing by the Borrower to such Lender by reason of
such participation as fully as if such Lender had made a Loan directly to the Borrower in the
amount of such participation.

          SECTION 2.19. Payments. (a) The Borrower shall make each payment (including principal of
or interest on any Borrowing or any L/C Disbursement or any Fees or other amounts) hereunder and
under any other Loan Document not later than 12:00 (noon), New York City time, on the date when due

57

 

in immediately available dollars, without setoff, defense or counterclaim. Any amounts received
after such time on any date may, in the discretion of the Administrative Agent, be deemed to have
been received on the next succeeding Business Day for purposes of calculating interest thereon.
Each such payment (other than (i) Issuing Bank Fees, which shall be paid directly to the applicable
Issuing Banks, (ii) principal of and interest on Swingline Loans, which shall be paid directly to
the Swingline Lender except as otherwise provided in Section 2.03(e) and (iii) payments pursuant to
Sections 2.14, 2.16, 2.20 and 9.05 shall be made directly to the persons entitled thereto and
payments pursuant to other Loan Documents shall be made to the persons specified therein) shall be
made to the Administrative Agent at its offices at Eleven Madison Avenue, New York, New York 10010,
or as otherwise directed.

          (b) The Administrative Agent shall distribute any such payments received by it for the
account of any other person to the appropriate recipient promptly following receipt thereof.
Whenever any payment (including principal of or interest on any Borrowing or any Fees or
other amounts) hereunder or under any other Loan Document shall become due, or otherwise
would occur, on a day that is not a Business Day, such payment may be made on the next
succeeding Business Day, and such extension of time shall in such case be included in the
computation of interest or Fees, if applicable.

          (c) If at any time insufficient funds are received by and available to the
Administrative Agent to pay fully all amounts of principal, unreimbursed L/C Disbursements,
interest and Fees then due hereunder, such funds shall be applied (i) first, towards payment
of interest and Fees then due hereunder, ratably among the parties entitled thereto in
accordance with the amounts of interest and Fees then due to such parties, and (ii) second,
towards payment of principal and unreimbursed L/C Disbursements then due hereunder, ratably
among the parties entitled thereto in accordance with the amounts of principal and
unreimbursed L/C Disbursements then due to such parties.

          SECTION 2.20. Taxes. (a) Any and all payments by or on account of any obligation of the
Borrower or any other Loan Party hereunder or under any other Loan Document shall be made free and
clear of and without deduction for any Indemnified Taxes or Other Taxes; provided that, if the
Borrower or any other Loan Party shall be required to deduct any Indemnified Taxes or Other Taxes
from such payments, then (i) the sum payable shall be increased as necessary so that after making
all required deductions (including deductions applicable to additional sums payable under this
Section) the Administrative Agent, each Lender and each Issuing Bank, as the case may be, receives
an amount equal to the sum it would have received had no such deductions been made, (ii) the
Borrower or such Loan Party shall make such deductions and (iii) the Borrower or such Loan Party
shall pay the full amount

58

 

deducted to the relevant Governmental Authority in accordance with applicable law.

          (b) In addition, the Borrower or any other Loan Party shall pay any Other Taxes to the
relevant Governmental Authority in accordance with applicable law.

          (c) The Borrower or any other Loan Party shall indemnify the Administrative Agent, each
Lender and each Issuing Bank, within 10 days after written demand therefor, for the full
amount of any Indemnified Taxes or Other Taxes paid by the Administrative Agent, such Lender
or such Issuing Bank, as the case may be, on or with respect to any payment by or on account
of any obligation of the Borrower or any other Loan Party hereunder or under any other Loan
Document (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable
to amounts payable under this Section) and any penalties, interest and reasonable expenses
arising therefrom or with respect thereto, whether or not such Indemnified Taxes or Other
Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.
A certificate as to the amount of such payment or liability delivered to the Borrower by a
Lender or Issuing Bank, or by the Administrative Agent on its own behalf or on behalf of a
Lender or Issuing Bank, shall be conclusive absent manifest error. The Administrative Agent,
Lender or Issuing Bank may, at its sole reasonable discretion, take such steps as the
Borrower reasonably requests to assist the Borrower, at the Borrower’s own expense, to
minimize or, as applicable, recover such Indemnified Taxes or Other Taxes.

          (d) As soon as practicable after any payment of Indemnified Taxes or Other Taxes by the
Borrower or any other Loan Party to a Governmental Authority, the Borrower shall deliver to
the Administrative Agent the original or a certified copy of a receipt issued by such
Governmental Authority evidencing such payment, a copy of the return reporting such payment
or other evidence of such payment reasonably satisfactory to the Administrative Agent.

          (e) Any Foreign Lender that is entitled to an exemption from or reduction of withholding
tax under the United States, or any treaty to which the United States is a party, with
respect to payments under this Agreement shall, after having received from the Borrower or
any other Loan Party notice of the availability of such exemptions from or reductions of
withholding tax, as well as all such appropriate documentation prescribed by applicable law,
deliver to the Borrower (with a copy to the Administrative Agent), at the time or times
prescribed by applicable law, such properly completed and executed documentation prescribed
by applicable law or reasonably requested by the Borrower or any other Loan Party as will
permit such payments to be made without withholding or at a reduced rate; provided

59

 

that such Foreign Lender is lawfully able to do so and that complying with such
requirements would not require such Lender Party to disclose any confidential or proprietary
information or be otherwise materially disadvantageous to such Lender Party (in form, in
procedure or in the substance of information disclosed).

          SECTION 2.21. Assignment of Commitments Under Certain Circumstances; Duty to Mitigate. (a)
In the event (i) any Lender or Issuing Bank delivers a certificate requesting compensation pursuant
to Section 2.14, (ii) any Lender or Issuing Bank delivers a notice described in Section 2.15,
(iii) the Borrower is required to pay any amount to any Lender or Issuing Bank or any Governmental
Authority on account of any Lender or Issuing Bank pursuant to Section 2.20, (iv) any Lender
becomes a Non-Consenting Lender, or (v) any Lender becomes a Defaulting Lender the Borrower may, at
its sole expense and effort (including with respect to the processing and recordation fee referred
to in Section 9.04(e)), upon notice to such Lender or Issuing Bank, and the Administrative Agent,
require such Lender or Issuing Bank to transfer and assign, without recourse (in accordance with
and subject to the restrictions contained in Section 9.04), all of its interests, rights and
obligations under this Agreement to an assignee that shall assume such assigned obligations (which
assignee may be another Lender, if a Lender accepts such assignment); provided that (w) with
respect to clauses (i) to (iii) above, such assignment will result in a reduction in the claim for
compensation under Section 2.14 or in the withdrawal of the notice under Section 2.15 or in the
reduction of payments under Section 2.20, as the case may be, (x) such assignment shall not
conflict with any law, rule or regulation or order of any court or other Governmental Authority
having jurisdiction, (y) the Borrower shall have received the prior written consent of the
Administrative Agent (and, if a Revolving Credit Commitment is being assigned, of each Issuing Bank
and the Swingline Lender), which consent shall not unreasonably be withheld, and (z) the Borrower
or such assignee shall have paid to the affected Lender or Issuing Bank in immediately available
funds an amount equal to the sum of the principal of and interest accrued to the date of such
payment on the outstanding Loans or L/C Disbursements of such Lender or Issuing Bank, respectively,
plus all Fees and other amounts accrued for the account of such Lender or Issuing Bank hereunder
(including any amounts under Section 2.14 and Section 2.16); provided further that, if prior to any
such transfer and assignment (A) in the case of clauses (i) to (iii) above, the circumstances or
event that resulted in such Lender’s or Issuing Bank’s claim for compensation under Section 2.14 or
notice under Section 2.15 or the amounts paid pursuant to Section 2.20, as the case may be, cease
to cause such Lender or Issuing Bank to suffer increased costs or reductions in amounts received or
receivable or reduction in return on capital, or cease to have the consequences specified in
Section 2.15, or cease to result in amounts being payable under Section 2.20, as the case may be
(including as a result of any action taken by such Lender or Issuing Bank pursuant to paragraph (b)
below), or if such Lender or Issuing Bank shall waive its right to

60

 

claim further compensation under Section 2.14 in respect of such circumstances or event or shall
withdraw its notice under Section 2.15 or shall waive its right to further payments under
Section 2.20 in respect of such circumstances or event, (B) in the case of clause (iv) above, such
Non-Consenting Lender ceases to be a Non-Consenting Lender and (C) in the case of clause (v) above,
such assigning Lender ceases to be a Defaulting Lender as the case may be, then such Lender or
Issuing Bank shall not thereafter be required to make any such transfer and assignment hereunder.

          (b) If (i) any Lender or Issuing Bank shall request compensation under Section 2.14,
(ii) any Lender or Issuing Bank delivers a notice described in Section 2.15 or (iii) the
Borrower is required to pay any amount to any Lender, the Issuing Bank or any Governmental
Authority on account of any Lender or Issuing Bank, pursuant to Section 2.20 then such Lender
or Issuing Bank shall use reasonable efforts (which shall not require such Lender or Issuing
Bank to incur an unreimbursed loss or unreimbursed cost or expense or otherwise take any
action inconsistent with its internal policies or legal or regulatory restrictions or suffer
any disadvantage or burden deemed by it to be significant) (x) to file any certificate or
document reasonably requested in writing by the Borrower or (y) to assign its rights and
delegate and transfer its obligations hereunder to another of its offices, branches or
affiliates, if such filing or assignment would reduce its claims for compensation under
Section 2.14 or enable it to withdraw its notice pursuant to Section 2.15 or would reduce
amounts payable pursuant to Section 2.20, as the case may be, in the future. The Borrower
hereby agrees to pay all reasonable costs and expenses incurred by any Lender or Issuing Bank
in connection with any such filing or assignment, delegation and transfer.

ARTICLE III

Representations and Warranties

          The Borrower represents and warrants to the Administrative Agent, the Collateral Agent, each
Issuing Bank and each of the Lenders that:

          SECTION 3.01. Organization; Powers. The Borrower and each of the Domestic Subsidiaries and
Material Foreign Subsidiaries (a) is duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization, (b) has all requisite power and authority to own
its property and assets and to carry on its business as now conducted and as proposed to be
conducted, (c) is qualified to do business in, and is in good standing in, every jurisdiction where
such qualification is required, except where the failure so to qualify could not reasonably be
expected to result in a Material Adverse Effect, and (d) has the power and authority to execute,
deliver and perform its obligations under each of the Loan Documents and each other agreement or
instrument

61

 

contemplated thereby to which it is or will be a party and, in the case of the Borrower, to borrow
hereunder.

          SECTION 3.02. Authorization. The Transactions have been duly authorized by all requisite
corporate and, if required, stockholder action. The Transactions will not (i) violate (A) any
provision of law, statute, rule or regulation, or of the certificate or articles of incorporation
or other constitutive documents or by-laws of the Borrower or any Subsidiary, (B) any order of any
Governmental Authority or (C) any provision of any indenture, agreement or other instrument to
which the Borrower or any Subsidiary is a party or by which any of them or any of their property is
or may be bound, (ii) be in conflict with, result in a breach of or constitute (alone or with
notice or lapse of time or both) a default under, or give rise to any right to accelerate or to
require the prepayment, repurchase or redemption of any obligation under any such indenture,
agreement or other instrument or (iii) result in the creation or imposition of any Lien upon or
with respect to any property or assets now owned or hereafter acquired by the Borrower or any
Subsidiary (other than any Lien created hereunder or under the Security Documents) except, with
respect to clauses (i)(C) and (ii), any defaults arising under any Indebtedness of the Target or
any subsidiary of the Target as a direct result of (i) the execution, delivery and performance by
the Borrower and the Merger Sub of the Merger Agreement and the consummation of the Merger and the
other transactions contemplated thereby or (ii) the consummation of the Tender Offer (together the
“Acquisition Transactions”), in each case to the extent that such defaults would not
reasonably be expected to have a Material Adverse Effect.

          SECTION 3.03. Enforceability. This Agreement has been duly executed and delivered by the
Borrower and constitutes, and each other Loan Document when executed and delivered by each Loan
Party party thereto will constitute, a legal, valid and binding obligation of the Borrower or such
Loan Party enforceable against the Borrower or such Loan Party in accordance with its terms.

          SECTION 3.04. Governmental Approvals. No action, consent or approval of, registration or
filing with or any other action by any Governmental Authority is or will be required in connection
with the Transactions, except (a) the filing of Uniform Commercial Code financing statements and
filings with the United States Patent and Trademark Office and the United States Copyright Office,
(b) recordation of the Mortgages, (c) such as have been made or obtained and are in full force and
effect and (d) in the case of any such action required to be taken in connection with the
Acquisition Transactions, to the extent the failure to take any such action could not reasonably be
expected to have a Material Adverse Effect.

          SECTION 3.05. Financial Statements. (a) The Borrower has heretofore furnished to the
Lenders its consolidated balance sheets and related

62

 

statements of income, stockholders’ equity and cash flows (i) as of the end of and for each fiscal
year in the three-fiscal year period ended December 31, 2007, audited by and accompanied by the
opinion of PricewaterhouseCoopers LLP, independent public accountants, (ii) as of and for the
fiscal quarter and the portion of the fiscal year ended September 30, 2008, certified by its chief
financial officer and (iii) as of and for the fiscal months and the portion of the fiscal year
ended after the date of the most recently ended fiscal quarter and not less than 30 days prior to
the Amendment No. 1 Effective Date, certified by its chief financial officer. Such financial
statements present fairly in all material respects the financial condition and results of
operations and cash flows of the Borrower and its consolidated Subsidiaries as of such dates and
for such periods. Such balance sheets and the notes thereto disclose all material liabilities,
direct or contingent, of the Borrower and its consolidated Subsidiaries as of the dates thereof.
Such financial statements (other than such monthly financial statements) were prepared in
accordance with GAAP applied on a consistent basis and are in compliance with the requirements of
Regulation S-X under the Securities Act of 1933, as amended, subject, in the case of unaudited
financial statements, to year-end audit adjustments and the absence of footnotes.

          (b) The Borrower has heretofore furnished to the Lenders the consolidated balance sheets
and related statements of income, stockholders’ equity and cash flows of the Target (i) as of
the end of and for each fiscal year in the three-fiscal year period ended December 31, 2007,
audited by and accompanied by the opinion of BDO Seidman, LLP, independent public
accountants, (ii) as of and for the fiscal quarter and the portion of the fiscal year ended
September 30, 2008 and (iii) as of and for the fiscal months and the portion of the fiscal
year ended after the date of the most recently ended fiscal quarter and not less than 30 days
prior to the Amendment No. 1 Effective Date. Such financial statements present fairly in all
material respects the financial condition and results of operations and cash flows of the
Target and its consolidated Subsidiaries as of such dates and for such periods. Such balance
sheets and the notes thereto disclose all material liabilities, direct or contingent, of the
Target and its consolidated Subsidiaries as of the dates thereof. Such financial statements
(other than such monthly financial statements) were prepared in accordance with GAAP applied
on a consistent basis and are in compliance with the requirements of Regulation S-X under the
Securities Act of 1933, as amended, subject, in the case of unaudited financial statements,
to year-end audit adjustments and the absence of footnotes.

          (c) The Borrower has heretofore delivered to the Lenders its unaudited pro forma
consolidated balance sheet and related pro forma statements of income, stockholder’s
equity and cash flows as of September 30, 2008, prepared giving effect to the Transactions as
if they had occurred, with respect to such balance sheet, on such date and, with respect to
such

63

 

other financial statements, on the first day of the twelve-month period ending on such
date. Such pro forma financial statements have been prepared in good faith by the Borrower,
based on the assumptions used to prepare the pro forma financial information contained in the
Confidential Information Memorandum (which assumptions are believed by the Borrower on the
Amendment No. 1 Effective Date to be reasonable), are based on the best information available
to the Borrower as of the date of delivery thereof, accurately reflect all adjustments
required to be made to give effect to the Transactions and present fairly in all material
respects on a pro forma basis the estimated consolidated financial position of the Borrower
and its consolidated Subsidiaries as of such date and for such period, assuming that the
Transactions had actually occurred at such date or at the beginning of such period, as the
case may be.

          SECTION 3.06. No Material Adverse Change. (a) There has been no Material Adverse Effect
since December 31, 2007.

          (b) No Default or Event of Default has occurred and is continuing.

          SECTION 3.07. Title to Properties; Possession Under Leases. (a) The Borrower and each of
the Domestic Subsidiaries and Material Foreign Subsidiaries has good and marketable title to, or
valid leasehold interests in, or easements or other limited property rights in, or is licensed to
use, all its material properties and assets (including all Mortgaged Property), except for minor
defects in title that do not interfere with its ability to conduct its business as currently
conducted or to utilize such properties and assets for their intended purposes. All such material
properties and assets are free and clear of Liens, other than Liens expressly permitted by Section
6.02.

          (b) The Borrower and each of the Domestic Subsidiaries and Material Foreign Subsidiaries
has complied with all material obligations under all material leases to which it is a party
and all such leases are in full force and effect. The Borrower and each Subsidiary enjoys
peaceful and undisturbed possession under all such material leases.

          (c) As of the Amendment No. 1 Effective Date, the Borrower has not received any notice
of, nor has any knowledge of, any pending or contemplated condemnation proceeding affecting
the Mortgaged Properties or any sale or disposition thereof in lieu of condemnation.

          (d) Except as disclosed on Schedule 3.20(a) or 3.20(b), as of the Amendment No. 1
Effective Date, none of the Borrower or any of the Subsidiaries is obligated under any right
of first refusal, option or other contractual right to sell, assign or otherwise dispose of
any Mortgaged Property or any interest therein.

64

 

          SECTION 3.08. Subsidiaries. Schedule 3.08 sets forth as of the Amendment No. 1 Effective
Date a list of all Subsidiaries and the direct or indirect ownership interests of the Borrower
therein, and identifies each Subsidiary that is a Material Foreign Subsidiary on the Amendment
No. 1 Effective Date. The shares of capital stock or other ownership interests so indicated on
Schedule 3.08 are fully paid and non-assessable and, as of the Amendment No. 1 Effective Date, are
owned by the Borrower, directly or indirectly, free and clear of all Liens (other than Liens
created under the Security Documents, the Term Liens and statutory nonconsensual Liens expressly
permitted by Section 6.02).

          SECTION 3.09. Litigation; Compliance with Laws. (a) Except as set forth on Schedule 3.09,
there are no actions, suits, proceedings or investigations at law or in equity or by or before any
Governmental Authority now pending or, to the knowledge of the Borrower, threatened against or
affecting the Borrower or any Subsidiary or any business, property or rights of any such person (i)
that involve any Loan Document or (ii) as to which there is a reasonable possibility of an adverse
determination and that, if adversely determined, could reasonably be expected, individually or in
the aggregate, to result in a Material Adverse Effect.

          (b) Since the Amendment No. 1 Effective Date, there has been no change in the status of
the matters disclosed on Schedule 3.09 that, individually or in the aggregate, has resulted
in, or materially increased the likelihood of, a Material Adverse Effect.

          (c) The Borrower and each of the Domestic Subsidiaries and Material Foreign Subsidiaries
is in compliance with all laws, regulations, consent decrees and orders of any Governmental
Authority applicable to it (including, without limitation, the Patriot Act, ERISA, employee
health and safety, margin regulations, Environmental Laws and Health Care Laws) or its
property and all indentures, agreements and other instruments binding upon it or its
property, except where the failure to comply, individually or in the aggregate, could not
reasonably be expected to result in a Material Adverse Effect.

          (d) None of the Borrower or any of the Domestic Subsidiaries or Material Foreign
Subsidiaries or any of their respective material properties or assets is in violation of, nor
will the continued operation of their material properties and assets as currently conducted
violate, any law, rule or regulation (including any zoning, building, Environmental Law,
ordinance, code or approval or any building permits) or any restrictions of record or
agreements affecting the Mortgaged Property, or is in default with respect to any judgment,
writ, injunction, decree or order of any Governmental Authority, where such violation or
default could reasonably be expected to result in a Material Adverse Effect.

65

 

          (e) Certificates of occupancy and permits (in each case, to the extent required by
applicable law) are in effect for each Mortgaged Property as currently constructed, and true
and complete copies of such certificates of occupancy have been delivered to the Collateral
Agent as mortgagee with respect to each Mortgaged Property.

          SECTION 3.10. Agreements. (a) Neither the Borrower nor any of the Domestic Subsidiaries or
Material Foreign Subsidiaries is a party to any agreement or instrument or subject to any corporate
restriction that has resulted or could reasonably be expected to result in a Material Adverse
Effect.

          (b) Neither the Borrower nor any of the Subsidiaries is in default in any manner under
any provision of any indenture or other agreement or instrument evidencing Indebtedness, or
any other material agreement or instrument to which it is a party or by which it or any of
its properties or assets are or may be bound, where such default could reasonably be expected
to result in a Material Adverse Effect.

          SECTION 3.11. Federal Reserve Regulations. (a) Neither the Borrower nor any of the
Subsidiaries is engaged principally, or as one of its important activities, in the business of
extending credit for the purpose of buying or carrying Margin Stock.

          (b) No part of the proceeds of any Loan or any Letter of Credit will be used, whether
directly or indirectly, and whether immediately, incidentally or ultimately, for any purpose
that entails a violation of, or that is inconsistent with, the provisions of the Regulations
of the Board, including Regulation T, U or X.

          SECTION 3.12. Investment Company Act. Neither the Borrower nor any of the Subsidiaries is
an “investment company” as defined in, or subject to regulation under, the Investment Company Act
of 1940.

          SECTION 3.13. Use of Proceeds. The Borrower will use the proceeds of the Loans and request
the issuance of Letters of Credit only to provide working capital and for other general corporate
purposes, including permitted acquisitions and the payment of the Acquisition Consideration and the
Letters of Credit are to be used by the Borrower and the Subsidiaries for general corporate
purposes

          SECTION 3.14. Tax Returns. Each of the Borrower and the Subsidiaries has filed or caused
to be filed all Federal and all other material state, local and foreign tax returns or materials
required to have been filed by it and has paid or caused to be paid all Federal and all other
material taxes due and payable by it and all assessments received by it, except taxes that are
being contested in good faith by appropriate proceedings and for which the Borrower or such

66

 

Subsidiary, as applicable, shall have set aside on its books adequate reserves in accordance with
GAAP.

          SECTION 3.15. No Material Misstatements. None of (a) the Confidential Information
Memorandum or (b) any other information, report, financial statement, exhibit or schedule furnished
by or on behalf of the Borrower to the Administrative Agent or any Lender in connection with the
negotiation of any Loan Document or included therein or delivered pursuant thereto taken as a whole
contained, contains or will contain any material misstatement of fact or omitted, omits or will
omit to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were, are or will be made, not misleading; provided that to the
extent any such information, report, financial statement, exhibit or schedule was based upon or
constitutes a forecast or projection, the Borrower represents only that it acted in good faith and
utilized reasonable assumptions (based upon accounting principles consistent with the historical
audited financial statements of the Borrower) and due care in the preparation of such information,
report, financial statement, exhibit or schedule (it being understood that any such forecast or
projection is not a guarantee of future performance and that actual results during the period
covered by such forecast or projection may materially differ from the projected results thereof).

          SECTION 3.16. Employee Benefit Plans. Each of the Borrower and its ERISA Affiliates is in
compliance in all material respects with the applicable provisions of ERISA and the Code and the
regulations and published interpretations thereunder. No ERISA Event has occurred or is reasonably
expected to occur that, when taken together with all other such ERISA Events, could reasonably be
expected to result in material liability of the Borrower or any of its ERISA Affiliates. The
present value of all benefit liabilities under each Plan (based on the assumptions used for
purposes of Statement of Financial Accounting Standards No. 87) did not, as of the last annual
valuation date applicable thereto, exceed the fair market value of the assets of such Plan.

          SECTION 3.17. Environmental Matters. (a) Except as set forth in Schedule 3.17:

     (i) To the knowledge of the Borrower, the properties and facilities
currently or formerly owned, leased or operated by the Borrower and the
Subsidiaries (the “Properties”) do not contain any Hazardous Materials in
amounts or concentrations which (i) constitute, or constituted, a violation of,
(ii) require Remedial Action under, or (iii) could reasonably be expected to give
rise to liability under, Environmental Laws, which violations, Remedial Actions
and liabilities, individually or in the aggregate, could reasonably be expected
to result in a Material Adverse Effect;

67

 

     (ii) The Borrower, the Subsidiaries and their respective operations are in
compliance, and in the last five years have been in compliance, with all
Environmental Laws, and all necessary Environmental Permits have been obtained
and are in effect, except to the extent that such noncompliance or failure to
obtain any necessary permits, individually or in the aggregate, could not
reasonably be expected to result in a Material Adverse Effect;

     (iii) To the knowledge of the Borrower, there have been no Releases or
threatened Releases at, from, on, to or under the Properties or otherwise in
connection with the operations of the Borrower or the Subsidiaries, which
Releases or threatened Releases, individually or in the aggregate, could
reasonably be expected to result in a Material Adverse Effect;

     (iv) Neither the Borrower nor any of the Subsidiaries has received any
Environmental Claim in connection with the Properties or the operations of the
Borrower or the Subsidiaries or with regard to any person whose liabilities for
environmental matters the Borrower or the Subsidiaries has retained or assumed,
in whole or in part, contractually, by operation of law or otherwise, which,
individually or in the aggregate, could reasonably be expected to result in a
Material Adverse Effect, nor do the Borrower or the Subsidiaries have any
reasonable basis to believe that any such Environmental Claim is being
threatened; and

     (v) (A) To the knowledge of the Borrower, Hazardous Materials have not been
transported from the Properties, nor have Hazardous Materials been generated,
treated, stored or disposed of at, on or under any of the Properties in a manner
that could give rise to any liability under any Environmental Law which in the
aggregate could be expected to result in a Material Adverse Effect, nor (B) have
the Borrower or the Subsidiaries retained or assumed any liability,
contractually, by operation of law or otherwise with respect to the generation,
treatment, storage or disposal of Hazardous Materials, which transportation,
generation, treatment, storage or disposal, or retained or assumed liabilities,
individually or in the aggregate could reasonably be expected to result in a
Material Adverse Effect.

          (b) Since the Amendment No. 1 Effective Date, there has been no change in the status of
the matters disclosed on Schedule 3.17 that, individually or in the aggregate, has resulted
in, or materially increased the likelihood of, a Material Adverse Effect.

68

 

          SECTION 3.18. Insurance. Schedule 3.18 sets forth a true, complete and correct description
of all insurance maintained by the Borrower or by the Borrower for its Subsidiaries as of the
Amendment No. 1 Effective Date. As of such date, such insurance is in full force and effect and
all premiums have been duly paid. The Borrower and its Subsidiaries have insurance in such amounts
and covering such risks and liabilities as are in accordance with normal industry practice.

          SECTION 3.19. Security Documents. (a) The Guarantee and Collateral Agreement, upon
execution and delivery thereof by the parties thereto, will create in favor of the Collateral
Agent, for the ratable benefit of the Secured Parties, a legal, valid and enforceable security
interest in the Collateral (as defined in the Guarantee and Collateral Agreement) and the proceeds
thereof and (i) when the Pledged Collateral (as defined in the Guarantee and Collateral Agreement)
is delivered to the Collateral Agent, the Lien created under the Guarantee and Collateral Agreement
in favor of the Collateral Agent for the ratable benefit of the Secured Parties shall constitute a
fully perfected first priority Lien on, and security interest in, all right, title and interest of
the Loan Parties in such Pledged Collateral, in each case, pari passu with the Term Liens and prior
and superior in right to any other person, and (ii) when financing statements in appropriate form
are filed in the offices specified on Schedule 3.19(a), the Lien created under the Guarantee and
Collateral Agreement in favor of the Collateral Agent for the ratable benefit of the Secured
Parties will constitute a fully perfected Lien on, and security interest in, all right, title and
interest of the Loan Parties in such Collateral (other than Intellectual Property, as defined in
the Guarantee and Collateral Agreement), in each case pari passu with the Term Liens and prior and
superior in right to any other person, other than with respect to Liens expressly permitted by
Section 6.02.

          (b) Upon the recordation of the Guarantee and Collateral Agreement (or a short-form
security agreement in form and substance reasonably satisfactory to the Borrower and the
Collateral Agent) with the United States Patent and Trademark Office and the United States
Copyright Office, together with the financing statements in appropriate form filed in the
offices specified on Schedule 3.19(a), the Lien created under the Guarantee and Collateral
Agreement in favor of the Collateral Agent for the ratable benefit of the Secured Parties
shall constitute a fully perfected Lien on, and security interest in, all right, title and
interest of the Loan Parties in the Intellectual Property (as defined in the Guarantee and
Collateral Agreement) in which a security interest may be perfected by filing in the United
States and its territories and possessions, in each case pari passu with the Term Liens and
prior and superior in right to any other person (it being understood that subsequent
recordings in the United States Patent and Trademark Office and the United States Copyright
Office may be necessary to perfect a Lien on registered trademarks and patents, trademark and
patent applications and

69

 

registered copyrights acquired by the Loan Parties after the Amendment No. 1 Effective
Date).

          (c) The Mortgages are effective to create in favor of the Collateral Agent, for the
ratable benefit of the Secured Parties, a legal, valid and enforceable Lien on all of the
Loan Parties’ right, title and interest in and to the Mortgaged Property thereunder and the
proceeds thereof, and when the Mortgages are filed in the offices specified on Schedule
3.19(c), the Mortgages shall constitute a fully perfected Lien on, and security interest in,
all right, title and interest of the Loan Parties in such Mortgaged Property and the proceeds
thereof, in each case pari passu with the Term Liens and prior and superior in right to any
other person, other than with respect to the rights of persons pursuant to Liens expressly
permitted by Section 6.02.

          SECTION 3.20. Location of Real Property and Leased Premises. (a) Schedule 3.20(a) lists
completely and correctly as of the Amendment No. 1 Effective Date all real property owned by the
Borrower and the Subsidiaries and the addresses thereof. The Borrower and the Subsidiaries own in
fee all the real property set forth on Schedule 3.20(a).

          (b) Schedule 3.20(b) lists completely and correctly as of the Amendment No. 1 Effective
Date all Material Leased Property (defined below) and the addresses thereof. The Borrower
and the Subsidiaries have valid leases in all the real property set forth on Schedule
3.20(b). For the purpose of the foregoing, “Material Leased Property” means real
property leased by the Borrower or any Subsidiary with respect to which such property lease
(i) has more than twelve (12) months remaining in the lease term and (ii) requires the
Borrower or any Subsidiary to make lease payments in excess of $500,000 in any year or
$1,000,000 in the aggregate over the remaining term of such lease.

          SECTION 3.21. Labor Matters. As of the Amendment No. 1 Effective Date, there are no
strikes, lockouts or slowdowns against the Borrower or any Subsidiary pending or, to the knowledge
of the Borrower, threatened. The hours worked by and payments made to employees of the Borrower
and the Subsidiaries have not been in violation of the Fair Labor Standards Act or any other
applicable Federal, state, local or foreign law dealing with such matters. All payments due from
the Borrower or any of the Domestic Subsidiaries or Material Foreign Subsidiaries, or for which any
claim may be made against the Borrower or any of the Domestic Subsidiaries or Material Foreign
Subsidiaries, on account of wages and employee health and welfare insurance and other benefits,
have been paid or accrued as a liability on the books of the Borrower or the applicable Subsidiary.

          SECTION 3.22. Solvency. Immediately after the consummation of the Transactions to occur on
the Amendment No. 1 Effective Date and

70

 

immediately following the making of each Loan and after giving effect to the application of the
proceeds of each Loan, (a) the fair value of the assets of the Borrower and the Subsidiaries on a
consolidated basis, at a fair valuation, will exceed their debts and liabilities, subordinated,
contingent or otherwise; (b) the present fair saleable value of the property of the Borrower and
the Subsidiaries on a consolidated basis will be greater than the amount that will be required to
pay the probable liability in respect of their debts and other liabilities, subordinated,
contingent or otherwise, as such debts and other liabilities become absolute and matured; (c) the
Borrower and the Subsidiaries on a consolidated basis will be able to pay their debts and
liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute
and matured; and (d) the Borrower and the Subsidiaries on a consolidated basis will not have
unreasonably small capital with which to conduct the business in which they are engaged as such
business is now conducted and is proposed to be conducted following the Amendment No. 1 Effective
Date.

          SECTION 3.23. Transaction Documents. (a) The Borrower has delivered to the Administrative
Agent a complete and correct copy of the Merger Agreement (including all schedules, exhibits,
amendments, supplements and modifications thereto). Neither the Borrower nor any Loan Party or, to
the knowledge of the Borrower or each Loan Party, any other person party thereto is in default in
the performance or compliance with any material provisions thereof. The Merger Agreement complies
in all material respects with all applicable laws. All representations and warranties set forth in
the Merger Agreement were true and correct in all material respects at the time as of which such
representations and warranties were made (or deemed made).

          (b) The Borrower has delivered to the Administrative Agent a complete and correct copy
of the Tender Offer Documentation (including all schedules, exhibits, amendments, supplements
and modifications thereto). The Tender Offer complies in all material respects with all
applicable laws.

          SECTION 3.24. Sanctioned Persons. None of the Borrower or any Subsidiary nor, to the
knowledge of the Borrower, any director, officer, agent, employee or Affiliate of the Borrower or
any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (“OFAC”); and the Borrower will not directly
or indirectly use the proceeds of the Loans or the Letters of Credit or otherwise make available
such proceeds to any person, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.

ARTICLE IV

Conditions of Lending

71

 

          The obligations of the Lenders to make Loans and of the Issuing Banks to issue Letters of
Credit hereunder are subject to the satisfaction of the following conditions:

          SECTION 4.01. All Credit Events. On (x) the date of each Borrowing (other than a
conversion or a continuation of a Borrowing), including each Borrowing of a Swingline Loan, and on
the date of each issuance, amendment, extension or renewal of a Letter of Credit and (y) solely for
the purpose of paragraph (b) and (c) below, the Amendment No. 1 Effective Date (each such event or
date being called a “Credit Event”):

          (a) The Administrative Agent shall have received a notice of such Borrowing as required
by Section 2.05 (or such notice shall have been deemed given in accordance with Section 2.02)
or, in the case of the issuance, amendment, extension or renewal of a Letter of Credit, the
applicable Issuing Bank and the Administrative Agent shall have received a notice requesting
the issuance, amendment, extension or renewal of such Letter of Credit as required by
Section 2.04(b) or, in the case of the Borrowing of a Swingline Loan, the Swingline Lender
and the Administrative Agent shall have received a notice requesting such Swingline Loan as
required by Section 2.03(b).

          (b) The representations and warranties set forth in Article III and in each Loan
Document shall be true and correct in all material respects on and as of the date of such
Credit Event with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date.

          (c) Borrower and each other Loan Party shall be in compliance with all the terms and
provisions set forth herein and in each other Loan Document on its part to be observed or
performed, and at the time of and immediately after such Credit Event, no Event of Default or
Default shall have occurred and be continuing.

          (d) Other than in the case of a Borrowing for the purpose of paying the Acquisition
Consideration, immediately after giving effect to any such Borrowing of Loans and the use of
proceeds thereof, the aggregate amount of unrestricted cash and Permitted Investments on hand
at the Borrower and the Domestic Subsidiaries shall not exceed $200,000,000.

          (e) Immediately prior to giving effect to any such Borrowing of Loans the proceeds of
which are to be used to pay the Acquisition Consideration, the full amount of the Term Loan
Credit Agreement as in effect on the Amendment No. 1 Effective Date shall have been drawn.

72

 

          Each Credit Event shall be deemed to constitute a representation and warranty by the Borrower
on the date of such Credit Event as to the satisfaction of the conditions set forth in paragraphs
(b), (c), (d) and (e) of this Section.

          SECTION 4.02. Effective Date. The obligations of the Lenders to make Loans and of the
Issuing Banks to issue Letters of Credit hereunder, and the incorporation of Existing Letters of
Credit as Letters of Credit hereunder shall not become effective until the date on which each of
the following conditions is satisfied (or waived in accordance with Section 9.08).

          (a) The Administrative Agent (or its counsel) shall have received from each party hereto
either (i) a counterpart of this Agreement signed on behalf of such party or (ii) written
evidence satisfactory to the Administrative Agent (which may include facsimile transmission
of a signed signature page of this Agreement) that such party has signed a counterpart of
this Agreement.

          (b) The Administrative Agent shall have received, on behalf of itself, the Lenders and
the Issuing Banks, (i)(A) a favorable written opinion of James Elrod, Esquire, General
Counsel of the Borrower, substantially to the effect set forth in Exhibit G-1, (B) a
favorable written opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., special
counsel to the Borrower, substantially to the effect set forth in Exhibit G-2, and (C) a
favorable written opinion of Bass, Berry & Sims PLC, Tennessee counsel to the Borrower,
substantially to the effect set forth in Exhibit G-3, in each case (1) dated the date hereof,
(2) addressed to the Administrative Agent, the Issuing Banks and the Lenders, and (3)
covering such other matters relating to the Loan Documents and the Transactions as the
Administrative Agent shall reasonably request. The Borrower hereby requests such counsel to
deliver such opinions.

          (c) The Administrative Agent shall have received (i) a copy of the certificate or
articles of incorporation, including all amendments thereto, of each Loan Party, certified as
of a recent date by the Secretary of State of the state of its organization, and a
certificate as to the good standing of each Loan Party as of a recent date, from such
Secretary of State; (ii) a certificate of the Secretary or Assistant Secretary of each Loan
Party dated the Effective Date and certifying (A) that attached thereto is a true and
complete copy of the by-laws of such Loan Party as in effect on the Effective Date and at all
times since a date prior to the date of the resolutions described in clause (B) below, (B)
that attached thereto is a true and complete copy of resolutions duly adopted by the Board of
Directors of such Loan Party authorizing the execution, delivery and performance of the Loan
Documents to which such person is a party and, in the case of the Borrower, the Borrowings
hereunder, and that such resolutions have not been modified,

73

 

rescinded or amended and are in full force and effect, (C) that the certificate or
articles of incorporation of such Loan Party have not been amended since the date of the last
amendment thereto shown on the certificate of good standing furnished pursuant to clause (i)
above, and (D) as to the incumbency and specimen signature of each officer executing any Loan
Document or any other document delivered in connection herewith on behalf of such Loan Party;
(iii) a certificate of another officer as to the incumbency and specimen signature of the
Secretary or Assistant Secretary executing the certificate pursuant to (ii) above; and (iv)
such other documents as the Lenders, the Issuing Banks or the Administrative Agent, may
reasonably request.

          (d) The Administrative Agent shall have received a certificate, dated the Effective Date
and signed by a Financial Officer of the Borrower, confirming compliance with the conditions
precedent set forth in paragraphs (b) and (c) of Section 4.01.

          (e) After giving effect to the Transactions occurring on the Effective Date, the
Borrower and the Subsidiaries shall have outstanding no Indebtedness for borrowed money or
preferred stock other than (i) Indebtedness under the Loan Documents, (ii) the Convertible
Notes, and (iii) other Indebtedness permitted under Section 6.01 (other than clause (h)
thereof of this Agreement (as in effect prior to the Amendment No. 1 Effective Date)).

          (f) The Administrative Agent shall have received all fees and other amounts due and
payable on or prior to the date hereof, including, to the extent invoiced, reimbursement or
payment of all fees and out-of-pocket expenses (including fees, charges and disbursements of
outside counsel) required to be reimbursed or paid by any Loan Party hereunder or under any
other Loan Document or under the Fee Letter.

          (g) The Administrative Agent and each Lender shall have received all such information as
shall have been reasonably requested by it in order to enable it to comply with the
requirements of the Patriot Act and any other “know your customer” or similar laws or
regulations.

          (h) The commitments under the Existing Credit Agreement shall have been or shall
simultaneously be terminated, the principal of and all accrued interest on all Loans
outstanding under such agreement and all fees and other amounts accrued for the accounts of
or owed to the lenders thereunder shall have been or shall simultaneously be paid in full
(except that the Existing Letters of Credit shall remain outstanding as Letters of Credit
hereunder) and all Liens securing the obligations of the Borrower and the Subsidiaries
thereunder shall have been released.

74

 

The Administrative Agent shall notify the Borrower and the Lenders of the Effective Date, and such
notice shall be conclusive and binding. Notwithstanding the foregoing, the obligations of the
Lenders to make Loans and of the Issuing Bank to issue Letters of Credit hereunder shall not become
effective unless each of the foregoing conditions is satisfied (or waived pursuant to Section 9.08)
at or prior to 5:00 p.m., New York City time, on April 27, 2007 subject to extension (by not more
than 10 Business Days) by the Administrative Agent in its sole discretion (and, in the event that
such conditions are not so satisfied, waived or extended, the Commitments shall terminate at such
time).

ARTICLE V

Affirmative Covenants

          The Borrower covenants and agrees with each Lender that so long as this Agreement shall remain
in effect and until the Commitments have been terminated and the principal of and interest on each
Loan, all Fees and all other expenses or amounts payable under any Loan Document shall have been
paid in full and all Letters of Credit have been canceled or have expired and all amounts drawn
thereunder have been reimbursed in full, unless the Required Lenders shall otherwise consent in
writing, the Borrower will, and will cause each of the Subsidiaries to:

          SECTION 5.01. Existence; Compliance with Laws; Businesses and Properties. (a) Do or cause
to be done all things necessary to preserve, renew and keep in full force and effect its legal
existence, except as otherwise expressly permitted under Section 6.05.

          (a) Do or cause to be done all things necessary to obtain, preserve, renew, extend and
keep in full force and effect its rights, licenses, permits, franchises, authorizations,
patents, copyrights, trademarks and trade names; maintain and operate its business in
substantially the manner in which it is presently conducted and operated; comply with all
applicable laws, rules, regulations, decrees and orders of any Governmental Authority,
whether now in effect or hereafter enacted; and at all times maintain and preserve all
property and keep such property in good repair, working order and condition and from time to
time make, or cause to be made, all needful and proper repairs, renewals, additions,
improvements and replacements thereto necessary in order that the business carried on in
connection therewith may be properly conducted at all times, in each case to the extent the
failure to do so, individually or in the aggregate, could reasonably be expected to result in
a Material Adverse Effect.

          SECTION 5.02. Insurance. (a) Keep its insurable properties adequately insured at all times
by financially sound and reputable insurers (or, if any insurer no longer qualifies as such,
promptly thereafter enter into replacement

75

 

insurance with a financially sound and reputable insurer); maintain such other insurance, to such
extent and against such risks, including fire and other risks insured against by extended coverage,
as is customary with companies in the same or similar businesses operating in the same or similar
locations, including public liability insurance against claims for personal injury or death or
property damage occurring upon, in, about or in connection with the use of any properties owned,
occupied or controlled by it; and maintain such other insurance as may be required by law.

          (b) Cause all such policies covering any Collateral to be endorsed or otherwise amended
to include a customary lender’s loss payable endorsement, in form and substance satisfactory
to the Administrative Agent and the Collateral Agent, which endorsement shall provide that,
from and after the Amendment No. 1 Effective Date, if the insurance carrier shall have
received written notice from the Administrative Agent or the Collateral Agent of the
occurrence of an Event of Default, the insurance carrier shall pay all proceeds otherwise
payable to the Borrower or the Loan Parties under such policies directly to the Collateral
Agent; cause all such policies to provide that neither the Borrower, the Administrative
Agent, the Collateral Agent nor any other party shall be a coinsurer thereunder and to
contain a “Replacement Cost Endorsement,” without any deduction for depreciation, and such
other provisions as the Administrative Agent or the Collateral Agent may reasonably require
from time to time to protect their interests; deliver original or certified copies of all
such policies to the Collateral Agent; cause each such policy to provide that it shall not be
canceled, modified or not renewed (i) by reason of nonpayment of premium upon not less than
10 days’ prior written notice thereof by the insurer to the Administrative Agent and the
Collateral Agent (giving the Administrative Agent and the Collateral Agent the right to cure
defaults in the payment of premiums) or (ii) for any other reason upon not less than 30 days’
prior written notice thereof by the insurer to the Administrative Agent and the Collateral
Agent; deliver to the Administrative Agent and the Collateral Agent, prior to the
cancellation, modification or nonrenewal of any such policy of insurance, a copy of a renewal
or replacement policy (or other evidence of renewal of a policy previously delivered to the
Administrative Agent and the Collateral Agent) together with evidence satisfactory to the
Administrative Agent and the Collateral Agent of payment of the premium therefor.

          (c) If at any time the area in which the Premises (as defined in the Mortgages) are
located is designated (i) a “flood hazard area” in any Flood Insurance Rate Map published by
the Federal Emergency Management Agency (or any successor agency), obtain flood insurance in
such total amount as the Administrative Agent, the Collateral Agent or the Required Lenders
may from time to time require, and otherwise comply with

76

 

the National Flood Insurance Program as set forth in the Flood Disaster Protection Act
of 1973, as it may be amended from time to time, or (ii) a “Zone 1” area, obtain earthquake
insurance in such total amount as the Administrative Agent, the Collateral Agent or the
Required Lenders may from time to time require.

          (d) With respect to any Mortgaged Property, carry and maintain comprehensive general
liability insurance including the “broad form CGL endorsement” and coverage on an occurrence
basis against claims made for personal injury (including bodily injury, death and property
damage) and umbrella liability insurance against any and all claims, in no event for a
combined single limit of less than that which is customary for companies in the same or
similar businesses operating in the same or similar locations, naming the Collateral Agent as
an additional insured, on forms satisfactory to the Collateral Agent.

          (e) Notify the Administrative Agent and the Collateral Agent promptly whenever any
separate insurance concurrent in form or contributing in the event of loss with that required
to be maintained under this Section 5.02 is taken out by any Loan Party; and promptly deliver
to the Administrative Agent and the Collateral Agent a duplicate original copy of such policy
or policies.

          SECTION 5.03. Obligations and Taxes. Pay its Indebtedness and other obligations promptly
when due and in accordance with their terms (it being understood that nothing in this Section shall
require the payment of amounts for which the Borrower or any Subsidiary is in good faith disputing
its liability so long as the Borrower shall have set aside on its books adequate reserves with
respect thereto in accordance with GAAP) and pay and discharge promptly when due all taxes,
assessments and governmental charges or levies imposed upon it or upon its income or profits or in
respect of its property, before the same shall become delinquent or in default, as well as all
lawful claims for labor, materials and supplies or otherwise that, if unpaid, might give rise to a
Lien upon such properties or any part thereof; provided, however, that such payment and discharge
shall not be required with respect to any such tax, assessment, charge, levy or claim so long as
the validity or amount thereof shall be contested in good faith by appropriate proceedings and the
Borrower shall have set aside on its books adequate reserves with respect thereto in accordance
with GAAP and such contest operates to suspend collection of the contested obligation, tax,
assessment or charge and enforcement of a Lien and, in the case of a Mortgaged Property, there is
no risk of forfeiture of such property.

          SECTION 5.04. Financial Statements, Reports, etc. In the case of the Borrower, furnish to
the Administrative Agent, which shall furnish to each Lender:

77

 

          (a) no later than the date that is the earlier of (i) the date by which the Annual
Report on Form 10-K of the Borrower for each fiscal year is required to be filed under the
rules and regulations of the SEC and (ii) 90 days after the end of such fiscal year, its
consolidated balance sheets and related statements of operations, stockholders’ equity and
cash flows showing the financial condition of the Borrower and its consolidated Subsidiaries
as of the close of such fiscal year and the results of its operations and the operations of
such Subsidiaries during such year, together with comparative figures for the immediately
preceding fiscal year, all audited by PricewaterhouseCoopers LLP or other independent public
accountants of recognized national standing reasonably acceptable to the Required Lenders and
accompanied by an opinion of such accountants (which shall not be qualified in any material
respect (it being agreed that any “going concern” or like qualification or exception or
exception as to the scope of such audit shall be deemed to be a material qualification)) to
the effect that such consolidated financial statements fairly present in all material
respects the financial condition and results of operations of the Borrower and its
consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently
applied, together with a customary “management discussion and analysis” provision;

          (b) no later than the date that is the earlier of (i) the date by which the Quarterly
Report on Form 10-Q of the Borrower for each of the first three fiscal quarters of each
fiscal year is required to be filed under the rules and regulations of the SEC and (ii) 45
days after the end of such fiscal quarter, its consolidated balance sheets and related
statements of operations, stockholders’ equity and cash flows showing the financial condition
of the Borrower and its consolidated Subsidiaries as of the close of such fiscal quarter and
the results of its operations and the operations of such Subsidiaries during such fiscal
quarter and the then elapsed portion of the fiscal year, and, other than with respect to
quarterly reports during the remainder of the first fiscal year after the Amendment No. 1
Effective Date, comparative figures for the same periods in the immediately preceding fiscal
year, all certified by one of its Financial Officers as fairly presenting in all material
respects the financial condition and results of operations of the Borrower and its
consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently
applied, subject to normal year-end audit adjustments, together with a customary “management
discussion and analysis” provision;

          (c) concurrently with any delivery of financial statements under paragraph (a) or (b)
above, a certificate of a Financial Officer in the form of Exhibit H (i) certifying that no
Event of Default or Default has occurred or, if such an Event of Default or Default has
occurred, specifying the nature and extent thereof and any corrective action taken or
proposed to

78

 

be taken with respect thereto and (ii) setting forth computations in reasonable detail
satisfactory to the Administrative Agent demonstrating compliance with the covenants
contained in Sections 6.10, 6.11 and 6.12 and, in the case of a certificate delivered with
the financial statements required by paragraph (a) above, setting forth the Borrower’s
calculation of Excess Cash Flow;

          (d) concurrently with any delivery of financial statements under paragraph (a) above, a
certificate of the accounting firm that reported on such statements (which certificate may be
prepared in accordance with professional accounting standards and may be limited to
accounting matters and disclaim responsibility for legal interpretations) stating that in
performing the audit necessary therefor, no knowledge was obtained of the existence of any
Event of Default or Default with respect to Sections 6.10, 6.11 or 6.12 or, if such knowledge
was obtained, specifying the existence thereof in reasonable detail;

          (e) on or prior to each date of delivery of financial statements under paragraph (a)
above, the Borrower shall provide to each Lender a business plan for the following two years,
in a form satisfactory to the Administrative Agent;

          (f) promptly after the same become publicly available, copies of all reports (excluding,
in any event, copies of press releases) which the Borrower sends to its stockholders, and
copies of all registration statements, reports on Form 10-K, Form 10-Q or Form 8-K (or, in
each case, any successor form) and other material reports which the Borrower or any
Subsidiary files with the SEC or any successor or analogous Governmental Authority (other
than public offerings of securities under employee benefit plans or dividend reinvestment
plans);

          (g) promptly after the receipt thereof by the Borrower or any Subsidiary, a copy of any
“management letter” received by any such person from its certified public accountants and the
management’s response thereto;

          (h) promptly after the request by any Lender, all documentation and other information
that such Lender reasonably requests in order to comply with its ongoing obligations under
applicable “know your customer” and anti-money laundering rules and regulations, including
the Patriot Act; and

          (i) promptly, from time to time, such other information regarding the operations,
business affairs and financial condition of the Borrower or any Subsidiary, or compliance
with the terms of any Loan Document, as the Administrative Agent or any Lender may reasonably
request.

79

 

          SECTION 5.05. Litigation and Other Notices. Furnish to the Administrative Agent, each
Issuing Bank and each Lender prompt written notice of the following:

          (a) promptly after the Borrower obtains knowledge thereof, any Event of Default or
Default, specifying the nature and extent thereof and the corrective action (if any) taken or
proposed to be taken with respect thereto;

          (b) the filing or commencement of, or any written threat or written notice of intention
of any person to file or commence, any action, suit or proceeding, whether at law or in
equity or by or before any Governmental Authority, against the Borrower or any Affiliate
thereof, as to which there is a reasonable likelihood of an adverse result and that could
reasonably be expected to result in a Material Adverse Effect;

          (c) promptly after the Borrower obtains knowledge thereof, any other development that
has resulted in, or could reasonably be expected to result in, a Material Adverse Effect; and

          (d) any change in the Borrower’s corporate rating by S&P, in the Borrower’s corporate
family rating by Moody’s or in the ratings of the Credit Facilities by S&P or Moody’s, or any
notice from either such agency indicating its intent to effect such a change or to place the
Borrower or the Credit Facilities on a “CreditWatch” or “WatchList” or any similar list, in
each case with negative implications, or its cessation of, or its intent to cease, rating the
Borrower or the Credit Facilities.

          SECTION 5.06. Information Regarding Collateral. (a) Furnish to the Administrative Agent
prompt written notice of any change (i) in any Loan Party’s corporate name, (ii) in the
jurisdiction of organization or formation of any Loan Party, (iii) in any Loan Party’s identity or
corporate structure or (iv) in any Loan Party’s Federal Taxpayer Identification Number. The
Borrower agrees not to effect or permit any change referred to in the preceding sentence unless all
filings have been made under the Uniform Commercial Code or otherwise that are required in order
for the Collateral Agent to continue at all times following such change to have a valid, legal and
perfected security interest in all the Collateral. The Borrower also agrees promptly to notify the
Administrative Agent if any material portion of the Collateral is damaged or destroyed.

          (b) In the case of the Borrower, each year commencing with the year ended December 31,
2009, at the time of delivery of the annual financial statements with respect to the
preceding fiscal year pursuant to Section 5.04(a), deliver to the Administrative Agent a
certificate of a Financial Officer setting forth the information required pursuant to Section
1 or 2 of the Perfection Certificate or confirming that there has been no change

80

 

in such information since the date of the Perfection Certificate delivered on the
Amendment No. 1 Effective Date or the date of the most recent certificate delivered pursuant
to this Section 5.06.

          SECTION 5.07. Maintaining Records; Access to Properties and Inspections; Maintenance of
Ratings. (a) Keep proper books of record and account in which full, true and correct entries
in conformity with GAAP and all requirements of law are made of all material dealings and
transactions in relation to its business and activities. Subject to the provisions of Section
9.16, each Loan Party will, and will cause each of the Subsidiaries to, permit any representatives
designated by the Administrative Agent or any Lender to visit and inspect the financial records and
the properties of the Borrower or any of the Subsidiaries upon reasonable prior notice to the
Borrower (and, unless a Default or Event of Default shall have occurred and be continuing, on not
more than two occasions during any fiscal year) and to make extracts from and copies of such
financial records, and permit any representatives designated by the Administrative Agent or any
Lender to discuss the affairs, finances and condition of the Borrower or any of the Subsidiaries
with the officers thereof and independent accountants therefor; provided that whether or not a
Default or Event of Default shall have occurred and be continuing, the Borrower shall have the
right to participate in all such discussions.

          (b) Use commercially reasonable efforts to cause the Credit Facilities to be
continuously rated by S&P and Moody’s on a public basis, and in the case of the Borrower, use
commercially reasonable efforts to maintain a public corporate rating from S&P and a public
corporate family rating from Moody’s, in each case in respect of the Borrower.

          SECTION 5.08. Use of Proceeds. Use the proceeds of the Loans and request the issuance of
Letters of Credit only to provide working capital and for other general corporate purposes,
including permitted acquisitions and the payment of the Acquisition Consideration, and the Letters
of Credit are to be used by the Borrower and the Subsidiaries for general corporate purposes.

          SECTION 5.09. Employee Benefits. (a) Comply in all material respects with the applicable
provisions of ERISA and the Code and (b) furnish to the Administrative Agent as soon as possible
after, and in any event within 10 days after any Responsible Officer of the Borrower knows that,
any ERISA Event has occurred that, alone or together with any other ERISA Events that have
occurred, could reasonably be expected to result in liability of the Borrower and/or the
Subsidiaries in an aggregate amount exceeding $5,000,000, a statement of a Financial Officer of the
Borrower setting forth details as to such ERISA Event and the action, if any, that the Borrower
proposes to take with respect thereto.

81

 

          SECTION 5.10. Compliance with Environmental Laws. Comply, and use reasonable efforts to
cause all lessees and other persons occupying its then current Properties to comply, in all
material respects with all Environmental Laws and Environmental Permits applicable to its
operations and then current Properties; obtain and renew all Environmental Permits necessary for
its operations and then current Properties except for such non-compliance as could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect;
and conduct any Remedial Action in accordance with Environmental Laws; provided, however, that
neither the Borrower nor any of the Subsidiaries shall be required to undertake any Remedial Action
to the extent that its obligation to do so is being contested in good faith and by proper
proceedings and appropriate reserves are being maintained by the Borrower with respect to such
circumstances in accordance with GAAP.

          SECTION 5.11. Preparation of Environmental Reports. If a Default caused by reason of a
breach of Section 3.17 or Section 5.10 shall have occurred and be continuing for more than 20 days
without the Borrower or any Subsidiary commencing activities reasonably likely to cure such
Default, at the written request of the Required Lenders through the Administrative Agent, provide
to the Lenders within 45 days after such request, at the expense of the Loan Parties, an
environmental site assessment report regarding the matters which are the subject of such Default
prepared by an environmental consulting firm reasonably acceptable to the Administrative Agent and
indicating the presence or absence of Hazardous Materials and the estimated cost of any compliance
or remedial action in connection with such Default.

          SECTION 5.12. Compliance with Laws. Comply with all laws, regulations, consent decrees and
orders of any Governmental Authority applicable to it or its property, except where the failure to
comply, individually or in the aggregate, could not reasonably be expected to result in a Material
Adverse Effect.

          SECTION 5.13. Further Assurances. Execute any and all further documents, financing
statements, agreements, amendments, supplements and instruments, and take all further actions
(including filing Uniform Commercial Code and other financing or continuation statements, mortgages
and deeds of trust) that may be required under applicable law, or that the Required Lenders, the
Administrative Agent or the Collateral Agent may reasonably request, in order to effectuate the
transactions contemplated by the Loan Documents and in order to grant, preserve, protect and
perfect the validity and first priority of the security interests created or intended to be created
by the Security Documents in favor of the Collateral Agent for the ratable benefit of the Secured
Parties. The Borrower will cause any subsequently acquired or organized Domestic Subsidiary to
become a Loan Party (in the case of the Target and each Domestic Subsidiary of the Target, by no
later than the Merger Date) by executing the Guarantee and Collateral Agreement and each applicable
Security Document in favor of the

82

 

Collateral Agent. In addition, from time to time, the Borrower will, at its cost and expense,
promptly secure the Obligations by pledging or creating, or causing to be pledged or created,
perfected security interests with respect to such of the assets and properties of the Loan Parties
as the Administrative Agent or the Required Lenders shall designate (it being understood that it is
the intent of the parties that the Obligations shall be secured by substantially all the assets of
the Borrower and its Domestic Subsidiaries (in the case of the Target and each Domestic Subsidiary
of the Target, such security to be granted by no later than the Merger Date) (including real and
other properties acquired subsequent to the Amendment No. 1 Effective Date but subject to
limitations and exceptions expressly set forth in the Security Documents)). Such security
interests and Liens will be created under the Security Documents and other security agreements,
mortgages, deeds of trust and other instruments and documents in form and substance reasonably
satisfactory to the Collateral Agent, and the Borrower shall deliver or cause to be delivered to
the Lenders all such instruments and documents (including legal opinions, title insurance policies
and lien searches) as the Collateral Agent shall reasonably request to evidence compliance with
this Section. The Borrower agrees to provide such evidence as the Collateral Agent shall
reasonably request as to the perfection and priority status of each such security interest and
Lien. In furtherance of the foregoing, the Borrower will give prompt notice to the Administrative
Agent of the acquisition by it or any of the Subsidiaries of any real property (or any interest in
real property) having a value in excess of $1,000,000.

          SECTION 5.14. Interest Rate Protection. No later than the 90th day after the Amendment
No. 1 Effective Date, enter into, and for a minimum of two years thereafter maintain, Hedging
Agreements acceptable to the Administrative Agent that result in at least 50% of the aggregate
principal amount of its funded long-term Indebtedness being effectively subject to a fixed or
maximum interest rate acceptable to the Administrative Agent.

          SECTION
5.15. Consummation of the Merger. Use commercially reasonable efforts to complete
the Merger (which efforts shall include voting, or causing to be voted, all of the Shares then
owned by the Borrower or any of its Subsidiaries in favor of the Merger, to the extent any such
vote is taken pursuant to the Merger Agreement) in accordance with the terms of the Merger
Agreement as promptly as practicable following the consummation of the Tender Offer.

          SECTION
5.16. Alpharma Escrow Account. If, on the date that is 45 days after the Amendment
No. 1 Effective Date, any principal remains outstanding under the Alpharma Convertible Notes,
deposit an amount equal to such unpaid principal amount into a Controlled Deposit Account subject
to a Deposit Account Control Agreement in form and substance reasonably satisfactory to the
Collateral Agent (such account, the “Alpharma Escrow Account”). The Deposit Account
Control Agreement governing the Alpharma Escrow Account shall provide that the amounts on deposit
in the Alpharma Escrow Account may only be withdrawn by the Borrower (and withdrawals shall be
subject to receipt by the Collateral Agent and

83

 

the applicable depositary bank of a certification from the Borrower (the “Withdrawal
Certificate”) that the amounts withdrawn shall be applied) for the following purposes: (i) to
make principal payments with respect to the Alpharma Convertible Notes, (ii) to pay Acquisition
Consideration (including Merger Consideration) due upon the conversion of the Alpharma Convertible
Notes in accordance with their terms or (iii) to voluntarily prepay (x) loans under the Term Loan
Credit Agreement or (y) following payment in full of the principal amount of the loans under the
Term Loan Credit Agreement, to repay Loans hereunder (which repayment shall be accompanied by a
permanent reduction in the Revolving Credit Commitments in an amount equal to such repayment).
Borrower agrees that any amounts withdrawn from the Alpharma Escrow Account shall be applied for
the purpose specified in the Withdrawal Certificate promptly and in any event not later than 3
Business Days following such withdrawal.

ARTICLE VI

Negative Covenants

          The Borrower covenants and agrees with each Lender that, so long as this Agreement shall
remain in effect and until the Commitments have been terminated and the principal of and interest
on each Loan, all Fees and all other expenses or amounts payable under any Loan Document have been
paid in full and all Letters of Credit have been cancelled or have expired and all amounts drawn
thereunder have been reimbursed in full, unless the Required Lenders shall otherwise consent in
writing, the Borrower will not, and will not cause or permit any of the Subsidiaries to:

          SECTION 6.01. Indebtedness. Incur, create, assume or permit to exist any Indebtedness,
except:

          (a) Indebtedness for borrowed money existing on the Amendment No. 1 Effective Date and
set forth in Schedule 6.01 and any extensions, renewals or replacements of such Indebtedness
to the extent that the principal amount of such Indebtedness is not increased, neither the
final maturity nor the weighted average life to maturity of such Indebtedness is decreased,
such Indebtedness, if subordinated to the Obligations, remains so subordinated on terms no
less favorable to the Lenders, and the original obligors in respect of such Indebtedness
remain the only obligors thereon;

          (b) Indebtedness of the Borrower outstanding from time to time hereunder and all
guarantees thereof by the Subsidiary Guarantors;

84

 

          (c) intercompany Indebtedness of the Borrower and the Subsidiaries to the extent
permitted by Section 6.04(c) so long as any such Indebtedness owed by any Loan Party to a
person that is not a Loan Party is subordinated to the Obligations pursuant to an Affiliate
Subordination Agreement;

          (d) Guarantees by any Loan Party of Indebtedness of any other Loan Party;

          (e) Indebtedness of the Borrower or any Subsidiary incurred to finance the acquisition,
construction or improvement of any fixed or capital assets, and extensions, renewals and
replacements of any such Indebtedness that do not increase the outstanding principal amount
thereof; provided that (i) such Indebtedness is incurred prior to or within 180 days after
such acquisition or the completion of such construction or improvement and (ii) the aggregate
principal amount of Indebtedness permitted by this Section 6.01(e), when combined with the
aggregate principal amount of all Capital Lease Obligations incurred pursuant to
Section 6.01(f) shall not exceed $25,000,000 at any time outstanding;

          (f) Capital Lease Obligations in an aggregate principal amount, when combined with the
aggregate principal amount of all Indebtedness incurred pursuant to Section 6.01(e), not in
excess of $25,000,000 at any time outstanding;

          (g) Indebtedness under performance bonds or with respect to workers’ compensation
claims, in each case incurred in the ordinary course of business;

          (h) Indebtedness incurred by Foreign Subsidiaries in an aggregate principal amount not
exceeding $25,000,000 at any time outstanding;

          (i) Indebtedness of any person that becomes a Subsidiary after the Amendment No. 1
Effective Date; provided that (i) such Indebtedness exists at the time such person becomes a
Subsidiary and is not created in contemplation of or in connection with such person becoming
a Subsidiary, (ii) immediately before and after such person becomes a Subsidiary, no Default
or Event of Default shall have occurred and be continuing and (iii) the aggregate principal
amount of Indebtedness permitted by this Section 6.01(i) shall not exceed $25,000,000 at any
time outstanding;

          (j) Indebtedness created under Hedging Agreements that (i) are required by Section 5.14
or (ii) are entered into in the ordinary course of business to hedge or mitigate risks to
which the Borrower or any

85

 

Subsidiary is exposed in the conduct of its business or the management of its
liabilities and not for speculative purposes or entered into to take advantage of reduced
interest rates by converting fixed rate obligations into floating rate obligations;

          (k) Permitted ARS Indebtedness; provided that the Specified Share of the Net Cash
Proceeds of such Indebtedness shall be applied as set forth in Section 2.13(i);

          (l) Indebtedness of the Borrower outstanding from time to time under the Term Loan
Credit Agreement in an aggregate principal amount not to exceed $200,000,000, all guarantees
thereof by any Subsidiary Guarantor and any refinancing, renewals or extensions of all or any
part thereof; provided that (i) the amount of the Indebtedness under the Term Refinanced
Indebtedness (defined below) at the time of such refinancing, renewal or extension is not
increased by the Term Refinancing Indebtedness (defined below) except by an amount equal to
reasonable fees and expenses incurred in connection with such refinancing, renewal or
extension, (ii) the maturity date of such refinancing, renewing or extending indebtedness
(the “Term Refinancing Indebtedness”) is no earlier than the maturity date of the
Indebtedness being refinanced, renewed or extended (“Term Refinanced Indebtedness”)
and the average life to maturity of such Term Refinancing Indebtedness is at least equal to
that of the Term Refinanced Indebtedness, (iii) the terms (other than pricing and yield) of
such Term Refinancing Indebtedness or of any agreement entered into or of any instrument
issued in connection therewith are not less favorable in any material respect to the Loan
Parties or the Lenders than the terms of Term Refinanced Indebtedness or any agreement or
instrument governing the Term Refinanced Indebtedness, (iv) the obligors of the Term
Refinancing Indebtedness shall not include any person that is not an obligor on the Term
Refinanced Indebtedness (unless such obligor is or becomes at such time a Loan Party), and
(v) if the Term Refinancing Indebtedness is secured, it is secured on an equal and ratable or
junior basis to the Obligations on substantially the same terms as the Term Indebtedness is
secured on the Amendment No. 1 Effective Date and otherwise on terms reasonably acceptable to
the Administrative Agent;

          (m) other Indebtedness of the Borrower or the Subsidiaries in an aggregate principal
amount not exceeding $50,000,000 at any time outstanding; provided that the aggregate
principal amount of Indebtedness of Subsidiaries that are not Subsidiary Guarantors permitted
by this clause shall not exceed $25,000,000 at any time outstanding; and

          (n) Indebtedness outstanding under the Alpharma Convertible Notes.

86

 

          SECTION 6.02. Liens. Create, incur, assume or permit to exist any Lien on any property or
assets (including Equity Interests or other securities of any person, including any Subsidiary) now
owned or hereafter acquired by it or on any income or revenues or rights in respect thereof, or
assign or transfer any such income or revenues or rights in respect thereof, except:

          (a) Liens on property or assets of the Borrower and the Subsidiaries existing on the
Amendment No. 1 Effective Date and set forth in Schedule 6.02; provided that such Liens shall
extend only to those assets to which they extend on the Amendment No. 1 Effective Date and
shall secure only those obligations which they secure on the Amendment No. 1 Effective Date;

          (b) any Lien (i) created under the Loan Documents or (ii) granted in favor of the
Swingline Lender or Issuing Bank pursuant to arrangements designed to eliminate such
Swingline Lender’s or Issuing Bank’s risk with respect to any Defaulting Lender’s or
Defaulting Lenders’ participation in Swingline Loans or Letters of Credit, respectively, as
contemplated by Section 2.03(a) or Section 2.04(a), respectively;

          (c) any Lien existing on any property or asset prior to the acquisition thereof by the
Borrower or any Subsidiary or existing on any property or assets of any person that becomes a
Subsidiary after the Amendment No. 1 Effective Date prior to the time such person becomes a
Subsidiary, as the case may be; provided that (i) such Lien is not created in contemplation
of or in connection with such acquisition or such person becoming a Subsidiary, (ii) such
Lien does not apply to any other property or assets of the Borrower or any Subsidiary, (iii)
such Lien secures only those obligations which it secures on the date of such acquisition or
the date such person becomes a Subsidiary, as the case may be and (iv) such Lien does not
materially interfere with the intended use, occupancy and operation of any asset or property
subject thereto;

          (d) Liens for taxes, assessments, charges or levies not yet due or which are being
contested in compliance with Section 5.03;

          (e) carriers’, warehousemen’s, mechanics’, landlord’s (or lessor’s under operating
leases), materialmen’s, repairmen’s, custom and revenue authorities’, or other like Liens
arising in the ordinary course of business and securing obligations that are not due and
payable beyond the applicable grace period therefor or that are being contested in compliance
with Section 5.03;

          (f) pledges and deposits made in the ordinary course of business in compliance with
workmen’s compensation, unemployment insurance and other social security laws or regulations;

87

 

          (g) deposits to secure the performance of bids, trade contracts (other than for
Indebtedness), leases (other than Capital Lease Obligations), statutory obligations,
liability to insurance carriers under insurance or self-insurance arrangements, surety and
appeal bonds, performance bonds, statutory bankers’ liens on moneys held in bank accounts and
other obligations of a like nature, in each case incurred in the ordinary course of business;

          (h) zoning restrictions, easements, rights-of-way, restrictions on use of real property
and other similar encumbrances incurred in the ordinary course of business which, in the
aggregate, are not substantial in amount and do not materially detract from the value of the
property subject thereto or interfere with the ordinary conduct of the business of the
Borrower or any of the Subsidiaries;

          (i) purchase money security interests in real property, improvements thereto or
equipment hereafter acquired (or, in the case of improvements, constructed) by the Borrower
or any Subsidiary; provided that (i) such security interests secure Indebtedness permitted by
Section 6.01, (ii) such security interests are incurred, and the Indebtedness secured thereby
is created, within 180 days after such acquisition (or construction), (iii) the Indebtedness
secured thereby does not exceed the lesser of the cost or the fair market value of such real
property, improvements or equipment at the time of such acquisition (or construction) and
(iv) such security interests do not apply to any other property or assets of the Borrower or
any Subsidiary;

          (j) Liens deemed to exist in connection with Capital Lease Obligations permitted under
Section 6.01;

          (k) attachment or judgment Liens not constituting an Event of Default under Article VII;

          (l) Liens on assets of Foreign Subsidiaries; provided that (i) such Liens do not extend
to, or encumber, assets that constitute Collateral or the Equity Interests of any of the
Subsidiaries, and (ii) such Liens extending to the assets of any Foreign Subsidiary secure
only Indebtedness incurred by such Foreign Subsidiary pursuant to Section 6.01(h);

          (m) Liens in favor of any Governmental Authority with respect to progress payments under
any governmental contract entered into in the ordinary course of business;

          (n) Liens on Margin Stock if and to the extent that the value of all such Margin Stock
exceeds 25% of the value of the total assets subject to the restrictions on Liens set forth
in this Section 6.02;

88

 

          (o) Liens on auction rate securities of the Borrower or any other Loan Party (or on the
securities account to which such auction rate securities are credited (so long as no other
securities are credited thereto) and proceeds thereof); provided that (i) such Liens secure
Permitted ARS Indebtedness and (ii) such Liens do not apply to any other property or assets
of the Borrower or any Subsidiary;

          (p) licenses, sublicenses, leases and subleases not relating to any financing, granted
to third persons in the ordinary course of business and not interfering in any material
respect with the business of the Borrower and the Subsidiaries;

          (q) Liens attaching to assets (other than Collateral) with an aggregate fair market
value at the time of attachment not in excess of, and securing liabilities not in excess of,
$20,000,000 in the aggregate at any time outstanding; and

          (r) Liens securing obligations under the Term Loan Documents or securing Term
Refinancing Indebtedness permitted by Section 6.01(l) covering Collateral that is also
subject to Liens in favor of the Collateral Agent for the benefit of the Secured Parties
(“Term Liens”); provided that such Liens are pari passu with, or junior to, the Liens
securing the Obligations on terms substantially the same as those applicable to the Liens
securing the obligations under the Term Loan Documents on the Amendment No. 1 Effective Date
or otherwise on terms reasonably acceptable to the Administrative Agent.

          SECTION 6.03. Sale and Leaseback Transactions. Enter into any arrangement, directly or
indirectly, with any person whereby it shall sell or transfer any property, real or personal, used
or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease
such property or other property which it intends to use for substantially the same purpose or
purposes as the property being sold or transferred unless (a) the sale or transfer of such property
is permitted by Section 6.05 and (b) any Capital Lease Obligations or Liens arising in connection
therewith are permitted by Sections 6.01 and 6.02, as the case may be.

          SECTION 6.04. Investments, Loans and Advances. Purchase, hold or acquire any Equity
Interests, evidences of indebtedness or other securities of, make or permit to exist any loans or
advances to, or make or permit to exist any similar investment or any other similar interest in,
any other person, except:

          (a) (i) investments by the Borrower and the Subsidiaries existing on the Amendment No. 1
Effective Date in the Equity Interests of the Subsidiaries and other investments existing on
the Amendment No. 1 Effective Date and set forth on Schedule 6.04(a) and (ii) additional

89

 

investments by the Borrower and the Subsidiaries in the Equity Interests of the
Subsidiaries; provided that (A) any such Equity Interests held by a Loan Party shall be
pledged pursuant to the Guarantee and Collateral Agreement (subject to the limitations
referred to therein) and (B) the aggregate amount of investments made after the Amendment
No. 1 Effective Date by Loan Parties in, and loans and advances made after the Amendment
No. 1 Effective Date by Loan Parties to, Subsidiaries that are not Loan Parties (determined
without regard to any write-downs or write-offs of such investments, loans and advances)
shall not exceed $20,000,000 at any time outstanding;

          (b) Permitted Investments;

          (c) loans or advances made by the Borrower to any Subsidiary and made by any Subsidiary
to the Borrower or any other Subsidiary; provided that (i) any such loans and advances made
by a Loan Party shall be evidenced by a promissory note pledged to the Collateral Agent for
the ratable benefit of the Secured Parties pursuant to the Guarantee and Collateral
Agreement, (ii) such loans and advances made to any Loan Party by any Subsidiary that is not
a Loan Party shall be unsecured and subordinated to the Obligations pursuant to an Affiliate
Subordination Agreement and (iii) the amount of such loans and advances made by Loan Parties
to Subsidiaries that are not Loan Parties shall be subject to the limitation set forth in
clause (a) above;

          (d) repurchases by the Borrower of its common stock to the extent permitted under
Section 6.06;

          (e) Guarantees by any Loan Party of the Convertible Notes;

          (f) extensions of trade credit in the ordinary course of business;

          (g) investments received in connection with the bankruptcy or reorganization of, or
settlement of delinquent accounts and disputes with, customers and suppliers, in each case in
the ordinary course of business;

          (h) loans and advances to officers and employees of the Borrower or any Subsidiary in
the ordinary course of business (including for travel, entertainment, payroll advances and
relocation expenses) in an aggregate principal amount outstanding at any time when taken
together with the aggregate principal amount outstanding of investments made under clause (i)
below (in each case determined without regard to any write-downs or write-offs of such loans
and advances) not to exceed $20,000,000 at such time;

90

 

          (i) promissory notes or other evidences of Indebtedness received by the Borrower from
officers or employees of the Borrower or any Subsidiary (or any loan or advance made to any
Plan) in connection with the purchase of Equity Interests in the Borrower in an aggregate
principal amount outstanding at any time when taken together with the aggregate principal
amount outstanding of investments made under clause (h) above (in each case determined
without regard to any write-downs or write-offs of such loans and advances) not to exceed
$20,000,000 at such time;

          (j) the Borrower and the Subsidiaries may enter into Hedging Agreements permitted under
Section 6.01(j);

          (k) the Acquisition;

          (l) the Borrower or any Subsidiary may acquire all or substantially all the assets of a
person or line of business of such person, or not less than 100% of the Equity Interests
(other than directors’ qualifying shares) of a person (referred to herein as the
“Acquired Entity”); provided that (i) such acquisition was not preceded by an
unsolicited tender offer for such Equity Interests by, or proxy contest initiated by, the
Borrower or any Subsidiary; (ii) the Acquired Entity shall be in a similar line of business
as that of the Borrower or any of its Subsidiaries as conducted during the current and most
recent calendar year (or business activities reasonably incidental thereto); and (iii) at the
time of such transaction (A) both before and after giving effect thereto, no Default or Event
of Default shall have occurred and be continuing; (B) the Borrower would be in compliance
with the covenants set forth in Sections 6.11 and 6.12 as of the most recently completed
period of four consecutive fiscal quarters ending prior to such transaction for which the
financial statements and certificates required by Section 5.04(a) or 5.04(b), as the case may
be, and 5.04(c) have been delivered or for which comparable financial statements have been
filed with the SEC, after giving pro forma effect to such transaction and to any other event
occurring after such period as to which pro forma recalculation is appropriate (including any
other transaction described in this Section 6.04(l) occurring after such period) as if such
transaction had occurred as of the first day of such period (assuming, for purposes of pro
forma compliance with Section 6.12, that the maximum Leverage Ratio permitted at the time by
such Section was in fact 0.25 to 1.00 less than the ratio actually provided for in such
Section at such time); (C) after giving effect to such acquisition, the aggregate amount of
unused and available Revolving Credit Commitments, cash and Permitted Investments of the
Borrower and the Subsidiaries must be at least $50,000,000; (D) the total consideration paid
in connection with such acquisition and any other acquisitions pursuant to this
Section 6.04(l) (including any Indebtedness of the Acquired Entity that is assumed by the
Borrower or any Subsidiary following such acquisition and any payments following such
acquisition pursuant to earn-out provisions or similar

91

 

obligations) shall not in the aggregate exceed $200,000,000 during the term of this
Agreement; (E) the Borrower shall have delivered a certificate of a Financial Officer,
certifying as to the foregoing and containing reasonably detailed calculations in support
thereof, in form and substance satisfactory to the Administrative Agent and (F) the Borrower
shall comply, and shall cause the Acquired Entity to comply, with the applicable provisions
of Section 5.13 and the Security Documents (any acquisition of an Acquired Entity meeting all
the criteria of this Section 6.04(l) being referred to herein as a “Permitted
Acquisition”);

          (m) investments, loans or advances made in connection with the license, development,
manufacture or distribution of pharmaceutical compounds or products or medical devices, in
each case from or through third parties (including other pharmaceutical companies) by
collaborative efforts or otherwise and in the ordinary course of business;

          (n)
investment received as consideration for Asset Sales permitted by
Section 6.05(b); and

          (o) additional investments, loans and advances by the Borrower and the Subsidiaries
(other than an investment of the type described in clause (h) or (i) above) so long as the
aggregate amount invested, loaned or advanced pursuant to this paragraph (o) (determined
without regard to any write-downs or write-offs of such investments, loans and advances) does
not exceed $50,000,000 in the aggregate.

          SECTION 6.05. Mergers, Consolidations, Sales of Assets and Acquisitions. (a) Merge into or
consolidate with any other person, or permit any other person to merge into or consolidate with it,
or sell, transfer, lease or otherwise dispose of (in one transaction or in a series of
transactions) all or substantially all the assets (whether now owned or hereafter acquired) of the
Borrower or less than all the Equity Interests of any Subsidiary, or purchase, lease or otherwise
acquire (in one transaction or a series of transactions) all or any substantial part of the assets
of any other person or assets that are substantial in relation to the Borrower and the Subsidiaries
taken as a whole, except that (i) the Borrower and any Subsidiary may purchase and sell inventory
in the ordinary course of business and (ii) if at the time thereof and immediately after giving
effect thereto no Event of Default or Default shall have occurred and be continuing, (A) any Wholly
Owned Subsidiary may merge into the Borrower in a transaction in which the Borrower is the
surviving corporation, (B) any Wholly Owned Subsidiary may merge into or consolidate with any other
Wholly Owned Subsidiary in a transaction in which the surviving entity is a Wholly Owned Subsidiary
and no person other than the Borrower or a Wholly Owned Subsidiary receives any consideration
(provided that if any party to any such transaction is a Loan Party, the surviving entity of such
transaction shall be a Loan Party), (C) the

92

 

Acquisition shall be permitted and (D) the Borrower and the Subsidiaries may make Permitted
Acquisitions.

               (b) Make any Asset Sale
otherwise permitted under paragraph (a)
above unless (i) such Asset Sale is for consideration at least 85% of which is cash; provided that
(x) any Asset Sales constituting licenses of intellectual property relating to pharmacological
products or medical devices may be for consideration at least 85% of which is cash or royalty
payments and (y) any Asset Sale constituting a Required Divestiture may be for consideration at
least 85% of which is cash payable within 20 months following the date of consummation of such
Asset Sale, (ii) such consideration is at least equal to the fair market value of the assets being
sold, transferred, leased or disposed of and (iii) the fair market value of all assets sold,
transferred, leased or disposed of pursuant to this
paragraph (b)
(other than auction rate securities and other than Required Divestitures) shall not exceed
$200,000,000 in the aggregate during the term of this Agreement.

          SECTION 6.06. Restricted Payments; Restrictive Agreements. (a) Declare or make, or agree
to declare or make, directly or indirectly, any Restricted Payment (including pursuant to any
Synthetic Purchase Agreement), or incur any obligation (contingent or otherwise) to do so;
provided, however, that (i) the Borrower may declare and pay dividends or make other distributions
on its capital stock to the extent made solely with common stock of the Borrower, (ii) any
Subsidiary may declare and pay dividends or make other distributions ratably to its equity holders,
(iii) so long as no Event of Default or Default shall have occurred and be continuing or would
result therefrom, the Borrower may repurchase its Equity Interests owned by employees of the
Borrower or the Subsidiaries or make payments to employees of the Borrower or the Subsidiaries upon
termination of employment in connection with the exercise of stock options, stock appreciation
rights or similar equity incentives or equity based incentives pursuant to management incentive
plans or in connection with the death or disability of such employees in an aggregate amount not to
exceed $5,000,000 in any fiscal year, (iv) so long as no Event of Default or Default shall have
occurred and be continuing or would result therefrom, the Borrower may make additional Restricted
Payments in an aggregate amount not to exceed $5,000,000 in any fiscal year and (v) the Borrower
may pay the Acquisition Consideration.

               (b) Enter into, incur or permit to exist any agreement or other arrangement that prohibits,
restricts or imposes any condition upon (i) the ability of the Borrower or any Subsidiary to
create, incur or permit to exist any Lien upon any of its property or assets, or (ii) the ability
of any Subsidiary to pay dividends or other distributions with respect to any of its Equity
Interests or to make or repay loans or advances to the Borrower or any other Subsidiary or to
Guarantee Indebtedness of the Borrower or any other Subsidiary; provided that (A) the foregoing
shall not apply to restrictions and conditions imposed by law,

93

 

any Loan Document, the Term Loan Credit Agreement or any agreement governing Term Refinancing
Indebtedness (subject to clause (iii) of Section 6.01(l)), (B) the foregoing shall not apply to
customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary
pending such sale, provided such restrictions and conditions apply only to the Subsidiary that is
to be sold and such sale is permitted hereunder, (C) the foregoing shall not apply to restrictions
and conditions imposed on any Foreign Subsidiary by the terms of any Indebtedness of such Foreign
Subsidiary permitted to be incurred hereunder, (D) clause (i) of the
foregoing shall not apply to restrictions or conditions imposed by any agreement relating to
secured Indebtedness permitted by this Agreement if such restrictions or conditions apply only to
the property or assets securing such Indebtedness and (E) clause (i)
of the foregoing shall not apply to customary provisions in leases and other contracts restricting
the assignment thereof.

          SECTION 6.07. Transactions with Affiliates. Sell or transfer any property or assets to, or
purchase or acquire any property or assets from, or otherwise engage in any other transactions
with, any of its Affiliates, except that (a) this Section shall not apply to transactions solely
between or among Loan Parties and (b) the Borrower or any Subsidiary may engage in any of the
foregoing transactions in the ordinary course of business at prices and on terms and conditions not
less favorable to the Borrower or such Subsidiary than could be obtained on an arm’s-length basis
from unrelated third parties.

          SECTION 6.08. Business of Borrower and Subsidiaries. Engage to any material extent at any
time in any business or business activity other than the business currently conducted by it and
business activities reasonably incidental thereto.

          SECTION 6.09. Other Indebtedness and Agreements. (a) Permit (i) any waiver, supplement,
modification or amendment of the Convertible Notes, the Convertible Note Indenture or any other
document relating to the Convertible Notes, (ii) except in connection with a refinancing permitted
by Section 6.01(l), any waiver, supplement, modification or amendment of the Term Loan Documents or
of documents governing Term Refinancing Indebtedness, if such waiver, supplement, modification or
amendment would (A) increase the amount of Term Indebtedness thereunder except by an amount equal
to reasonable fees and expenses incurred in connection with such waiver, supplement, modification
or amendment (B) change the maturity date to a date that is earlier than the maturity date in
effect immediately prior to such amendment, (C) shorten the average life to maturity of such Term
Indebtedness, (D) result in the terms of such Term Indebtedness or of any agreement entered into or
of any instrument issued in connection therewith to be less favorable in any material respect to
the Loan Parties or the Lenders, (E) add any obligor (unless such obligor is or becomes at such
time a Loan Party) or (F) cause the Term Indebtedness to be secured on a

94

 

basis other than equally and ratably with, or junior to, the Obligations on substantially the same
terms as the Term Indebtedness is secured on the Amendment No. 1 Effective Date except as shall be
acceptable to the Administrative Agent, (iii) any waiver, supplement, modification, amendment,
termination or release of any other indenture, instrument or agreement pursuant to which any other
Material Indebtedness of the Borrower or any of the Subsidiaries is outstanding if the effect of
such waiver, supplement, modification, amendment, termination or release would materially increase
the obligations of the obligor or confer additional material rights on the holder of such
Indebtedness in a manner adverse to the Borrower, any of the Subsidiaries or the Lenders or (iv)
any waiver, supplement, modification or amendment of (A) its certificate of incorporation, bylaws,
operating, management or partnership agreement or other organizational documents or (B) any other
agreement that is material to the conduct of its business, to the extent any such waiver,
supplement, modification or amendment would be adverse to the Lenders in any material respect.

               (b) (i) Permit any alteration, amendment or other change or supplement to the Tender Offer
Documentation or the Merger Agreement that could reasonably be expected to be materially adverse to
the rights or interests of the Administrative Agent or the Lenders or (ii) permit any waiver,
alteration, amendment or other change or supplement to any condition to the Tender Offer
Documentation or the Merger Agreement without the prior written consent of the Joint Arrangers
(such consent not to be unreasonably withheld or delayed).

               (c) (i) Make any distribution, whether in cash, property, securities or a combination thereof,
other than regular scheduled payments of principal and interest as and when due (to the extent not
prohibited by applicable subordination provisions), in respect of, or pay, or commit to pay, or
directly or indirectly (including pursuant to any Synthetic Purchase Agreement) redeem, repurchase,
retire or otherwise acquire for consideration, or set apart any sum for the aforesaid purposes, any
Indebtedness except (A) the payment of the Indebtedness created hereunder, (B) the payment of the
Term Indebtedness, (C) refinancings of Indebtedness permitted by Section 6.01(a), (D) the payment
of secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the
property or assets securing such Indebtedness, (E) any payment of Indebtedness owed by Foreign
Subsidiaries that is not subordinated in right of payment to the Obligations , (F) so long as no
Default or Event of Default shall have occurred and be continuing, any payments with respect to
Indebtedness that (x) has an aggregate outstanding principal amount not greater than $25,000,000
and (y) is not subordinated in right of payment to the Obligations and (G) the payment of the
Indebtedness under Alpharma Convertible Notes or (ii) pay in cash any amount in respect of any
Indebtedness or preferred Equity Interests that may at the obligor’s option be paid in kind or in
other securities.

          SECTION
6.10. Capital Expenditures. (a) Permit the aggregate amount of Capital
Expenditures made by the Borrower and the Subsidiaries in any

95

 

fiscal year set forth below to exceed the amount set forth below for such fiscal year:

	 	 	 	 	 
	Period	 	Amount
	Fiscal year ended 12/31/09
	 	$	95,000,000	 
	Fiscal year ended 12/31/10
	 	$	95,000,000	 
	Fiscal year ended 12/31/11
	 	$	100,000,000	 
	Fiscal year ended 12/31/12
	 	$	105,000,000	 

          The amount of permitted Capital Expenditures set forth above in respect of any fiscal year
commencing with the fiscal year ending on December 31, 2010, shall be increased (but not decreased)
by (a) an amount equal to 50% of the amount of unused permitted Capital Expenditures for the
immediately preceding fiscal year less (b) an amount equal to unused Capital Expenditures carried
forward to such preceding fiscal year.

          SECTION 6.11. Consolidated Interest Expense Coverage Ratio. Permit the Consolidated
Interest Expense Coverage Ratio for any period of four consecutive fiscal quarters, in each case
taken as one accounting period, ending on a date set forth below (excluding any such date occurring
prior to the last day of the first full fiscal quarter following the Amendment No. 1 Effective
Date) to be less than:

          (a) for any such date occurring on or prior to the last day of the fiscal quarter in which the
Skelaxin Trigger Event occurs, the ratio set forth below opposite such date:

	 	 	 	 	 
	Date	 	Ratio
	03/31/09
	 	 	4.00:1	 
	06/30/09
	 	 	4.00:1	 
	09/30/09
	 	 	4.00:1	 
	12/31/09
	 	 	4.00:1	 
	03/31/10
	 	 	4.00:1	 
	06/30/10
	 	 	4.00:1	 
	09/30/10
	 	 	4.00:1	 
	12/31/10
	 	 	4.00:1	 
	03/31/11
	 	 	4.00:1	 
	06/30/11
	 	 	4.00:1	 

96

 

	 	 	 	 	 
	Date	 	Ratio
	09/30/11
	 	 	4.00:1	 
	12/31/11
	 	 	4.00:1	 
	03/31/12
	 	 	4.00:1	 

          (b) thereafter, the ratio set forth below opposite such date:

	 	 	 	 	 
	Date	 	Ratio
	03/31/09
	 	 	3.75:1	 
	06/30/09
	 	 	3.75:1	 
	09/30/09
	 	 	3.75:1	 
	12/31/09
	 	 	3.75:1	 
	03/31/10
	 	 	3.75:1	 
	06/30/10
	 	 	3.75:1	 
	09/30/10
	 	 	4.00:1	 
	12/31/10
	 	 	4.00:1	 
	03/31/11
	 	 	4.00:1	 
	06/30/11
	 	 	4.00:1	 
	09/30/11
	 	 	4.00:1	 
	12/31/11
	 	 	4.00:1	 
	03/31/12
	 	 	4.00:1	 

          SECTION 6.12. Maximum Leverage Ratio. Permit the Leverage Ratio on any date during a
period set forth below (excluding any such date prior to the last day of the first full fiscal
quarter to end following the Amendment No. 1 Effective Date) to be greater than:

          (a) for any such date prior to the last day of the fiscal quarter in which the Skelaxin
Trigger Event occurs, the ratio set forth below opposite such period:

	 	 	 	 	 
	Period	 	Ratio
	03/31/09 through 06/29/09
	 	 	2.25:1	 
	06/30/09 through 09/29/09
	 	 	2.50:1	 

97

 

	 	 	 	 	 
	Period	 	Ratio
	09/30/09 through 12/30/09
	 	 	2.65:1	 
	12/31/09 through 03/30/10
	 	 	2.30:1	 
	03/31/10 through 06/29/10
	 	 	2.10:1	 
	06/30/10 through 09/29/10
	 	 	2.00:1	 
	09/30/10 through 12/30/10
	 	 	1.75:1	 
	12/31/10 through 03/30/11
	 	 	1.50:1	 
	03/31/11 through 06/29/11
	 	 	1.50:1	 
	06/30/11 through 09/29/11
	 	 	1.50:1	 
	09/30/11 through 12/30/11
	 	 	1.50:1	 
	12/31/11 through 03/30/12
	 	 	1.50:1	 
	03/31/12 through Maturity Date
	 	 	1.50:1	 

          (b) thereafter, the ratio set forth below opposite such period:

	 	 	 	 	 
	Period	 	Ratio
	03/31/09 through 06/29/09
	 	 	2.25:1	 
	06/30/09 through 09/29/09
	 	 	2.50:1	 
	09/30/09 through 12/30/09
	 	 	3.25:1	 
	12/31/09 through 03/30/10
	 	 	3.25:1	 
	03/31/10 through 06/29/10
	 	 	3.25:1	 
	06/30/10 through 09/29/10
	 	 	3.15:1	 
	09/30/10 through 12/30/10
	 	 	2.70:1	 
	12/31/10 through 03/30/11
	 	 	2.10:1	 
	03/31/11 through 06/29/11
	 	 	2.00:1	 
	06/30/11 through 09/29/11
	 	 	2.00:1	 
	09/30/11 through 12/30/11
	 	 	2.00:1	 
	12/31/11 through 03/30/12
	 	 	2.00:1	 
	03/31/12 through Maturity Date
	 	 	1.50:1	 

98

 

          SECTION 6.13. Fiscal Year. Change the end of its fiscal year from December 31 to any other
date.

          SECTION 6.14. Certain Equity Securities. Issue any Equity Interest that is not Qualified
Capital Stock.

ARTICLE VII

Events of Default

          In case of the happening of any of the following events (“Events of Default”):

          (a) any representation or warranty made or deemed made in or in connection with any Loan
Document or the Borrowings or issuances of Letters of Credit hereunder, or any
representation, warranty, statement or information contained in any report, certificate,
financial statement or other instrument furnished in connection with or pursuant to any Loan
Document, shall prove to have been false or misleading in any material respect when so made,
deemed made or furnished;

          (b) default shall be made in the payment of any principal of any Loan or any
reimbursement with respect to any L/C Disbursement when and as the same shall become due and
payable, whether at the due date thereof or at a date fixed for prepayment thereof or by
acceleration thereof or otherwise;

          (c) default shall be made in the payment of any interest on any Loan or any Fee or L/C
Disbursement or any other amount (other than an amount referred to in (b) above) due under
any Loan Document, when and as the same shall become due and payable, and such default shall
continue unremedied for a period of three Business Days;

          (d) default shall be made in the due observance or performance by the Borrower or any
Subsidiary of any covenant, condition or agreement contained in Section 5.01(a), 5.02, 5.05,
5.08 or 5.16 or in Article VI;

          (e) default shall be made in the due observance or performance by the Borrower or any
Subsidiary of any covenant, condition or agreement contained in any Loan Document (other than
those specified in (b), (c) or (d) above) and such default shall continue unremedied for a
period of 30 days after the earlier of (i) notice thereof from the Administrative Agent or
any Lender to the Borrower or (ii) knowledge thereof of the Borrower;

99

 

          (f) (i) the Borrower or any Subsidiary shall fail to pay any principal or interest,
regardless of amount, due in respect of any Material Indebtedness, when and as the same shall
become due and payable, (ii) any other event or condition occurs that results in any Material
Indebtedness becoming due prior to its scheduled maturity or that enables or permits (with or
without the giving of notice, the lapse of time or both) the holder or holders of any
Material Indebtedness (other than any Term Indebtedness) or any trustee or agent on its or
their behalf to cause any Material Indebtedness (other than any Term Indebtedness) to become
due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its
scheduled maturity; provided that this clause (ii) shall not apply to secured Indebtedness
that becomes due as a result of the voluntary sale or transfer of the property or assets
securing such Indebtedness or (iii) any “Event of Default” (as defined in the Term Loan
Credit Agreement) shall occur;

          (g) an involuntary proceeding shall be commenced or an involuntary petition shall be
filed in a court of competent jurisdiction seeking (i) relief in respect of the Borrower or
any Subsidiary, or of a substantial part of the property or assets of the Borrower or a
Subsidiary, under Title 11 of the United States Code, as now constituted or hereafter
amended, or any other Federal, state or foreign bankruptcy, insolvency, receivership or
similar law, (ii) the appointment of a receiver, trustee, custodian, sequestrator,
conservator or similar official for the Borrower or any Subsidiary or for a substantial part
of the property or assets of the Borrower or a Subsidiary or (iii) the winding-up or
liquidation of the Borrower or any Subsidiary; and such proceeding or petition shall continue
undismissed for 60 days or an order or decree approving or ordering any of the foregoing
shall be entered;

          (h) the Borrower or any Subsidiary shall (i) voluntarily commence any proceeding or file
any petition seeking relief under Title 11 of the United States Code, as now constituted or
hereafter amended, or any other Federal, state or foreign bankruptcy, insolvency,
receivership or similar law, (ii) consent to the institution of, or fail to contest in a
timely and appropriate manner, any proceeding or the filing of any petition described in (g)
above, (iii) apply for or consent to the appointment of a receiver, trustee, custodian,
sequestrator, conservator or similar official for the Borrower or any Subsidiary or for a
substantial part of the property or assets of the Borrower or any Subsidiary, (iv) file an
answer admitting the material allegations of a petition filed against it in any such
proceeding, (v) make a general assignment for the benefit of creditors, (vi) become unable,
admit in writing its inability or fail generally to pay its debts as they become due or (vii)
take any action for the purpose of effecting any of the foregoing;

          (i) one or more judgments shall be rendered against the Borrower, any Subsidiary or any
combination thereof and the same shall remain undischarged for a period of 30 consecutive
days during which

100

 

execution shall not be effectively stayed, or any action shall be legally taken by a
judgment creditor to levy upon assets or properties of the Borrower or any Subsidiary to
enforce any such judgment and such judgment either (i) is for the payment of money in an
aggregate amount in excess of $35,000,000 or (ii) is for injunctive relief and could
reasonably be expected to result in a Material Adverse Effect;

          (j) an ERISA Event shall have occurred that, when taken together with all other such
ERISA Events, could reasonably be expected to result in liability of the Borrower and its
ERISA Affiliates in an aggregate amount exceeding $35,000,000;

          (k) any Guarantee under the Guarantee and Collateral Agreement for any reason shall
cease to be in full force and effect (other than in accordance with its terms), or any
Guarantor shall deny in writing that it has any further liability under the Guarantee and
Collateral Agreement (other than as a result of the discharge of such Guarantor in accordance
with the terms of the Loan Documents);

          (l) any security interest purported to be created by any Security Document shall cease
to be, or shall be asserted by the Borrower or any other Loan Party not to be, a valid,
perfected, first priority (except as otherwise expressly provided in this Agreement or such
Security Document) security interest in the securities, assets or properties covered thereby,
except to the extent that any such loss of perfection or priority results from the failure of
the Collateral Agent to (i) maintain possession of certificates representing securities
pledged under the Guarantee and Collateral Agreement or (ii) file or record any financing
statement delivered to the Collateral Agent by the Borrower; or

          (m) there shall have occurred a Change in Control;

then, and in every such event (other than an event with respect to the Borrower described in
paragraph (g) or (h) above), and at any time thereafter during the continuance of such event, the
Administrative Agent may, and at the request of the Required Lenders shall, by notice to the
Borrower, take either or both of the following actions, at the same or different times: (i)
terminate forthwith the Commitments and (ii) declare the Loans then outstanding to be forthwith due
and payable in whole or in part, whereupon the principal of the Loans so declared to be due and
payable, together with accrued interest thereon and any unpaid accrued Fees and all other
liabilities of the Borrower accrued hereunder and under any other Loan Document, shall become
forthwith due and payable, without presentment, demand, protest or any other notice of any kind,
all of which are hereby expressly waived by the Borrower, anything contained herein or in any other
Loan Document to the contrary notwithstanding; and in any event with respect to the Borrower
described in paragraph (g) or (h) above, the Commitments

101

 

shall automatically terminate and the principal of the Loans then outstanding, together with
accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower
accrued hereunder and under any other Loan Document, shall automatically become due and payable,
without presentment, demand, protest or any other notice of any kind, all of which are hereby
expressly waived by the Borrower, anything contained herein or in any other Loan Document to the
contrary notwithstanding.

ARTICLE VIII

The Administrative Agent and the Collateral Agent

          Each Lender and each Issuing Bank hereby irrevocably appoints the Administrative Agent and the
Collateral Agent (for purposes of this Article VIII, the Administrative Agent and the Collateral
Agent are referred to collectively as the “Agents”) its agent and authorizes the Agents to
take such actions on its behalf and to exercise such powers as are delegated to such Agent by the
terms of the Loan Documents, together with such actions and powers as are reasonably incidental
thereto. Without limiting the generality of the foregoing, the Agents are hereby expressly
authorized to (i) execute any and all documents (including releases) with respect to the Collateral
and the rights of the Secured Parties with respect thereto, as contemplated by and in accordance
with the provisions of this Agreement and the Security Documents and (ii) negotiate, enforce or
settle any claim, action or proceeding affecting the Lenders in their capacity as such, at the
direction of the Required Lenders, which negotiation, enforcement or settlement will be binding
upon each Lender. The institution serving as the Administrative Agent and/or the Collateral Agent
hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and
may exercise the same as though it were not an Agent, and such bank and its Affiliates may accept
deposits from, lend money to and generally engage in any kind of business with the Borrower or any
Subsidiary or other Affiliate thereof as if it were not an Agent hereunder.

          Neither Agent shall have any duties or obligations except those expressly set forth in the
Loan Documents. Without limiting the generality of the foregoing, (a) neither Agent shall be
subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and
is continuing, (b) neither Agent shall have any duty to take any discretionary action or exercise
any discretionary powers, except discretionary rights and powers expressly contemplated hereby that
such Agent is instructed in writing to exercise by the Required Lenders (or such other number or
percentage of the Lenders as shall be necessary under the circumstances as provided in
Section 9.08), and (c) except as expressly set forth in the Loan Documents, neither Agent shall
have any duty to disclose, nor shall it be liable for the failure to disclose, any information
relating to the Borrower or any of the Subsidiaries that is communicated to or obtained by the bank
serving as Administrative Agent and/or Collateral Agent or any of its

102

 

Affiliates in any capacity. Neither Agent shall be liable for any action taken or not taken
by it with the consent or at the request of the Required Lenders (or such other number or
percentage of the Lenders as shall be necessary under the circumstances as provided in
Section 9.08) or in the absence of its own gross negligence or willful misconduct. Neither Agent
shall be deemed to have knowledge of any Default unless and until written notice thereof is given
to such Agent by the Borrower or a Lender, and neither Agent shall be responsible for or have any
duty to ascertain or inquire into (i) any statement, warranty or representation made in or in
connection with any Loan Document, (ii) the contents of any certificate, report or other document
delivered thereunder or in connection therewith, (iii) the performance or observance of any of the
covenants, agreements or other terms or conditions set forth in any Loan Document, (iv) the
validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement,
instrument or document, or (v) the satisfaction of any condition set forth in Article IV or
elsewhere in any Loan Document, other than to confirm receipt of items expressly required to be
delivered to such Agent.

          Each Agent shall be entitled to rely upon, and shall not incur any liability for relying upon,
any notice, request, certificate, consent, statement, instrument, document or other writing
believed by it to be genuine and to have been signed or sent by the proper person. Each Agent may
also rely upon any statement made to it orally or by telephone and believed by it to have been made
by the proper person, and shall not incur any liability for relying thereon. Each Agent may
consult with legal counsel (who may be counsel for the Borrower), independent accountants and other
experts selected by it, and shall not be liable for any action taken or not taken by it in
accordance with the advice of any such counsel, accountants or experts.

          Each Agent may perform any and all its duties and exercise its rights and powers by or through
any one or more sub-agents appointed by it. Each Agent and any such sub-agent may perform any and
all its duties and exercise its rights and powers by or through their respective Related Parties.
The exculpatory provisions of the preceding paragraphs shall apply to any such sub-agent and to the
Related Parties of each Agent and any such sub-agent, and shall apply to their respective
activities in connection with the syndication of the Credit Facilities as well as activities as
Agent.

          Subject to the appointment and acceptance of a successor Agent as provided below, either Agent
may resign at any time by notifying the Lenders, the Issuing Banks and the Borrower. Upon any such
resignation, the Required Lenders shall have the right, in consultation with the Borrower, to
appoint a successor (subject to any restriction on appointing a successor Collateral Agent set
forth in the Security Documents). If no successor shall have been so appointed by the Required
Lenders and shall have accepted such appointment within 30 days after the retiring Agent gives
notice of its resignation, then the retiring Agent may, on behalf of the Lenders and the Issuing
Banks, appoint a

103

 

successor Agent which shall be a bank with an office in New York, New York, or an Affiliate of
any such bank. If no successor Agent has been appointed pursuant to the immediately preceding
sentence by the 30th day after the date such notice of resignation was given by such
Agent, such Agent’s resignation shall become effective and the Required Lenders shall thereafter
perform all the duties of such Agent hereunder and/or under any other Loan Document until such
time, if any, as the Required Lenders appoint a successor Administrative Agent and/or Collateral
Agent, as the case may be (subject to any restriction on appointing a successor Collateral Agent
set forth in the Security Documents). Any such resignation by such Agent hereunder shall also
constitute, to the extent applicable, its resignation as an Issuing Bank and the Swingline Lender,
in which case such resigning Agent (x) shall not be required to issue any further Letters of Credit
or make any additional Swingline Loans hereunder and (y) shall maintain all of its rights as
Issuing Bank or Swingline Lender, as the case may be, with respect to any Letters of Credit issued
by it, or Swingline Loans made by it, prior to the date of such resignation. Upon the acceptance
of its appointment as Agent hereunder by a successor, such successor shall succeed to and become
vested with all the rights, powers, privileges and duties of the retiring Agent, and the retiring
Agent shall be discharged from its duties and obligations hereunder. The fees payable by the
Borrower to a successor Agent shall be the same as those payable to its predecessor unless
otherwise agreed between the Borrower and such successor. After an Agent’s resignation hereunder,
the provisions of this Article and Section 9.05 shall continue in effect for the benefit of such
retiring Agent, its sub-agents and their respective Related Parties in respect of any actions taken
or omitted to be taken by any of them while acting as Agent.

          Each Lender acknowledges that it has, independently and without reliance upon the Agents or
any other Lender and based on such documents and information as it has deemed appropriate, made its
own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that
it will, independently and without reliance upon the Agents or any other Lender and based on such
documents and information as it shall from time to time deem appropriate, continue to make its own
decisions in taking or not taking action under or based upon this Agreement or any other Loan
Document, any related agreement or any document furnished hereunder or thereunder.

          Notwithstanding any other provision of this Agreement or any provision of any other Loan
Document, each of the Joint Arrangers, the Co-Syndication Agents, the Co-Documentation Agents and
the Managing Agent are named as such for recognition purposes only, and in their respective
capacities as such shall have no duties, responsibilities or liabilities with respect to this
Agreement or any other Loan Document; it being understood and agreed that each of the Joint
Arrangers, the Co-Syndication Agents, the Co-Documentation Agents and the Managing Agent shall be
entitled to all indemnification and reimbursement rights in favor of the Agents provided herein and
in the other Loan

104

 

Documents. Without limitation of the foregoing, neither the Joint Arrangers, the
Co-Syndication Agents, the Co-Documentation Agents nor the Managing Agent in their respective
capacities as such shall, by reason of this Agreement or any other Loan Document, have any
fiduciary relationship in respect of any Lender, Loan Party or any other person.

          In furtherance of the foregoing, each Lender and each Issuing Bank hereby irrevocably
authorize the Agents, at their option and in their discretion, to:

     (a) release any Lien on any property granted or held by the Agents under the Loan
Documents (i) upon termination or expiration of the Total Revolving Credit Commitments and
payment in full of all Obligations (other than contingent indemnification and expense
reimbursement obligations as to which no claim shall have been asserted) and the
expiration or termination of Letters of Credit (or entry into arrangements satisfactory to
the Issuing Banks with respect thereto), (ii) that is sold or to be sold as part of or in
connection with any sale permitted hereunder or under any other Loan Document or (iii) if
approved, authorized or ratified in writing in accordance with Section 9.08; and

     (b) release any Guarantor from its obligations under its guaranty if such person
ceases to be a Subsidiary as a result of a transaction permitted hereunder.

          Upon request by either Agent, the Required Lenders will confirm in writing such Agent’s
authority to release its interests in particular types of collateral or to release any Guarantor
from its obligations to guarantee pursuant to this Article VIII (it being understood that any
Agent’s failure to make such a request shall not affect the authority expressly granted to the
Agent by the terms hereof or any other Loan Document).

          Each Lender (and each person that becomes a Lender hereunder pursuant to Section 9.04) and
each Issuing Bank hereby (i) acknowledges that Credit Suisse (and any successor to Credit Suisse in
such capacities) is acting under the Security Documents in multiple capacities as the
Administrative Agent, the Collateral Agent and the administrative agent and the collateral agent
for the lenders party to the Term Loan Credit Agreement pursuant to the Term Loan Documents and
(ii) waives any conflict of interest, now contemplated or arising hereafter, in connection
therewith and agrees not to assert against Credit Suisse (and such successor) any claims, causes of
action, damages or liabilities of whatever kind or nature relating thereto. Each Lender (and each
person that becomes a Lender hereunder pursuant to Section 9.04) and each Issuing Bank hereby
authorizes and directs Credit Suisse (and such successor) to enter into the Security Documents on
behalf of such Lender and such Issuing Bank and agrees that Credit Suisse (and such successor), in
its various capacities thereunder, may

105

 

take such actions on its behalf as is contemplated by the terms of the Security Documents.

ARTICLE IX

Miscellaneous

          SECTION 9.01. Notices. Notices and other communications provided for herein and in the
other Loan Documents shall be in writing and shall be delivered by hand or overnight courier
service, mailed by certified or registered mail or sent by facsimile, as follows:

          (a) if to the Borrower, to it at 501 Fifth Street, Bristol, TN 37620, Attention of Randy
Sharrow (Facsimile No.                       ), with a copy to James Elrod at the above address
(Facsimile No.                       );

          (b) if to the Administrative Agent, to Credit Suisse, Agency Manager, One Madison
Avenue, New York, NY 10010, Facsimile No.                       , Email:
                      ;

          (c) if to a Lender, to it at its address (or facsimile number) set forth on
Schedule 2.01 or in the Assignment and Acceptance pursuant to which such Lender shall
have become a party hereto; and

          (d) if to an Issuing Bank, to it at its address (or facsimile number) set forth on
Schedule 2.01 or in the Issuing Bank Agreement pursuant to which such person became
an Issuing Bank.

All notices and other communications given to any party hereto in accordance with the provisions of
this Agreement shall be deemed to have been given on the date of receipt if delivered by hand or
overnight courier service, or sent by facsimile, or on the date that is five (5) Business Days
after dispatch by certified or registered mail, if mailed, in each case delivered, sent or mailed
(properly addressed) to such party, as provided in this Section or in accordance with the latest
unrevoked direction from such party in accordance with this Section.

          As agreed to among the Borrower, the Administrative Agent and the applicable Lenders from time
to time, notices and other communications may also be delivered by e-mail to the e-mail address of
a representative of the applicable person provided from time to time by such person.

          The Borrower hereby agrees, unless directed otherwise by the Administrative Agent or unless
the electronic mail address referred to below has not been provided by the Administrative Agent to
the Borrower, that it will, or will cause its Subsidiaries to, provide to the Administrative Agent
all information, documents and other materials that it is obligated to furnish to the
Administrative

106

 

Agent pursuant to the Loan Documents or to the Lenders under Article V, including all notices,
requests, financial statements, financial and other reports, certificates and other information
materials, but excluding any such communication that (i) is or relates to a Borrowing Request, a
notice pursuant to Section 2.12 or a notice requesting the issuance, amendment, extension or
renewal of a Letter of Credit pursuant to Section 2.04, (ii) relates to the payment of any
principal or other amount due under this Agreement prior to the scheduled date therefor, (iii)
provides notice of any Default or Event of Default under this Agreement or any other Loan Document
or (iv) is required to be delivered to satisfy any condition precedent to the effectiveness of this
Agreement and/or any Borrowing or other extension of credit hereunder (all such non-excluded
communications being referred to herein collectively as “Communications”), by transmitting
the Communications in an electronic/soft medium that is properly identified in a format acceptable
to the Administrative Agent to an electronic mail address as directed by the Administrative Agent.
In addition, the Borrower agrees, and agrees to cause its Subsidiaries, to continue to provide the
Communications to the Administrative Agent or the Lenders, as the case may be, in the manner
specified in the Loan Documents but only to the extent requested by the Administrative Agent.

          The Borrower hereby acknowledges that (a) the Administrative Agent will make available to the
Lenders and the Issuing Bank materials and/or information provided by or on behalf of the Borrower
hereunder (collectively, the “Borrower Materials”) by posting the Borrower Materials on
Intralinks or another similar electronic system (the “Platform”) and (b) certain of the
Lenders may be “public-side” Lenders (i.e., Lenders that do not wish to receive material non-public
information with respect to the Borrower or its securities) (each, a “Public Lender”). The
Borrower hereby agrees that (w) all Borrower Materials that are to be made available to Public
Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the
word “PUBLIC” shall appear prominently on the first page thereof; (x) by marking Borrower Materials
“PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent and the Lenders
to treat such Borrower Materials as not containing any material non-public information with respect
to the Borrower or its securities for purposes of United States federal and state securities laws
(provided, however, that to the extent such Borrower Materials constitute Confidential Information,
they shall be treated as set forth in Section 9.16); (y) all Borrower Materials marked “PUBLIC” are
permitted to be made available through a portion of the Platform designated as “Public Investor”;
and (z) the Administrative Agent shall be entitled to treat any Borrower Materials that are not
marked “PUBLIC” as being suitable only for posting on a portion of the Platform not marked as
“Public Investor.” Notwithstanding the foregoing, the following Borrower Materials shall be marked
“PUBLIC,” unless the Borrower notifies the Administrative Agent promptly that any such document
contains material non-public information: (1)

107

 

the Loan Documents and (2) notification of changes in the terms of the Loan Documents.

          Each Public Lender agrees to cause at least one individual at or on behalf of such Public
Lender to at all times have selected the “Private Side Information” or similar designation on the
content declaration screen of the Platform in order to enable such Public Lender or its delegate,
in accordance with such Public Lender’s compliance procedures and applicable law, including United
States Federal and state securities laws, to make reference to Communications that are not made
available through the “Public Side Information” portion of the Platform and that may contain
material non-public information with respect to the Borrower or its securities for purposes of
United States Federal or state securities laws.

          THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” NEITHER THE ADMINISTRATIVE AGENT NOR ANY
OF ITS RELATED PARTIES WARRANTS THE ACCURACY OR COMPLETENESS OF THE COMMUNICATIONS OR THE ADEQUACY
OF THE PLATFORM AND EACH EXPRESSLY DISCLAIMS LIABILITY FOR ERRORS OR OMISSIONS IN THE
COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR
FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS IS MADE BY THE ADMINISTRATIVE AGENT OR ANY OF ITS
RELATED PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO EVENT SHALL THE
ADMINISTRATIVE AGENT OR ANY OF ITS RELATED PARTIES HAVE ANY LIABILITY TO ANY LOAN PARTY, ANY LENDER
OR ANY OTHER PERSON FOR DAMAGES OF ANY KIND, WHETHER OR NOT BASED ON STRICT LIABILITY AND INCLUDING
DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN
TORT, CONTRACT OR OTHERWISE) ARISING OUT OF ANY LOAN PARTY’S OR THE ADMINISTRATIVE AGENT’S
TRANSMISSION OF COMMUNICATIONS THROUGH THE INTERNET, EXCEPT TO THE EXTENT THE LIABILITY OF ANY SUCH
PERSON IS FOUND IN A FINAL RULING BY A COURT OF COMPETENT JURISDICTION TO HAVE RESULTED PRIMARILY
FROM SUCH PERSON’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT.

          The Administrative Agent agrees that the receipt of the Communications by the Administrative
Agent at its e-mail address set forth above shall constitute effective delivery of the
Communications to the Administrative Agent for purposes of the Loan Documents. Each Lender agrees
that receipt of notice to it (as provided in the next sentence) specifying that the Communications
have been posted to the Platform shall constitute effective delivery of the Communications to such
Lender for purposes of the Loan Documents. Each

108

 

Lender agrees to notify the Administrative Agent in writing (including by electronic
communication) from time to time of such Lender’s e-mail address to which the foregoing notice may
be sent by electronic transmission and that the foregoing notice may be sent to such e-mail
address.

          Nothing herein shall prejudice the right of the Administrative Agent or any Lender to give any
notice or other communication pursuant to any Loan Document in any other manner specified in such
Loan Document.

          SECTION 9.02. Survival of Agreement. All covenants, agreements, representations and
warranties made by the Borrower herein and in the certificates or other instruments prepared or
delivered in connection with or pursuant to this Agreement or any other Loan Document shall be
considered to have been relied upon by the Lenders and the Issuing Banks and shall survive the
making by the Lenders of the Loans and the issuance of Letters of Credit by the Issuing Banks,
regardless of any investigation made by the Lenders or the Issuing Banks or on their behalf, and
shall continue in full force and effect as long as the principal of or any accrued interest on any
Loan or any Fee or any other amount payable under this Agreement or any other Loan Document is
outstanding and unpaid or any Letter of Credit is outstanding and so long as the Commitments or the
L/C Commitments have not been terminated. The provisions of Sections 2.14, 2.16, 2.20 and 9.05
shall remain operative and in full force and effect regardless of the expiration of the term of
this Agreement, the consummation of the Transactions, the repayment of any of the Loans, the
expiration of the Commitments, the expiration of any Letter of Credit, the invalidity or
unenforceability of any term or provision of this Agreement or any other Loan Document, or any
investigation made by or on behalf of the Administrative Agent, the Collateral Agent, any Lender or
Issuing Bank.

          SECTION 9.03. Binding Effect. This Agreement shall become effective and legally binding on
the parties hereto when it shall have been executed by the Borrower and the Administrative Agent
and when the Administrative Agent shall have received counterparts hereof which, when taken
together, bear the signatures of each of the other parties hereto, and thereafter shall be binding
upon and inure to the benefit of the parties hereto and their respective permitted successors and
assigns.

          SECTION 9.04. Successors and Assigns. (a) Whenever in this Agreement any of the parties
hereto is referred to, such reference shall be deemed to include the permitted successors and
assigns of such party; and all covenants, promises and agreements by or on behalf of the Borrower,
the Administrative Agent, the Collateral Agent, the Issuing Banks or the Lenders that are contained
in this Agreement shall bind and inure to the benefit of their respective successors and assigns.

109

 

          (b) Each Lender may assign to one or more assignees all or a portion of its interests,
rights and obligations under this Agreement (including all or a portion of its Commitments
and the Loans at the time owing to it); provided, however, that (i) except in the case of an
assignment to another Lender or an Affiliate or Related Fund of the assigning Lender or
another Lender, (x) each of the Borrower, the Administrative Agent, each Issuing Bank and the
Swingline Lender must give its prior written consent to such assignment (which consent shall
not be unreasonably withheld or delayed); provided, that the consent of the Borrower shall
not be required to any such assignment made (A) to another Lender or an Affiliate or Related
Fund of the assigning Lender or another Lender or (B) after the occurrence and during the
continuance of any Default or Event of Default and (y) the amount of the Commitments of the
assigning Lender subject to each such assignment (determined as of the date the Assignment
and Acceptance with respect to such assignment is delivered to the Administrative Agent)
shall be in an aggregate amount that is an integral multiple of $1,000,000 and not less than
$5,000,000 (or, if less, the entire remaining amount of such Lender’s Commitments); provided
that simultaneous assignments by or to two or more Related Funds shall be combined for the
purpose of determining whether the minimum assignment requirement is met, (ii) the assignee,
if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative
Questionnaire and any tax form as required by the Internal Revenue Service and (iii) the
parties to each assignment shall (A) execute and deliver to the Administrative Agent an
Assignment and Acceptance via an electronic settlement system acceptable to the
Administrative Agent or (B) if previously agreed with the Administrative Agent, manually
execute and deliver to the Administrative Agent and Assignment and Acceptance. Upon
acceptance and recording pursuant to paragraph (e) of this Section and payment of the
processing and recording fee referred to therein, from and after the effective date specified
in each Assignment and Acceptance, which effective date shall be at least five Business Days
after the execution thereof, (A) the assignee thereunder shall be a party hereto and, to the
extent of the interest assigned by such Assignment and Acceptance, have the rights and
obligations of a Lender under this Agreement and (B) the assigning Lender thereunder shall,
to the extent of the interest assigned by such Assignment and Acceptance, be released from
its obligations under this Agreement, other than any claims by the Borrower for violations by
such Lender of the provisions of this Agreement (and, in the case of an Assignment and
Acceptance covering all or the remaining portion of an assigning Lender’s rights and
obligations under this Agreement, such Lender shall cease to be a party hereto but shall
continue to be entitled to the benefits of Sections 2.14, 2.16, 2.20 and 9.05, as well as to
any Fees accrued for its account and not yet paid).

110

 

          (c) By executing and delivering an Assignment and Acceptance, the assigning Lender
thereunder and the assignee thereunder shall be deemed to confirm to and agree with each
other and the other parties hereto as follows:  (i) such assigning Lender warrants that it is
the legal and beneficial owner of the interest being assigned thereby free and clear of any
adverse claim and that its Commitments, and the outstanding balances of its Loans, without
giving effect to assignments thereof which have not become effective, are as set forth in
such Assignment and Acceptance; (ii) except as set forth in (i) above, such assigning Lender
makes no representation or warranty and assumes no responsibility with respect to any
statements, warranties or representations made in or in connection with this Agreement, or
the execution, legality, validity, enforceability, genuineness, sufficiency or value of this
Agreement, any other Loan Document or any other instrument or document furnished pursuant
hereto, or the financial condition of the Borrower or any of the Subsidiaries or the
performance or observance by the Borrower or any of the Subsidiaries of any of its
obligations under this Agreement, any other Loan Document or any other instrument or document
furnished pursuant hereto; (iii) such assignee represents and warrants that it is legally
authorized to enter into such Assignment and Acceptance; (iv) such assignee confirms that it
has received a copy of this Agreement, together with copies of the most recent financial
statements referred to in Section 3.05(a) or delivered pursuant to Section 5.04 and such
other documents and information as it has deemed appropriate to make its own credit analysis
and decision to enter into such Assignment and Acceptance; (v) such assignee will
independently and without reliance upon the Administrative Agent, the Collateral Agent, such
assigning Lender or any other Lender and based on such documents and information as it shall
deem appropriate at the time, continue to make its own credit decisions in taking or not
taking action under this Agreement; (vi) such assignee appoints and authorizes the
Administrative Agent and the Collateral Agent to take such action as agent on its behalf and
to exercise such powers under this Agreement as are delegated to the Administrative Agent and
the Collateral Agent, respectively, by the terms hereof, together with such powers as are
reasonably incidental thereto; and (vii) such assignee agrees that it will perform in
accordance with their terms all the obligations which by the terms of this Agreement are
required to be performed by it as a Lender.

          (d) The Administrative Agent, acting for this purpose as an agent of the Borrower, shall
maintain at one of its offices in The City of New York a copy of each Assignment and
Acceptance delivered to it and a register for the recordation of the names and addresses of
the Lenders, all L/C Disbursements, and the Commitment of, and principal amount of the Loans
owing to, each Lender pursuant to the terms hereof from time to time (the
“Register”). The entries in the Register shall be prima facie evidence of the
matters recorded therein and the Borrower, the Administrative Agent, the

111

 

Issuing Banks, the Collateral Agent and the Lenders may treat each person whose name is
recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes
of this Agreement, notwithstanding notice to the contrary. The Register and any Assignments
and Acceptances delivered to the Administrative Agent pursuant to this Section 9.04(d) shall
be available for inspection by the Borrower, the Issuing Banks, the Collateral Agent and any
Lender, at any reasonable time and from time to time upon reasonable prior notice.

          (e) Upon its receipt of a duly completed Assignment and Acceptance executed by an
assigning Lender and an assignee, an Administrative Questionnaire completed in respect of the
assignee (unless the assignee shall already be a Lender hereunder) and any tax form required
by the Internal Revenue Service, a processing and recordation fee of $3,500 (which fee may be
waived or reduced in the sole discretion of the Administrative Agent) and, if required, the
written consent of the Borrower, the Swingline Lender, each Issuing Bank and the
Administrative Agent to such assignment, the Administrative Agent shall (i) accept such
Assignment and Acceptance, (ii) record the information contained therein in the Register and
(iii) give prompt notice thereof to the Borrower, Lenders, each Issuing Bank and the
Swingline Lender. No assignment shall be effective unless it has been recorded in the
Register as provided in this paragraph (e).

          (f) Each Lender may without the consent of the Borrower, the Swingline Lender, any
Issuing Bank or the Administrative Agent sell participations to one or more banks or other
entities in all or a portion of its rights and obligations under this Agreement (including
all or a portion of its Commitment and the Loans owing to it); provided, however, that
(i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender
shall remain solely responsible to the other parties hereto for the performance of such
obligations, (iii) the participating banks or other entities shall be entitled to the benefit
of the provisions contained in Sections 2.14, 2.16 and 2.20 to the same extent as if they
were Lenders; provided that no participant shall be entitled to receive any greater amount
pursuant to Section 2.14 or 2.20 than the transferor Lender would have been entitled to
receive in respect of the amount of the participation transferred by such transferor Lender
to such participant had no such transfer occurred and (iv) the Borrower, the Administrative
Agent, the Issuing Banks and the Lenders shall continue to deal solely and directly with such
Lender in connection with such Lender’s rights and obligations under this Agreement, and such
Lender shall retain the sole right to enforce the obligations of the Borrower relating to the
Loans or L/C Disbursements and to approve any amendment, modification or waiver of any
provision of this Agreement (other than amendments, modifications or waivers decreasing any
fees payable hereunder or the amount of principal of or the rate at which interest is

112

 

payable on the Loans, extending any scheduled principal payment date or date fixed for
the payment of interest on the Loans, increasing or extending the Commitments or releasing
all or substantially all the Guarantors or the Collateral).

          (g) Any Lender or participant may, in connection with any assignment or participation or
proposed assignment or participation pursuant to this Section 9.04, disclose to the assignee
or participant or proposed assignee or participant any information relating to the Borrower
furnished to such Lender by or on behalf of the Borrower; provided that, prior to any such
disclosure of information, each such assignee or participant or proposed assignee or
participant shall execute an agreement whereby such assignee or participant shall agree to
preserve the confidentiality of such confidential information on terms no less restrictive
than those applicable to the Lenders pursuant to Section 9.16 and, in the case of any
assignee, the Administrative Agent shall provide the Borrower with an execution copy of such
agreement.

          (h) Any Lender may at any time pledge or assign a security interest in all or any
portion of its rights under this Agreement to secure obligations of such Lender, including
any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section
shall not apply to any such pledge or assignment of a security interest; provided that no
such pledge or assignment of a security interest shall release a Lender from any of its
obligations hereunder or substitute any such pledgee or assignee for such Lender as a party
hereto. In order to facilitate such an assignment to a Federal Reserve Bank, the Borrower
shall, at the request of the assigning Lender, duly execute and deliver to the assigning
Lender a promissory note or notes evidencing the Loans made to the Borrower by the assigning
Lender hereunder.

          (i) Notwithstanding anything to the contrary contained herein, any Lender (a
“Granting Lender”) may grant to a special purpose funding vehicle (an “SPC”),
identified as such in writing from time to time by the Granting Lender to the Administrative
Agent and the Borrower, the option to provide to the Borrower all or any part of any Loan
that such Granting Lender would otherwise be obligated to make to the Borrower pursuant to
this Agreement; provided that (i) nothing herein shall constitute a commitment by any SPC to
make any Loan and (ii) if an SPC elects not to exercise such option or otherwise fails to
provide all or any part of such Loan, the Granting Lender shall be obligated to make such
Loan pursuant to the terms hereof. The making of a Loan by an SPC hereunder shall utilize
the Commitment of the Granting Lender to the same extent, and as if, such Loan were made by
such Granting Lender. Each party hereto hereby agrees that no SPC shall be liable for any
indemnity or similar payment obligation under this Agreement (all liability for which shall
remain with the Granting Lender). In furtherance of the foregoing, each party hereto hereby
agrees

113

 

(which agreement shall survive the termination of this Agreement) that, prior to the
date that is one year and one day after the payment in full of all outstanding commercial
paper or other senior indebtedness of any SPC, it will not institute against, or join any
other person in instituting against, such SPC any bankruptcy, reorganization, arrangement,
insolvency or liquidation proceedings under the laws of the United States or any state
thereof. In addition, notwithstanding anything to the contrary in this Section, any SPC may
(i) with notice to, but without the prior written consent of, the Borrower and the
Administrative Agent and without paying any processing fee therefor, assign all or a portion
of its interests in any Loans to the Granting Lender or to any financial institutions
(consented to by the Borrower and the Administrative Agent) providing liquidity and/or credit
support to or for the account of such SPC to support the funding or maintenance of Loans and
(ii) disclose on a confidential basis any non-public information relating to its Loans to any
rating agency, commercial paper dealer or provider of any surety, guarantee or credit or
liquidity enhancement to such SPC. This Section may not be amended without the written
consent of the SPC.

               (j) The Borrower shall not assign or delegate any of its rights or duties hereunder
without the prior written consent of the Administrative Agent, each Issuing Bank and each
Lender, and any attempted assignment without such consent shall be null and void.

               (k) In the event that any Lender shall become a Defaulting Lender or S&P, Moody’s or
Thompson’s Bank Watch (or Insurance Watch Ratings Service, in the case of Lenders that are
insurance companies (or Best’s Insurance Reports, if such insurance company is not rated by
Insurance Watch Ratings Service)) shall, after the date that any Lender becomes a Lender,
downgrade the long-term certificate deposit ratings of such Lender, and the resulting ratings
shall be below BBB, Baa3 and C (or BB, in the case of a Lender that is an insurance company
(or B, in the case of an insurance company not rated by Insurance Watch Ratings Service))
(or, with respect to any Lender that is not rated by any such ratings service or provider,
any Issuing Bank or the Swingline Lender shall have reasonably determined that there has
occurred a material adverse change in the financial condition of any such Lender, or a
material impairment of the ability of any such Lender to perform its obligations hereunder,
as compared to such condition or ability as of the date that any such Lender became a Lender)
then such Issuing Bank or the Swingline Lender shall have the right, but not the obligation,
at its own expense, upon notice to such Lender and the Administrative Agent, to replace such
Lender with an assignee (in accordance with and subject to the restrictions contained in
paragraph (b) above), and such Lender hereby agrees to transfer and assign without recourse
(in accordance with and subject to the restrictions contained in paragraph (b) above) all its
interests, rights and obligations in respect of its

114

 

Revolving Credit Commitment to such assignee; provided, however, that (i) no such
assignment shall conflict with any law, rule and regulation or order of any Governmental
Authority and (ii) such Issuing Bank, the Swingline Lender or such assignee, as the case may
be, shall pay to such Lender in immediately available funds on the date of such assignment
the principal of and interest accrued to the date of payment on the Loans made by such Lender
hereunder and all other amounts accrued for such Lender’s account or owed to it hereunder.

          SECTION 9.05. Expenses; Indemnity. (a) The Borrower agrees to pay all reasonable
out-of-pocket expenses incurred by the Joint Arrangers, the Administrative Agent, the Collateral
Agent, the Issuing Banks and the Swingline Lender in connection with the preparation and
administration of this Agreement and the other Loan Documents or in connection with any amendments,
modifications or waivers of the provisions hereof or thereof (whether or not the transactions
hereby or thereby contemplated shall be consummated) or incurred by the Joint Arrangers, the
Administrative Agent, the Collateral Agent or any Issuing Bank or Lender in connection with the
enforcement or protection of its rights in connection with this Agreement and the other Loan
Documents or in connection with the Loans made or Letters of Credit issued hereunder, including the
reasonable fees, charges and disbursements of Davis Polk & Wardwell, counsel for the Joint
Arrangers, the Administrative Agent and the Collateral Agent, and, in connection with any such
enforcement or protection, the fees, charges and disbursements of any counsel for the Joint
Arrangers, the Administrative Agent, the Collateral Agent or any Lender.

          (b) The Borrower agrees to indemnify the Joint Arrangers, the Administrative Agent, the
Collateral Agent, each Lender and Issuing Bank, the Swingline Lender and each Related Party
of any of the foregoing persons (each such person being called an “Indemnitee”)
against, and to hold each Indemnitee harmless from, any and all losses, claims, damages,
penalties, liabilities and related expenses, including reasonable outside counsel fees,
charges and disbursements, incurred by or asserted against any Indemnitee arising out of, in
any way connected with or as a result of (i) the execution or delivery of this Agreement or
any other Loan Document or any agreement or instrument contemplated thereby, the performance
by the parties thereto of their respective obligations thereunder or the consummation of the
Transactions and the other transactions contemplated thereby, (ii) the use of the proceeds of
the Loans or issuance of Letters of Credit, (iii) any claim, litigation, investigation or
proceeding relating to any of the foregoing, whether or not any Indemnitee is a party thereto
(and regardless of whether such matter is initiated by a third party or by the Borrower, any
other Loan Party or any of their respective shareholders or Affiliates) or (iv) any actual or
alleged presence, Release or threatened Release of Hazardous Materials on any property or
facility presently or

115

 

formerly owned, leased or operated by the Borrower or any of the Subsidiaries, or any
Environmental Claim related in any way to the Borrower or the Subsidiaries; provided that
such indemnity shall not, as to any Indemnitee, be available to the extent that such losses,
claims, damages, liabilities or related expenses are determined by a court of competent
jurisdiction by final and nonappealable judgment to have resulted primarily from the gross
negligence or willful misconduct of such Indemnitee.

          (c) To the extent that the Borrower fails to pay any amount required to be paid by it to
the Administrative Agent, the Collateral Agent, any Issuing Bank or the Swingline Lender
under paragraph (a) or (b) of this Section, each Lender severally agrees to pay to the
Administrative Agent, the Collateral Agent, such Issuing Bank or the Swingline Lender, as the
case may be, such Lender’s pro rata share (determined as of the time that the applicable
unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the
unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the
case may be, was incurred by or asserted against the Administrative Agent, the Collateral
Agent, such Issuing Bank or the Swingline Lender in its capacity as such. For purposes
hereof, a Lender’s “pro rata share” shall be determined based upon its share of the sum of
the Aggregate Revolving Credit Exposure and unused Commitments at the time (in each case,
determined as if no Lender were a Defaulting Lender).

          (d) To the extent permitted by applicable law, the Borrower shall not assert, and hereby
waives, any claim against any Indemnitee, on any theory of liability, for special, indirect,
consequential or punitive damages (as opposed to direct or actual damages) arising out of, in
connection with, or as a result of, this Agreement or any agreement or instrument
contemplated hereby, the Transactions, any Loan or Letter of Credit or the use of the
proceeds thereof.

          (e) The provisions of this Section shall remain operative and in full force and effect
regardless of the expiration of the term of this Agreement, the consummation of the
transactions contemplated hereby, the repayment of any of the Loans, the expiration of the
Commitments, the expiration of any Letter of Credit, the invalidity or unenforceability of
any term or provision of this Agreement or any other Loan Document, or any investigation made
by or on behalf of the Administrative Agent, the Collateral Agent or any Lender or Issuing
Bank. All amounts due under this Section shall be payable on written demand therefor.

          SECTION 9.06. Right of Setoff. If an Event of Default shall have occurred and be
continuing, each Lender is hereby authorized at any time and from time to time, except to the
extent prohibited by law, to set off and apply any and all deposits (general or special, time or
demand, provisional or final, but

116

 

excluding payroll and related trust fund accounts) at any time held and other indebtedness at any
time owing by such Lender (or its Affiliates) to or for the credit or the account of the Borrower
against any of and all the obligations of the Borrower now or hereafter existing under this
Agreement and other Loan Documents held by such Lender, irrespective of whether or not such Lender
shall have made any demand under this Agreement or such other Loan Document and although such
obligations may be unmatured. Each Lender agrees promptly to notify the Borrower and the
Administrative Agent after any such setoff and application made by such Lender; provided that the
failure to give such notice shall not affect the validity of such setoff and application. The
rights of each Lender under this Section are in addition to other rights and remedies (including
other rights of setoff) which such Lender may have.

          SECTION 9.07. APPLICABLE LAW. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (OTHER THAN
LETTERS OF CREDIT AND AS EXPRESSLY SET FORTH IN THE OTHER LOAN DOCUMENTS) SHALL BE CONSTRUED IN
ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. EACH LETTER OF CREDIT SHALL BE
GOVERNED BY, AND SHALL BE CONSTRUED IN ACCORDANCE WITH, THE LAWS OR RULES DESIGNATED IN SUCH LETTER
OF CREDIT, OR IF NO SUCH LAWS OR RULES ARE DESIGNATED, THE UNIFORM CUSTOMS AND PRACTICE FOR
DOCUMENTARY CREDITS (1993 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 500 (THE
“UNIFORM CUSTOMS”) AND, AS TO MATTERS NOT GOVERNED BY THE UNIFORM CUSTOMS, THE LAWS OF THE
STATE OF NEW YORK.

          SECTION
9.08. Waivers; Amendments. (a) No failure or delay of the Borrower, the
Administrative Agent, the Collateral Agent or any Issuing Bank or Lender in exercising any power or
right hereunder or under any other Loan Document shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right or power, or any abandonment or discontinuance of
steps to enforce such a right or power, preclude any other or further exercise thereof or the
exercise of any other right or power. The rights and remedies of the Borrower, the Administrative
Agent, the Collateral Agent, the Issuing Banks and the Lenders hereunder and under the other Loan
Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise
have. No waiver of any provision of this Agreement or any other Loan Document or consent to any
departure by the Borrower or any other Loan Party therefrom shall in any event be effective unless
the same shall be permitted by paragraph (b) below, and then such waiver or consent shall be
effective only in the specific instance and for the purpose for which given. No notice or demand
on the Borrower in any case shall entitle the Borrower to any other or further notice or demand in
similar or other circumstances.

117

 

          (b) Neither this Agreement nor any other Loan Document nor any provision hereof or
thereof may be waived, amended or modified other than pursuant to an agreement or agreements
in writing entered into by the Borrower and the Required Lenders or, in the case of any other
Loan Document, by the Loan Parties party thereto and the Administrative Agent or the
Collateral Agent, as the case may be, with the consent of the Required Lenders. No agreement
referred to in the preceding sentence shall (i) decrease the principal amount, or extend the
maturity, of any scheduled date of payment or date for reimbursement of or any date for the
payment of any interest on, any Loan or L/C Disbursement, or waive or excuse any such payment
or any part thereof, or decrease the rate of interest on any Loan or L/C Disbursement or
decrease the amount, or extend any scheduled date of payment, of any Fees, without the prior
written consent of each Lender affected thereby, (ii) increase or extend any Commitment or
decrease or extend the date for payment of the Commitment Fees of any Lender without the
prior written consent of such Lender, (iii) amend or modify the provisions of Section 2.17 or
9.04(j), the provisions of this Section (other than to impose additional restrictions on
amendments) or the definition of the term “Required Lenders” without the prior written
consent of each Lender, (iv) release any Guarantor (A) whose total assets represent at the
time of such release more than 10% of the total assets of the Borrower and its consolidated
Subsidiaries or (B) whose total revenues represent at the time of such release more than 10%
of the total revenues of the Borrower and its consolidated Subsidiaries or all or
substantially all the Collateral without the prior written consent of each Lender or
(v) amend, modify or otherwise affect the rights or duties of the Administrative Agent, the
Collateral Agent, any Issuing Bank or the Swingline Lender hereunder or under any other Loan
Document without the prior written consent of the Administrative Agent, the Collateral Agent,
such Issuing Bank or the Swingline Lender.

          SECTION 9.09. Interest Rate Limitation. Notwithstanding anything herein to the contrary,
if at any time the interest rate applicable to any Loan or participation in any L/C Disbursement,
together with all fees, charges and other amounts which are treated as interest on such Loan or
participation in such L/C Disbursement under applicable law (collectively the “Charges”),
shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for,
charged, taken, received or reserved by the Lender holding such Loan or participation in accordance
with applicable law, the rate of interest payable in respect of such Loan or participation
hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum
Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of
such Loan or participation but were not payable as a result of the operation of this Section 9.09
shall be cumulated and the interest and Charges payable to such Lender in respect of other Loans or
participations or periods shall be increased (but not above the Maximum Rate therefor) until such
cumulated amount, together with interest

118

 

thereon at the Federal Funds Effective Rate to the date of repayment, shall have been received by
such Lender.

          SECTION 9.10. Entire Agreement. This Agreement, the Fee Letter and the other Loan
Documents constitute the entire contract between the parties relative to the subject matter hereof.
Any other previous agreement among the parties with respect to the subject matter hereof is
superseded by this Agreement and the other Loan Documents, except as expressly agreed therein.
Nothing in this Agreement or in the other Loan Documents, expressed or implied, is intended to
confer upon any person (other than the parties hereto and thereto, their respective successors and
assigns permitted hereunder and, to the extent expressly contemplated hereby, the Related Parties
of each of the Administrative Agent, the Collateral Agent and the Lenders) any rights, remedies,
obligations or liabilities under or by reason of this Agreement or the other Loan Documents.

          SECTION 9.11. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE
OTHER LOAN DOCUMENTS. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE
OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS,
AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.11.

          SECTION 9.12. Severability. In the event any one or more of the provisions contained in
this Agreement or in any other Loan Document should be held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein
and therein shall not in any way be affected or impaired thereby (it being understood that the
invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect
the validity of such provision in any other jurisdiction). The parties shall endeavor in
good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid
provisions, the economic effect of which comes as close as possible to that of the invalid, illegal
or unenforceable provisions.

          SECTION 9.13. Counterparts. This Agreement may be executed in counterparts (and by
different parties hereto on different counterparts), each of which shall constitute an original but
all of which when taken together shall constitute a single contract, and shall become effective as
provided in

119

 

Section 9.03. Delivery of an executed signature page to this Agreement by facsimile transmission
shall be as effective as delivery of a manually signed counterpart of this Agreement.

          SECTION 9.14. Headings. Article and Section headings and the Table of Contents used herein
are for convenience of reference only, are not part of this Agreement and are not to affect the
construction of, or to be taken into consideration in interpreting, this Agreement.

          SECTION 9.15. Jurisdiction; Consent to Service of Process. (a)The Borrower hereby
irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction
of any New York State court or Federal court of the United States of America sitting in New York
City, and any appellate court from any thereof, in any action or proceeding arising out of or
relating to this Agreement or the other Loan Documents, or for recognition or enforcement of any
judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all
claims in respect of any such action or proceeding may be heard and determined in such New York
State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in
other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in
this Agreement shall affect any right that the Administrative Agent, the Collateral Agent, any
Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this
Agreement or the other Loan Documents against the Borrower or its properties in the courts of any
jurisdiction.

          (b) The Borrower hereby irrevocably and unconditionally waives, to the fullest extent it
may legally and effectively do so, any objection which it may now or hereafter have to the
laying of venue of any suit, action or proceeding arising out of or relating to this
Agreement or the other Loan Documents in any New York State or Federal court. Each of the
parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any such court.

          (c) Each party to this Agreement irrevocably consents to service of process in the
manner provided for notices in Section 9.01. Nothing in this Agreement will affect the right
of any party to this Agreement to serve process in any other manner permitted by law.

120

 

          SECTION 9.16. Confidentiality.

          Each of the Administrative Agent, the Collateral Agent, the Issuing Banks and the Lenders
agrees to maintain the confidentiality of the Confidential Information (as defined below), except
that Confidential Information may be disclosed (i) to its and its Affiliates’ officers, directors,
employees and agents, including accountants, legal counsel and other advisors (it being understood
that the persons to whom such disclosure is made will be informed of the confidential nature of
such Confidential Information and instructed to keep such Confidential Information confidential),
(ii) to the extent requested by any regulatory authority or quasi-regulatory authority (such as the
National Association of Insurance Commissioners), (iii) to the extent required by applicable laws
or regulations or by any subpoena or similar legal process, (iv) in connection with the exercise of
any remedies hereunder or under the other Loan Documents or any suit, action or proceeding relating
to the enforcement of its rights hereunder or thereunder, (v) subject to an agreement containing
provisions substantially the same as those of this Section 9.16, to (x) any actual or prospective
assignee of or participant in any of its rights or obligations under this Agreement and the other
Loan Documents or (y) any actual or prospective counterparty (or its advisors) to any swap or
derivative transaction relating to the Borrower or any Subsidiary or any of their respective
obligations, (vi) with the consent of the Borrower or (vii) to the extent such Confidential
Information becomes publicly available other than as a result of a breach of this Section 9.16.
For the purposes of this Section, “Confidential Information” shall mean all information
received from the Borrower and related to the Borrower or its business, other than any such
information that was available to the Administrative Agent, the Collateral Agent, any Issuing Bank
or any Lender on a nonconfidential basis prior to its disclosure by the Borrower; provided that, in
the case of Confidential Information received from the Borrower after the Amendment No. 1 Effective
Date, such information is clearly identified at the time of delivery as confidential. Any person
required to maintain the confidentiality of Confidential Information as provided in this
Section 9.16 shall be considered to have complied with its obligation to do so if such person has
exercised the same degree of care to maintain the confidentiality of such Confidential Information
as such person would accord its own confidential information.

          SECTION 9.17. Lender Action. Each Lender agrees that it shall not take or institute any
actions or proceedings, judicial or otherwise, for any right or remedy against any Loan Party or
any other obligor under any of the Loan Documents (including the exercise of any right of setoff,
rights on account of any banker’s lien or similar claim or other rights of self-help), or institute
any actions or proceedings, or otherwise commence any remedial procedures, with respect to any
Collateral or any other property of any such Loan Party, unless expressly provided for herein or in
any other Loan Document, without the prior written consent of the Administrative Agent. The
provisions of this Section 9.17 are for

121

 

the sole benefit of the Lenders and shall not afford any right to, or constitute a defense
available to, any Loan Party.

          SECTION 9.18. Patriot Act. Each Lender and the Administrative Agent(for itself and not on
behalf of any Lender) hereby notifies the Borrower, for itself and the Subsidiaries, that pursuant
to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law
October 26, 2001)) (the “Patriot Act”), it is required to obtain, verify and record
information that identifies the Borrower and the Subsidiaries, which information includes the name
and address of the Borrower and the Subsidiaries and other information that will allow such Lender
or the Administrative Agent, as applicable, to identify the Borrower and the Subsidiaries in
accordance with the Patriot Act.

          SECTION 9.19. No Fiduciary Duty. The Borrower, on behalf of itself and the Subsidiaries,
agrees that in connection with all aspects of the transactions contemplated hereby or by any other
Loan Document and any communications in connection therewith, the Borrower, the Subsidiaries and
their Affiliates, on the one hand, and the Administrative Agent, the Issuing Banks, the Lenders and
their Affiliates, on the other hand, will have a business relationship that does not create, by
implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the Issuing
Banks, the Lenders or their Affiliates, and no such duty will be deemed to have arisen in
connection with any such transactions or communications.

122EX-10.89

Exhibit 10.89

 

ASSET PURCHASE AGREEMENT

by and between

KING PHARMACEUTICALS, INC.

and

ACTAVIS ELIZABETH, L.L.C.

dated as of December 17, 2008

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	Article I. Definitions
	 	1	 
	Section 1.01
	Defined Terms	 	1	 
	Section 1.02 
	Construction of Certain Terms and Phrases. 	 	12	 
	Article II. Purchase and Sale of Assets
	 	12	 
	Section 2.01 
	Purchase and Sale of Assets 	 	12	 
	Article III. Assumption of Liabilities
	 	13	 
	Section 3.01 
	Assumption of Assumed Liabilities 	 	13	 
	Section 3.02 
	Excluded Liabilities 	 	13	 
	Article IV. Purchase Price and Payment
	 	13	 
	Section 4.01 
	Purchase Price 	 	13	 
	Section 4.02 
	Inventory Payment 	 	14	 
	Section 4.03 
	Allocation of Purchase Price 	 	14	 
	Section 4.04 
	Payment of Sales, Use and Other Taxes 	 	15	 
	Section 4.05 
	Statements and Audit Rights 	 	15	 
	Article V. Closing
	 	16	 
	Section 5.01 
	Time and Place 	 	16	 
	Section 5.02 
	Deliveries at Closing 	 	16	 
	Article VI. Representations and Warranties of Seller
	 	16	 
	Section 6.01 
	Organization, Etc. 	 	17	 
	Section 6.02 
	Authority of Seller 	 	17	 
	Section 6.03 
	Consents and Approvals 	 	17	 
	Section 6.04 
	Non-Contravention 	 	18	 
	Section 6.05 
	Solvency 	 	18	 
	Section 6.06 
	Title 	 	18	 
	Section 6.07 
	Litigation 	 	18	 
	Section 6.08
	Purchased Assets 	 	19	 
	Section 6.09 
	Regulatory 	 	19	 
	Section 6.10 
	Brokers 	 	20	 
	Section 6.11 
	No Other Representations and Warranties 	 	20	 
	Article VII. Representations and Warranties of Buyer
	 	20	 
	Section 7.01 
	Corporate Organization 	 	20	 
	Section 7.02 
	Authority of Buyer 	 	20	 

i

 

	 	 	 	 	 	 	 	 	 
	Section 7.03
	Consents and Approvals 	 	21	 
	Section 7.04
	Non-Contravention	 	21	 
	Section 7.05 
	Solvency 	 	21	 
	Section 7.06 
	Brokers	 	21	 
	Section 7.07 
	No Other Representations and Warranties 	 	22	 
	Article VIII. Covenants of the Parties
	 	22	 
	Section 8.01 
	Reasonable Best Efforts 	 	22	 
	Section 8.02 
	Cooperation and Transition 	 	22	 
	Section 8.03 
	Public Announcements 	 	22	 
	Section 8.04 
	Bulk Sales 	 	23	 
	Section 8.05 
	Corporate Names 	 	23	 
	Section 8.06 
	Regulatory Matters 	 	23	 
	Section 8.07 
	Product Returns 	 	24	 
	Section 8.08 
	Further Assurances 	 	24	 
	Section 8.09 
	Government Price Reporting Obligations 	 	25	 
	Section 8.10 
	Kadian Patent License 	 	25	 
	Section 8.11 
	DEA Notification 	 	28	 
	Section 8.12 
	Representations True 	 	28	 
	Section 8.13 
	Confidentiality; Non-Public Purchased Assets 	 	28	 
	Section 8.14 
	Filings 	 	29	 
	Section 8.15 
	Recalls. 	 	29	 
	Section 8.16 
	Rebates and Coupons 	 	30	 
	Section 8.17 
	Chargeback and Rebate Period 	 	30	 
	Section 8.18 
	Chargebacks 	 	31	 
	Section 8.19 
	GPO Administration Fees and IFF Payments 	 	31	 
	Section 8.20 
	Manufacturing Agreements 	 	32	 
	Section 8.21 
	Sale of Product 	 	32	 
	Section 8.22 
	Delivery of Inventory 	 	32	 
	Section 8.23 
	Assumed Contracts 	 	32	 
	Section 8.24 
	Regulatory Actions 	 	32	 
	Article IX. Conditions to the Obligations of Seller
	 	33	 
	Section 9.01 
	Alpharma Acquisition 	 	33	 
	Section 9.02 
	No Legal Prohibition 	 	33	 
	Article X.
Conditions to the Obligations of Buyer
	 	33	 
	Section 10.01 
	No Legal Prohibition 	 	33	 
	Section 10.02 
	Alpharma Acquisition 	 	33	 
	Article XI. Additional Post-Closing Covenants
	 	33	 
	Section 11.01 
	Access to Information 	 	33	 
	Article XII.
Indemnification
	 	34	 

3

 

	 	 	 	 	 	 	 	 	 
	Section 12.01 
	Survival of Representations and Warranties 	 	34	 
	Section 12.02 
	Indemnification 	 	34	 
	Section 12.03 
	Limitations 	 	37	 
	Section 12.04 
	Remedies Exclusive 	 	37	 
	Article XIII. Termination and Abandonment
	 	37	 
	Section 13.01 
	Methods of Termination 	 	37	 
	Section 13.02 
	Procedure upon and Effect of Termination 	 	38	 
	Article XIV. Miscellaneous
	 	38	 
	Section 14.01 
	Notices 	 	38	 
	Section 14.02 
	Entire Agreement 	 	39	 
	Section 14.03 
	Waiver 	 	40	 
	Section 14.04 
	Amendment 	 	40	 
	Section 14.05 
	Third Party Beneficiaries 	 	40	 
	Section 14.06 
	Assignment; Binding Effect 	 	40	 
	Section 14.07 
	Headings 	 	40	 
	Section 14.08 
	Severability 	 	40	 
	Section 14.09 
	Governing Law 	 	41	 
	Section 14.10 
	Consent to Jurisdiction and Forum Selection 	 	41	 
	Section 14.11 
	Expenses 	 	41	 
	Section 14.12 
	Counterparts 	 	42	 

iii

 

ASSET PURCHASE AGREEMENT

     This Asset Purchase Agreement (this “Agreement”) is made and entered into as of
December 17, 2008 (the “Execution Date”), by and between Actavis Elizabeth, L.L.C., a
Delaware limited liability company (“Buyer”), and King Pharmaceuticals, Inc., a Tennessee
corporation (“King”).

RECITALS

     WHEREAS, King is party to an Agreement and Plan of Merger, dated as of November 23, 2008, by
and among King, Albert Acquisition Corp. and Alpharma Inc. (the “Merger Agreement”)
pursuant to which, subject to the terms and conditions set forth therein, King has agreed to
acquire Alpharma Inc. (“Alpharma”);

     WHEREAS, Alpharma is engaged in the business of selling in the Territory the Product that
contains morphine sulfate as its sole active ingredient that is approved for distribution as of the
Closing Date in the Territory under the Regulatory Approval (the “Business”);

     WHEREAS, effective upon the acquisition by King of Alpharma pursuant to the Merger Agreement,
King desires to sell to Buyer the Product and certain related assets, and Buyer desires to purchase
the Product and such assets from Seller and to assume certain related obligations; and

     WHEREAS, this Agreement and the consummation of the transactions contemplated hereby are not
in consideration of, or intended to induce or encourage, the settlement or other resolution of the
litigation captioned King Pharmaceuticals, Inc., King Pharmaceuticals Research and Development,
Inc., Elan Corporation plc and Elan Pharma International Ltd. v. Actavis, Inc. and Actavis
Elizabeth LLC, Civil Action No. 07-CV-5041 (JMA, SDW) (DNJ).

AGREEMENT

     NOW, THEREFORE, in consideration of the premises and the mutual covenants and promises
contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which hereby are acknowledged, the Parties agree as follows:

Article I.

Definitions

Section 1.01 Defined Terms

     As used in this Agreement, the following defined terms have the meanings described below:

     (a) “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly, through one or more intermediaries controls, is controlled by, or is under
common control with, such Person. For purposes of this definition, “control” means the

 

possession, direct or indirect, of the power to direct or cause the direction of the management and
policies of a Person, whether through ownership of voting securities or general partnership or
managing member interests, by contract or otherwise. Without limiting the generality of the
foregoing, a Person shall be deemed to control any other Person in which it owns, directly or
indirectly, a majority of the ownership interests.

     (b) “AG Distributor” shall mean a third party pharmaceutical company that is taking on
the role of distributing Authorized Generic Versions to trade customers (e.g. wholesalers, retail
chains, managed care organizations, government agencies, pharmacy benefit managers, etc.), which
third party pharmaceutical company shall exclude ordinary trade customers such as wholesalers.

     (c) “Aggregate Inventory Amount” has the meaning set forth in Section 4.02(b).

     (d) “Aggregate Wholesaler Amount” has the meaning set forth in Section 8.17(a).

     (e) “Aggregate Wholesale/Retail Amount” has the meaning set forth in Section 8.17(b).

     (f) “Agreement” has the meaning set forth in the Preamble to this Agreement.

     (g) “Alpharma” has the meaning set forth in the Recitals to this Agreement.

     (h) “Alpharma Subsidiary” means each subsidiary of Alpharma owning or controlling
assets or having liabilities relating to the Business.

     (i) “API” means active pharmaceutical ingredient.

     (j) “Assets and Properties” of any Person means all assets and properties of any kind,
nature, character and description (whether real, personal or mixed, whether tangible or intangible,
whether absolute, accrued, contingent, fixed or otherwise and wherever situated), including the
goodwill related thereto, operated, owned or leased by such Person, including cash, cash
equivalents, accounts and notes receivable, chattel paper, documents, instruments, general
intangibles, real estate, equipment, inventory, goods and intellectual property.

     (k) “Assumed Contract” means (i) each Contract relating to the Product, as in effect
on the Closing Date that is set forth in Section 1.01(k) of the Seller’s Disclosure Schedule, and
(ii) each Contract (or any portion thereof) that is assumed by the Buyer after the Closing Date
pursuant to Section 8.23, excluding any Excluded Rights under any such Contract (or portion
thereof).

     (l) “Assumed Liabilities” means (i) all Liabilities and obligations that Buyer has
expressly assumed or agreed to assume or perform under this Agreement, (ii) all Liabilities and
obligations under or pursuant to the Assumed Contracts arising after the Closing, other than
the Liabilities and obligations listed in items (ii)-(iv) of the Excluded Liabilities, (iii)

2

 

any obligations of Seller under an Assumed Contract to deliver Product following the Closing under
purchase orders of Persons entered into prior to the Closing in the ordinary course of business for
delivery of Product within thirty (30) days of the Closing Date and for which Buyer shall receive
payment, (iv) all Liabilities and obligations to pay Rebates attributable to Product bearing any of
Buyer’s NDC numbers, (v) all Liabilities and obligations to pay GPO Administration Fees and IFF
payments attributable to Product bearing any of Buyer’s NDC numbers, (vi) all Liabilities and
obligations to pay Chargebacks that are submitted to Buyer, Seller, or their respective Affiliates,
with respect to Product bearing any of Buyer’s NDC numbers, (vii) all Liabilities and obligations
relating to recalls or product liability claims or threatened claims or injuries caused by Product
sold by Buyer after the Closing, except to the extent that such Product was included in Inventory
and was defective when delivered by Seller to Buyer hereunder, (viii) Seller’s obligations under
the Federal Supply Schedule to supply the Product at the prices set forth in the Federal Supply
Schedule after the Closing for the period required by applicable Law, (ix) Seller’s obligations
under Section 340B of the Public Health Services Act to sell Product at the prices required by
applicable Law with respect to Product sold after the Closing Date, and (x) all other Liabilities
and obligations that (A) arise out of or are related to the Purchased Assets (including the
Regulatory Approval), the Product or the ownership, operation or conduct of the Business by or on
behalf of Buyer, its Affiliates or (sub)licensees, or their respective successors or assigns, (B)
arise after the Closing, and (C) are not otherwise expressly excluded under this definition.

     (m) “Authorized Generic Version” means any Product that is distributed under no
trademark or under a trademark other than Kadian®.

     (n) “Books and Records” means all files, documents, instruments, papers, books and
records (scientific, developmental, distribution, marketing, financial or other) owned by Seller
and relating to the Product or the Business in the Territory, including any pricing lists, customer
lists, vendor lists, financial data (including sales histories, sales force call activities and
market studies), Regulatory Documentation, clinical data, safety data, research and testing data
and pharmacology and toxicology data, validation documents and data, quality control histories,
litigation, adverse claims or demands, investigation information or files, trademark registration
certificates, trademark renewal certificates, and other documentation relating to the Purchased
Assets, the Product or the Regulatory Approval, but excluding any such items (i) to the extent that
any applicable Law prohibits their transfer, (ii) that were specifically prepared by Seller for the
negotiation of this Agreement, and (iii) to the extent such items are included in the definition of
“Marketing Materials”. The Parties acknowledge and agree that to the extent that any such Books
and Records contain information that relates to any product other than the Product or to any
business or operations of Seller other than the Business, such Books and Records may be copies and
in any event shall be redacted to delete such information.

     (o) “Business” has the meaning set forth in the Recitals to this Agreement.

     (p) “Business Day” means a calendar day other than Saturday, Sunday or any other
calendar day on which banks located in New York are authorized or obligated to close.

     (q) “Buyer” has the meaning set forth in the Preamble to this Agreement.

3

 

     (r) “Calendar Quarter” means each successive period of three consecutive calendar
months commencing on January 1, April 1, July 1 and October 1.

     (s) “Chargeback” means a credit, chargeback, reimbursement, purchase discount or other
payment to any pharmaceutical wholesaler or distributor in connection with the sale of a Product in
the United States by such wholesaler or distributor to a customer at a discount price pursuant to a
Contract between such customer and Seller or Buyer or pursuant to the Federal Supply Schedule or
Section 340B of the Public Health Service Act, 42 U.S.C. Section 201 et. seq..

     (t) “Chargeback Period” has the meaning set forth in Section 8.17(a).

     (u) “Closing” has the meaning set forth in Section 5.01.

     (v) “Closing Date” means the date that the Closing actually occurs as provided in
Section 5.01.

     (w) “Consultant” has the meaning set forth in Section 8.17(a).

     (x) “Contract” means any and all legally binding commitments, contracts, purchase
orders, leases, licenses, security agreements or other agreements, whether written or oral,
including any amendments, supplements or modifications thereto.

     (y) “Corporate Names” has the meaning set forth in Section 8.05(a).

     (z) “Costs of Goods Sold” means, with respect to any period, Buyer’s actual direct
costs to manufacture, or purchase from a third party, the Product sold in the Territory during such
period, excluding the Purchase Price.

     (aa) “Coupons” means any coupons, vouchers, co-pay cards or similar promotional
incentives distributed by Alpharma or any subsidiary of Alpharma prior to the Closing Date pursuant
to which Alpharma or such subsidiary of Alpharma is obligated to reimburse or pay a portion of the
purchase price of the Product directly or indirectly to an eligible patient.

     (bb) “Daily Sales Amount” has the meaning set forth in Section 8.17(a).

     (cc) “Daily Utilization Amount” has the meaning set forth in Section 8.17(b).

     (dd) “Damages” has the meaning set forth in Section 12.02(a).

     (ee) “DEA” means the United States Drug Enforcement Administration, and any successor
agency thereto.

     (ff) “Detail” means a face-to-face contact in which a Buyer sales representative makes
a presentation, including selling message and features and benefits of the Product, to a medical
professional with prescribing authority.

4

 

     (gg) “Direct Cost” means the cost of direct labor and direct materials used to provide
the relevant assistance or service.

     (hh) “Embeda NDA” means New Drug Application 22-321 filed pursuant to the Federal
Food, Drug, and Cosmetic Act and applicable FDA rules and regulations for marketing authorization
of the pharmaceutical product containing morphine sulfate as an active ingredient, known as Embeda,
within the United States (including all additions, amendments, supplements, extensions and
modifications thereto and the official regulatory files relating thereto).

     (ii) “Encumbrance” means any lien, pledge, hypothecation, charge, mortgage, security
interest, encumbrance, claim, option, right of first refusal, preemptive right, community property
interest or restriction of any nature (including any restriction on any other asset and any
restriction on the possession or exercise of any attribute or ownership of any asset).

     (jj) “Excluded Assets” means all Assets and Properties of Seller, including the
Licensed Intellectual Property, except the Purchased Assets.

     (kk) “Excluded Liabilities” means all Liabilities of Seller except the Assumed
Liabilities, including (i) all Liabilities and obligations under any Contract other than the
Assumed Contracts, (ii) all Liabilities and obligations of Seller to pay Rebates and Coupons
pursuant to Section 8.16, (iii) all Liabilities and obligations of Seller to pay GPO Administration
Fees and IFF payments pursuant to Section 8.19, (iv) all Liabilities and obligations of Seller to
pay Chargebacks pursuant to Section 8.18, (v) all Liabilities of Seller for Taxes with respect to
any taxable period, and all Liabilities for Taxes relating or attributable to the Product, the
Business, the Purchased Assets or the sale, operating or use of any of the foregoing with respect
to any taxable period or portion thereof ending on or prior to the Closing Date, with any property,
ad valorem or similar Taxes allocated to any period that includes but does not end on the Closing
Date on a per diem basis and (vi) any and all Liabilities of Seller accruing or arising prior to
the Closing, including Liabilities with respect to any claim or action asserted after the Closing
to the extent the conduct giving rise to such claim or action occurred prior to the Closing.

     (ll) “Excluded Rights” means, with respect to any Assumed Contract, any rights of any
Seller Indemnified Party to seek and obtain defense and indemnification thereunder from any
indemnifying party pursuant to the terms and conditions of the applicable Assumed Contract based on
any Damages incurred by any Seller Indemnified Party, whether prior to, on or after the Closing
Date, to the extent that such Damages (i) are attributable to occurrences and circumstances arising
prior to the Closing, and (ii) are otherwise subject, prior to the Closing, to an obligation of
defense or indemnity by any indemnifying party.

     (mm) “Execution Date” has the meaning set forth in the Preamble to this Agreement.

     (nn) “FDA” means the United States Food and Drug Administration and any successor
agency thereto.

5

 

     (oo) “GAAP” means generally accepted accounting principles, consistently applied, as
applied in the United States.

     (pp) “Generic Product” means a drug product containing morphine sulfate as its sole
active ingredient that refers to the Licensed Product as the reference-listed drug in an
Abbreviated New Drug Application or pursuant to an application under 21 U.S.C. § 355(b)(2).

     (qq) “Governmental or Regulatory Authority” means any court, tribunal, arbitrator,
authority, agency, commission, official or other instrumentality of the United States or other
country, or any supra-national organization, state, county, city or other political subdivision.

     (rr) “GPO Administration Fee” means any administration, service or similar fee paid to
a group purchasing organization, buying group or similar organization pursuant to a Contract
between Seller or Buyer and such group purchasing organization, buying group or similar
organization relating to the sale of Product to members of or participants in such group purchasing
organization, buying group or similar organization.

     (ss) “Gross Profit” means, with respect to any period, (i) Net Sales for such period,
less (ii) Cost of Goods Sold for such period, less (iii) an amount equal to five percent (5%) of
Net Sales for such period (as an allowance for handling and distribution costs).

     (tt) “IFF” means the industrial funding fee payable to the United States Department of
Veterans Affairs in connection with the sale of the Product to the United States Department of
Veterans Affairs under the Federal Supply Schedule, as in effect from time to time.

     (uu) “Indemnification Claim Notice” has the meaning set forth in Section 12.02(c).

     (vv) “Indemnified
Party” has the meaning set forth in Section 12.02(c).

     (ww) “Indemnifying
Party” has the meaning set forth in Section 12.02(c).

     (xx) “Inventory” means all inventory in whole lots of Product owned as of the Closing
by Seller in finished, packaged form, whether held at a location or facility of Seller (or of any
other Person on behalf of Seller) in the Territory, or in transit within the Territory to or from
Seller (or any such other Person).

     (yy) “Kadian” means pharmaceutical product (i) approved for distribution under the
Regulatory Approval in the Territory in any dosage or form, whether or not distributed under the
Trademark Kadian® or (ii) otherwise marketed or sold by Seller in the Territory under the Trademark
Kadian® as of the Closing Date.

     (zz) “Kadian Patents” means United States patent number 5,202,128, United States
patent number 5,378,474, and United States patent number 5,330,766, and any continuations,
continuations-in-part, divisionals, reexaminations, reissues and extensions thereof.

6

 

     (aaa) “Knowledge of King” means the actual knowledge of those employees who hold the
position of vice president or are more senior at King that were engaged in the diligence of
acquisition of Alpharma by King, including but not limited to, the following people, without any
duty to conduct an investigation: Eric Carter, Ken Touw, Brad Knoll, Chris McClendon, James Elrod
and Mary Flipse.

     (bbb) “Law” means any federal, state or local law, statute or ordinance, or any rule,
regulation, or published guidelines or pronouncements promulgated by any Governmental or Regulatory
Authority.

     (ccc) “Liability” means any debt, liability, losses, damages, cost, expenses and
obligations of every kind (whether fixed or contingent, known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due),
including any liability for Taxes.

     (ddd) “License Term” means the period commencing on the Closing Date and ending on the
earlier of (i) the date of expiration of the last to expire of the Licensed Patents and (ii) the
date on which a court enters a final decision from which no appeal has been or can be taken holding
that all claims of the Licensed Patents that would otherwise be infringed by the making, having
made, using, selling, offering for sale or importation of any Licensed Product or Generic Product
are unenforceable or invalid.

     (eee) “Licensed Intellectual Property” means all Product Patents (including the Kadian
Patents), unpatented inventions, know-how, trade secrets, technical data (including the Seller
Data), trade dress, and package designs owned or controlled by Sellers and their Affiliates that
are not exclusively related to the Product and that would be infringed or violated by the making,
having made, using, selling, offering for sale or importation of the Licensed Product in the
Territory.

     (fff) “Licensed Patents” means United States patent number 5,202,128 and United States
patent number 5,378,474, and any continuations, continuations-in-part, divisionals, reexaminations,
reissues and extensions thereof.

     (ggg) “Licensed Product” means the Product in the dosage strengths and formulations
approved for distribution in the Territory pursuant to the Regulatory Approval as of the Closing
Date and manufactured in accordance with the manufacturing process used as of the Closing Date,
including, after the Closing Date, any Minor Changes.

     (hhh) “Marketing Materials” means all market research, marketing plans and strategies,
media plans, advertising, form letters, sales force training materials, advertising, promotional
and marketing data and materials (including competitor information, product data, market
intelligence reports and marketing and sales statistical programs), advertising and promotional
materials and literature, mailing lists, sales data and detailing reports, reimbursement data,
customer information (including customer sales information, sales forecasting models, medical
educational materials, website content and advertising and display materials and speakers lists),
packaging artwork and television masters, in each case (i) owned by Seller and used exclusively in
connection with the marketing, advertising and promotion of

7

 

the Product in the Territory that Seller, in its sole discretion, determines to transfer to
Buyer and (ii) to the extent that Seller is able to share such materials with Buyer without
violation of any third party agreement; provided that “Marketing Materials” shall exclude the
labeling of the Product, which shall be deemed part of the Regulatory Approval.

     (iii) “Material Adverse Effect” means an effect, condition or change that individually
or in the aggregate is materially adverse to the Purchased Assets taken as a whole or the business,
results of operations, or financial condition of the Business taken as a whole, other than changes
in general economic or market conditions or changes or developments generally affecting the
pharmaceutical industry.

     (jjj) “Merger Agreement” has the meaning set forth in the Recitals to this Agreement.

     (kkk) “Minor Changes” means changes to the Licensed Product that would not cause the
manufacture, use or sale of the Licensed Product to fall within the Licensed Intellectual Property
owned or controlled by Seller or its Affiliates after the Closing Date, other than the Kadian
Patents.

     (lll) “NDC” means the unique identifying number assigned to a drug product, including
the labeler code, product code and package code, in connection with the drug listing requirements
of Section 510(j) of the Federal Food, Drug, and Cosmetic Act and applicable FDA rules and
regulations.

     (mmm) “Net Sales” means, with respect to any period, the gross sales recorded by Buyer
and its Affiliates or sublicensees, on its books and records, in accordance with GAAP, for sales of
the Product to third parties in the Territory during such period, less (if not already deducted or
reflected in the amount recorded and to the extent actually allowed by Buyer) (i) trade and
quantity discounts, Rebates, Chargebacks paid by Buyer, GPO Administrative Fees paid by Buyer, and
IFF paid by Buyer and other ordinary course administrative or promotional fees, (ii) repayments,
credits and allowances to customers on account of ordinary course promotional allowances,
rejection, withdrawal, recall, or return of the Product or on account of retroactive price
reductions affecting the Product, and (iii) customary cash discounts (“fast pay”), which,
in each case ((i), (ii), and (iii)), for the avoidance of doubt, shall be paid in accordance with
GAAP and shall not include write-offs, bad debts or freight, insurance and handling costs, Taxes
and expenses for all activities related to the distribution of the Product incurred by Buyer. Net
Sales with respect to sales of the Product that are not made on an arm’s length basis or that are
made for consideration other than cash shall be calculated based on the average per-unit Net Sales
of the Product during the applicable period without regard to such non-arm’s length or non-cash
sales. If the Product is sold with other products on a portfolio basis, any commercially
reasonable discounts or other adjustments with respect to the Product shall be allocated pro rata
across all products in such portfolio based on the non-discounted, non-adjusted price for each such
product. In the event that one or more Authorized Generic Versions are sold by an AG Distributor,
(A) sales from Buyer or its Affiliates to an AG Distributor shall not be included in Net Sales and
(B) such AG Distributor’s sales to third parties shall be included in Net Sales.

8

 

     (nnn) “Order” means any writ, judgment, decree, injunction, charge, ruling or similar
order of any Governmental or Regulatory Authority (in each such case whether preliminary or final).

     (ooo) “Party” means either Buyer or Seller. “Parties” means Buyer and Seller,
collectively.

     (ppp) “Patent” means (i) all patents, patent applications and statutory invention
registrations, (ii) any substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions, supplementary protection
certificates and the like, and any provisional applications, of any such patents, patent
application or statutory invention registrations, (iii) all inventions disclosed in the foregoing,
(iv) all rights therein provided by international treaties and conventions, and (v) all rights to
obtain and file for patents and registrations thereto anywhere in the Territory.

     (qqq) “Permitted Encumbrance” means (i) any Encumbrance for Taxes not yet due or
delinquent or for those Taxes being contested in good faith by appropriate proceedings for which
adequate reserves have been established and (ii) any Encumbrance that does not materially detract
from the value of, or interfere with the present use of, the properties or assets it affects.

     (rrr) “Person” means any natural person, corporation, general partnership, limited
partnership, limited liability company, proprietorship, other business organization, trust, union,
association or Governmental or Regulatory Authority.

     (sss) “Product” means Kadian.

     (ttt) “Product Copyrights” means any and all copyrights owned by Seller relating
exclusively to the Product, including copyrights in Marketing Materials for the Product.

     (uuu) “Product Domain Names” means (i) the domain names set forth in Section 1.01(uuu)
of the Seller’s Disclosure Schedule and (ii) any other domain name owned by Seller as of the
Closing Date the includes the word “Kadian”.

     (vvv) “Product IND” means Investigational New Drug Application 35,553 filed in
accordance with Section 505(i) of the Federal Food, Drug, and Cosmetic Act, as amended, and
applicable FDA rules and regulations (including all additions, amendments, supplements, extensions
and modifications thereto and the official regulatory files relating thereto).

     (www) “Product Intellectual Property” means the Product Copyrights, Product Know-How,
Product Marks and Product Trade Dress, in each case relating to the Territory, and the Product
Domain Names.

     (xxx) “Product Know-How” means any research and development information, validation
methods and procedures, unpatented inventions, know-how, trade secrets or technical data (including
clinical data and safety data) or information that exclusively relate to the Product or the
Business and are owned by Seller, other than such know-how that is or becomes the subject of a
Patent.

9

 

     (yyy) “Product Mark(s)” means (i) the Trademark “Kadian®” and (ii) such other
Trademark(s) owned by Seller and exclusively used in connection with the Product.

     (zzz) “Product Patent” means all Patents in the Territory owned or controlled by
Seller that claim the Product or the manufacture, use or sale of the Product.

     (aaaa) “Product Trade Dress” means the trade dress, package designs, product inserts,
labels and associated artwork owned by Seller that is used exclusively in connection with the
Product, the packaging thereof or the Business, excluding all Seller Brands used thereon other than
the Product Marks.

     (bbbb) “Public Filings” means all of Alpharma’s periodic reports and registration
statements filed or furnished on EDGAR with the Securities and Exchange Commission under the
Securities Exchange Act of 1934 or Securities Act of 1933.

     (cccc) “Purchase Price” shall have the meaning set forth in Section 4.01(a).

     (dddd) “Purchased Assets” means: (i) the Assumed Contracts; (ii) the Marketing
Materials; (iii) the Books and Records; (iv) the Regulatory Approval; (v) the Inventory, (vi) the
Product Intellectual Property and (vii) the Product IND. The Purchased Assets do not include any
fixed assets, entities, the Seller Data or the Licensed Intellectual Property.

     (eeee) “Reasonable Best Efforts” means such prompt, substantial and persistent efforts
as a prudent Person desirous of achieving a result would use in similar circumstances; provided,
that the Parties shall be required to expend only such resources to achieve such results as are
commercially reasonable in similar circumstances.

     (ffff) “Rebate” means any rebate payable pursuant to (i) state Medicaid or other state
and governmental pharmaceutical assistance programs or (ii) Contracts between Seller or Buyer and
managed care organizations (including pharmacy benefit management companies, health plans and
insurance companies), in each case relating to utilization of the Product in the United States
during any particular period.

     (gggg) “Rebate Period” has the meaning set forth in Section 8.17(b).

     (hhhh) “Regulatory Approval” means the New Drug Application 20-616 filed pursuant to
Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act and applicable FDA rules and
regulations for marketing authorization of the Product within the United States (including all
additions, amendments, supplements, extensions and modifications thereto and the official
regulatory files relating thereto).

     (iiii) “Regulatory Documentation” means (i) registrations or applications for, or
other filings or submissions with respect to, the Regulatory Approval or the Product, including
regulatory compliance reports and other reports, and other written materials filed as part of or
referenced in, the Regulatory Approval, and the risk management plan with respect to the Product,
(ii) any other filings or submissions with respect to the Product with any Governmental or
Regulatory Authority in the Territory other than the FDA and (iii) written communications,

10

 

and written summaries and minutes of other communications, with the FDA or other Governmental
or Regulatory Authorities to the extent relating to any of the foregoing.

     (jjjj) “Seller” means King and, from and after the Closing, shall also include
Alpharma and any subsidiary of Alpharma owning or controlling assets or having liabilities relating
to the Business, jointly and severally, or if the context so requires individually.

     (kkkk) “Seller Brands” means all Trademarks owned by, licensed to, controlled by or
used by Seller, whether or not registered, including the name “King”, but excluding the Product
Marks and excluding any trade dress rights in the shape, configuration, coloring or appearance of
the Product or its packaging as sold by Seller before the Closing Date.

     (llll) “Seller Data” means the clinical data, safety data and other information that
is included or referenced in the Regulatory Approval as of the Closing Date, but excluding the
Product Know-How.

     (mmmm) “Seller’s Disclosure Schedule” has the meaning set forth in Article VI.

     (nnnn) “Seller Indemnified Parties” has the meaning set forth in Section 12.02(b).

     (oooo) “Solvent” means, with respect to any Person on a particular date, that at fair
valuations, the sum of such Person’s assets is greater than all of such Person’s debts.

     (pppp) “Tax” means any and all taxes, customs, duties, fees or other like assessments,
charges or Liabilities imposed by any governmental, regulatory or administrative entity or agency
responsible for the imposition of any amount, including (i) any net income, alternative or add-on
minimum tax, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits,
license, excise, severance, stamp, occupation, premium, property, withholding, employment, payroll,
recapture, environmental or windfall profit tax; (ii) any Liability for the payment of any amounts
of the type described in clause (i) above as a result of being a member of any affiliated,
consolidated, combined, unitary or other group for any Taxable period; and (iii) any Liability for
the payment of any amounts of the type described in clause (i) or (ii) above as a result of any
express or implied obligation to indemnify any other Person, and including any liability for taxes
of a predecessor or transferor or otherwise by operation of law.

     (qqqq) “Tax Return” means any return, form, estimate, information statement or report
relating to Taxes, including any attachment, appendix, addendum or amendment.

     (rrrr) “Territory” means the United States.

     (ssss) “Third Party Claim” has the meaning set forth in Section 12.02(d).

     (tttt) “Toll Manufacturing Agreement” has the meaning set forth in Section 8.20(a).

     (uuuu) “Trademark” means trademarks, service marks, certification marks, trade dress,
Internet domain names, trade names, product names, company names and any other source

11

 

identifying symbols, designs, slogans, logos or insignia, whether registered or unregistered,
and all common law rights, applications and registrations therefor, and all goodwill associated
therewith.

     (vvvv) “United States” means the United States of America, its territories and
possessions, including Washington, D.C. and Puerto Rico.

Section 1.02 Construction of Certain Terms and Phrases.

     Unless the context of this Agreement otherwise requires: (a) words of any gender include each
other gender; (b) words using the singular or plural number also include the plural or singular
number, respectively; (c) the terms “hereof,” “herein,” “hereby” and derivative or similar words
refer to this entire Agreement; (d) the terms “Article” or “Section” refer to the specified Article
or Section of this Agreement; (e) the term “or” has, except where otherwise indicated, the
inclusive meaning represented by the phrase “and/or”; (f) the terms “including” and “includes” mean
“including without limitation” and “includes without limitation,” respectively; and (g) a reference
to a Law includes any amendments or modifications to such Law. Whenever this Agreement refers to a
number of days, such number shall refer to calendar days unless Business Days are specified.

Article II.

Purchase and Sale of Assets

Section 2.01 Purchase and Sale of Assets

     (a) Subject to the terms and conditions of this Agreement, at the Closing, Seller shall sell,
transfer, convey, assign and deliver to Buyer, and Buyer shall purchase, acquire and accept from
Seller, free and clear of any Encumbrance, other than a Permitted Encumbrance, all of Seller’s
right, title and interest, as of the Closing, in and to the Purchased Assets.

     (b) From and after the Closing, Seller shall retain all of its right, title and interest in
and to the Excluded Assets and Seller may retain an archival copy of all Assumed Contracts, Books
and Records (or with respect to any Books and Records that contain information that relates to any
product other than the Product or to any business or operation of Seller and its applicable
subsidiaries other than the Business, the original Books and Records), Marketing Materials and
other documents or materials conveyed hereunder.

     (c) King shall cause Alpharma and each Alpharma Subsidiary to perform all obligations required
of it as a Seller under this Agreement.

     (d) Prior to the Closing, Seller shall use commercially reasonable efforts to obtain all
consents required for the assignment to Buyer of the Contracts listed on Schedule 1.01(k). If such
consent is not obtained prior to the Closing, (a) Seller shall continue to use commercially
reasonable efforts to obtain such consent and (b) Seller and Buyer shall cooperate in a mutually
agreeable arrangement under which Buyer would obtain the benefits and assume the obligations under
such Contract in accordance with this Agreement, and under which Seller would enforce for the
benefit of the Buyer, with Buyer assuming Seller’s obligations, any and all rights of Seller
against a third party thereto. To the extent, and only to the extent, that the

12

 

benefits arising therefrom and obligations thereunder have been provided by alternative
arrangements as provided above, such Contract (or any portion thereof) shall be deemed an Assumed
Contract, provided that Buyer shall not be responsible for any Liabilities (i) arising out of a
claim of breach of such Contract due to the establishment of the alternative arrangements, or (ii)
arising out of such Contract as a result of Seller’s action without Buyer’s approval in a manner
inconsistent with the alternative arrangements.

Article III.

Assumption of Liabilities

Section 3.01 Assumption of Assumed Liabilities

     Subject to the terms and conditions of this Agreement, as of the Closing Date, Buyer agrees to
assume, satisfy, perform, pay and discharge only the Assumed Liabilities.

Section 3.02 Excluded Liabilities

     Seller shall retain and remain solely responsible for, and shall satisfy, perform, pay and
discharge when due, any and all Excluded Liabilities.

Article IV.

Purchase Price and Payment

Section 4.01 Purchase Price

     As full and complete consideration for the Purchased Assets, Buyer shall:

     (a) pay, or cause to be paid the following amounts (together, the “Purchase Price”) in
immediately available funds by wire transfer into an account designated by Seller not later than
three Business Days prior to the date such payment is due:

                    (i) not later than forty-five (45) days (or, upon the certification by Buyer to Seller prior
to such forty-fifth (45th) day that it has not collected sufficient receivables with respect to the
Product to enable it to pay such amount by such forty-fifth (45th) day, fifty-five (55) days)
following the last day of the first Calendar Quarter of 2009, $30,000,000;

                    (ii) not later than thirty (30) days following the last day of the second Calendar Quarter of
2009, $25,000,000, plus any unpaid amounts previously payable pursuant to Section 4(a)(i);

                    (iii) not later than thirty (30) days following the last day of the third Calendar Quarter of
2009, $25,000,000, plus any unpaid amounts previously payable pursuant to Section 4(a)(ii);

                    (iv) not later than thirty (30) days following the last day of the fourth Calendar Quarter of
2009, $20,000,000, plus any unpaid amounts previously payable pursuant to Section 4(a)(iii);

13

 

                    (v) not later than thirty (30) days following the last day of the first Calendar Quarter of
2010, $20,000,000, plus any unpaid amounts previously payable pursuant to Section 4(a)(iv); and

                    (vi) not later than thirty (30) days following the last day of the second Calendar Quarter of
2010, $7,500,000, plus any unpaid amounts previously payable pursuant to Section 4(a)(v);

provided, however, that no payment pursuant to any of Sections 4.01(a)(i) through 4.01(a)(vi)
following any single Calendar Quarter shall, when combined with all prior payments made by Buyer
pursuant to Section 4.01(a), exceed the aggregate amount of Gross Profits for the period beginning
on January 1, 2009 and ending on the last day of such Calendar Quarter; provided further, however,
that any amount that is not paid by reason of the foregoing proviso shall be deemed to be “payable”
but “unpaid” for the purposes of Section 4(a)(ii) through Section 4(a)(vi), but in no case shall
the application of this proviso cause the cumulative Purchase Price to exceed the lesser of (A)
$127,500,000 and (B) the Gross Profits for the period from January 1, 2009, through June 30, 2010;

     (b) not later than the date on which the payment in Section 4.01(a)(i) is due, pay the
Aggregate Inventory Amount as determined in accordance with Section 4.02; and

     (c) assume the Assumed Liabilities at Closing.

Section 4.02 Inventory Payment

     (a) On the day immediately following the Closing Date, representatives of Buyer and Seller
shall count the number of finished packages of the Product included in Inventory where such
Inventory is located.

     (b) The “Aggregate Inventory Amount” shall mean the aggregate cost paid or payable by
Seller to the manufacturer of the Inventory (other than Inventory with a remaining shelf life of
less than twelve (12) months) for all of the Inventory included in the Purchased Assets.

     (c) Not later than the date on which the payment in Section 4.01(a)(i) is due, Buyer shall pay
to Seller the Aggregate Inventory Amount in immediately available funds by wire transfer into an
account designated by Seller not later than three (3) Business Days after such count.

Section 4.03 Allocation of Purchase Price

     Promptly following the Closing, Seller and Buyer shall agree in good faith on an allocation of
the Purchase Price among the Purchased Assets. Buyer and Seller agree (a) to report the sale and
purchase of the Purchased Assets for Tax purposes in accordance with such allocations and (b) not
to take any position inconsistent with such allocations on any of their respective tax returns.
All payments made pursuant to Article XII shall be deemed adjustments to the Purchase Price.

14

 

Section 4.04 Payment of Sales, Use and Other Taxes

     Buyer shall be solely responsible for all sales, use, transfer, value added, gross receipts
and other similar Taxes, if any, arising out of the sale by Seller of the Purchased Assets to Buyer
pursuant to this Agreement.

Section 4.05 Statements and Audit Rights

     (a) Any payment under Section 4.01(a) that is based upon Gross Profits shall be accompanied by
a statement of the amount of Gross Profits during the applicable period represented by such
payment.

     (b) Buyer shall, and shall cause its sublicensees and AG Distributors, to maintain at a
location in the United States, complete and accurate books and records in such detail as is
necessary to accurately calculate the amounts payable to Seller under this Agreement. Such books
and records shall be maintained for a period of at least five (5) years after the end of the
Calendar Quarter in which they were generated, or for such longer period as may be required by
applicable Law. Once per each calendar year and for a period of two (2) years after the end of the
second Calendar Quarter of 2010, Seller shall have the right upon reasonable prior notice to have
an independent accounting firm reasonably acceptable to Buyer audit and examine the relevant books
and records as may be reasonably necessary to determine and/or verify the amount of payments due
hereunder and Buyer’s compliance with its obligations hereunder; provided, however, that Seller
shall not have the right to conduct such an audit until the expiration of the Licensed Patents.
Such audit and examination shall be conducted and shall take place, and Buyer shall, and shall
cause its Affiliates, sublicensees, AG Distributors and third party distributors of Authorized
Generic Versions to, make such books and records available, during normal business hours at the
facility(ies) where such books and records are maintained. Each such audit and examination shall
be limited to pertinent books and records for any Calendar Quarter ending not more than twenty-four
(24) months prior to the date of the audit. Before permitting such independent accounting firm to
have access to such books and records, Buyer may require such independent accounting firm and its
personnel involved in such audit to sign a customary confidentiality agreement in form and
substance reasonably acceptable to Buyer as to any confidential information which is to be provided
to such accounting firm or to which such accounting firm will have access while conducting the
audit under this Section. The independent accounting firm will prepare and provide to Seller and
Buyer a written report stating only whether the reports submitted and amounts paid pursuant to this
Agreement were correct or incorrect, and the amounts of any discrepancies. In the event that such
report indicates that there was an underpayment or overpayment by Buyer of any amount to Seller
hereunder, Buyer or Seller, as the case may be, shall promptly (but in no event later than thirty
(30) days after its receipt of the independent accountant’s report so concluding) make payment to
the other of the amount of such underpayment or overpayment. Seller shall bear all costs and
expenses of any such audit, except that if any audit discloses an underpayment or overpayment by
Buyer with respect to any audit period in excess of five percent (5%) of the aggregate amount
required to be paid with respect to such audit period, all costs and expenses of the audit,
including the expenses of the independent accounting firm, shall be borne and promptly paid by
Buyer.

15

 

Article V.

Closing

Section 5.01 Time and Place

     Unless this Agreement is earlier terminated pursuant to Article XIII, the closing of the
transactions contemplated by this Agreement, including the purchase and sale of the Purchased
Assets and the assumption of the Assumed Liabilities (the “Closing”), shall take place
automatically, and the conveyances to be made at Closing are hereby made by the parties and shall
be effective without any further action by any party, immediately following the satisfaction or
waiver of the conditions set forth in Articles IX and X.

Section 5.02 Deliveries at Closing

     (a) Closing Deliveries by Seller. Effective as of the Closing, Seller hereby sells,
assigns and conveys to Buyer the Purchased Assets and assigns to the Seller the Assumed
Liabilities. Effective as of the Closing, Buyer hereby accepts the Purchased Assets and assumes
and agrees to perform the Assumed Liabilities. At the Closing, Seller shall deliver or cause to be
delivered to Buyer: a letter from Seller to the FDA duly executed by Seller transferring the rights
to the Regulatory Approval to Buyer; and such bills of sale, assignment and assumption agreements
and other instruments of assignment, conveyance and transfer as are necessary to effect and confirm
the sale, transfer, conveyance, and assignment of the Purchased Assets and the assumption of the
Assumed Liabilities (provided, however, that the failure to execute or deliver any such agreement
or instrument shall not affect the effectiveness of any sale, assignment and conveyance and
assumption effected hereby, or the obligations of the parties at Closing). As soon as reasonably
practicably following the Closing, and in any event no later than ten (10) days after the Closing,
Seller shall deliver the Marketing Materials and the Books and Records.

     (b) Closing Deliveries by Buyer. At the Closing, Buyer shall deliver or cause to be
delivered to Seller: a letter from Buyer to the FDA duly executed by Buyer agreeing to assume
certain obligations with respect to the Regulatory Approval; and such bills of sale, assignment and
assumption agreements and other instruments of assignment, conveyance and transfer as are necessary
to effect and confirm the sale, transfer, conveyance, and assignment of the Purchased Assets and
the assumption of the Assumed Liabilities (provided, however, that the failure to execute or
deliver any such agreement or instrument shall not affect the effectiveness of any sale, assignment
and conveyance and assumption effected hereby or the obligations of the parties at Closing).

Article VI.

Representations and Warranties of Seller

     Seller represents and warrants to Buyer as of the date of this Agreement, subject to such
exceptions as are specifically disclosed in the disclosure schedules supplied by Seller to Buyer
and attached to this Agreement (the “Seller’s Disclosure Schedule”), as follows:

16

 

Section 6.01 Organization, Etc.

     King is a corporation duly organized, validly existing and in good standing under the laws of
Tennessee and has all requisite power and authority to own its assets and carry on its business as
currently conducted by it. Alpharma and each Alpharma Subsidiary is a corporation, limited
liability company or partnership duly organized, validly existing and in good standing under the
laws of its jurisdiction of organization and has all requisite power and authority to own its
assets and carry on the Business as currently conducted by it. King, Alpharma and each Alpharma
Subsidiary is duly authorized to conduct its business and is in good standing in each jurisdiction
where such qualification is required, except for any jurisdiction where failure to so qualify would
not reasonably be expected to have a Material Adverse Effect or materially impair or delay Seller’s
ability to perform its obligations hereunder.

Section 6.02 Authority of Seller

     King has, and at the Closing Alpharma and each Alpharma Subsidiary will have, all necessary
power and authority to enter into this Agreement and to carry out the transactions contemplated
hereby. The execution, delivery and performance by King of its obligations under this Agreement
have been duly and validly authorized and no additional corporate or shareholder authorization or
consent is required in connection with the execution, delivery and performance by King of this
Agreement. This Agreement has been duly and validly executed and delivered by King and, when
executed and delivered by Buyer, will constitute a legal, valid and binding obligation of King
enforceable against it in accordance with its terms except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors rights generally, and (b) as limited by Laws relating to the availability of specific
performance, injunctive relief or other equitable remedies.

Section 6.03 Consents and Approvals

     (a) No consents, waivers, approvals, Orders or authorizations of, or registrations,
declarations or filings with, any Governmental or Regulatory Authority are required by or with
respect to Seller in connection with the execution and delivery of this Agreement by Seller or the
performance of its obligations hereunder, except for such consents, waivers, approvals, Orders or
authorizations the failure to obtain which, and such registrations, declarations or filings the
failure to make which, would not reasonably be expected to have a Material Adverse Effect on the
Business or materially impair or delay Seller’s ability to perform its obligations hereunder.

     (b) No consents, waivers, approvals, or authorizations of, or notices to, any third party
(other than a Governmental or Regulatory Authority) that are required by or with respect to Seller
in connection with the execution and delivery of this Agreement by Seller or the performance of its
obligations hereunder, except for such consents, waivers, approvals, or authorizations the failure
to obtain which, and such notices the failure to give which, would not reasonably be expected to
have a Material Adverse Effect or materially impair or delay Seller’s ability to perform its
obligations hereunder.

17

 

Section 6.04 Non-Contravention

     The execution and delivery by King of this Agreement does not, and the performance by Seller
of its obligations under this Agreement and the consummation of the transactions contemplated
hereby will not:

     (a) conflict with or violate any provisions of the organization documents of Seller;

     (b) conflict with or result in a violation or breach of any term or provision of any Law
applicable to King, Alpharma and each Alpharma Subsidiary, the Business or the Purchased Assets,
other than breaches and violations that, in the aggregate, would not reasonably be expected to have
a Material Adverse Effect or materially impair or delay Seller’s ability to perform its obligations
hereunder; or

     (c) conflict with or result in a breach or default (or an event that, with notice or lapse of
time or both, would constitute a breach or default) under, or termination of, any Assumed Contract
or any other Contract to which Seller is a party or by which Seller or any of its assets is bound,
other than such conflicts, breaches or defaults as would not reasonably be expected to have a
Material Adverse Effect.

Section 6.05 Solvency

     (a) King, Alpharma and each Alpharma Subsidiary is Solvent.

     (b) No transfer of property is being made by Seller and no obligation is being incurred by
Seller pursuant to this Agreement with the intent to hinder, delay or defraud either present or
future creditors of Seller.

Section 6.06 Title

     Seller will have as of Closing, and upon transfer of the Purchased Assets to Buyer at Closing
as contemplated by this Agreement Buyer shall acquire, good and marketable title thereto free and
clear of any Encumbrance, other than Permitted Encumbrances.

Section 6.07 Litigation

     To the Knowledge of King, (a) there are no material claims, actions, suits or proceedings
pending or, any investigation by any Governmental or Regulatory Authority pending against any
Seller or any of their respective properties or rights in connection with the Business or the
Purchased Assets, (b) neither Seller nor any of its respective properties or rights is subject to
any outstanding Order in connection with the Purchased Assets and (c) no third party, including any
of its employees, has any cause for filing, threatening or contemplating any material claim,
action, suit or proceeding or investigation against any of them in connection with the Business or
the Purchased Assets.

18

 

Section 6.08 Purchased Assets

     (a) To the Knowledge of King, there are no pending claims, disputes, litigation or proceedings
challenging any of Seller’s right, title or interest in, or Seller’s use of, the Purchased Assets
and there are no facts which would provide a basis for any other Person to claim that it owns,
possesses or controls any rights in any of the Purchased Assets.

     (b) A true and complete copy of the executed version of each agreement listed in Section
1.01(k) of the Seller’s Disclosure Schedule has been provided to the Buyer prior to execution of
this Agreement.

     (c) To the Knowledge of King, Seller is not in breach of any of the Assumed Contracts listed
in Section 1.01(k) of the Seller’s Disclosure Schedule, and no third party has notified Seller of
any breach thereof.

     (d) Except to the extent resulting from any action or inaction by Buyer or its Affiliates, at
the time of delivery to Buyer or its designee, all Inventory (i) conforms in all respects to the
specifications and requirements of the Regulatory Approval for the Product, (ii) has been stored,
transported and handled in compliance with all current Good Manufacturing Practices applicable to
pharmaceutical products sold in the Territory and (ii) is not adulterated or misbranded.

Section 6.09 Regulatory

     (a) To the Knowledge of King, and except as disclosed in the Public Filings, the operation of
the Business, including the manufacture, import, export, testing, development, processing,
packaging, labeling, storage, marketing, and distribution of the Product in the Territory, is and
has been in material compliance for the last three (3) years with all applicable Laws.

     (b) To the Knowledge of King, during the three (3) year period ending on December 10, 2008,
Seller has not had any Product or manufacturing site for the Product subject to a Governmental or
Regulatory Authority (including FDA) shutdown or import or export prohibition, nor received any FDA
Form 483 or other material Governmental or Regulatory Authority notice of inspectional
observations, “warning letters,” or “untitled letters” with respect to the Product or the Business
or any requests or requirements to make changes to the Products that if not complied with would
reasonably be expected to result in a material liability to the Seller or the Business.

     (c) To the Knowledge of King, Seller has filed, or caused to be filed, with the applicable
Governmental and Regulatory Authorities all material required notices and reports, including
adverse experience reports, with respect to manufacture, development, marketing and other
commercial exploitation of the Product in or for the Territory.

     (d) To the Knowledge of King, neither Seller, nor any Person working for or with Seller in
performing or rendering, any activities or services related to the Business, including the
development, use or commercialization of the Product, has ever been or is currently debarred by the
FDA or any other Governmental or Regulatory Authority, nor has any such

19

 

Person been convicted of any crime or engaged in any conduct that would reasonably be expected
to result in exclusion under 42 U.S.C. Section 1320a-7 or any similar state law or regulation.

Section 6.10 Brokers

     Seller has not retained any broker in connection with the transactions contemplated hereunder.
Buyer has no, and will have no, obligation to pay any brokers, finders, investment bankers,
financial advisors or similar fees in connection with this Agreement or the transactions
contemplated hereby by reason of any action taken by or on behalf of Seller.

Section 6.11 No Other Representations and Warranties

     EXCEPT FOR THE REPRESENTATIONS OR WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, SELLER
DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, WITH
REGARD TO THE PRODUCT, THE PURCHASED ASSETS AND THE BUSINESS, INCLUDING THE FUTURE PROFITABILITY OF
THE PURCHASED ASSETS, THE PRODUCT OR THE BUSINESS, AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.

Article VII.

Representations and Warranties of Buyer

     Buyer represents and warrants to Seller as of the date of this Agreement, subject to such
exceptions as are specifically disclosed in the disclosure schedule supplied by Buyer to Seller and
dated as of the date of this Agreement, if any, as follows:

Section 7.01 Corporate Organization

     Buyer is a limited liability company duly organized, validly existing and in good standing
under the laws of Delaware and has all requisite power and authority to own its assets and carry on
its business as currently conducted by it. Buyer is duly authorized to conduct its business and is
in good standing in each jurisdiction where such qualification is required, except for any
jurisdiction where failure to so qualify could not reasonably be expected, individually or in the
aggregate, to materially impair or delay Buyer’s ability to perform its obligations hereunder.

Section 7.02 Authority of Buyer

     Buyer has all necessary power and authority to enter into this Agreement and to carry out the
transactions contemplated hereby. The execution, delivery and performance by Buyer of this
Agreement have been duly and validly authorized and no additional corporate or shareholder
authorization or consent is required in connection with the execution, delivery and performance by
Buyer of this Agreement. This Agreement has been duly and validly executed and delivered by Buyer
and, when executed and delivered by Seller, will constitute a legal, valid and binding obligation
of Buyer enforceable against it in accordance with its terms except (a) as

20

 

limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Laws of
general application affecting enforcement of creditors’ rights generally, and (b) as limited by
Laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.

Section 7.03 Consents and Approvals

     No consents, waivers, approvals, Orders or authorizations of, or registrations, declarations
or filings with, any Governmental or Regulatory Authority are required by Buyer in connection with
the execution and delivery of this Agreement by Buyer or the performance of its obligations
hereunder.

Section 7.04 Non-Contravention

     The execution and delivery by Buyer of this Agreement does not, and the performance by it of
its obligations under this Agreement and the consummation of the transactions contemplated hereby
will not:

     (a) conflict with or violate any provision of the organizational documents of Buyer;

     (b) assuming the receipt of all Buyer governmental consents, conflict with or result in a
violation or breach of any term or provision of any Law applicable to Buyer; or

     (c) conflict with or result in a breach or default (or an event that, with notice or lapse of
time or both, would constitute a breach or default) under, or termination of, any Contract to which
Buyer is a party or by which Buyer or any of its assets is bound, other than such conflicts,
breaches or defaults as would not reasonably be expected to or materially impair or delay Buyer’s
ability to perform its obligations hereunder.

Section 7.05 Solvency

     (a) Buyer is Solvent.

     (b) No transfer of property is being made by Buyer and no obligation is being incurred by
Buyer pursuant to this Agreement with the intent to hinder, delay or defraud either present or
future creditors of Buyer.

Section 7.06 Brokers

     Buyer has not retained any broker in connection with the transactions contemplated hereunder.
Seller has no, and will have no, obligation to pay any brokers, finders, investment bankers,
financial advisors or similar fees in connection with this Agreement or the transactions
contemplated hereby by reason of any action taken by or on behalf of Buyer.

21

 

Section 7.07 No Other Representations and Warranties

     EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT, BUYER HEREBY
DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN.

Article VIII.

Covenants of the Parties

Section 8.01 Reasonable Best Efforts

     Each Party shall use its Reasonable Best Efforts to take, or cause to be taken, all action, or
to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to
consummate and make effective the transactions contemplated by this Agreement and to cause the
conditions to the obligations of the other Party to consummate the transactions contemplated hereby
to be satisfied, including (a) obtaining all consents and approvals of all Persons and Governmental
or Regulatory Authorities and removing any injunctions or other impairments or delays that are
necessary, proper or advisable to the consummation of the transactions contemplated by this
Agreement and (b) furnishing upon request to each other such information as is required in
connection with the foregoing.

Section 8.02 Cooperation and Transition

     (a) Each Party shall cooperate fully with the other in preparing and filing all notices,
applications, submissions, reports and other instruments and documents that are necessary, proper
or advisable under applicable Laws to consummate and make effective the transactions contemplated
by this Agreement, including Seller’s cooperation in the efforts of Buyer to obtain any consents
and approvals of any Governmental or Regulatory Authority required for Buyer to be able to own the
Purchased Assets.

     (b) For a period of seventy (70) days following the Closing, Seller shall provide to Buyer, at
Seller’s expense, (i) such services in connection with the transition of the marketing and sale of
the Product from Seller to Buyer as Buyer may reasonably request, including with respect to
regulatory affairs, pharmacovigilance, customer service, and risk management programs and related
processes, provided that such services can be provided by Seller without unreasonable burden (such
as the engagement of additional employees or securing of services from independent contractors) to
Seller and without unreasonable interference with Seller’s ongoing operations, and (ii) reasonable
access to appropriate personnel in order to effect an orderly and rapid transition of material
commercial information related to the conduct by Seller of the Business.

Section 8.03 Public Announcements

     Each of Seller and Buyer agrees that, prior and subsequent to the Closing, it and its
representatives shall keep the terms of this Agreement confidential and shall not disclose such
information to any other Person (except as necessary to carry out the express terms of this
Agreement or to the extent such information becomes public information or generally available

22

 

to the public through no fault of such Party or its Affiliates) without the prior written
consent of the other Party (which shall not be unreasonably withheld), unless such Party has been
advised by counsel that disclosure is required to be made under applicable Law or the requirements
of a national securities exchange or another similar regulatory body (in which event such Party
shall, upon request of the non-disclosing Party, exercise its Reasonable Best Efforts to obtain a
protective order or other reliable assurance that confidential treatment will be accorded to the
information so disclosed).

Section 8.04 Bulk Sales

     Buyer and Seller waive compliance with all bulk sales Laws applicable to the transactions
contemplated by this Agreement.

Section 8.05 Corporate Names

     (a) Buyer shall have the right, but not the obligation, to sell the Inventory using applicable
NDC numbers of Seller or Seller Brands that are incorporated into the Inventory or otherwise
included on the label or labeling for the Inventory at time of delivery to Buyer or its designee
(“Corporate Names”), and Seller hereby grants Buyer a limited, non-exclusive, royalty-free
license under Seller’s right, title and interest in the Corporate Names, effective from and after
the Closing Date until the first anniversary of the Closing Date, to market, promote and sell the
Inventory. Buyer shall use its Reasonable Best Efforts to obtain its own NDC numbers for the
Product promptly following the Closing. For clarity, Buyer shall not use any Corporate Names on
any Product other than Inventory.

     (b) Buyer may use, copy, reproduce, modify, display, perform, execute, distribute, translate
into any language or form, and prepare derivative works (and take all of the above actions with
respect to such derivative works) of any Marketing Materials included in the Purchased Assets (and
Buyer shall be the owner of, and have all title to any copyrights in such derivative works created
by or for Buyer); provided, that Buyer uses its own name (or the name of its licensee or designee)
on such materials and completely removes all Seller Corporate Names and logos from, or completely
covers all Corporate Names on, such materials; and provided further, that Buyer acknowledges and
agrees that Seller shall have no Liability arising out of or in connection with Buyer’s or its
Affiliates’ use of such Marketing Materials.

Section 8.06 Regulatory Matters

     (a) As soon as practicable following the Closing Date, but in any event no later than ten (10)
days after the Closing Date, Seller shall transfer the Regulatory Documentation to Buyer, at
Seller’s expense. In addition to closing deliveries in accordance with Section 5.02, each Party
shall promptly after Closing submit to the FDA and any other Governmental or Regulatory Authorities
any other documentation and applications required to effect or provide notice of such transfer
required under applicable Laws, including 21 C.F.R. § 314.72.

     (b) Subject to Section 8.07(a), and except as otherwise provided in Section 8.02, from and
after the Closing, Buyer, at its cost, shall be solely responsible and liable (provided, however,
that Seller shall remain responsible and liable for all Excluded Liabilities)

23

 

for (i) taking all actions, paying all fees and conducting all communication with the
appropriate Governmental or Regulatory Authority required by Law in respect of the Regulatory
Approvals or the Regulatory Documentation, including preparing and filing all reports (including
adverse drug experience reports) with the appropriate Governmental or Regulatory Authority, (ii)
taking all actions and conducting all communication with third parties in respect of the Product
(whether sold before or after Closing), including responding to (A) complaints in respect thereof,
including complaints related to tampering or contamination, and (B) all medical information
requests, and (iii) investigating all complaints and adverse drug experiences in respect of the
Product (whether sold before or after Closing).

Section 8.07 Product Returns

     (a) Buyer shall accept and process all returns of Product following the Closing and disburse
refunds and credits in respect thereof to third parties (whether such Product was sold before or
after Closing) in accordance with the return policy in place for the Product at the time of sale
and applicable Laws. Seller shall reimburse Buyer for all reasonable, documented costs and
expenses incurred by Buyer in connection with (i) Product sold prior to Closing (as determined by
lot numbers) that is returned any time after Closing due to defect, damage or shipping errors or
(ii) Product sold prior to Closing (as determined by lot numbers) that is returned due to
expiration during the period commencing on the Closing Date and ending twenty-four (24) months
thereafter. For purposes of this Section 8.07, the calculation of Buyer’s reasonable costs and
expenses incurred in connection with Products returned shall be equal to Buyer’s actual costs and
expenses of Products returned (including refunds and credits). From and after the date of this
Agreement, neither Buyer nor Seller shall initiate or encourage any acceleration of or delay in the
return of the Product.

     (b) Promptly after the Closing, and except as may otherwise be provided in Section 8.02,
Seller and Buyer shall provide written notice to all Persons to which Product was sold by Seller
during the twelve (12) months prior to Closing stating that the Business has been purchased by
Buyer and that Seller no longer accepts returns of Product, and directing such Persons to contact
Buyer in connection with returns, purchase orders and all other inquiries regarding the Product.

Section 8.08 Further Assurances

     (a) On and after the Closing, Seller shall from time to time, at the request of Buyer, execute
and deliver, or cause to be executed and delivered, such other documents or instruments of
conveyance and transfer and take such other actions as Buyer may reasonably request, in order to
carry out the provisions of this Agreement or more effectively consummate the transactions
contemplated hereby and to vest in Buyer good and marketable title to the Purchased Assets
(including assistance in the collection or reduction to possession of any of the Purchased Assets).

     (b) On and after the Closing, Buyer shall from time to time, at the request of Seller, take
such actions as Seller may reasonably request, in order to more effectively consummate the
transactions contemplated hereby, including Buyer’s assumption of the Assumed Liabilities.

24

 

Section 8.09 Government Price Reporting Obligations

     (a) As soon as practicable following the Closing, Seller will modify its Pharmaceutical
Pricing Agreement with the Department of Veterans Affairs to remove the Product, and post-Closing
Buyer will be responsible for all Veterans Health Care Act obligations related to the Product. The
Parties shall cooperate fully to add the Product to Buyer’s agreement with the Department of
Veterans Affairs. Seller will provide all information needed by the Buyer to price its product for
the remainder of calendar year 2008, as well as all information needed to calculate and report the
quarterly and annual non-FAMP and the annual Federal Ceiling Price for the Product pursuant to the
Veterans Health Care Act of 1992. Seller shall indemnify Buyer pursuant to Article 12 from and
against any and all Damages incurred by any or all of the Buyer Indemnified Parties to the extent
arising or resulting from errors or omissions in such information.

     (b) Buyer agrees to provide to Seller, on a monthly and quarterly basis, all pricing
submissions, fully calculated, that are required under applicable Law to be submitted by Seller to
comply with its price reporting obligations with respect to the Product pursuant to Section 1927 of
the Social Security Act, as amended by the Deficit Reduction Act of 2005 (Pub. L. No. 109-171).
Buyer shall provide such submissions to Seller no later than twenty (20) days following the end of
each month. Further, the parties agree to cooperate to facilitate compliance with such price
reporting obligations with respect to the Product, including any price reporting obligations that
may be enacted subsequent to the Closing Date under applicable Law. Seller agrees to hold
confidential and not to disclose to any third party (except as required by applicable Law) pricing
data and submissions furnished by Buyer pursuant to this Section 8.09(b). Further, Seller agrees
not to use such data or submissions for any purpose other than meeting its price reporting
obligations under applicable Law and shall implement procedures to limit the personnel who may have
access to such data to those employees, contractors and agents of Seller who have a need to know
such information and solely to the extent reasonably necessary to facilitate such reporting, which
employees, contractors or agents shall in no event include any employee, contractor or agent with
responsibility for the pricing, marketing or sale of Avinza. Nothing herein shall be construed to
relieve Buyer of any duty that it may have to report pricing data with respect to the Product
pursuant to applicable Law. Buyer shall certify to Seller that, to the best of Buyer’s knowledge,
the results included in each such submission fall with the applicable guidelines provided by the
Centers for Medicare and Medicaid Services (CMS), to the extent such a certification is required to
accompany their submission to CMS by the Seller, and Buyer shall indemnify Seller pursuant to
Article 12 from and against any and all Damages incurred by any or all of the Seller Indemnified
Parties to the extent arising or resulting from errors or omissions in such information.

Section 8.10 Kadian Patent License

     (a) Effective upon the Closing:

                    (i) Seller hereby grants to Buyer and its Affiliates an exclusive, irrevocable, perpetual,
sublicensable, fully paid up, royalty-free license under the Licensed Intellectual Property solely
to use, make, distribute, offer for sale, promote, advertise, sell,

25

 

import, export, or have used, made, distributed, offered for sale, promoted, advertised, sold,
imported, or exported the Licensed Product in the Territory; and

                    (ii) Seller hereby grants to Buyer and its Affiliates an exclusive, irrevocable, perpetual,
sublicensable, fully paid up, royalty-free license under the Kadian Patents solely to use, make,
distribute, offer for sale, promote, advertise, sell, import, export, or have used, made,
distributed, offered for sale, promoted, advertised, sold, imported, or exported the Product in the
Territory.

     (b) In furtherance of the foregoing:

                    (i) Seller shall not, and shall cause its Affiliates not to, grant to any third party a
license under the Licensed Patents to make, have made, import, use, sell, or offer for sale any
Licensed Product or Generic Product in the Territory during the License Term.

                    (ii) During the License Term, each Party shall promptly notify the other Party in writing of
(A) any declaratory judgment action or other proceeding asserting the non-infringement, invalidity
or unenforceability of any Licensed Patent in the Territory in connection with a Licensed Product
or Generic Product by a third party, or (B) any “Paragraph IV Certification” under the Hatch-Waxman
Act, including any certification under 21 U.S.C. § 355(b)(2)(A)(iv) or § 355(j)(2)(A)(vii)(IV) (or
any amendment or successor statute thereto) of which it becomes aware asserting that any Licensed
Patent is invalid, unenforceable or will not be infringed by the manufacture use or sale of any
Generic Product in the Territory by a third party. Seller shall have the sole right to and, during
the License Term shall be obligated to, bring and prosecute in good faith, on behalf of Seller and
Buyer, for purposes of protecting Buyer’s exclusive rights under the exclusive license, an
infringement action against such third party and/or defend such declaratory judgment action or
other proceeding brought by the third party through counsel of Seller’s choosing, and Buyer, at its
expense, agrees to provide all reasonable cooperation in connection with such an action as Seller
may request. With regard to such foregoing infringement action that Seller is obligated to bring,
Seller shall, in each instance, bring such action within forty-five (45) days of receiving a
notification of a “Paragraph IV Certification” under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). All
recoveries from such an action that Seller is obligated to bring that are attributable to an
infringement related to Licensed Products or Generic Products shall be first allocated to reimburse
the Seller for its costs and expenses in bringing or defending such action, and the remainder shall
belong to Buyer and, to the extent attributable to lost sales of Products, constitute Net Sales.
All other recoveries from any such action that Seller is obligated to bring shall be retained by
Seller. In no case during the License Term may Seller enter into any settlement or consent
judgment or other voluntary disposition of such an action that Seller is obligated to bring without
Buyer’s prior written consent, which shall not be unreasonably withheld or delayed, that: (1)
limits Buyer’s rights under the Licensed Patents, (2) makes any admission of the invalidity,
unenforceability or non-infringement of the Licensed Patents with respect to any Licensed Product
or Generic Product, (3) subjects Buyer to an injunction or other equitable relief, (4) purports to
grant a license under the Licensed Patents to any third party to make, use or sell any Licensed
Product or Generic Product.

     (c) Effective upon the Closing, Seller hereby grants to Buyer and its Affiliates a
non-exclusive, irrevocable, perpetual, fully paid-up, royalty-free right and license to use and

26

 

reference the Seller Data to the extent necessary to maintain the Regulatory Approval, which
right and license shall be transferable to any subsequent owner of the Regulatory Approval.

     (d) Seller hereby covenants to Buyer that from and after the Closing Seller and its Affiliates
shall not join, file, prosecute or maintain any suit, in law or equity, against Buyer or its
Affiliates claiming that the research, development, manufacture, use, import, export, distribution
or sale of the Product by Buyer or its Affiliates infringes the Kadian Patents.

     (e) Seller hereby covenants to Buyer that from and after the Closing Seller and its Affiliates
shall not join, file, prosecute or maintain any suit, in law or equity, against Buyer or its
Affiliates claiming that the research, development, manufacture, use, import, export, distribution
or sale of the Licensed Product by Buyer or its Affiliates infringes the Product Patents.

     (f) As a condition to the assignment, transfer or license of any of the Product Patents to a
third party by Seller or its Affiliates, such third party shall agree to provide to Buyer a
covenant not to sue at least as protective as those set forth in the foregoing clauses (d) and (e).

     (g) With respect to any Product Patents licensed to Seller or its Affiliates as to which
Seller or its Affiliates do not control the right of prosecution of any legal action, from and
after the Closing Seller and its Affiliates shall not actively induce, assist or participate in any
legal action or proceeding relating to the Licensed Product against Buyer unless required by Law or
Contract (which Contract shall not be solicited or entered into for the purpose of circumventing
any rights granted to Buyer hereunder).

     (h) Upon the reasonable request of Buyer and with reasonable notice to Seller, from and after
the Closing, Seller shall provide in a timely manner to Buyer, at no greater than Seller’s Direct
Cost, assistance of knowledgeable employees of Seller and its Affiliates in defending against,
responding to or otherwise participating in any litigation related to the Product Intellectual
Property.

     (i) Effective upon the Closing, Buyer hereby grants to Seller and its Affiliates a
non-exclusive, irrevocable, perpetual, fully paid-up, royalty-free right and license to reference
the Regulatory Approval and other Regulatory Documentation in the Embeda NDA solely to the extent
that the Regulatory Approval and other Regulatory Documentation are referenced in the Embeda NDA as
of the Closing Date (the “Right of Reference”). As a condition to the assignment, transfer or
license of any of the Regulatory Approval or other Regulatory Documentation to a third party by
Buyer or its Affiliates, such third party shall agree to grant to Seller and its Affiliates the
foregoing right and license. Any and all use of the Right of Reference is without any
representation or warranty of any kind from Buyer, and Seller waives any and all warranties of any
kind including any express or implied warranty, whether oral or written, including any implied
warranty of the merchantability or fitness for a particular purpose.

     (j) Except as expressly set forth herein, no right or license is granted hereby with respect
to any Trademark, copyright, Patent or other intellectual property of Seller or its Affiliates.

27

 

     (k) Except as expressly set forth herein, no right or license is granted hereby with respect
to any Trademark, copyright, Patent or other intellectual property of Buyer or its Affiliates.

Section 8.11 DEA Notification

     Buyer and Seller shall, as required by Law, notify the DEA that, as of the Closing Date, Buyer
is or will be marketing and selling the Product in the United States either directly or indirectly
through one or more authorized distributors. As required by Law, each of Buyer and each such
authorized distributor, as applicable, shall obtain a valid registration(s) with the DEA permitting
Buyer or such authorized distributor, as applicable, to receive, hold, store, ship and sell the
Product in the United States.

Section 8.12 Representations True

     King shall not knowingly or intentionally take any action or knowingly or intentionally omit
to take any action to the extent such action or omission would result in any of its representations
or warranties being inaccurate or incorrect in any material respect as if given on and as of the
Closing Date.

Section 8.13 Confidentiality; Non-Public Purchased Assets

     (a) Each Party shall use its Reasonable Best Efforts to maintain and assure the
confidentiality of the confidential information of the other Party hereto. In the event that a
Party receives a request to disclose all or any part of the other Party’s confidential information
under the terms of a valid and effective subpoena or order issued by a court of competent
jurisdiction or by any other Governmental or Regulatory Authority, such Party agrees to: (i)
promptly notify the other Party of the existence, terms and circumstances surrounding such a
request, so that the other Party may seek an appropriate protective order and/or waive compliance
with the provisions of this Agreement; (ii) provide the other Party full and complete cooperation
to seek an appropriate order or remedy; (iii) cooperate with the other Party in obtaining reliable
assurances that confidential treatment will be accorded to the disclosed confidential information
if disclosure of such confidential information is required; and (iv) limit disclosure of the
confidential information to only that part necessary to comply with the request.

     (b) Notwithstanding that Seller disclosed the Purchased Assets to Buyer, all non-public
information within the Purchased Assets shall be considered, from and after the Closing Date, the
confidential information of Buyer. Unless and until this Agreement terminates or expires without
Closing, (i) Seller will keep all non-public information in its possession within the Purchased
Assets or related to Buyer and disclosed to Seller pursuant to this Agreement or in connection with
the negotiation hereof confidential and will not disclose such non-public information within the
Purchased Assets or related to Buyer and disclosed to Seller pursuant to this Agreement or in
connection with the negotiation hereof to third parties who are not under confidentiality
obligations adequate to maintain the confidentiality thereof, except for such disclosures as may be
required to comply with applicable Laws or the rules of a national securities exchange, and (ii)
before permitting any Person to receive non-public information or undertake any activity in
connection with Purchased Assets, Seller shall obtain a signed

28

 

agreement from each Person undertaking to maintain the confidentiality of all non-public
information within the Purchased Assets.

Section 8.14 Filings

     (a) The Parties specifically agree to promptly prepare and file any required filings under the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, with respect to the
transactions contemplated hereby to the extent required by applicable Law.

     (b) Each of the Parties shall furnish to the other such information and assistance as the
other Party may reasonably request in connection with the preparation of any filings or submissions
contemplated in Section 8.14(a) and provide the other with copies of all correspondence, filings or
communications (or memoranda setting forth the substance thereof) between such Party or any of its
representatives, on the one hand, and the applicable Governmental or Regulatory Authority, on the
other, with respect to this Agreement and the transactions contemplated hereby.

Section 8.15 Recalls.

     (a) From and after the Closing Date, Buyer, at its cost (subject to clause (c) below), shall
be solely responsible and liable for conducting all voluntary and involuntary recalls or market
withdrawals of units of the Product (whether sold before or after Closing), including (i) recalls
required by any Governmental or Regulatory Authority and (ii) voluntary recalls and market
withdrawals of Product sold prior to Closing or Product included in Inventory that was defective
when delivered to Buyer hereunder that are deemed necessary by Seller in its reasonable discretion.
Seller promptly shall notify Buyer in the event that a recall of Product sold prior to Closing or
Product included in Inventory that was defective when delivered to Buyer hereunder is necessary and
Seller shall, and shall cause its relevant Affiliates to, cooperate with Buyer’s reasonable
requests and use Reasonable Best Efforts to assist Buyer in implementing and effecting such recall
or market withdrawal.

     (b) Notwithstanding the foregoing, Seller (or an Affiliate designated by Seller) shall have
the right at its expense to conduct any recall or market withdrawal of Product sold prior to
Closing or Product included in Inventory if Seller determines that significant health and safety
concerns require that Seller or its Affiliates conduct such recall or market withdrawal; provided
that prior to initiating any such recall or market withdrawal, Seller shall consult in good faith
with Buyer to determine how such recall or market withdrawal shall be implemented. Buyer shall use
Reasonable Best Efforts to cooperate with Seller’s and its Affiliates’ reasonable requests and
assist Seller and its Affiliates in implementing and effecting such recall or market withdrawal.

     (c) Seller promptly shall reimburse Buyer for all reasonable, documented costs incurred by
Buyer in connection with any recall or market withdrawal (i) of Product sold prior to Closing or
Product included in Inventory that was defective when delivered to Buyer hereunder or (ii)
otherwise required by Seller pursuant to Sections 8.15(a) or (b) above.

29

 

Section 8.16 Rebates and Coupons

     (a) As between Buyer and Seller, Seller shall be responsible for and pay all Rebates relating
to utilization of the Product prior to and during the Rebate Period; provided that if the Rebate
Period ends on a day other than the last day of a Calendar Quarter, the amount of Rebates payable
by Seller pursuant to this Section 8.16 with respect to utilization of the Product during the
Calendar Quarter in which the Rebate Period ends shall be equal to (a) the aggregate amount of all
Rebates relating to utilization of the Product during such Calendar Quarter, multiplied by (b) a
fraction, the numerator of which is the number of days from and including the first day of such
Calendar Quarter through and including the last day of the Rebate Period and the denominator of
which is the total number of days in such Calendar Quarter. As between Buyer and Seller, Buyer
shall be responsible for and pay all Rebates relating to utilization of the Product after the
Rebate Period; provided that if the Rebate Period ends on a day other than the last day of a
Calendar Quarter, the amount of Rebates payable by Buyer pursuant to this Section 8.16 with respect
to utilization of the Product during the Calendar Quarter in which the Rebate Period ends shall be
equal to (x) the aggregate amount of all Rebates relating to utilization of the Product during such
Calendar Quarter, multiplied by (y) a fraction, the numerator of which is the number of days from
and including the day immediately following the last day of the Rebate Period through and including
the last day of such Calendar Quarter and the denominator of which is the total number of days in
such Calendar Quarter. Buyer shall not enter into any Contract requiring payment of a Rebate
during the Rebate Period except in the ordinary course of business and consistent with Seller’s
past practices regarding the amount of Rebates. Notwithstanding anything herein to the contrary,
in no event shall Seller be liable for, and Buyer shall be solely responsible for and shall pay all
rebates relating to utilization of any Product bearing Buyer’s NDC number.

     (b) As between Buyer and Seller, Seller shall be responsible for and pay all obligations under
and pursuant to Coupons relating to utilization of the Product prior to and during the Rebate
Period. As between Buyer and Seller, Buyer shall be responsible for and pay all obligations under
and pursuant to Coupons relating to utilization of the Product after the Rebate Period; provided
that Buyer’s aggregate liability pursuant to Coupons shall not exceed $60,000.

Section 8.17 Chargeback and Rebate Period

     (a) Promptly after the Closing Date, Buyer and Seller jointly shall select a third party
consultant (the “Consultant”) which shall determine the quantity of Product owned by all
wholesalers in the Territory as of the Closing Date (the “Aggregate Wholesaler Amount”) and
the average amount of Product sold by such wholesalers per day in the thirteen (13) weeks
immediately preceding the Closing Date (the “Daily Sales Amount”). The “Chargeback
Period” means the period commencing on the Closing Date and ending the number of days
thereafter equal to the Aggregate Wholesaler Amount divided by the Daily Sales Amount.

     (b) The Consultant also shall determine the quantity of Product owned by all wholesalers and
retailers in the Territory as of the Closing Date (the “Aggregate Wholesale/Retail Amount”)
and the average amount of Product utilized per day in the thirteen (13) weeks immediately preceding
the Closing Date (the “Daily Utilization Amount”). The

30

 

Rebate Period” means the period commencing on the Closing Date and ending the number
of days thereafter equal to the Aggregate Wholesale/Retail Amount divided by the Daily Utilization
Amount.

     (c) The Parties shall bear equally the fees and expenses of the Consultant.

Section 8.18 Chargebacks

     As between Buyer and Seller, Seller shall be responsible for and pay all Chargebacks that are
submitted by wholesalers and other distributors to either Seller and its Affiliates or Buyer prior
to and during the Chargeback Period. As between Buyer and Seller, Buyer shall be responsible for
and pay all Chargebacks submitted by wholesalers and other distributors to either Seller and its
Affiliates or Buyer after the Chargeback Period. Buyer shall not enter into any Contract requiring
payment of a Chargeback during the Chargeback Period except in the ordinary course of business and
consistent with Seller’s past practices regarding the amount of Chargebacks. Notwithstanding
anything herein to the contrary, in no event shall Seller be liable for, and Buyer shall be solely
responsible for and shall pay, any and all Chargebacks with respect to Product bearing Buyer’s NDC
number.

Section 8.19 GPO Administration Fees and IFF Payments

     As between Buyer and Seller, Seller shall be responsible for and pay all GPO Administration
Fees and IFF payments relating to sales of the Product during the Chargeback Period; provided that
if the Chargeback Period ends on a day other than the last day of a Calendar Quarter, the amount of
GPO Administration Fees and IFF payments payable by Seller pursuant to this Section 8.19 with
respect to sales of the Product during the Calendar Quarter in which the Chargeback Period ends
shall be equal to (a) the aggregate amount of all GPO Administration Fees and IFF payments relating
to sales of the Product during such Calendar Quarter, multiplied by (b) a fraction, the numerator
of which is the number of days from and including the first day of such Calendar Quarter through
and including the last day of the Chargeback Period and the denominator of which is the total
number of days in such Calendar Quarter. As between Buyer and Seller, Buyer shall be responsible
for and pay all GPO Administration Fees and IFF payments relating to sales of the Product after the
Chargeback Period; provided that if the Chargeback Period ends on a day other than the last day of
a Calendar Quarter, the amount of GPO Administration Fees and IFF payments payable by Buyer
pursuant to this Section 8.19 with respect to sales of the Product during the Calendar Quarter in
which the Chargeback Period ends shall be equal to (x) the aggregate amount of all GPO
Administration Fees and IFF payments relating to sales of the Product during such Calendar Quarter,
multiplied by (y) a fraction, the numerator of which is the number of days from and including the
day immediately following the last day of the Chargeback Period through and including the last day
of such Calendar Quarter and the denominator of which is the total number of days in such Calendar
Quarter. Buyer shall not enter into any Contract requiring payment of a GPO Administration Fee
during the Chargeback Period except in the ordinary course of business and consistent with Seller’s
past practices regarding the amount of GPO Administration Fees. Notwithstanding anything herein to
the contrary, in no event shall Seller be liable for, and Buyer shall be solely responsible for and
shall pay any and all GPO Administration Fees and IFF payments relating sales of any Product
bearing Buyer’s NDC number.

31

 

Section 8.20 Manufacturing Agreements

     (a) Effective as of the Closing, the Toll Manufacturing Agreement, dated as of December 19,
2005, by and between Alpharma Branded Products Division Inc. and Buyer (formerly Purepac
Pharmaceutical Co.), as amended (the “Toll Manufacturing Agreement”) shall terminate;
provided that to the extent any surviving provisions therein are inconsistent with the terms of
this Agreement, the terms of this Agreement shall govern. Additionally, following the Closing the
Parties agree to negotiate in good faith to amend any surviving provisions of the Toll
Manufacturing Agreement or other provisions of the Toll Manufacturing Agreement in order to address
issues impacted by this Agreement.

     (b) Effective as of the Closing, the Development and Manufacturing Services Agreement, dated
as of February 1, 2008, by and between Actavis Elizabeth LLC and Alpharma Pharmaceuticals LLC, as
amended shall continue in force; provided that following the Closing the Parties agree to negotiate
in good faith to amend such Development and Manufacturing Services Agreement to address issues
impacted by this Agreement.

Section 8.21 Sale of Product

     Buyer, through the second Calendar Quarter of 2010, shall use commercially reasonable efforts
to sell the Product and maximize Gross Profits of the Product; provided, however that Buyer shall
not have any obligation under this Section 8.21 to perform Details or to sell the Product if in the
reasonable view of Buyer such sales expose Buyer to material third party liability.

Section 8.22 Delivery of Inventory

     On the Closing Date, Seller shall tender Inventory at the place where it is located as
requested by Buyer to either Buyer or a third party designated by Buyer.

Section 8.23 Assumed Contracts

     Promptly following the Execution Date, Seller shall provide to Buyer a copy of any Contract to
which Seller is a party that relates to the Product or the Business. Buyer shall designate from
among such Contracts (a) those Contracts (if relating exclusively to the Products or the Business)
and (b) the portion of those Contracts (if relating to the Products or the Business but not
exclusively thereto), to be added, at Buyer’s request, to Section 1.01(k) of the Seller’s
Disclosure Schedule. Seller shall cooperate in good faith with Buyer to effect the transfer and
assignment to Buyer of such Contract, or portion thereof, subject to any required third party
consent. Any Contract or portion of a Contract that has been designated by Buyer pursuant to this
Section shall be deemed added to Section 1.01(k) of the Seller’s Disclosure Schedule as of the date
of such designation and shall be subject to Section 2.01(d).

Section 8.24 Regulatory Actions

     Seller hereby covenants to Buyer that from and after the Closing Seller and its Affiliates
shall not file any Citizen’s Petition with the FDA against Buyer or its Affiliates based

32

 

on any non-public information contained in the Regulatory Approval or other Regulatory
Documentation.

Article IX.

Conditions to the Obligations of Seller

     The obligation of Seller to effect the transactions contemplated hereby is subject to the
satisfaction (or waiver by Seller), at or before the Closing, of each of the following conditions:

Section 9.01 Alpharma Acquisition

     The acquisition of Alpharma by King shall have been consummated pursuant to the Merger
Agreement.

Section 9.02 No Legal Prohibition

     No provision of applicable Law and no Order shall prohibit the consummation of the Closing.

Article X.

Conditions to the Obligations of Buyer

     The obligation of Buyer to effect the transactions contemplated hereby is subject to the
satisfaction (or waiver by Buyer), at or before the Closing, of the following conditions:

Section 10.01 No Legal Prohibition

     No provision of applicable Law and no Order shall prohibit the consummation of the Closing.

Section 10.02 Alpharma Acquisition

     The acquisition of Alpharma by King shall have been consummated pursuant to the Merger
Agreement.

Article XI.

Additional Post-Closing Covenants

Section 11.01 Access to Information

     (a) Upon the request of Seller, from and after the Closing, to the extent permitted by
applicable Law, Buyer shall permit Seller and its representatives to have access, during regular
business hours and upon reasonable advance notice, to inspect and copy the Books and Records and
other documents in Buyer’s possession to the extent pertaining to the operation of the Business
prior to the Closing Date for Tax purposes and in connection with any action, suit, proceeding,
arbitration, Order, inquiry, hearing, assessment with respect to fines or

33

 

penalties or litigation commenced, brought, conducted or heard by or before, any Governmental
or Regulatory Authority.

     (b) To the extent relevant to the Product, Purchased Assets or the Business prior to the
Closing Date, Seller shall provide Buyer with such assistance as may be reasonably be required in
connection with the preparation of any Tax Return and the conduct of any audit or other examination
by any taxing authority or in connection with judicial or administrative proceedings relating to
any liability for Taxes, and shall retain and provide Buyer with all records or other information
that may be related to the preparation of any Tax Returns, or the conduct of any audit or
examination or other Tax proceeding. Seller shall retain all relevant documents, including prior
year’s Tax Returns, supporting work schedules and other records or information that may be relevant
to such Tax Returns and shall not destroy or otherwise dispose of any such records without the
prior written consent of Buyer.

     (c) In the event that Seller transfers to Buyer copies of any Books and Records in accordance
with the last sentence of Section 1.01(n), Seller shall provide Buyer access to the original
documents under circumstances where copies of such documents are insufficient for regulatory or
evidentiary purposes.

Article XII.

Indemnification

Section 12.01 Survival of Representations and Warranties

     The representations and warranties of Seller or Buyer contained in this Agreement shall
terminate twenty four (24) months following the Closing.

Section 12.02 Indemnification

     (a) By Seller. Subject to Section 12.03, from and after the Closing, Seller shall
indemnify, reimburse, defend and hold harmless Buyer, its Affiliates, and their respective
officers, directors, employees, agents, successors and assigns (the “Buyer Indemnified
Parties”) from and against any and all costs, losses, Liabilities, damages, lawsuits,
deficiencies, claims, fines, demands, penalties, interest and expenses (including reasonable fees
and disbursements of attorneys) (collectively, the “Damages”), incurred in connection with,
arising out of, or resulting from (i) any breach of any covenant or agreement of Seller herein,
(ii) the inaccuracy or breach of any representation or warranty made by Seller in this Agreement,
(iii) the failure of Seller to assume, pay, perform and discharge any Excluded Liabilities, (iv)
the ownership and operation of the Purchased Assets or the conduct of the Business prior to the
Closing, (v) the use by Seller or its Affiliates of the Marketing Materials prior to the Closing,
(vi) Third Party Claims in connection with, arising out of, or resulting from the use of the
Regulatory Approval and other Regulatory Documentation in the Embeda NDA and Books and Records,
including any Damages associated with the promotion, marketing, distribution, sale or use of any
products associated with the use of the Regulatory Approval and other Regulatory Documentation in
the Embeda NDA, and Books and Records pursuant to Section 8.10(i) and (vii) the enforcement by the
Buyer Indemnified Parties of their rights under this Section 12.02(a).

34

 

     (b) By Buyer. Subject to Section 12.03, from and after the Closing, Buyer shall
indemnify, defend and hold harmless Seller, its Affiliates and their respective officers,
directors, employees, agents, successors and assigns (the “Seller Indemnified Parties”)
from and against any and all Damages incurred in connection with, arising out of, or resulting from
(i) any breach of any covenant or agreement of Buyer herein, (ii) the inaccuracy or breach of any
representation or warranty made by Buyer in this Agreement, (iii) the failure of Buyer to assume,
pay, perform and discharge any Assumed Liabilities, (iv) the ownership and operation of the
Purchased Assets or the conduct of the Business after Closing, (v) the use by Buyer or its
Affiliates of the Marketing Materials after Closing, and (vi) the enforcement by the Seller
Indemnified Parties of their rights under this Section 12.02(b).

     (c) Procedures. The Person entitled to indemnification under this Agreement (the
“Indemnified Party”), shall give the indemnifying Party (the “Indemnifying Party”)
prompt written notice (an “Indemnification Claim Notice”) of any Damages or discovery of
fact upon which such Indemnified Party intends to base a request for indemnification under Section
12.02(a) or Section 12.02(b), provided, however, that any failure to give such notice shall not
waive any rights of an Indemnified Party except to the extent that the rights of the Indemnifying
Party are actually prejudiced or to the extent that any applicable period contemplated by Section
12.01 has expired without notice being given. Each Indemnification Claim Notice must contain a
description of the claim and the nature and amount of such Damages (to the extent that the nature
and amount of such Damages are known at such time). The Indemnified Party shall furnish promptly
to the Indemnifying Party copies of all papers and official documents received in respect of any
Damages.

     (d) Third Party Claims. The obligations of an Indemnifying Party under this Section
12.02 with respect to Damages arising from claims, lawsuits, demands or other proceedings by any
third party (each, a “Third Party Claim”) that are subject to indemnification as provided
for in Section 12.02(a) or Section 12.02(b) shall be governed by and be contingent upon the
following additional terms and conditions:

                    (i) At its option, the Indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within fifteen (15) days after the Indemnifying
Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party
Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying
Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor shall
it constitute a waiver by the Indemnifying Party of any defenses it may assert against any
Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim,
the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any
legal counsel selected by the Indemnifying Party, subject to the consent of the Indemnified Party,
which consent shall not be unreasonably withheld or delayed. In the event the Indemnifying Party
assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the
Indemnifying Party all original notices and documents (including court papers) received by any
Indemnified Party in connection with the Third Party Claim. Should the Indemnifying Party assume
the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified
Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the
analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately
determined that the

35

 

Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnified Party
from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying
Party for any and all costs and expenses (including reasonable attorneys’ fees and costs of suit)
and any Damages incurred by the Indemnifying Party in its defense of the Third Party Claim with
respect to such Indemnified Party.

                    (ii) Without limiting Section 12.02(d)(i), any Indemnified Party shall be entitled to
participate in, but not control, the defense of such Third Party Claim and to employ counsel of its
choice for such purpose; provided, however, that such employment shall be at the Indemnified
Party’s own expense unless (A) the employment thereof has been specifically authorized by the
Indemnifying Party in writing, (B) the Indemnifying Party has failed to assume the defense and
employ counsel in accordance with Section 12.02(d)(i) (in which case the Indemnified Party shall
control the defense), or (C) the interests of the Indemnified Party and the Indemnifying Party with
respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the
same counsel of both parties under applicable Law, ethical rules or equitable principles.

                    (iii) With respect to any Damages relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnified Party’s becoming
subject to injunctive or other relief or otherwise adversely affect the business of the Indemnified
Party in any manner, and as to which the Indemnifying Party shall have acknowledged in writing the
obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole
right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of
such Damages, on such terms as the Indemnifying Party, in its sole discretion, shall deem
appropriate. With respect to all other Damages in connection with Third Party Claims, where the
Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section
12.02(d)(i), the Indemnifying Party shall have authority to consent to the entry of any judgment,
enter into any settlement or otherwise dispose of such Damages; provided that it obtains the prior
written consent of the Indemnified Party (which consent shall not be unreasonably withheld or
delayed). The Indemnifying Party shall not be liable for any settlement or other disposition of
Damages by an Indemnified Party in connection with a Third Party Claim that is reached without the
prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld
or delayed). No Indemnified Party shall admit any liability with respect to, or settle, compromise
or discharge, any Third Party Claim without the prior written consent of the Indemnifying Party
(which consent shall not be unreasonably withheld or delayed).

                    (iv) If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party shall cooperate in the defense or prosecution thereof and promptly shall furnish
such records, information and testimony, provide such witnesses and attend such conferences,
discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection
therewith. Such cooperation shall include access during normal business hours afforded to the
Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making relevant employees
and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the

36

 

Indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket
expenses in connection therewith.

     (e) Expenses. Except as provided above, the reasonable and verifiable costs and
expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in
connection with any claim shall be reimbursed on a quarterly basis by the Indemnifying Party,
without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party

Section 12.03 Limitations

     (a) In no event shall the aggregate liability of Seller for Damages pursuant to Section
12.02(a)(i) and 12.02(a)(ii) exceed the Purchase Price.

     (b) EXCEPT FOR AND ONLY TO THE EXTENT OF ANY AMOUNTS PAID UNDER AN INDEMNIFIABLE THIRD PARTY
CLAIM UNDER SECTION 12.02, OR IN THE CASE OF A PARTY’S WILLFUL MISCONDUCT, IN NO EVENT SHALL EITHER
PARTY BE LIABLE FOR SPECIAL, EXEMPLARY, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING
BUSINESS INTERRUPTION OR LOST PROFITS, OR PUNITIVE DAMAGES.

Section 12.04 Remedies Exclusive

     From and after the Closing, the remedies set forth in this Article XII shall be exclusive and
in lieu of any other remedies that may be available to the Indemnified Parties under any theory of
liability and pursuant to any statutory or common law with respect to any Damages of any kind or
nature directly or indirectly resulting from or arising out of any breach of this Agreement
(including alleged breaches or inaccuracies of any representation, warranty or covenant or for any
alleged misrepresentation) or the transactions contemplated hereby.

Article XIII.

Termination and Abandonment

Section 13.01 Methods of Termination

     Except as provided in Section 13.02 below, the transactions contemplated herein may be
terminated and abandoned at any time prior to the Closing:

     (a) by mutual written consent executed and delivered by Seller and Buyer; or

     (b) by either Seller or Buyer if (i) the Closing shall not have occurred by December 31, 2008;
provided that the terminating Party is not then in material breach of its representations,
warranties, or obligations hereunder; (ii) there shall be a final nonappealable Order of a federal
or state court in effect preventing consummation of the transactions contemplated hereby; or (iii)
there shall be any statute, rule, regulation or order enacted,

37

 

promulgated or issued or deemed applicable to the transactions contemplated hereby by any
governmental entity that would make consummation of the transactions contemplated hereby illegal.

     A termination pursuant to this Section 13.01 shall be effected by delivery of written notice
of such termination by the terminating party to the other Party. Where action is taken to
terminate this Agreement pursuant to this Section 13.01, it shall be sufficient for such action to
be authorized by the board of the Party taking such action.

Section 13.02 Procedure upon and Effect of Termination

     In the event of termination and abandonment under Section 13.01, written notice thereof shall
forthwith be given to the other Party and the transactions, conveyances, and other actions
contemplated by this Agreement shall be terminated and abandoned immediately, without further
action by the Parties. If the transactions contemplated by this Agreement are terminated as
provided herein, no Party and none of the directors, officers, stockholders, affiliates or
controlling Persons of such Party shall have any further liability or obligation to any other Party
to this Agreement except for a willful failure of a Party to fulfill a condition to the performance
of the obligations of the other Party or a willful breach of a covenant or representation or
warranty. The provisions of Article XIII and Article XIV shall survive any termination of this
Agreement.

Article XIV.

Miscellaneous

Section 14.01 Notices

     All notices, requests and other communications hereunder must be in writing and will be deemed
to have been duly given only if delivered personally against written receipt or by facsimile
transmission with answer back confirmation or mailed (postage prepaid by certified or registered
mail, return receipt requested) or by nationally recognized overnight courier that maintains
records of delivery to the Parties at the following addresses or facsimile numbers:

     If to Buyer to:

Actavis Elizabeth, L.L.C.

60 Columbia Road, Building, B

Morristown, NJ 07960

Attention: Chief Legal Officer

Facsimile:

38

 

     With copies to:

Wilson Sonsini Goodrich & Rosati, P.C.

1301 Avenue of the Americas

40th Floor

New York, NY 10019

Attention: Arthur L. Hoag

Facsimile:

     If to Seller to:

King Pharmaceuticals, Inc.

501 Fifth Street

Bristol, Tennessee 37620

Attention: General Counsel

Facsimile:

     With a copy to:

King Pharmaceuticals, Inc.

400 Crossing Boulevard

8th Floor

Bridgewater, New Jersey 08807

Attention: General Counsel

Facsimile:

     All such notices, requests and other communications will (a) if delivered personally to the
address as provided in this Section, be deemed given upon receipt, (b) if delivered by facsimile to
the facsimile number as provided in this Section, be deemed given upon receipt by the sender of the
answer back confirmation and (c) if delivered by mail in the manner described above or by overnight
courier to the address as provided in this Section, be deemed given upon receipt (in each case
regardless of whether such notice, request or other communication is received by any other Person
to whom a copy of such notice, request or other communication is to be delivered pursuant to this
Section). Either Party from time to time may change its address, facsimile number or other
information for the purpose of notices to that Party by giving notice specifying such change to the
other Party in accordance with the terms of this Section.

Section 14.02 Entire Agreement

     This Agreement (and all schedules attached hereto and all other documents delivered in
connection herewith) contains the sole and entire agreement between the Parties with respect to the
subject matter hereof and supersedes all prior discussions and agreements between the Parties with
respect to the subject matter hereof. Except as expressly provided herein, nothing in this
Agreement shall modify or amend any provision of the Toll Manufacturing Agreement or the
Development and Manufacturing Services Agreement, dated as of February 1, 2008, by and between
Alpharma Pharmaceuticals LLC and Buyer.

39

 

Section 14.03 Waiver

     Any term or condition of this Agreement may be waived at any time by the Party that is
entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a
written instrument duly executed by or on behalf of the Party waiving such term or condition. No
waiver by either Party of any term or condition of this Agreement, in any one or more instances,
shall be deemed to be or construed as a waiver of the same or any other term or condition of this
Agreement on any future occasion. All remedies, either under this Agreement or by law or otherwise
afforded, will be cumulative and not alternative.

Section 14.04 Amendment

     This Agreement may be amended, supplemented or modified only by a written instrument duly
executed by each Party.

Section 14.05 Third Party Beneficiaries

     The terms and provisions of this Agreement are intended solely for the benefit of each Party
and its respective successors or permitted assigns and it is not the intention of the Parties to
confer third-party beneficiary rights upon any other Person.

Section 14.06 Assignment; Binding Effect

     Neither this Agreement nor any right, interest or obligation hereunder may be assigned by
either Party without the prior written consent of the other Party, which shall not be unreasonably
withheld or delayed, and any attempt to do so will be void. This Agreement is binding upon, inures
to the benefit of and is enforceable by the Parties and their respective successors and permitted
assigns.

Section 14.07 Headings

     The headings used in this Agreement have been inserted for convenience of reference only and
do not define or limit the provisions hereof.

Section 14.08 Severability

     If any provision of this Agreement is held to be illegal, invalid or unenforceable under any
present or future Law, and if the rights or obligations of either Party under this Agreement will
not be materially and adversely affected thereby, (a) such provision will be fully severable, (b)
this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will
remain in full force and effect and will not be affected by the illegal, invalid or unenforceable
provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable
provision, there will be added automatically as a part of this Agreement a legal, valid and
enforceable provision as similar to such illegal, invalid or unenforceable provision as may be
possible and reasonably acceptable to the Parties.

40

 

Section 14.09 Governing Law

     THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
NEW YORK EXCLUDING ANY CONFLICTS OR CHOICE OF LAW RULE OR PRINCIPLE THAT MIGHT OTHERWISE REFER
CONSTRUCTION OR INTERPRETATION OF THIS AGREEMENT TO THE SUBSTANTIVE LAW OF ANOTHER JURISDICTION.

Section 14.10 Consent to Jurisdiction and Forum Selection

     THE PARTIES AGREE THAT ALL ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT
(OTHER THAN APPEALS THEREFROM) SHALL BE INITIATED AND TRIED EXCLUSIVELY IN THE LOCAL AND FEDERAL
COURTS LOCATED IN THE SOUTHERN DISTRICT OF NEW YORK. THE AFOREMENTIONED CHOICE OF VENUE IS
INTENDED BY THE PARTIES TO BE MANDATORY AND NOT PERMISSIVE IN NATURE, THEREBY PRECLUDING THE
POSSIBILITY OF LITIGATION BETWEEN THE PARTIES WITH RESPECT TO OR ARISING OUT OF THIS AGREEMENT IN
ANY JURISDICTION OTHER THAN THAT SPECIFIED IN THIS SECTION. EACH PARTY HEREBY WAIVES ANY RIGHT IT
MAY HAVE TO ASSERT THE DOCTRINE OF FORUM NON CONVENIENS OR SIMILAR DOCTRINE OR TO OBJECT TO VENUE
WITH RESPECT TO ANY PROCEEDING BROUGHT IN ACCORDANCE WITH THIS SECTION, AND STIPULATES THAT THE
LOCAL AND FEDERAL COURTS LOCATED IN THE SOUTHERN DISTRICT OF NEW YORK SHALL HAVE PERSONAL
JURISDICTION AND VENUE OVER EACH OF THEM FOR PURPOSES OF LITIGATING ANY DISPUTE, CONTROVERSY OR
PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT. EACH PARTY HEREBY AUTHORIZES AND AGREES TO
ACCEPT SERVICE OF PROCESS SUFFICIENT FOR PERSONAL JURISDICTION IN ANY ACTION AGAINST IT AS
CONTEMPLATED BY THIS SECTION BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, POSTAGE
PREPAID TO ITS ADDRESS FOR THE GIVING OF NOTICES AS SET FORTH IN THIS AGREEMENT, OR IN THE MANNER
SET FORTH IN SECTION 14.01 OF THIS AGREEMENT FOR THE GIVING OF NOTICE. ANY FINAL JUDGMENT RECEIVED
AGAINST A PARTY IN ANY ACTION OR PROCEEDING SHALL BE CONCLUSIVE AS TO THE SUBJECT OF SUCH FINAL
JUDGMENT AND MAY BE ENFORCED IN OTHER JURISDICTIONS IN ANY MANNER PROVIDED BY LAW.

Section 14.11 Expenses

     Except as otherwise expressly provided in this Agreement, each Party shall pay its own
expenses and costs incidental to the preparation of this Agreement and to the consummation of the
transactions contemplated hereby.

41

 

Section 14.12 Counterparts

     This Agreement may be executed in any number of counterparts and by facsimile or other
electronic transmission, each of which will be deemed an original, but all of which together will
constitute one and the same instrument.

(The remainder of this page is left blank intentionally.)

42

 

     IN WITNESS WHEREOF, this Agreement has been executed by the Parties as of the date first above
written.

	 	 	 	 	 
	 	KING PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Brian A. Markison
 	 
	 	 	Name:  	Brian A. Markison	 
	 	 	Title:  	Chairman, President and CEO 	 
	 

	 	 	 	 	 
	 	ACTAVIS ELIZABETH, L.L.C.

 	 
	 	By:  	/s/ Douglas S. Boothe
 	 
	 	 	Name:  	Douglas S. Boothe	 
	 	 	Title:  	President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]